

# Programa/Program

42º Congresso Brasileiro de  
Farmacologia e Terapêutica Experimental

42<sup>nd</sup> Brazilian Congress of Pharmacology and  
Experimental Therapeutics

Centro de Convenções de Ribeirão Preto  
Ribeirão Preto, SP  
18-21 de outubro de 2010



## Mensagem do Presidente

Prezado(a) Congressista,

Em nome da Diretoria da SBFTE dou as boas-vindas ao Congresso de 2010. Dedicamos nossos melhores esforços para proporcionar a todos um Congresso abrangente e interessante. Este Congresso é o resultado de um ano de duro trabalho da Diretoria, do Conselho, da Secretaria da SBFTE e da Eventus, a empresa que organiza as atividades, pelo que já os agradeço aqui. Nossos patrocinadores, Biolab-Sanus e Atem & Remer como sempre, tornaram possível a existência dos Prêmios José Ribeiro do Valle e Inovação que já se tornaram partes nobres do calendário científico da nossa Sociedade. Nossos efusivos agradecimentos a eles. Da mesma forma, faço um agradecimento especial às empresas que aceitaram nosso convite e trouxeram seus estandes para mostrar seus produtos e serviços. Gostaria também de agradecer os nossos patrocinadores institucionais CNPq, CAPES, FAPESP e FAPERJ. Finalmente, agradeço aos avaliadores de Resumos e de Painéis e aos membros das diversas Comissões. Cada um deles despendeu uma parcela importante do seu tempo para que você tenha um Congresso proveitoso. Imperfeições são inerentes a um evento tão complexo como este. Por favor, mandem suas críticas e sugestões para o email [sbfte@sbfte.org.br](mailto:sbfte@sbfte.org.br).

O Programa de 2010 está mais denso e vamos usar até parte do horário do almoço para atividades. É a consequência de estarmos crescendo e melhorando.

Como já informado o Congresso de 2011 será feito em conjunto com a FeSBE na cidade do Rio de Janeiro. A Comissão Científica multi-Sociedade que está montando a programação de atividades está construindo um programa de alto nível e multidisciplinar. Estamos antecipando que o Congresso Conjunto de 2011 será muito proveitoso.

Desejo a você um excelente Congresso e uma ótima estada em Ribeirão Preto. Aproveite para conhecer gente nova, rever os amigos e começar uma colaboração científica.

Um abraço,

Jamil Assreuy

Presidente do 42o Congresso Brasileiro de Farmacologia e Terapêutica Experimental

## Message from the President

Dear Colleague,

On behalf of the Brazilian Society of Pharmacology and Experimental Therapeutics I welcome you to the 2010 Congress. We made our best efforts to build an interesting and attractive Congress. It is the result of one year of hard work by the Board of Directors, by the Council, Executive Secretariat and Eventus. I very much thank all these people for their efforts. A big "Thank you" goes to Biolab-Sanus and Atem & Remer who kindly support the two Awards given by the Society, the Prof José Ribeiro do Valle Award and the Innovation Award. I also have to express my gratitude to the companies of scientific equipments and reagents which accepted our invitation to show their products and services. My thanks also to our institutional supporters CNPq, CAPES, FAPESP and FAPERJ. Finally, I thank very much to the Abstract and Poster reviewers whom spend a considerable time and effort to ensure that our standards are met. An event this size is likely to have some imperfections. We very much appreciate your feedback, comments and suggestions to the email [sbfte@sbfte.org.br](mailto:sbfte@sbfte.org.br).

The 2010 Scientific Program is denser and we will use part of the lunch time for activities. This is the consequence of the Society increase in size and quality.

As already informed, the 2011 Congress will be held in Rio de Janeiro together with the Brazilian Federation of Experimental Biology Societies. A multi-Society scientific Committee is building up a high level program and we are sure that this event will be a success.

I wish you an excellent Congress and a very nice stay in Ribeirão Preto. Take your time to meet old and new friends.

My best regards,

Jamil Assreuy

President of the Congress

## Support Agencies

---



## Enterprise Support

---



## Exhibitors

---

ADInstruments  
AVS Projetos  
Delta Livros  
Inova  
Insight Equipamentos Científicos – Ensino e Pesquisa  
Novalab Científica Ltda.

## Support

---



Sociedade Brasileira de Farmacologia e Terapêutica Experimental  
sbfte@pratica.com.br / sbfte@sbfte.org.br  
www.sbfte.org.br

## Organization

---



Eventus Planejamento e Organização  
Rua Marquês de Itu, 408, cj.34/35  
São Paulo SP  
CEP 01223-000  
www.eventus.com.br  
eventus@eventus.com.br  
Telefone 11 3361 3056  
Fax 11 3361 3089

**Revisão, Supervisão e Editoração**  
Sandra Helena Rocha da Cruz

**Congress President**

Jamil Assreuy (UFSC)

**Scientific Committee**

Cristoforo Scavone (USP)

João Batista Calixto (UFSC)

Lusiane M. Bendhack (USP)

Maria Christina W. de Avellar (UNIFESP)

Rosely Oliveira Godinho (UNIFESP, Coordenadora)

**Organizing Committee**

Jamil Assreuy (UFSC, Coordenador)

Mauro Martins Teixeira (UFMG)

Rosely Oliveira Godinho (UNIFESP)

Teresa C. T. Dalla Costa (UFRGS)

Ronaldo A. Ribeiro (UFC)

**Poster Committee**

Ana Lucia de Aguiar Pires (FIOCRUZ, Secretária)

Patrícia M. R. S. Martins (FIOCRUZ, Coordenadora)

Sandra Helena P. Farsky (USP)

Teresa C. T. Dalla Costa (UFRGS)

**Innovation Award Committee**

Fernando de Queiroz Cunha (USP)

Mauro M. Martins (UFMG)

Ricardo Amaral Remer

Regina Pekelmann Markus (USP, Coordenadora)

**José Ribeiro do Valle Award Committee**

Giles A. Rae (UFSC, Coordenador)

Gloria E. P. de Souza (USP)

Soraya S. Smaili (UNIFESP)

**Local Committee**

Fernando de Queiroz Cunha (USP)

Glória E. P. de Souza (USP)

**Abstract Reviewers**

Adair R. S. Santos (UFSC)

Adriana Lino dos Santos (USP)

Albetiza Lobo Araújo (UNICAMP)

Aleksander Roberto Zampronio (UFPR)

Andrea Grabe Guimarães (UFOP)

Antonio Claudio Lucas da Nóbrega (UFF)

Bagnólia Araújo da Silva (UFPB)

Bruno Lourenço Diaz (UFRJ)

Caden Souccar (UNIFESP)

Carlos Renato Tirapelli (USP)

Catarina Segreti Porto (UNIFESP)

Christianne Bandeira de Melo (UFRJ)

Ciomar A Bersani-Amado (UEM)

Cláudia F. Benjamim (UFRJ)

Cláudia Lúcia M. Silva (UFRJ)

Cláudia Padovan (USP)

Cláudia do Ó Pessoa (UFC)

Claudio Miguel Costa Neto (USP)

Cristina Setim Freitas (UFPR)

Cristóforo Scavone (USP)

Daniella Bonaventura (USP)

Danielle da Gloria de Souza (UFMG)

Edgar Paredes Gamero (UNIFESP)

Edson Antunes (UNICAMP)

Eduardo Vera Tibiriçá (FIOCRUZ)

Eliezer J. Barreiro (UFRJ)

Elisa Mitiko Kawamoto (USP)

Emer S. Ferro (USP)

Emiliano de Oliveira Barreto (UFAL)

Francisco J. R. Paumgarten (FIOCRUZ)

Fúlvio R. Mendes (UNIFESP)

Gilberto de Nucci (UNICAMP/USP)

Giles A. Rae (UFSC)

Glória E. P. de Souza (USP)

Gustavo Ballejo Oliveira (USP)

Iolanda M. Fierro (UERJ)

Isac A. de Medeiros (UFPB)

Jamil Assreuy (UFSC)

João Ernesto de Carvalho (UNICAMP)

José Eduardo Tanus-Santos (USP)

José Francisco Fracasso (UNESP-Araraquara)

Josélia A. Lima (UFRJ)

Leticia Veras Costa-Lotufo (UFC)

Magda Fráguas Serra (FIOCRUZ)

Manoel Odorico de Moraes (UFC)

Marcelo N. Muscará (USP)

Marco Aurélio Martins (FIOCRUZ)

Maria Cristina de O. Salgado (USP)

Maria de Fátima M. Lazari (UNIFESP)

Maria Fernanda de Paula Werner (UFPR)

Maria Martha Campos (PUCRS)

Marília Zaluar P. Guimarães (UFRJ)

Newton G. de Castro (UFRJ)

Norma Yamanouye (Instituto Butantan)

Patrícia M. R. S. Martins (FIOCRUZ)

Patrícia Torres Bozza (FIOCRUZ)

Paulina Sannomiya (USP)

Paulo de Assis Melo (UFRJ)

Pedro Paulo X. Elsas (UFRJ)

Renato S. B. Cordeiro (FIOCRUZ)

Rita de Cássia Elias Estrela (INCa)

Roberto Takashi Sudo (UFRJ)

Ronaldo A. Ribeiro (UFC)

Rosana Camarini (USP)

Rosane Vianna-Jorge (UFRJ)

Rosely Oliveira Godinho (UNIFESP)

Rui D. S. Prediger (UFSC)

Sandra Aurora C. Perez (FIOCRUZ)

Soraia Katia Costa Pereira (USP)

Stela Maris K. Rates (UFRGS)

Stella Regina Zamuner (UNINOVE)

Tania Araújo Viel (USP)

Teresa C. T. Dalla Costa (UFRGS)

Thereza C. Barja Fidalgo (UERJ)

Valber da Silva Frutuoso (FIOCRUZ)

Valéria do Monti N. Cunha (UFRJ)

Vinicius Frias Carvalho (FIOCRUZ)

Wothan Tavares de Lima (USP)

Yara Cury (Instituto Butantan)

Zuleica Bruno Fortes (USP)

Zulma Silva Ferreira (USP)

### ***On-site Poster Reviewers***

Adair Roberto Soares dos Santos (UFSC)  
Albetiza Lobo Araújo (UNICAMP)  
Aleksander Roberto Zampronio (UFPR)  
Alessandra Beirith (FURB)  
América Scopinho de Oliveira (USP)  
Ana Luisa Palhares de Miranda (UFRJ)  
André Klein (UFMG)  
André Sampaio Pupo (UNESP-Botucatu)  
Andrea Carla Pessini (USP)  
Ângela de Castro Resende (UERJ)  
Bibiana Verlindo de Araújo (UFRGS)  
Bruno S. Herrera (UNESP-Araraquara)  
Caden Souccar (UNIFESP)  
Carolina Baraldi Araújo Restini (USP)  
Carolina Demarchi Munhoz (USP)  
Célia Aparecida Paulino (UNIBAN)  
Christianne Brêtas Vieira Scaramello (UFF)  
Ciomar A. Bersani-Amado (UEM)  
Cláudia F. Benjamim (UFRJ)  
Cláudia Padovan (USP)  
Cláudia do Ó Pessoa (UFC)  
Cristiano Gonçalves Ponte (IFRJ)  
Cristina Antoniali Silva (UNESP-Araçatuba)  
Cristina Bichels Hebeda (USP)  
Cristina Maria Fernandes (Instituto Butantan)  
Cristina Setim Freitas (UFPR)  
Cristóforo Scavone (ICB)  
Daniel Fernandes (UEPG)  
Daniela Dal Secco Abbud (UFSC)  
Daniela de Almeida Cabrini (UFPR)  
Daniella Bonaventura (USP)  
Disney Oliver Sivieri Jr (UFVJM)  
Edna Alves dos Anjos-Valotta (FIOCRUZ)  
Edson Antunes (UNIFESP)  
Eduardo Tamura (USP)  
Edvaldo Rodrigues de Almeida (UFPE)  
Elena Malpezzi-Marinho (UBC)  
Eliana Horomi Akamine (USP)  
Emiliano de Oliveira Barreto (UFAL)  
Enilton Aparecido Camargo (UFS)  
Fabíola de Almeida Brito (UFAL)  
Fabrício Alano Pamplona (UFSC)  
Fernanda B. Marinho Priviero (UNESP-Rio Claro)  
Fernanda Regina Castro Almeida (UFPI)  
Fernando de Queiroz Cunha (USP)  
Flavio Aimberê Soares de Carvalho (UNICASTELO)  
François G. Noel (UFRJ)  
Gilberto de Nucci (UNICAMP/USP)  
Giles A. Rae (UFSC)  
Gloria E. P. de Souza (USP)  
Helena Serra Azul Monteiro (UFC)  
Heloisa Helena Araújo Ferreira (USF)  
Hudson S. Buck (FCMSCSP)  
Hugo Caire de Castro Faria Neto (FIOCRUZ)  
Janetti Nogueira de Francischi (UFMG)  
João Ernesto de Carvalho (UNICAMP)  
José Francisco Fracasso (UNESP-Araraquara)  
Josélia A. Lima (UFRJ)  
Juliano Ferreira (UFSM)  
Laura Letícia Souza (USP)  
Leonardo Resstel Barbosa Moraes (USP)  
Leticia Lintomen (UNICAMP)  
Leticia Veras Costa-Lotufu (UFC)  
Lusiane Maria Bendhack (USP)  
Marcelo Gomes Damário (USP)  
Marcelo N. Muscará (USP)  
Maria de Fátima M. Lazari (UNIFESP)  
Maria Fernanda de Paula Werner (UFPR)  
Maria Martha Campos (PUCRS)  
Marília Zaluar P. Guimarães (UFRJ)  
Michel Fleith Otuki (UFPR)  
Newton G. de Castro (UFRJ)  
Patrícia Torres Bozza (FIOCRUZ)  
Paulo César Ghendini (UFG)  
Paulo de Assis Melo (UFRJ)  
Pedro Augusto Carlos Magno Fernandes (USP)  
Rita Tostes (USP)  
Roberto César Pereira Lima Júnior (UFC)  
Roberto Kenji Nakamura Cuman (UEM)  
Ronaldo A. Ribeiro (UFC)  
Rosa M. Ribeiro do Valle Nicolau (UFSC)  
Rosana I. Reis (USP)  
Rosely Oliveira Godinho (UNIFESP)  
Rui D. S. Prediger (UFSC)  
Sandra Helena P. de Oliveira (UNESP-Araçatuba)  
Silvia Dal Bó (UFSC)  
Simone A. Teixeira (USP)  
Soraia Katia Costa Pereira (USP)  
Stela Maris K Rates (UFRGS)  
Stella Regina Zamuner (UNINOVE)  
Tania Araújo Viel (USP)  
Tarcilia Aparecida Silva (USP)  
Tereza C. T. Dalla Costa (UFRGS)  
Thereza Christina Barja Fidalgo (UERJ)  
Thiago Mattar Cunha (USP)  
Valber da Silva Frutuoso (FIOCRUZ)  
Valéria do Monti N. Cunha (UFRJ)  
Valquíria Camin Bortoli (USP)  
Vinícius Frias Carvalho (FIOCRUZ)  
Waldiceu Aparecido Verri Jr. (UEL)  
Yara Cury (Instituto Butantan)  
Zulma Silva Ferreira (USP)

Informações úteis/Useful Information	8
Schematic Program	9
Scientific Program	
18 October 2010	10
19 October 2010	10
20 October 2010	12
21 October 2010	14
<b>Poster Session 1</b>	
01. Cellular and Molecular Pharmacology (01.001-01.013)	16
02. Neuropharmacology (02.001-02.022)	16
03. Psychopharmacology (03.001-03.012)	18
04. Inflammation (04.001-04.046)	18
05. Pain and Nociception (05.001-05.026)	21
06. Cardiovascular and Renal Pharmacology (06.001-06.026)	23
09. Natural Products and Toxinology (09.001-09.035)	25
11. Clinical Pharmacology, Pharmacokinetics, Pharmacogenomics and Preclinical Toxicology (11.001-11.011)	27
<b>Poster Session 2</b>	
01. Cellular and Molecular Pharmacology (01.014-01.027)	29
02. Neuropharmacology (02.023-02.044)	29
03. Psychopharmacology (03.013-03.024)	31
04. Inflammation (04.047-04.092)	31
05. Pain and Nociception (05.027-05.052)	34
06. Cardiovascular and Renal Pharmacology (06.027-06.052)	36
09. Natural Products and Toxinology (09.036-09.070)	38
11. Clinical Pharmacology, Pharmacokinetics, Pharmacogenomics and Preclinical Toxicology (11.012-11.022)	40
<b>Poster Session 3</b>	
01. Cellular and Molecular Pharmacology (01.028-01.040)	42
02. Neuropharmacology (02.045-02.057)	42
03. Psychopharmacology (03.025-03.036)	43
04. Inflammation (04.093-04.138)	44
05. Pain and Nociception (05.053-05.079)	47
06. Cardiovascular and Renal Pharmacology (06.053-06.089)	49
07. Endocrine and Gastrointestinal Pharmacology (07.001-07.013)	51
08. Respiratory, Urinary and Reproductive (08.001-08.009)	52
09. Natural Products and Toxinology (09.071-09.107)	52
10. Cancer and Cell Proliferation (10.001-10.018)	55
11. Clinical Pharmacology, Pharmacokinetics, Pharmacogenomics and Preclinical Toxicology (11.023-11.034)	56
Lecture Abstracts	58
Author Index	81

### **Painéis**

A Sessão de Painéis será realizada nos dias 19/10 das 18h30 as 20h30; 20/10 das 18h00 as 20h00 e 21/10 das 10h10 as 12h10, períodos em que os autores deverão permanecer ao lado dos painéis. O painel deverá ser afixado no dia da apresentação, às 8h00 da manhã, devendo ser retirado após o encerramento da sessão.

### **Young Investigator Session**

Sessões de apresentação oral com a duração de 1h15. Esta sessão será coordenada por um pesquisador sênior que apresentará o tema e dirigirá as discussões ao final das apresentações, quando será dada oportunidade de debate entre os apresentadores. Após o debate, a sessão será encerrada pelo coordenador, que fará uma breve avaliação da experiência.

### **Certificados:**

*Conferências, simpósios e comunicações orais:* nas salas, no horário de apresentação.

*Pôsteres:* durante a exposição.

*Cursos:* nas salas, no último dia do curso, para alunos que assistiram a no mínimo duas aulas.

### **Media-Desk**

O *Media-Desk* estará funcionando das 08h00 às 18h00.

Os congressistas deverão entregar seu material com duas horas de antecedência.

Todas as salas estarão equipadas com *data show*. Caso haja necessidade de material especial, favor informar no *Media-Desk*.

Congressistas com apresentações marcadas para 08h00 deverão entregar seu material e demais recomendações na véspera de sua apresentação.

### **Secretaria**

A Secretaria estará aberta de 08h00 as 18h00, e contará com um painel para informações, recados e eventuais alterações de programa.

### **Crachás**

O uso de crachá é obrigatório em todas as atividades e em áreas de circulação

No caso de perda será cobrada uma taxa para emissão da segunda via do crachá.

### **Resumos**

Os resumos apresentados nas sessões de painéis estarão disponíveis na Home Page da Sociedade.

<http://www.sbfte.org.br>

## Useful information

### **Media-Desk**

*Media-Desk* will be open from 8 am to 6 pm. Please, leave your material at Media Desk at least two hours before your presentation. All rooms have datashow. If you need any other equipment, please inform Media Desk as soon as possible.

### **Secretariat**

Congress Secretariat will be open from 8 am to 6 pm. A board for messages, changes in the Programs, etc will be available

### **Badges**

Please wear your badge during all venue.

### **Resumos**

Abstracts presented at the poster session will be available at the Society site <http://www.sbfte.org.br>



**18/10/2010 (Monday)**

09h00-12h00	Reunião do Conselho Deliberativo da SBFTE (somente para Membros do Conselho e Diretoria)/Meeting of the Deliberative Council (only for Members of the Council and Society Board)
13h30-16h30	Fórum Permanente de Pós-Graduação em Farmacologia da SBFTE (somente para Representantes dos Programas de Pós-graduação em Farmacologia, Conselho e Diretoria da SBFTE)/SBFTE Permanent Forum of Graduate Programs in Pharmacology (only for Heads of Pharmacology Graduate Programs, Council and Society Board)
14h00	Abertura da Secretaria do Congresso e da SBFTE/ Venue Secretariat and Society Secretariat Opening
19h00-19h30	Opening Session
19h30-20h30	Opening Conference
21h00	Cocktail

**19/10/2010 (Tuesday)**

08h00-09h00	Courses
09h10-10h10	Conferences
10h10-10h30	Coffee-break
10h30-12h00	Symposia
12h10-14h10	Almoço e Pós-graduação / Lunch and Post-graduation
14h20-15h50	Young Investigator Presentation
15h50-16h20	Coffee-break
16h20-18h20	Symposia
18h30-20h30	Posters Session
20h30-22h30	Assembleia Geral da SBFTE / SBFTE General Assembly

**20/10/2010 (Wednesday)**

08h00-09h00	Courses
09h10-10h10	Conference
10h10-10h30	Coffee-break
10h30-12h00	Symposia
12h10-13h50	Almoço e Inovação / Lunch and Innovation
14h00-16h00	José Ribeiro do Valle Award Symposium
16h00-16h20	Coffee-break
16h20-17h50	Symposia
18h00-20h00	Posters Session

**21/10/2009 (Thursday)**

08h00-09h00	Courses
09h10-10h10	Conferences
10h10-12h10	Posters Session & Coffee-break
12h10-13h10	Conferences
13h20-13h40	President's Remarks
13h30	Awarding Session

## **18 October, 2010 (Monday)**

---

**09h00-12h00**

*Room Turquesa*

Reunião do Conselho Deliberativo da SBFTE (somente para Membros do Conselho e Diretoria)/Meeting of the Deliberative Council (only for Members of the Council and Society Board)

**13h30-16h30**

*Room Turquesa*

Fórum Permanente de Pós-Graduação em Farmacologia da SBFTE (somente para Representantes dos Programas de Pós-graduação em Farmacologia, Conselho e Diretoria da SBFTE)/SBFTE Permanent Forum of Graduate Programs in Pharmacology (only for Heads of Pharmacology Graduate Programs, Council and Society Board)

**14h00**

Abertura da Secretaria do Congresso e da SBFTE/Venue Secretariat and Society Secretariat Opening

**19h00-19h30**

*Room Rubi*

**Opening Session**

**19h30-20h30**

*Room Rubi*

**Opening Conference**

Ligand-directed signaling bias and its potential for new therapeutics

Roger J. Summers (Monash Institute, Australia)

Presenter: Jamil Assreuy (UFSC)

**21h00**

**Cocktail**

## **19 October 2010 (Tuesday)**

---

**08h00-09h00**

**Courses**

*Room Ametista*

Pharmacological modulation of memory during aging and neurodegenerative diseases

Chairperson: Hudson de Sousa Buck (FCMSCSP)

- *1<sup>st</sup> Class: Pharmacology of learning and memory formation*

Hudson de Sousa Buck (FCMSCSP)

*Room Topázio*

Writing a scientific paper: theory and practice

Chairperson: Y. S. Bakhle (Imperial College, UK)

- *1<sup>st</sup> Class: Theory on how to write a scientific paper*

Y. S. Bakhle (Imperial College, UK)

*Room Rubi*

Quantitative and qualitative analysis of drug-receptor interactions

Chairperson: André Sampaio Pupo (UNESP-Botucatu)

- *1<sup>st</sup> Class: Theoretical and practical aspects of dose-response curves plotting*

Fernando Morgan de Aguiar Corrêa (USP)

*Room Turquesa*

Biology of kinase proteins: exemplification with the immune system

Chairperson: Daniel Santos Mansur (UFMG)

- *1<sup>st</sup> Class: The proteins kinase and their role in the cellular immune response*

Aristobolo M. Silva (UFMG)

**09h10-10h10**

**Conferences**

*Room Rubi*

Anti-inflammatory GPCRs as targets for novel therapeutics

Mauro Perretti (Queen Mary University of London, UK)

Presenter: Sandra Helena P. Farsky (USP)

*Room Topázio*

Pharmacomimetics of flow-mediated endothelial vasoprotection

**10h10-10h30**

**Coffee-break**

**10h30-12h00**

**Symposia**

*Room Rubi*

G protein coupled receptors as drug targets: the role of G protein coupled receptor kinases (GRKs) beta-arrestins.

Chairperson: Fernando de Queiroz Cunha (USP)

- *Roles of GRKs and beta-arrestins activities in the regulation of  $\beta_2$  adrenergic signaling*

Jamil Assreuy (UFSC)

- *Roles of GRKs and beta-arrestins activities in the regulation of CXCR2 chemotactic receptor signaling during severe sepsis*

José Carlos Alves-Filho (USP)

- *Therapeutic potential of blocking PI3K $\gamma$  in inflammation*

Mauro Martins Teixeira (UFMG)

### Room Ametista

Antioxidants as therapeutic agents in epilepsy, late dyskinesia, inflammation and pain models  
Chairperson: Carlos Fernando de Mello (UFMS)

- *Do antioxidants cause analgesia?*  
Adair Roberto Soares dos Santos (UFSC)
- *Antioxidants as anti-inflammatory agents*  
Juliano Ferreira (UFMS)
- *Can antioxidants prevent dyskinesia?*  
Roberto Frussa-Filho (UNIFESP)

### Room Topázio

Technology transfer x entrepreneurship in the institutions of science and technology  
Chairperson: Claudia do Ó Pessoa (UFC)

- *Binomial of world progress: innovation and entrepreneurship*  
Cristina M. Quintella (UFBA)
- *From idea to the market - The way of innovation to the customer*  
Gerd Wassenberg (Gelsenkirchen University, Germany)
- *Biotechnology innovation in developing countries: products, interaction with universities and funding. Experience of FK-Biotecnologia S.A. in Brazil*  
Fernando Thomé Kreutz (Fk Biotecnologia)

---

### 12h10-14h10

#### Room Topázio

Almoço e Pós-graduação / Lunch and Graduate Programs in Pharmacology

Chairperson: Cristoforo Scavone (USP)

- Benedito H. Machado(USP)
- Jose Cipolla-Neto (ICB-USP)

---

### 14h20-15h50

#### Young Investigator Presentation

#### Room Rubi

New potential pharmacological approaches to treat central nervous system disorders

Chairperson: Francisco Silveira Guimarães (USP)

- 02.023 The selective A-type K<sup>+</sup> current blocker Tx3-1 rescues memory of mice submitted to a model of Alzheimer's disease. Gomes GM<sup>1</sup>, Dalmolin GD<sup>2</sup>, Ferreira J<sup>1</sup>, Gomez MV<sup>2</sup>, Rubin MA<sup>1</sup> <sup>1</sup>UFMSM - Química, <sup>2</sup>UFMG - Farmacologia
- 03.001 Activation of CB1 receptors reduces marble burying behavior in mice. Casarotto PC<sup>1</sup>, Gomes FV<sup>1</sup>, Resstel LBM<sup>1</sup>, Guimarães FS<sup>1</sup> <sup>1</sup>FMRP-USP - Pharmacology
- 02.035 Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease. Barbiero JK, Santiago RM, Lima MMS, Ariza D, Morais LH, Andreatini R, Vital MABF UFPR - Farmacologia
- 02.037 Inhibition of spinal c-Jun-N-terminal kinase (JNK) after spinal cord injury improves

locomotor performance. Martini AC<sup>1</sup>, Forner S<sup>1</sup>, Koepf J<sup>2</sup>, Rae GA<sup>1</sup> <sup>1</sup>UFSC - Pharmacology, <sup>2</sup>UFSC - Chemical and Food Engineering

#### Room Ametista

Clinical Pharmacology, Pharmacokinetics, Pharmacogenomics and Preclinical Toxicology  
Chairperson: Teresa Cristina Tavares Dalla Costa (UFRGS)

- 11.028 Susceptible NOS3 (endothelial nitric oxide synthase) gene haplotypes in hypertension and resistant hypertension. Luizon MR<sup>1</sup>, Sandrim VC<sup>2</sup>, Izidoro-Toledo TC<sup>1</sup>, Coelho EB<sup>3</sup>, Tanus-Santos JE<sup>1</sup> <sup>1</sup>FMRP-USP - Farmacologia, <sup>2</sup>Santa Casa de Belo Horizonte, <sup>3</sup>FMRP-USP - Clínica Médica
- 11.018 Adverse reactions to chemotherapy for breast cancer and impact of genetic polymorphisms. Martins CL<sup>1</sup>, Índio-do-Brasil V<sup>1</sup>, Telles C<sup>1</sup>, Vianna-Jorge R<sup>2</sup>, Koifman S<sup>3</sup> <sup>1</sup>INCa - Farmacologia, <sup>2</sup>UFRJ - Farmacologia Básica e Clínica <sup>3</sup>ENSP-FIOCRUZ -Saúde Pública e Meio Ambiente
- 11.011 Endothelial nitric oxide synthase (ENOS) haplotypes associated with aura in women with migraine. Gonçalves FM<sup>1</sup>, Oliveira AM<sup>2</sup>, Speciali JG<sup>3</sup>, Izidoro-Toledo TC<sup>4</sup>, Silva PS<sup>1</sup>, Dach F<sup>3</sup>, Tanus-Santos JE<sup>4</sup> <sup>1</sup>UNICAMP - Farmacologia, <sup>2</sup>USP - Farmacologia, <sup>3</sup>FMRP - Neurologia, <sup>4</sup>FMRP-USP - Farmacologia
- 11.031 Interference of matrix metalloproteinase (MMP)-9 genotypes and haplotypes in the responsiveness to antihypertensive therapy of patients with preeclampsia or gestational hypertension. Palei ACT<sup>1</sup>, Sandrim VC<sup>2</sup>, Cavalli RC<sup>3</sup>, Gerlach RF<sup>4</sup>, Tanus-Santos JE<sup>5</sup> <sup>1</sup>FCM - UNICAMP - Farmacologia, <sup>2</sup>Santa Casa de Belo Horizonte - Farmacologia, <sup>3</sup>FMRP-USP - Ginecologia e Obstetrícia, <sup>4</sup>FORP-USP - Morfologia, <sup>5</sup>FMRP-USP - Farmacologia

#### Room Topázio

Natural Products

Chairperson: João Batista Calixto (UFSC)

- 09.008 Antinociceptive effect of uliginosin B is mediated by the activation of dopaminergic and opioid systems. Stolz ED<sup>1</sup>, Viana AF<sup>2</sup>, Haas JS<sup>2</sup>, Hasse DR<sup>2</sup>, Von Poser GL<sup>2</sup>, Costentin J<sup>3</sup>, Do Rego JC<sup>3</sup>, Rates SMK<sup>2</sup> <sup>1</sup>UFRGS - Neurociências, <sup>2</sup>UFRGS - Farmácia, <sup>3</sup>Université de Rouen - Neuro-psychopharmacologie Expérimentale
- 09.017 The antinociceptive effect of triterpene 3beta, 6beta, 16beta-trihydroxylup-20(29)-ene against acute and chronic pain in mice: the involvement of glutamatergic system. Longhi-Balbinot DT<sup>1</sup>, Lanznaster D<sup>1</sup>, Martins DF<sup>1</sup>, Villarinho JG<sup>2</sup>, Ferreira J<sup>2</sup>, Facundo VA<sup>3</sup>, Santos ARS<sup>1</sup> <sup>1</sup>UFSC - Ciências Fisiológicas, <sup>2</sup>UFMSM - Química, <sup>3</sup>UNIR - Química
- 09.022 *Lonomia obliqua* venom-induced pro-inflammatory profile in endothelial cell *in vitro*

and increased leukocyte trafficking *in vivo*. Nascimento-Silva V<sup>1</sup>, Rodrigues GS<sup>1</sup>, Moraes JA<sup>1</sup>, Cyrino FZ<sup>2</sup>, Bouskela E<sup>2</sup>, Guimarães JA<sup>3</sup>, Barja Fidalgo TC<sup>1</sup> <sup>1</sup>UERJ – Farmacologia, <sup>2</sup>UERJ – Fisiologia, <sup>3</sup>UFRGS – Farmacologia

- 09.031 Modulation of T lymphocyte and eosinophil functions *in vitro* by natural tetranortriterpenoids isolated from *Carapa guianensis* Aublet. Ferraris FK<sup>1</sup>, Rodrigues R<sup>2</sup>, Silva VP<sup>2</sup>, Figueiredo MR<sup>2</sup>, Penido C<sup>1</sup>, Henriques MGMO<sup>1</sup> – <sup>1</sup>Farmanguinhos-FIOCRUZ – Farmacologia Aplicada, <sup>2</sup>Farmanguinhos-FIOCRUZ – Química de Produtos Naturais

---

### 15h50-16h20

#### Coffee-break

---

### 16h20-18h20

#### Symposia

##### Room Rubi

Brain: where inflammation and neuroscience meet

Chairperson: Mauro M. Teixeira (UFMG)

- *Chemokines and inflammation in the CNS*  
Antonio Lúcio Teixeira (UFMG)
- *Neurochemical and behavioral changes after systemic inflammation and sepsis*  
Felipe dal Pizzol (UNESC)
- *New vistas for an old friend: Lipoxin A4 as an allosteric endocannabinoid in the brain*  
Fabrício Pamplona (UFSC)
- *Stress and inflammation*  
Moises Evandro Bauer (PUCRS)

##### Room Ametista

Body weight: its determinants and its consequences

Chairperson: Rita de C. A. Tostes (USP)

- *The impact of stress on body weight gain*  
Ruth Harris (Medical College of Georgia, EUA)
- *High- or low-salt diet: effect on body weight, food intake and energy balance*  
Joel Claudio Heimann (USP)
- *Hypertension, kidney disease, and cardiovascular outcomes in childhood: is there a role for birth weight*  
Maria do Carmo Pinho Franco (UNIFESP)
- *Metabolic determinants of cardiovascular disease in obesity*  
David Stepp (Medical College of Georgia, EUA)

##### Room Topázio

Diabetes mellitus: mechanisms of vascular dysfunction, risk factor associations and potential treatment targets

Chairperson: Edson Antunes (UNICAMP)

- *Vascular bed specific remodeling in type 2 Diabetes*  
Loren Eugene Wold (Nationwide Children's Hospital, EUA)
- *Vascular reactivity of femoral arteries from diabetic trained rats*

Angelina Zanesco (UNESP-Rio Claro)

- *Potential application of flavonoids in the therapeutics of diabetes mellitus*  
Gabriel Forato Anhô (UNICAMP)
- *Erectile dysfunction and diabetes*  
Kanchan Chitaley (University of Washington, USA)

---

### 18h30-20h30

#### Room Esmeralda

#### Poster Session 1

01. Cellular and Molecular Pharmacology  
01.001 to 01.013
02. Neuropharmacology  
02.001 to 02.022
03. Psychopharmacology  
03.001 to 03.012
04. Inflammation  
04.001 to 04.046
05. Pain and Nociception  
05.001 to 05.026
06. Cardiovascular and Renal Pharmacology  
06.001 to 06.026
09. Natural Products and Toxinology  
09.001 to 09.035
11. Clinical Pharmacology, Pharmacokinetics, Pharmacogenomics and Preclinical Toxicology  
11.001-11.011

---

### 20h30-22h30

#### Room Topázio

Assembleia Geral da SBFTE / SBFTE General Assembly

---

## 20 October, 2010 (Wednesday)

### 08h00-09h00

#### Courses

##### Room Ametista

Pharmacological modulation of memory during aging and neurodegenerative diseases

Chairperson: Hudson de Sousa Buck (FCMSCSP)

- *2nd Class: Neuropharmacological changes along the aging process*  
Tânia Araújo Viel (USP)

##### Room Topázio

Writing a Scientific Paper: Theory and Practice

Chairperson: Y. S. Bakhle (Imperial College, UK)

- *2nd Class: Practical Session 1*  
Y. S. Bakhle (Imperial College, UK)

##### Room Rubi

Quantitative and qualitative analysis of drug-receptor interactions

Chairperson: André Sampaio Pupo (UNESP-Botucatu)

- *2nd Class: Analysis of competitive antagonism*  
André Sampaio Pupo (UNESP-Botucatu)

#### Room Turquesa

Biology of kinase proteins: exemplification with the immune system

Chairperson: Daniel Santos Mansur (UFMG)

- *2ndClass: Pi3kinase and inflammation*  
Remo de Castro Russo (UFMG)

---

#### 09h10-10h10

##### Conferences

#### Room Rubi

Toll-like receptors: emerging roles in reproductive physiology and therapeutics

Mark Hedger (Monash Institute, Australia)

Presenter: Maria Christina W. de Avellar (UNIFESP)

#### Room Topázio

Indoleamine 2,3-dioxygenase (IDO) inhibitors: from bench to bedside.

Andrew L. Mellor (Medical College of Georgia, EUA)

Presenter: Fernando de Queiroz Cunha (USP)

---

#### 10h10-10h30

##### Coffee-break

---

#### 10h30-12h00

##### Symposia

#### Room Rubi

Cannabinoids: pharmacology and cell signaling

Chairperson: Camila Squarzoni Dale (Hospital Sírio Libanês)

- *Novel endogenous peptide agonists of cannabinoid receptors*  
Lakshmi Devi (Mount Sinai School of Medicine, USA)
- *Therapeutic potential and mechanisms of non-psychoactive phytocannabinoids*  
Francisco Silveira Guimarães (USP)
- *Hemopressin: a new target for drug development*  
Camila Squarzoni Dale (Hospital Sírio Libanês)

#### Room Ametista

Computational, structural and ligand-based methods in drug design

Chairperson: Maria Christina W. de Avellar (UNIFESP)

- *Inverse agonism in G-protein coupled receptors (GPCRs) seen in light of classical mechanisms of receptor activation*  
Laerte Oliveira (UNIFESP)
- *Computational chemistry underpinning carbohydrate drug discovery*  
Ivone Carvalho (USP)
- *Structure-based discovery of novel anti-inflammatory protein kinase inhibitors.*  
Carlos Alberto Manssour Fraga (UFRJ)

#### Room Topázio

Muscular atrophy: molecular mechanisms and signaling

Chairperson: Marcelo Damário Gomes (USP) / Rosely Oliveira Godinho (UNIFESP)

- *Skeletal muscle atrophy in heart failure: effect of aerobic exercise training*  
Patricia Chackur Brum (USP)
- *Sympathetic actions on the skeletal muscle protein metabolism.*  
Luiz Carlos Navegantes (USP)
- *New function of the kallikrein system in the muscular atrophy*  
Lucas Tabajara Parreiras e Silva (USP)

---

#### 12h10-13h50

#### Room Topázio

Almoço e Inovação / Lunch and Innovation

Chairperson: Regina P. Markus (USP) / Jamil Assrey (UFSC)

- *Inovação e start-ups no setor biofarmacêutico no Brasil: apresentação de um case*  
Rafael Roesler (UFRGS)
- *Nos rumos da política de inovação no Brasil. Um exemplo de Santa Catarina*  
João Batista Calixto (UFSC)

---

#### 14h00-16h00

#### Room Rubi

##### José Ribeiro do Valle Award Symposium

Chairperson: Jamil Assrey (UFSC)

#### Larissa Staurengo Ferrari

- 05.009 IL-33 receptor deficiency reduces inflammation in septic arthritis in mice. Staurengo-Ferrari L<sup>1</sup>, Cardoso RDR<sup>1</sup>, Xu D<sup>2</sup>, Liew FY<sup>2</sup>, Cunha FQ<sup>3</sup>, Pelayo JS<sup>4</sup>, Saridakis HO<sup>4</sup>, Verri Jr WA<sup>1</sup> <sup>1</sup>UEL – Ciências Patológicas, <sup>2</sup>University of Glasgow – Immunology Infection, Inflammation, <sup>3</sup>FMRP-USP, <sup>4</sup>UEL – Microbiologia, <sup>6</sup>UEL – Ciências Patológicas

#### Amanda Juliana Sales

- 03.015 DNA demethylating agents: new antidepressant drugs? Sales AJ<sup>1</sup>, Biojone C<sup>2</sup>, Gomes MVM<sup>3</sup>, Joca SRL<sup>1</sup> <sup>1</sup>FCFRP-USP – Física e Química, <sup>2</sup>FMRP-USP – Farmacologia, <sup>3</sup>UNOPAR – Genética

#### Vanessa Olzon Zambelli

- 05.028 Peripheral sensitization increases opioid receptor activation and expression in both dorsal root ganglia and nerve paw of rats. Zambelli VO<sup>1</sup>, Gutierrez VP<sup>1</sup>, Fernandes ACO<sup>1</sup>, Parada CA<sup>2</sup>, Cury Y<sup>1</sup> <sup>1</sup>IBu – Dor e Sinalização, <sup>2</sup>UNICAMP – Farmacologia

#### Eduardo Moreira de Oliveira

- 02.052 Relationship of long-term memory evocation and cholinergic markers in hippocampus, along the aging process of rats. Oliveira EM<sup>1</sup>, Souza LHJ<sup>1</sup>, Schowe NM<sup>1</sup>, Albuquerque MS<sup>1</sup>, Baraldi T<sup>1</sup>, Chambergó FS<sup>1</sup>, Pina dos Santos VP<sup>2</sup>, Araújo MS<sup>2</sup>, Buck HS<sup>3</sup>, Viel TA<sup>1</sup> <sup>1</sup>EACH-USP, <sup>2</sup>UNIFESP – Bioquímica, <sup>3</sup>FCMSCSP – Ciências Fisiológicas

Narayana Fazolini P. Bastos

- 10.014 Leptin activates the mTOR pathway in epithelial cells: roles in lipid metabolism, inflammatory mediator production and cell proliferation. Bastos NFP<sup>1</sup>, Viola JPB<sup>2</sup>, Maya-Monteiro CM<sup>1</sup>, Bozza PT<sup>1</sup>. <sup>1</sup>IOC-FIOCRUZ – Imunofarmacologia, <sup>2</sup>INCa – Cellular Biology

---

### 16h00-16h20

#### Coffee-break

---

### 16h20-17h50

#### Symposia

Room Rubi

Calcium Signaling

Chairperson: Lusiane M. Bendhack (USP)

- *Excitation-secretion coupling in Leydig cells*  
Wamberto A. Varanda (USP)
- *Nucleoplasmic calcium regulates cell through legumain*  
Maria de Fátima Leite (UFMG)
- *Physiological and pathological aspects of brain mitochondrial Ca<sup>2+</sup> transport*  
Roger Frigério Castilho (UNICAMP)

Room Ametista

Cell Signaling in Parkinson's disease: from bench to bedside

Chairperson: Rui D. S. Prediger (UFSC)

- *Dopamine turnover following administration of 7-nitroindazole to rats with L-DOPA-induced dyskinesia*  
Elaine A. Del Bel (USP)
- *Brain in movement: the role of physical exercise in Parkinson's disease.*  
Aderbal S. Aguiar-Jr. (UFSC)
- *Behavioral and neurochemical alterations induced by intranasal administration of MPTP, an experimental model of Parkinson's disease, in mice with genetic deletion of the heparin binding growth factors Pleiotrophin and Midkine*  
Rita Raisman-Vozari (Université Pierre et Marie Curie, França)

Room Topázio

Nociceptor models for investigation of toxins from animals and plants

Chairperson: Paulo de Assis Melo (UFRJ) / Marília Zaluar P. Guimarães (UFRJ)

- *Molecular approaches to the study of natural products modulating nociception*  
Marília Zaluar P. Guimarães (UFRJ)
- *Cell and tissue responses to melittin and its antagonist*  
Camila El-Kik (UFRJ)
- *Evaluation of nociception in a model of angioneurotic edema in mice*  
Etyene Castro Dip (UFF)

---

### 18h00-20h00

Room Esmeralda

#### Posters Session 2

01. Cellular and Molecular Pharmacology  
01.014 to 01.027
02. Neuropharmacology  
02.023 to 02.044
03. Psychopharmacology  
03.013 to 03.024
04. Inflammation  
04.047 to 04.092
05. Pain and Nociception  
05.027 to 05.052
06. Cardiovascular and Renal Pharmacology  
06.027 to 06.052
09. Natural Products and Toxinology  
09.036 to 09.070
11. Clinical Pharmacology, Pharmacokinetics, Pharmacogenomics and Preclinical Toxicology  
11.012 to 11.022

---

## 21 October 2010 (Thursday)

---

### 08h00-09h00

#### Courses

Room Ametista

Pharmacological modulation of memory during aging and neurodegenerative diseases

Chairperson: Hudson de Sousa Buck (FCMSCSP)

- *3<sup>rd</sup> Class: Pharmacological modulation of memory process in neurodegenerative diseases.*  
Marelza Andrade Nunes (FCMSCSP)

Room Topázio

Writing a Scientific Paper: Theory and Practice

Chairperson: Y. S. Bakhle (Imperial College, UK)

- *3<sup>rd</sup> Class: Practical Session 2*  
Y. S. Bakhle (Imperial College, UK)

Room Rubi

Quantitative and qualitative analysis of drug-receptor interactions

Chairperson: André Sampaio Pupo (UNESP-Botucatu)

- *3<sup>rd</sup> Class: Functional analysis of dose-response curves*  
Ana Maria de Oliveira (USP)

Room Turquesa

Biology of kinase proteins: exemplification with the immune system

Chairperson: Daniel Santos Mansur (UFMG)

- *3<sup>rd</sup> Class: NFκB and IRF3/7 signaling pathway in the innate immunity*  
Daniel Santos Mansur (UFMG)

---

**09h10-10h10****Conferences***Room Rubi*

The stressed CNS: when glucocorticoids aggravate inflammation.

Javier R. Caso (Stanford University, USA)

Presenter: Carolina Demarchi Munhoz de Souza (USP)

*Room Topázio*

Genetic modeling of PI3K inhibition

Emilio Hirsch (University of Turin, Italy)

Presenter: Fernando de Queiroz Cunha (USP)

---

**10h10-12h10***Room Esmeralda***Poster Session 3 & Coffee-break**

01. Cellular and Molecular Pharmacology  
01.028 to 01.040
  02. Neuropharmacology  
02.045 to 02.057
  03. Psychopharmacology  
03.025 to 03.036
  04. Inflammation  
04.093 to 04.138
  05. Pain and Nociception  
05.053 to 05.079
  06. Cardiovascular and Renal Pharmacology  
06.053 to 06.089
  07. Endocrine and Gastrointestinal  
Pharmacology  
07.001 to 07.013
  08. Respiratory, Urinary and Reproductive  
08.001 to 08.009
  09. Natural Products and Toxinology  
09.071 to 09.107
  10. Cancer and Cell Proliferation  
10.001 to 10.018
  11. Clinical Pharmacology, Pharmacokinetics,  
Pharmacogenomics and Preclinical Toxicology  
11.023 to 11.034
- 

**12h10-13h10****Conferences***Room Topázio*

Chemokines and their receptors: the nexus of neurobiology and immunobiology

Richard Ransohoff (Cleveland Clinic, USA)

Presenter: Mauro M. Teixeira (UFMG)

---

**13h20-13h40****President's Remarks**

---

**13h30****Closing Session****Awarding Session**

## 01. Cellular and Molecular Pharmacology

### 01.001

Pharmacologic evaluation of new alpha-1 adrenoceptor antagonists: structural characteristics of the derivatives N-phenylpiperazines that affect the affinity for alpha-1 adrenoceptors. Nascimento JB<sup>1</sup>, Romeiro LAS<sup>2</sup>, Nascente LC<sup>3</sup>, Lemes LFN<sup>3</sup>, Noel F<sup>1</sup>, Silva CLM<sup>1</sup> <sup>1</sup>UFRJ - Farmacologia Básica e Clínica, <sup>2</sup>FCS-UnB - Desenvolvimento de Estratégias Terapêuticas, <sup>3</sup>UCB-LADETER

### 01.002

Decreased bone resorption by low  $\beta$ 2-adrenergic antagonist. Rodrigues WF<sup>1</sup>, da-Silva-Filho VJ<sup>1</sup>, Campos-Júnior JC<sup>1</sup>, Dias da Silva VJ<sup>2</sup>, Barbosa Neto O<sup>2</sup>, Lopes AHP<sup>1</sup>, Napimoga MH<sup>3</sup> <sup>1</sup>UNIUBE - Biopatologia e Biologia Molecular, <sup>2</sup>UMTM-Fisiologia, <sup>3</sup>UNIUBE - Biologia Celular e Molecular

### 01.003

The lidocaine analogue JMF2-1 prevents allergen-induced lung inflammation without causing immunosuppression. Olsen PC<sup>1</sup>, Ferreira TPT<sup>1</sup>, Serra MF<sup>1</sup>, Costa JCS<sup>2</sup>, Cordeiro RSB<sup>1</sup>, Silva PMR<sup>1</sup>, Martins MA<sup>1</sup> <sup>1</sup>IOC-FIOCRUZ - Inflammation, <sup>2</sup>FIOCRUZ - Farmanguinhos

### 01.004

Pharmacologic evaluation of new alpha adrenoceptor antagonists. Chagas-Silva F<sup>1</sup>, Nascimento JB<sup>1</sup>, Vieira RO<sup>2</sup>, Romeiro LAS<sup>3</sup>, Barberato LC<sup>4</sup>, Noel F<sup>5</sup>, Silva CLM<sup>5</sup> <sup>1</sup>ICB-UFRJ, <sup>2</sup>UFRJ - Farmacologia Celular e Molecular, <sup>3</sup>UCB - Química Bioorgânica e Medicinal, <sup>4</sup>UCB - Desenvolvimento de Estratégias Terapêuticas, <sup>5</sup>UFRJ - Farmacologia Básica e Clínica

### 01.005

Morphological study of protective effect of glutamine and alanil-glutamine injury induced by TxA from *Clostridium difficile* in rat intestinal epithelial cells. Santos AAQA<sup>1</sup>, Leite LL<sup>2</sup>, Brito GAC<sup>3</sup>, Oliveira MR<sup>4</sup>, Ribeiro RA<sup>4</sup>, Braga Neto MB<sup>4</sup>, Barreto LRF<sup>4</sup> <sup>1</sup>UFC - Ciências Médicas, <sup>2</sup>UFC - Medicina, <sup>3</sup>UFC - Morfologia, <sup>4</sup>UFC - Fisiologia e Farmacologia

### 01.006

Effect of annexin-1 derived peptide AC 2-26 on mice pulmonary fibroblasts. Trentin PG<sup>1</sup>, Ferreira TPT<sup>1</sup>, Pires ALA<sup>1</sup>, Ciambarella BT<sup>1</sup>, Flower RJ<sup>2</sup>, Perretti M<sup>2</sup>, Martins MA<sup>1</sup>, Silva PMR<sup>1</sup> <sup>1</sup>FIOCRUZ - Inflamação, <sup>2</sup>William Harvey Institute - Biochemical Pharmacology

### 01.007

Investigation of the binding of trypanosomal FKBP12 to the ryanodine receptor-3 of rat vas deferens: possible implications in heart failure due to Chagas disease. Perissé L<sup>1</sup>, Muzi-Filho H<sup>2</sup>,

Aido-Machado R<sup>1</sup>, Cunha VMN<sup>2</sup>, Salmon DJJ<sup>1</sup> <sup>1</sup>UFRJ - Bioquímica Médica, <sup>2</sup>ICB-UFRJ - Farmacologia Celular e Molecular

### 01.008

Maternal protein deprivation during lactation increases leptin secretion and inhibits apoptosis of thymic cells from young offspring. Salama Rodrigues C<sup>1</sup>, Renovato-Martins M<sup>2</sup>, Vargas da Silva S<sup>1</sup>, Barja Fidalgo TC<sup>1</sup> <sup>1</sup>UERJ - Farmacologia, <sup>2</sup>UERJ - Farmacologia e Psicobiologia

### 01.009

LASSBio-1135: a multi-target antinociceptive imidazopyridinic derivative that is a TRPV1 antagonist. Silva RM<sup>1</sup>, Guimarães MZP<sup>1</sup>, Lima CKF<sup>2</sup>, Lacerda RB<sup>2</sup>, Barreiro EJ<sup>2</sup>, Fraga CAM<sup>2</sup>, Miranda ALP<sup>2</sup> <sup>1</sup>UFRJ - Farmacologia Básica e Clínica, <sup>2</sup>FF-UFRJ - Fármacos - LASSBio

### 01.010

Effect of a new compound, thiophenacetamide, against *Mycobacterium bovis* (BCG) infection. Vergara FMF<sup>1</sup>, Candea ALP<sup>1</sup>, Rosas EC<sup>1</sup>, de Souza MVN<sup>2</sup>, Henriques MGMO<sup>1</sup> <sup>1</sup>FarManguinhos-FIOCRUZ - Farmacologia Aplicada, <sup>2</sup>FarManguinhos-FIOCRUZ - Síntese Orgânica

### 01.011

Anti-inflammatory and antimicrobial activity of pyrazinamide analogs. Mendonça MSA<sup>1</sup>, Candea ALP<sup>1</sup>, Lima CHS<sup>2</sup>, de Souza MVN<sup>2</sup>, Henriques MGMO<sup>2</sup> <sup>1</sup>FIOCRUZ - Farmacologia Aplicada, <sup>2</sup>FarManguinhos-FIOCRUZ - Síntese Orgânica

### 01.012

O-glcNacylation contributes to the vascular effects of ET-1 via activation of the RHOA/RHO-kinase pathway. Lima VV<sup>1</sup>, Giachini FR<sup>1</sup>, Carneiro FS<sup>1</sup>, Webb RC<sup>2</sup>, Tostes RCA<sup>1</sup> <sup>1</sup>USP - Farmacologia, <sup>2</sup>Medical College of Georgia - Physiology

### 01.013

Intravascular danger signals guide neutrophils to sites of sterile inflammation. Menezes GB<sup>1</sup>, Braedon B<sup>2</sup>, Pittman K<sup>2</sup>, Teixeira MM<sup>3</sup>, Kubes P<sup>2</sup> <sup>1</sup>UFMG - Morfologia, <sup>2</sup>University of Calgary - Immunology, <sup>3</sup>UFMG - Bioquímica e Imunologia

## 02. Neuropharmacology

### 02.001

Role of iNOS in the anxiogenic effect induced by withdrawal from chronic ethanol consumption. Padovan D<sup>1</sup>, Silva K<sup>1</sup>, Tirapelli CR<sup>2</sup>, Padovan CM<sup>1</sup> <sup>1</sup>FFCLRP-USP - Psicologia e Educação, <sup>2</sup>EERP-USP - Farmacologia

### 02.002

Role of P2X receptors, glia and gap junction in the modulation of glutamatergic transmission in



NTS neurons projecting to RVLM. Accorsi-Mendonça D, Bonagamba LGH, Leão RX, Machado BH FMRP-USP – Physiology

#### 02.003

Mechanisms involved in the mediation of pressor effects of L-proline injected in the third ventricle of unanesthetized rats. Lopes-Silva S, Scopinho AA, Corrêa FMA USP – Farmacologia

#### 02.004

Central nitric oxide synthase inhibition after 3-amino-1,2,4-triazole into the fourth cerebral ventricle influences parasympathetic response to increase in arterial pressure in spontaneously hypertensive rats. Abreu LC<sup>1</sup>, Valenti VE<sup>2</sup>, Ferreira C<sup>2</sup> <sup>1</sup>FMABC – Morfologia e Fisiologia, <sup>2</sup>UNIFESP – Cardiologia

#### 02.005

Physical exercise reduces motor alterations associated to dopamine receptors imbalance in neurotoxicant models of Parkinson's disease. Aguiar-Jr AS<sup>1</sup>, Boemer G<sup>1</sup>, Rial D<sup>1</sup>, Matheus FC<sup>1</sup>, Moreira ELG<sup>1</sup>, Da Cunha C<sup>2</sup>, Prediger RD<sup>1</sup> <sup>1</sup>UFSC – Farmacologia, <sup>2</sup>UFPR – Farmacologia

#### 02.006

B<sub>1</sub> and B<sub>2</sub> kinin receptors antagonists modulate the bladder overactivity induced by spinal cord injury in rats. Forner S, Andrade EL, Martini AC, Bento AF, Medeiros R, Koepp J, Calixto JB UFSC – Farmacologia

#### 02.007

Involvement of muscarinic receptors of subtype M<sub>2</sub> in the cardiovascular responses of acetylcholine microinjected into lateral periaqueductal gray area of unanesthetized rats. Deolindo MV, Corrêa FMA FMRP-USP Farmacologia

#### 02.008

Intra-bed nucleus of the stria terminalis cannabidiol administration alters cardiovascular changes to acute restraint stress through 5-HT<sub>1A</sub> receptors. Gomes FV, Crestani CC, Alves FHF, Guimarães FS, Corrêa FMA, Resstel LBM FMRP-USP – Farmacologia

#### 02.009

Effect of LASSBio-767 on apoptosis and inhibitory synaptic transmission in neurons. Vieira KST<sup>1</sup>, Fraga CAM<sup>2</sup>, Barreiro EJ<sup>2</sup>, Bolzani V<sup>3</sup>, Castro NG<sup>1</sup> <sup>1</sup>ICB-UFRJ – Farmacologia Molecular, <sup>2</sup>FF-UFRJ – LASSBio, <sup>3</sup>NUBBE-UNESP-Araquara – Química Orgânica

#### 02.010

High and low rearing rats selected in the open field differ in the binding of [<sup>3</sup>H]RO 15-4513 to the limbic cortex. Alves R, Carvalho JGB, Venditti, MAC UNIFESP – Psicobiologia

#### 02.011

LASSBio-579 prevents hyperlocomotion induced by ketamine A behavior suggestive of atypical antipsychotic activity. Antonio CB<sup>1</sup>, Betti AH<sup>1</sup>, Neves G<sup>1</sup>, Hasse DR<sup>2</sup>, Barreiro EJ<sup>3</sup>, Fraga CAM<sup>3</sup>,

Rates SMK<sup>1</sup> <sup>1</sup>UFRGS – Ciências Farmacêuticas, <sup>2</sup>FF-UFRGS – Psicofarmacologia Experimental, <sup>3</sup>FF-UFRJ – LASSBio

#### 02.012

Medial prefrontal cortex CB<sub>1</sub> receptors are involved with modulation of the baroreflex in rats. Ferreira Junior NC, Alves FHF, Fedoce AG, Corrêa FMA, Resstel LBM FMRP-USP – Farmacologia

#### 02.013

Putative role of Bradykinin (BK) in cognitive deficits in rats. Dong KE<sup>1</sup>, Amaral FA<sup>1</sup>, Lemos MTR<sup>1</sup>, Caetano AL<sup>1</sup>, Buck HS<sup>1</sup>, Viel TA<sup>2</sup> <sup>1</sup>FCMSCSP – Ciências Fisiológicas, <sup>2</sup>EACH-USP

#### 02.014

Inhibitory influence of lateral hypothalamus neurotransmission in the cardiac response to fear conditioning to context. Reis DG, Deolindo MV, Guimarães FS, Corrêa FMA, Resstel LBM FMRP-USP

#### 02.015

Evaluation of the effect of a *Hypericum polyanthemum* cyclohexane extract in an animal model of Parkinson disease induced by 6-OHDA. Borsoi M<sup>1</sup>, Betti AH<sup>2</sup>, Batassini C<sup>3</sup>, Silvestrin RB<sup>4</sup>, Lazzaretti C<sup>1</sup>, Pranke M<sup>5</sup>, Antonio CB<sup>2</sup>, Salles LA<sup>5</sup>, Rosa HS<sup>5</sup>, von Poser GL<sup>6</sup>, Rates SMK<sup>2</sup>, Souza TM<sup>3</sup> <sup>1</sup>ICBS-UFRGS, <sup>2</sup>UFRGS – Ciências Farmacêuticas, <sup>3</sup>UFRGS – Bioquímica, <sup>4</sup>ICBS-UFRGS – Neurociências, <sup>5</sup>UFRGS – Farmácia, <sup>6</sup>UFRGS – Produção de Matéria-Prima

#### 02.016

Neuropharmacological profile of parawixin 11, purified from the venom of the social spider *Parawixia bistriata* (Araneae, Araneidae), in Wistar rats. Pereira AC<sup>1</sup>, Cunha AOS<sup>1</sup>, Fachim H<sup>1</sup>, Lopes NP<sup>2</sup>, Santos WF<sup>1</sup> <sup>1</sup>FFCLRP-USP – Biology, <sup>2</sup>USP – Physics and Chemistry

#### 02.017

Involvement of serotonergic and dopaminergic neurotransmission in effect of semi-purified constituent from guaraná seeds in the elevated T maze. Roncon CM, Almeida CB, Mello JCP, Audi EA UEL – Farmácia e Farmacologia

#### 02.018

Kinin receptors blockade ameliorates the neuroinflammation and the clinical severity in experimental autoimmune encephalomyelitis: the dominant role of kinin B<sub>1</sub> receptor. Dutra RC<sup>1</sup>, Leite DFP<sup>1</sup>, Manjavachi MN<sup>1</sup>, Bento AF<sup>1</sup>, Patricio ES<sup>1</sup>, Figueiredo CP<sup>1</sup>, Pesquero JB<sup>2</sup>, Calixto JB<sup>1</sup> <sup>1</sup>UFSC – Farmacologia, <sup>2</sup>UNIFESP – Biofísica

#### 02.019

Dorsal hippocampus glutamate receptors modulate the expression of contextual fear conditioning. Fabri DRS, Reis DG, Hott SC, Corrêa FMA, Resstel LBM FMRP-USP – Farmacologia

## 02.020

Involvement of  $\beta$ -adrenergic receptors in the bed nucleus of the stria terminalis on the expression of contextual fear conditioning. Hott SC, Gomes FV, Reis DG, Fabri DRS, Corrêa FMA, Resstel LBM – Farmacologia

## 02.021

Glutamate and NMDA modulate A2 adrenergic expression in cell cultures of the medulla oblongata of newborn rats. Silva SM<sup>1</sup>, Carrettiero DC<sup>2</sup>, Fior-Chadi DR<sup>1</sup> <sup>1</sup>IB – Fisiologia, <sup>2</sup>UFABC – Ciências Naturais e Humanas

## 02.022

L-arginine into the CA1 hippocampal subfield did not change retention of inhibitory avoidance task in rats. Yoneyama B, Contardi EB, Milani H<sup>1</sup>, Oliveira RMMW UEL – Farmácia e Farmacologia

## 03. Psychopharmacology

### 03.001

Activation of CB1 receptors reduces marble burying behavior in mice. Casarotto PC<sup>1</sup>, Gomes FV<sup>1</sup>, Resstel LBM<sup>1</sup>, Guimarães FS<sup>1</sup> <sup>1</sup>FMRP-USP – Pharmacology

### 03.002

iNOS knockout mice show increased expression of contextual fear conditioning: involvement of nNOS. Lisboa SF<sup>1</sup>, Gomes FV<sup>1</sup>, Cunha TM<sup>1</sup>, Cunha FQ<sup>1</sup>, Guimarães FS<sup>1</sup>, Corrêa FMA<sup>1</sup>, Joca SRL<sup>2</sup>, Resstel LBM<sup>1</sup> <sup>1</sup>FMRP-USP, <sup>2</sup>FCFRP-USP – Física e Química

### 03.003

Evaluation of the anxiolytic activity of the imidazolidinic derivative HPA-14. Carvalho FL<sup>1</sup>, Mota VG<sup>1</sup>, Nóbrega FFF<sup>1</sup>, Salgado PRR<sup>1</sup>, Fonsêca DV<sup>1</sup>, Morais LCSL<sup>1</sup>, Souza SA<sup>2</sup>, Athayde-Filho PF<sup>2</sup> <sup>1</sup>UFPB – Pharmaceutical Technology, <sup>2</sup>UFPB – Chemistry

### 03.004

Effects of hippocampal iNOS or nNOS inhibition in models of anxiety and depression. Sato VAH<sup>1</sup>, Sales AJ<sup>2</sup>, Joca SRL<sup>2</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>FCFRP-USP – Física e Química

### 03.005

Intra-hippocampal injection of cannabidiol induces antidepressant-like effect in the rat forced swimming test. Biojone C<sup>1</sup>, Silva M<sup>1</sup>, Moreira FA<sup>2</sup>, Guimarães FS<sup>1</sup>, Joca SRL<sup>3</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>ICB-UFMG – Farmacologia, <sup>3</sup>FCFRP-USP – Física e Química

### 03.006

Systemic inhibition of inducible NO synthase (iNOS) evokes antidepressant-like effects. Montezuma K<sup>1</sup>, Biojone C<sup>2</sup>, Guimarães FS<sup>2</sup>, Joca SRL<sup>1</sup> <sup>1</sup>FCFRP-USP – Física e Química, <sup>2</sup>FMRP-USP – Farmacologia

## 03.007

Shock intensity and duration: importance to induce learned helplessness in rats. Donadon MF, Padovan CM FFCLRP-USP – Psicologia e Educação

## 03.008

Cannabidiol attenuates MCPP-induced increase in marble burying behavior. Nardo M, Casarotto PC, Guimarães FS FMRP-USP

## 03.009

Withdrawal from methylphenidate increases neural reactivity of dorsal midbrain. Ferreira R, Shimizu-Bassi G, Nobre MJ FFCLRP-USP – Psicologia e Educação

## 03.010

Truck drivers take indiscriminated use of amphetamines concomitant with toxic substances. Vieira BAC<sup>1</sup>, Souza LA<sup>2</sup>, Marques CD<sup>2</sup>, Salomão PAV<sup>2</sup>, Souza CL<sup>3</sup> <sup>1</sup>CEUNSP, <sup>2</sup>CEUNSP – Farmácia, <sup>3</sup>CEUNSP – Nutrição

## 03.011

Effects of anti-inflammatory and antidepressant strategies on depressive-like behavior in complete Freund's adjuvant (CFA)-treated mice. Maciel IS<sup>1</sup>, Silva RBM<sup>1</sup>, Calixto JB<sup>2</sup>, Morrone FB<sup>3</sup>, Campos MM<sup>4</sup> <sup>1</sup>PUCRS – Farmacologia, <sup>2</sup>UFSC – Farmacologia, <sup>3</sup>PUCRS – Farmácia, <sup>4</sup>PUCRS – Cirurgia-Odontologia

## 03.012

One trial tolerance phenomenon to benzodiazepines: contribution of dorsal hippocampus protein synthesis. Gazarini L, Stern CAJ, Bertoglio LJ UFSC – Farmacologia

## 04. Inflammation

### 04.001

Nitroxides regulate protein phosphorylation linked to NOX2 complex activity in neutrophils: prototype of a new anti-inflammatory. Ribeiro ACG<sup>1</sup>, Chavasco LS<sup>1</sup>, Santos GB<sup>1</sup>, Cardoso MHM<sup>2</sup>, Brigagão MRPL<sup>1</sup> <sup>1</sup>UNIFAL – Ciências Exatas, <sup>2</sup>UNIFAL – Farmácia

### 04.002

Periodontitis induces functional alterations in rat aorta. Campi P<sup>1</sup>, Ceravolo GS<sup>1</sup>, Martins Porto R<sup>1</sup>, Maia-Dantas A<sup>1</sup>, Yamamoto, M<sup>1</sup>, Teixeira SA<sup>1</sup>, Carvalho MHC<sup>1</sup>, Herrera BS<sup>2</sup>, Costa SKP<sup>1</sup>, Spolidório LC<sup>3</sup>, Muscará MN<sup>1</sup> <sup>1</sup>ICB-USP Farmacologia, <sup>2</sup>FO-UNESP – Patologia, <sup>3</sup>UNESP – Patologia

### 04.003

Effect of ovariectomy on LPS-induced acute lung inflammation in female mice. Gimenes-Júnior JA<sup>1</sup>, Ligeiro de Oliveira AP<sup>2</sup>, Vitoretto LB<sup>1</sup>, Domingos HV<sup>1</sup>, Oliveira-Filho RM<sup>1</sup>, Vargaftig BB<sup>1</sup>, Tavares de Lima W<sup>1</sup> <sup>1</sup>ICB-USP – Pharmacology, <sup>2</sup>ICB-USP – Immunology

**04.004**

Initial characterization of toll-like receptor (TLR)4 signaling pathway on pollutant-induced increased neonate mice susceptibility to asthma. Santos KT<sup>1</sup>, Florenzano J<sup>1</sup>, Peron JPS<sup>2</sup>, Muscará MN<sup>1</sup>, Rizzo LV<sup>2</sup>, Costa SKP<sup>1</sup> <sup>1</sup>ICB-USP – Farmacologia, <sup>2</sup>ICB-USP – Imunologia

**04.005**

Platelet activating factor participate in the control of adiposity and inflammatory process in epididymal adipose tissues of mice fed with palatable diet. Menezes Z<sup>1</sup>, Oliveira MC<sup>1</sup>, Shang, FLT<sup>1</sup> Lima RL<sup>2</sup>, Teixeira MM<sup>2</sup>, Ferreira AVM<sup>3</sup>, Souza DG<sup>1</sup> <sup>1</sup>UFMG – Microbiologia, <sup>2</sup>ICB-UFMG, <sup>3</sup>UFMG – Enfermagem e Nutrição

**04.006**

Anti-inflammatory properties of fullerol in irinotecan-induced intestinal mucositis in mice. Arifa RDN<sup>1</sup>, Madeira MFM<sup>1</sup>, de Paula TP<sup>1</sup>, Ávila TV<sup>2</sup>, Souza DG<sup>1</sup>, Menezes Z<sup>3</sup>, Lima RL<sup>4</sup> <sup>1</sup>UFMG – Microbiologia, <sup>2</sup>UFPR – Farmacologia, <sup>3</sup>UFMG – Fisiologia e Farmacologia, <sup>4</sup>ICB-UFMG

**04.007**

The role of 5-lipoxygenase in an experimental periodontal disease by *Aggregatibacter actinomycetemcomitans* in a murine model. Madeira MFM<sup>1</sup>, Silva TA<sup>2</sup>, Corrêa JD<sup>3</sup>, Mitre GC<sup>1</sup>, Marprates CVB<sup>1</sup>, Souza DG<sup>1</sup> <sup>1</sup>UFMG – Microbiologia, <sup>2</sup>UFMG – Patologia, Clínica e Cirurgia Odontológicas, <sup>3</sup>UFMG – Farmacologia

**04.008**

Microspheres loading prostanoids as modulators of phagocytosis. Pereira PAT<sup>1</sup>, Gelfuso GM<sup>1</sup>, Santos DF<sup>1</sup>, Nicolete R<sup>2</sup>, Bitencourt CS<sup>1</sup>, Faccioli LH<sup>1</sup> <sup>1</sup>FCFRP – Análises Clínicas, Toxicológicas e Bromatológicas, <sup>2</sup>UNICEUMA

**04.009**

Evidence of adenosine receptors in the inosine anti-inflammatory effects in a murine model of ovalbumin-induced asthma. Lapa FR<sup>1</sup>, Ligeiro de Oliveira AP<sup>2</sup>, Golega BA<sup>2</sup>, Tavares de Lima W<sup>2</sup>, Cabrini DA<sup>1</sup>, Santos ARS<sup>3</sup> <sup>1</sup>UFPR – Farmacologia, <sup>2</sup>ICB-USP – Farmacologia, <sup>3</sup>UFSC – Ciências Fisiológicas

**04.010**

Role of inflammatory chemokines and their decoy receptor D6 in modulation of the inflammatory response associated with murine GVHD. Castor MGM<sup>1</sup>, Rezende B<sup>2</sup>, Bernardes PTT<sup>3</sup>, Reis AC<sup>3</sup>, Teixeira MM<sup>2</sup>, Locati M<sup>4</sup>, Pinho V<sup>2</sup> <sup>1</sup>UFMG – Fisiologia e Farmacologia, <sup>2</sup>ICB-UFMG – Bioquímica e Imunologia / Morfologia, <sup>3</sup>ICB-UFMG – Morfologia, <sup>4</sup>Università di Milano

**04.011**

Exacerbation of dengue disease by the blockage of NADPH-oxidase complex and nitric oxide production. Avila TV<sup>1</sup>, Costa VV<sup>1</sup>, Fagundes CT<sup>1</sup>, Silveira KD<sup>2</sup>, Morcatty TQ<sup>1</sup>, Valadão DF<sup>1</sup>, Santos AG<sup>1</sup>, Prospero T<sup>1</sup>, Souza DG<sup>1</sup>, Silva TA<sup>1</sup>, Teixeira

MM<sup>2</sup> Souza DG<sup>1</sup> <sup>1</sup>UFMG – Microbiologia, <sup>2</sup>UFMG – Bioquímica e Imunologia

**04.012**

Change of skeletal muscle caffeine-induced contracture by sepsis. Pachá BP<sup>1</sup>, Borges RS<sup>1</sup>, Rico, T B<sup>2</sup>, Carmo PL<sup>1</sup>, Benjamim CF<sup>2</sup>, Zapata-Sudo G<sup>1</sup>, Sudo RT<sup>1</sup> <sup>1</sup>UFRJ – FÁRMACOS, <sup>2</sup>UFRJ – Farmacologia Celular e Molecular

**04.013**

Evaluation of mechanisms of action of fatty acids from vegetables oils on wound healing. Brogliato AR<sup>1</sup>, Figueiredo JB<sup>2</sup>, Branco AMC<sup>1</sup>, Almendra LR<sup>2</sup>, Martins V<sup>1</sup>, Monte-Alto-Costa A<sup>3</sup> Benjamim CF<sup>4</sup> <sup>1</sup>UFRJ – Farmacologia, <sup>2</sup>ICB-UFRJ, <sup>3</sup>UERJ – Histologia e Embriologia, <sup>4</sup>UFRJ – Farmacologia Básica e Clínica

**04.014**

Cooperative DP1- and CRTH2-activated signaling is required to elicit enhanced leukotriene C<sub>4</sub> synthesis induced by prostaglandin D<sub>2</sub> within eosinophils. Mesquita-Santos FP<sup>1</sup>, Bakker-Abreu I<sup>2</sup>, Luna-Gomes T<sup>2</sup>, Bozza PT<sup>3</sup>, Diaz BL<sup>2</sup>, Bandeira-Melo C<sup>2</sup> <sup>1</sup>UFRJ / FIOCRUZ – Inflamação / Imunofarmacologia, <sup>2</sup>IBCCF-UFRJ – Inflamação, <sup>3</sup>FIOCRUZ – Imunofarmacologia

**04.015**

L-arginine up-regulated and protects the skeletal muscle tissue after resistance training for production of collagen, TGF- $\beta$  and decreased TNF- $\alpha$ . Morais, SRL<sup>2</sup>, Mello, WG<sup>2</sup>, Oliveira SHP<sup>1</sup> – <sup>1</sup>UNESP-Araçatuba – Farmacologia, <sup>2</sup>UNESP-Araçatuba – Fisiologia

**04.016**

Effects of resveratrol on the pruritogenic and inflammatory events evoked by trypsin in mice. Lazarotto LF<sup>1</sup>, Pereira PJS<sup>2</sup>, Souto AA<sup>3</sup>, Campos MM<sup>4</sup>, Morrone FB<sup>3</sup> <sup>1</sup>PUCRS – Farmácia, <sup>2</sup>PUCRS – Medicina e Ciências da Saúde, <sup>3</sup>PUCRS – Biologia Celular e Molecular, <sup>4</sup>PUCRS – Cirurgia-Odontologia

**04.017**

Evaluation of selective phosphatidylinositol-3 Kinase inhibitors in the inflammatory, nociceptive and pruritogenic responses induced by different agents in mice. Pereira PJS<sup>1</sup>, Lazarotto LF<sup>2</sup>, Leal PC<sup>3</sup>, Calixto JB<sup>4</sup>, Morrone FB<sup>5</sup>, Campos MM<sup>6</sup> <sup>1</sup>PUCRS – Medicina e Ciências da Saúde, <sup>2</sup>PUCRS – Farmácia, <sup>3</sup>QMC-CFM-UFSC, <sup>4</sup>UFSC – Farmacologia, <sup>5</sup>PUCRS – Biologia Celular e Molecular, <sup>6</sup>PUCRS – Cirurgia-Odontologia

**04.018**

Effect of Annexin-1 derived peptide AC2-26 on allergic lung inflammation in mice. Matheus-Souza D<sup>1</sup>, Trentin PG<sup>2</sup>, Arantes ACS<sup>2</sup>, Ferreira TPT<sup>2</sup>, Pires ALA<sup>2</sup>, Flower RJ<sup>3</sup>, Perretti M<sup>3</sup>, Martins MA<sup>2</sup>, Silva PMR<sup>2</sup> <sup>1</sup>FIOCRUZ – Inflamação, <sup>2</sup>IOC-FIOCRUZ – Fisiologia e Farmacodinâmica, <sup>3</sup>William Harvey Institute – Biochemical Pharmacology

**04.019**

Effects of an anti-TNF- $\alpha$  therapy on *Aggregatibacter actinomycetemcomitans*-induced alveolar bone loss in mice with experimental arthritis. Queiroz Júnior CM<sup>1</sup>, Coelho FM<sup>2</sup>, Madeira MFM<sup>3</sup>, Candico LCM<sup>2</sup>, Sousa LFC<sup>2</sup>, Teixeira MM<sup>2</sup>, Souza DG<sup>3</sup>, Silva TA<sup>4</sup> <sup>1</sup>UFMG – Farmacologia, <sup>2</sup>UFMG – Bioquímica e Imunologia, <sup>3</sup>UFMG – Microbiologia, <sup>4</sup>UFMG – Patologia, Clínica e Cirurgia Odontológicas

**04.020**

Pancreatic injection of phospholipases A<sub>2</sub> causes abdominal hyperalgesia mediated by NK-1 receptors without leading to systemic toxicity in rats. Zanoni CIS<sup>1</sup>, Camargo E<sup>2</sup>, Teixeira SA<sup>1</sup>, Martins Porto R<sup>1</sup>, Santos KT<sup>1</sup>, Florenzano J<sup>1</sup>, Muscará MN<sup>1</sup>, Costa SKP<sup>1</sup> – <sup>1</sup>USP – Farmacologia, <sup>2</sup>UFS – Fisiologia

**04.021**

Amphetamine decreases inflammation and TH2-cytokines production in murine model of asthma. Hamasato EK<sup>1</sup>, Ribeiro A<sup>1</sup>, Ferraz-de-Paula V<sup>1</sup>, Pinheiro ML<sup>1</sup>, Ligeiro de Oliveira AP<sup>2</sup>, Palermo-Neto J<sup>1</sup> <sup>1</sup>FMVZ-USP – Patologia, <sup>2</sup>ICB-USP – Imunologia

**04.022**

Intravital imaging by confocal and multiphoton microscopy: a new tool for understanding dengue pathogenesis. Santos AG<sup>1</sup>, Costa VV<sup>2</sup>, Menezes GB<sup>3</sup>, Fagundes CT<sup>2</sup>, Paula AM<sup>4</sup>, Valadão DF<sup>1</sup>, Morcatty TQ<sup>2</sup>, Vilela MC<sup>5</sup>, Pinho V<sup>2</sup>, Teixeira MM<sup>2</sup> Souza DG<sup>1</sup> <sup>1</sup>UFMG – Microbiologia, <sup>2</sup>UFMG – Bioquímica e Imunologia, <sup>3</sup>UFMG – Patologia Geral, <sup>4</sup>UFMG – Física, <sup>5</sup>ICB-UFMG

**04.023**

Effects of formaldehyde inhalation on allergic lung inflammation: role of female sex hormones. Amemiya RM, Lino dos Santos Franco A, Ligeiro de Oliveira AP, Oliveira-Filho RM, Tavares de Lima W USP – Pharmacology

**04.024**

Phospholipase A<sub>2</sub> group V in leishmaniasis: role in immunity. Zamith-Miranda D<sup>1</sup>, Pouban LE<sup>1</sup>, Araújo Souza PS<sup>2</sup>, Siqueira EA<sup>1</sup>, Viola JPB<sup>2</sup>, Diaz BL<sup>3</sup> <sup>1</sup>UFRJ-IBCCF, <sup>2</sup>INCa – Biologia Celular, <sup>3</sup>IBCCF-UFRJ – Imunobiologia

**04.025**

Role of 5-Lipoxygenase products in acute respiratory distress syndrome induced by severe sepsis. Monteiro APT<sup>1</sup>, Pinheiro CS<sup>1</sup>, Benjamim CF<sup>2</sup>, Soledade ES<sup>3</sup>, Rocco PRM<sup>4</sup>, Canetti C<sup>1</sup> <sup>1</sup>IBCCF-UFRJ, <sup>2</sup>UFRJ – Farmacologia Básica e Clínica, <sup>3</sup>UFRJ – Farmacologia, <sup>4</sup>UFRJ – Investigação Pulmonar

**04.026**

Rosiglitazone potentiates alveolar bone loss due to ligature-induced periodontitis in rats. Martins Porto R<sup>1</sup>, Teixeira SA<sup>1</sup>, Maia-Dantas A<sup>1</sup>, Herrera BS<sup>2</sup>, Campi P<sup>2</sup>, Costa SKP<sup>1</sup>, Nucci G<sup>3</sup>, Spolidório

LC<sup>2</sup>, Muscará MN<sup>1</sup> <sup>1</sup>ICB-USP – Farmacologia, <sup>2</sup>FO-UNESP – Patologia, <sup>3</sup>UNICAMP

**04.027**

Ligature-induced periodontal disease affects salivation and saliva composition in rats. Maia-Dantas A<sup>1</sup>, Campi P<sup>1</sup>, Martins Porto R<sup>1</sup>, Teixeira SA<sup>1</sup>, Herrera BS<sup>2</sup>, Costa SKP<sup>1</sup>, Spolidório LC<sup>2</sup>, Muscará MN<sup>1</sup> <sup>1</sup>USP – Farmacologia, <sup>2</sup>UNESP – Patologia

**04.028**

Reparixin, via CXCR1/CXCR2, does not reduce fever induced by PGE<sub>2</sub> mediators. Yamashiro LH<sup>1</sup>, Soares DM<sup>1</sup>, Melo MCC<sup>2</sup>, Teixeira MM<sup>3</sup>, Souza GEP<sup>2</sup> <sup>1</sup>USP – Farmacologia, <sup>2</sup>FCFRP-USP – Física e Química, <sup>3</sup>UFMG

**04.029**

Essential oil of *Mansoa standleyi* exerts anti-inflammatory effect by inhibition of macrophage activity. Santos IVF<sup>1</sup>, Magalhães RC<sup>1</sup>, Nascimento MVL<sup>1</sup>, Zoghbi MGB<sup>2</sup>, Maués LAL<sup>1</sup>, Bastos GNT<sup>1</sup>, Do Nascimento JLM<sup>1</sup> <sup>1</sup>UFPA – Neuroquímica Molecular e Celular, <sup>2</sup>Museu Emilio Goeldi

**04.030**

Efficacy of H<sub>2</sub>S in the management of pruritus and oedema evoked by different mediators in the mouse skin. Rodrigues L<sup>1</sup>, Florenzano J<sup>1</sup>, Ekundi-Valentim E<sup>1</sup>, Teixeira SA<sup>1</sup>, Muscará MN<sup>1</sup>, Costa SKP<sup>1</sup> <sup>1</sup>USP – Pharmacology

**04.031**

Anti-inflammatory activity of new isatin derivatives. Zardo RS<sup>1</sup>, Figueiredo GSM<sup>2</sup>, Silva BV<sup>3</sup>, Matheus ME<sup>1</sup>, Pinto AC<sup>4</sup>, Fernandes PD<sup>1</sup> <sup>1</sup>UFRJ – Farmacologia Básica e Clínica, <sup>2</sup>ICB-UFRJ – Farmacologia, <sup>3</sup>IQ-UFRJ – Química Orgânica, <sup>4</sup>UFRJ – Química

**04.032**

Lipopolysaccharide stimulates NF $\kappa$ B and glucocorticoid receptor translocation to the nucleus of A7r5 rat smooth muscle cells. Scheschowitsch K, DalBó S, Assreuy J UFSC – Pharmacology

**04.033**

Nicotinic receptors modulate IL-12 production by dendritic cell. Pinheiro ML, Ribeiro A, Ferraz-de-Paula V, Quinteiro-Filho WM, Palermo-Neto J FMVZ-USP – Patologia

**04.034**

The role of suppressor of cytokine signaling 2 (SOCS-2) in an experimental pulmonary disease by pathogenic fungus *Paracoccidioides brasiliensis*. Santos PC<sup>1</sup>, Santos DA<sup>1</sup>, Machado FS<sup>2</sup>, Souza DG<sup>1</sup> Cisalpino PS<sup>1</sup> <sup>1</sup>UFMG – Microbiologia, <sup>2</sup>UFMG – Bioquímica e Imunologia

**04.035**

Lipoxin A<sub>4</sub> attenuates zymosan-induced arthritis modulating endothelin-1 effects. Conte FP<sup>1</sup>, Menezes-de-Lima Jr O<sup>1</sup>, Verri Jr WA<sup>2</sup>, Cunha FQ<sup>3</sup>, Penido C<sup>1</sup>, Henriques MGMO<sup>1</sup> <sup>1</sup>FIOCRUZ –

Farmacologia Aplicada, <sup>2</sup>UEL - Ciências Patológicas, <sup>3</sup>FMRP-USP

#### 04.036

Anti-hypernociceptive and anti-oedematogenic properties of bis selenide in inflammatory models in mice. Jesse CR<sup>1</sup>, Wilhelm EA<sup>2</sup>, Bortolatto CF<sup>2</sup>, Nogueira CW<sup>2</sup> <sup>1</sup>UNIPAMPA - Nutrição, <sup>2</sup>UFSM - Química

#### 04.037

Effects of hydroquinone inhalation on functions of tracheal tissue. Shimada ALB<sup>1</sup>, Ribeiro ALT<sup>1</sup>, Hebeda CB<sup>1</sup>, Bolonheis SM<sup>1</sup>, Lino dos Santos Franco A<sup>2</sup>, Tavares de Lima W<sup>2</sup>, Farsky S<sup>2</sup> <sup>1</sup>USP-Análises Clínicas e Toxicológicas, <sup>2</sup>USP - Farmacologia

#### 04.038

An exploratory study of H<sub>2</sub>S-releasing enzymes in rat synovial tissue. Ekundi-Valentim E, Rodrigues L, Teixeira SA, Munhoz CD, Muscará MN, Costa SKP ICB-USP - Farmacologia

#### 04.039

Effects of endogenous glucocorticoid and TSP0 ligands on L-selectin expression in rat lymphocytes. Lima CB<sup>1</sup>, Palermo-Neto J<sup>2</sup>, Farsky S<sup>1</sup> <sup>1</sup>FCF-USP - Experimental Toxicology, <sup>2</sup>FMVZ-USP - Neuroimmunomodulation

#### 04.040

Cellular influx and vascular permeability are modulated differentially by formaldehyde exposure in a rat model of allergic lung inflammation. Lino dos Santos Franco A, Amemiya RM, Domingos HV, Ligeiro de Oliveira AP, Breithaupt-Faloppa AC, Oliveira-Filho RM, Tavares de Lima W USP - Pharmacology

#### 04.041

Cannabidiol, a nonpsychotropic plant-derived cannabinoid, decreases inflammation and alters leukocyte distribution in a murine model of acute lung injury. Ribeiro A<sup>1</sup>, Ferraz-de-Paula V<sup>1</sup>, Pinheiro ML<sup>1</sup>, Zager A<sup>1</sup>, Hallak JEC<sup>2</sup>, Zuardi AW<sup>2</sup>, Crippa JA<sup>2</sup>, Palermo-Neto J<sup>1</sup> <sup>1</sup>FMVZ-USP - Patologia, <sup>2</sup>FMRP-USP - Neurologia, Psiquiatria e Psicologia Médica

#### 04.042

FPR2/ALX agonist modulates neutrophil migration in mouse air pouch. Sordi R<sup>1</sup>, Della Justina AM<sup>1</sup>, Menezes de Lima Jr O<sup>2</sup>, Fernandes D<sup>3</sup>, Assreuy J<sup>1</sup> <sup>1</sup>UFSC - Farmacologia, <sup>2</sup>FIOCRUZ - Farmacologia, <sup>3</sup>UEPG - Ciências Farmacêuticas

#### 04.043

The role of CXCR2 in mediating neutrophil accumulation in liver microvasculature depends on the nature of the stimulus. Barroso LC<sup>1</sup>, Paula AM<sup>2</sup>, Teixeira MM<sup>1</sup>, Menezes GB<sup>1</sup> <sup>1</sup>UFMG - Bioquímica e Imunologia, <sup>2</sup>UFMG - Física

#### 04.044

Participation of PI3K/AKT pathway in the pathogenesis of dengue virus infection. Valadão

DF<sup>1</sup>, Costa VV<sup>1</sup>, Santos AG<sup>1</sup>, Morcatty TQ<sup>2</sup>, Fagundes CT<sup>2</sup>, Cisalpino D<sup>2</sup>, Silveira KD<sup>3</sup>, Ávila TV<sup>4</sup>, Sousa LP<sup>5</sup>, Tavares LD<sup>4</sup>, Teixeira MM<sup>2</sup>, Souza DG<sup>1</sup> <sup>1</sup>UFMG - Microbiologia, <sup>2</sup>UFMG - Bioquímica e Imunologia, <sup>3</sup>UFMG - Fisiologia e Biofísica, <sup>4</sup>UFMG - Fisiologia e Farmacologia, <sup>5</sup>UFMG - Patologia Clínica

#### 04.045

Blockade of angiotensin converting enzyme and AT<sub>1</sub> receptor in T cells during malaria infection: mechanisms of t-cell regulation mediated by angiotensin II. Silva-Filho JL<sup>1</sup>, Morrot A<sup>2</sup>, Costa MFS<sup>3</sup>, Souza MC<sup>3</sup>, Henriques MGMO<sup>3</sup>, Savino W<sup>4</sup>, Caruso-Neves C<sup>1</sup>, Pinheiro AAS<sup>1</sup> <sup>1</sup>BCCF-UFRJ - Ciências da Saúde, <sup>2</sup>FIOCRUZ - Imunologia, <sup>3</sup>FIOCRUZ - Tecnologia em Fármacos, <sup>4</sup>FIOCRUZ - Pesquisa Sobre o Timo

#### 04.046

Immature thymocytes are released into the periphery of *Trypanosoma cruzi* acutely infected mice by a S1P-dependent mechanism. Lepletier A<sup>1</sup>, Borja GP<sup>2</sup>, Einicker-Lamas M<sup>3</sup>, Silva Barbosa SD<sup>1</sup>, Perez AR<sup>4</sup>, Terra-Granado E<sup>1</sup>, Carvalho CE<sup>1</sup>, Melendes A<sup>5</sup>, Savino W<sup>6</sup>, Morrot A<sup>1</sup> <sup>1</sup>FIOCRUZ - Imunologia, <sup>2</sup>UFRJ - Imunologia e Microbiologia, <sup>3</sup>BCCF-UFRJ, <sup>4</sup>Universidade Nacional de Rosario, <sup>5</sup>Glasgow University - Biomedical Research, <sup>6</sup>FIOCRUZ - Pesquisa Sobre o Timo

## 05. Pain and Nociception

#### 05.001

The involvement of TRPA1 receptors in the induction and maintenance of prostaglandin-induced hyperalgesia. Bonet IJM<sup>1</sup>, Dall'Acqua M<sup>2</sup>, Zampronio AR<sup>3</sup>, Tambeli CH<sup>1</sup>, Parada CA<sup>4</sup>, Fischer L<sup>2</sup> <sup>1</sup>FOP-UNICAMP - Ciências Fisiológicas, <sup>2</sup>UFPR - Fisiologia, <sup>3</sup>UFPR - Farmacologia, <sup>4</sup>UNICAMP - Farmacologia

#### 05.002

Evaluation of the involvement of kinin receptors in the nociceptive behavior of mice submitted to the brachial plexus avulsion. Jorge IP<sup>1</sup>, Quintão NLM<sup>2</sup> <sup>1</sup>CCS-UNIVALI, <sup>2</sup>UNIVALI - Ciências Farmacêuticas

#### 05.003

Mechanisms underlying the scratching behavior induced by the activation of proteinase activated receptor-4 (PAR-4) in mice. Patricio ES, Costa R, Figueiredo CP, Motta EM, Calixto JB UFSC - Farmacologia

#### 05.004

Inflammatory muscle hypernociception depends on activation of ERK and NF-κB signaling pathways. Lima FO<sup>1</sup>, Verri Jr WA<sup>2</sup>, Ribeiro dos Santos R<sup>3</sup>, Soares MBP<sup>3</sup>, Villarreal CF<sup>4</sup> <sup>1</sup>UEFS - Biotecnologia, <sup>2</sup>UEL - Ciências Patológicas, <sup>3</sup>CPqGM-FIOCRUZ-Bahia, <sup>4</sup>USP - Farmacologia

**05.005**

Contribution of vanilloid receptor to the nociception induced by peripheral injection of spermine in mice. Gewehr CCV<sup>1</sup>, Silva, MA da<sup>2</sup>, Trevisan, G<sup>2</sup>, Rossato M<sup>2</sup>, Drewes, CC<sup>4</sup>, Guerra GP<sup>2</sup>, Rubin MA<sup>2</sup>, Ferreira J<sup>2</sup> <sup>1</sup>UFMSM – Fisiologia e Farmacologia, <sup>2</sup>UFMSM – Química, <sup>3</sup>USP – Toxicologia e Análises Toxicológicas

**05.006**

Cnidaria venom as pharmacological tool for studying the signaling pathways of pain and its control. Ferreira-Junior WA<sup>1</sup>, Zaharenko AJ<sup>2</sup>, Fernandes ACO<sup>1</sup>, Zambelli VO<sup>1</sup>, Gutierrez VP<sup>1</sup>, Konno K<sup>3</sup>, Tytgat<sup>4</sup>, Picolo G<sup>1</sup>, Cury Y<sup>1</sup> <sup>1</sup>IBu – Dor e Sinalização, <sup>2</sup>IB-USP – Fisiologia, <sup>3</sup>Universidade de Toyama – Medicina Natural, <sup>4</sup>Universidade Católica de Leuven – Toxicologia

**05.007**

Reduced hyperalgesia and allodynia in neuropathic pain models by intraperitoneal and oral administration of new pirazol pirrol piridine derivative. Mendes TCF<sup>1</sup>, Nascimento-Jr NM<sup>2</sup>, Antunes F<sup>3</sup>, Barreiro EJ<sup>4</sup>, Fraga CAM<sup>4</sup>, Sudo RT<sup>1</sup>, Zapata-Sudo G<sup>4</sup> <sup>1</sup>UFRJ – Farmacologia e Química Medicinal, <sup>2</sup>IQ-UFRJ – Química, <sup>3</sup>CCTA-UENF, <sup>4</sup>UFRJ

**05.008**

Interaction between cyclooxygenase-2 and heme oxygenase-1 / biliverdin / carbon monoxide pathways in nociception control in mice. Grangeiro NMCG<sup>1</sup>, Silva AAR<sup>2</sup>, Chaves HV<sup>2</sup>, Val DR<sup>1</sup>, Aguiar JA<sup>3</sup>, Souza RB<sup>1</sup>, Albuquerque RAF<sup>3</sup>, Bezerra MM<sup>1</sup> <sup>1</sup>FM-UFC-Sobral – Biotechnology, <sup>2</sup>UFC-Sobral – Dentistry, <sup>3</sup>FM-UFC-Sobral

**05.009**

IL-33 receptor deficiency reduces inflammation in septic arthritis in mice. Staurengo-Ferrari L<sup>1</sup>, Cardoso RDR<sup>1</sup>, Xu D<sup>2</sup>, Liew FY<sup>2</sup>, Cunha FQ<sup>3</sup>, Pelayo JS<sup>4</sup>, Saridakis HO<sup>4</sup>, Verri Jr WA<sup>1</sup> <sup>1</sup>UEL – Ciências Patológicas, <sup>2</sup>University of Glasgow – Immunology Infection, Inflammation, <sup>3</sup>FMRP-USP, <sup>4</sup>UEL – Microbiologia, <sup>6</sup>UEL – Ciências Patológicas

**05.010**

Antinociception induced by LASSBio-1410 in neuropathic pain model. Leal DM<sup>1</sup>, Nascimento-Jr NM<sup>2</sup>, Leal, CM<sup>2</sup>, Mendes TCF<sup>3</sup>, Fraga CAM<sup>4</sup>, Barreiro EJ<sup>4</sup>, Sudo RT<sup>5</sup>, Zapata-Sudo G<sup>3</sup> <sup>1</sup>UFRJ – Farmacologia, <sup>2</sup>IQ-UFRJ, <sup>3</sup>UFRJ – Farmacologia Básica e Clínica, <sup>4</sup>FF-UFRJ – LASSBio, <sup>5</sup>UFRJ

**05.011**

Analysis of the antinociceptive activity of fractions from *Pterodon polygalaeflorus*. Pinto FA, Vigliano MV, Silva GP, Freitas GM, Gayer CRM, Coelho MGP UERJ – Bioquímica

**05.012**

Antinociceptive activity of (-)-(2S,6S)-(6-ethyl-tetrahydropyran-2-yl)-formic acid on acute pain in mice. Marinho BG<sup>1</sup>, Miranda, LSM<sup>2</sup>, Meireles,

BA<sup>2</sup>, Vasconcellos, MLAA<sup>3</sup>, Pereira, VLP<sup>2</sup>, Fernandes PD<sup>4</sup> <sup>1</sup>UFES – Medicina Veterinária, <sup>2</sup>NPPN-UFRJ, <sup>3</sup>UFPB – Química, <sup>4</sup>UFRJ

**05.013**

(±)-trans-4-hydroxy-6-propyl-1-oxocyclohexan-2-one: a novel substance with antinociceptive properties. Marinho BG<sup>1</sup>, Miranda, LSM<sup>2</sup>, Costa JS<sup>2</sup>, Delle Monache F<sup>3</sup>, Leitão SG<sup>4</sup>, Vasconcellos, MLAA<sup>5</sup>, Pereira, VLP<sup>2</sup>, Fernandes PD<sup>6</sup> <sup>1</sup>UFES – Medicina Veterinária, <sup>2</sup>NPPN-UFRJ, <sup>3</sup>UIN – Farmacologia, <sup>4</sup>UFRJ – Farmácia, <sup>5</sup>UFPB – Química, <sup>6</sup>ICB-UFRJ – Farmacologia

**05.014**

CB<sub>1</sub> and CB<sub>2</sub> cannabinoid receptors are involved in the effect of crotalphine, an opioid-like analgesic peptide. Machado FC<sup>1</sup>, Zambelli VO<sup>1</sup>, Fernandes ACO<sup>1</sup>, Heimann AS<sup>2</sup>, Cury Y<sup>1</sup>, Picolo G<sup>1</sup> <sup>1</sup>IBu – Dor e Sinalização, <sup>2</sup>Proteimax Biotecnologia Ltda. – P&D

**05.015**

Antinociceptive and anti-inflammatory activities of novel *N*-acylhydrazone derivatives designed as piroxicam analogues. Bispo Junior W<sup>1</sup>, Miranda AS<sup>2</sup>, Queiroz AC<sup>1</sup>, Cavalcante-Silva LHA<sup>1</sup>, Matta CBB<sup>1</sup>, Lima LM<sup>2</sup>, Barreiro EJ<sup>2</sup>, Alexandre-Moreira MS<sup>1</sup> <sup>1</sup>UFAL – Farmacologia e Imunidade, <sup>2</sup>FF-UFRJ – LASSBio

**05.016**

Anti-hypernociceptive effect of dichlorpromethane and methanolic extracts obtained from *Piper variable* C. DC. (Piperaceae) in mice. Alves DR<sup>1</sup>, Silva S<sup>1</sup>, Cechinel Filho V<sup>2</sup>, Cruz SM<sup>3</sup>, Caceres A<sup>3</sup>, Alvarez L<sup>4</sup>, Quintão NLM<sup>2</sup> <sup>1</sup>UNIVALI – Ciências da Saúde, <sup>2</sup>NIQFAR-UNIVALI – Ciências Farmacêuticas, <sup>3</sup>USAC – CCQQ y Farmacia, <sup>4</sup>UAEM – Investigaciones Químicas

**05.017**

Inosine reduces pain-related behavior in mice: involvement of adenosine A<sub>1</sub> and A<sub>2A</sub> receptor subtypes and protein kinase C pathways. Nascimento FP<sup>1</sup>, Macedo Junior SJ<sup>2</sup>, Lopez SMF<sup>2</sup>, Martins DF<sup>3</sup>, Cerutti M<sup>1</sup>, Marcon R<sup>1</sup>, Santos ARS<sup>2</sup> <sup>1</sup>UFSC – Farmacologia, <sup>2</sup>UFSC – Ciências Fisiológicas, <sup>3</sup>UFSC – Fisiologia

**05.018**

Mechanisms through which endogenous ATP via P2X<sub>3</sub> and P2X<sub>2/3</sub> receptors activation contributes to inflammatory nociception induced by formalin on rat's hind paw. Krimon S<sup>1</sup>, Parada CA<sup>2</sup>, Oliveira MC<sup>3</sup> <sup>1</sup>UNICAMP – Fisiologia e Biofísica, <sup>2</sup>UNICAMP – Farmacologia, <sup>3</sup>UNICAMP – Ciências Fisiológicas

**05.019**

Nociceptive responses and thermal hyperalgesia evoked by substance P and CGRP in the rat trigeminal system. Teodoro FC, Tronco Junior MF, Cruz L, Dotto G, Zampronio AR, Chichorro JG UFPR – Farmacologia

**05.020**

Evaluation of potential antinociceptive the benzofuranones. Gonçalves CJ<sup>1</sup>, Lenoir AS<sup>1</sup>, Padaratz P<sup>1</sup>, Cechinel Filho V<sup>2</sup>, Niero R<sup>3</sup>, De Campos-Buzzi F<sup>3</sup> <sup>1</sup>UNIVALI – Ciências da Saúde, <sup>2</sup>NIQFAR-UNIVALI – Ciências Farmacêuticas, <sup>3</sup>NIQFAR-UNIVALI

**05.021**

Effect of hemopressin on Fos and Egr-1 expression on an experimental model of neuropathic pain. Maique ET<sup>1</sup>, Alves AS<sup>2</sup>, Ferro ES<sup>3</sup>, Heimann AS<sup>4</sup>, Britto LRG<sup>2</sup>, Dale CS<sup>1</sup> <sup>1</sup>IEP-HSL – Neuromodulação e Dor Experimental, <sup>2</sup>ICB-USP – Fisiologia e Biofísica, <sup>3</sup>ICB-USP, <sup>4</sup>Proteimax Biotecnologia Ltda. – P&D

**05.022**

Antinociceptive and anti-inflammatory effects of apocynin, an NADPH -oxidase inhibitor. Castor LRG<sup>1</sup>, Ximenes VF<sup>2</sup>, Hiruma-Lima CA<sup>3</sup> <sup>1</sup>UNESP-Botucatu – Farmacologia, <sup>2</sup>FC-UNESP-Bauru, <sup>3</sup>UNESP-Botucatu – Fisiologia

**05.023**

Antinociceptive properties of a new series of indan-hydrazine compounds. Reis RC<sup>3</sup>, Motta NAV<sup>1</sup>, Canal PF<sup>1</sup>, Ávila RMD<sup>2</sup>, Miranda ALP<sup>3</sup>, Veloso MP<sup>3</sup>, Brito FCF<sup>1</sup> <sup>1</sup>UFF – Fisiologia e Farmacologia, <sup>2</sup>UNIFAL – Ciências Farmacêuticas, <sup>3</sup>FF-UFRJ – LASSBio

**05.024**

Sensitivity of cisplatin-induced sustained mechanical hyperalgesia of face and hind paw to inhibition by classical analgesics. Guginski G, Rae GA UFSC – Farmacologia

**05.025**

Fractalkine expressed in dorsal root ganglion mediates inflammatory pain. Souza GR<sup>1</sup>, Cunha TM, Lotufo CMC, Talbot J, Bozzo TA, Cunha FQ, Ferreira SH – FMRP-USP – Farmacologia

**05.026**

Evaluation of the analgesic effect of bupivacaine-hydroxypropyl- $\beta$ -cyclodextrin inclusion complex in association to sufentanil, after intrathecal administration in rats. Queiroz VA<sup>1</sup>, de Araújo DR<sup>2</sup>, Cereda CMS<sup>1</sup>, de Paula E<sup>1</sup> <sup>1</sup>UNICAMP – Bioquímica, <sup>2</sup>UFABC – Ciências Naturais e Humanas

**06. Cardiovascular and Renal Pharmacology****06.001**

Ruthenium red reverts endothelium-dependent relaxations and enhances contractions of arterial rings from pigs, rats and rabbits. Silva JDP<sup>1</sup>, Alves Filho FC<sup>2</sup>, Ballejo G<sup>3</sup> <sup>1</sup>NPPM-UFPI, <sup>2</sup>UFPI – Pharmacology and Biochemistry, <sup>3</sup>FMRP-USP – Pharmacology

**06.002**

Pharmacological and morphological evidences for the presence of TRPV4 channels in endothelial cells from rat vessels. Alves Filho FC<sup>1</sup>, Silva

JDP<sup>2</sup>, Salgado MCO<sup>1</sup>, Ballejo G<sup>1</sup> <sup>1</sup>FMRP-USP – Pharmacology, <sup>2</sup>NPPM-UFPI

**06.003**

Reactive oxygen species and PGF<sub>2</sub>alpha receptor activation modulate SNP relaxation in denuded mice aorta. Kangussu L, Côrtes SF, Bonaventura D UFMG – Farmacologia

**06.004**

Chronic ethanol consumption decreases the relaxation induced by adrenomedullin and increases its expression in the isolated rat aorta. Hipólito UV<sup>1</sup>, Tirapelli DP<sup>2</sup>, Jacob Ferreira ALB<sup>3</sup>, Batalhão ME<sup>4</sup>, Tanus-Santos JE<sup>5</sup>, Carnio EC<sup>4</sup>, Queiroz RHC<sup>6</sup>, Tirapelli CR<sup>7</sup> <sup>1</sup>EERP-USP – Enfermagem Psiquiátrica e Ciências Humanas, <sup>2</sup>FMRP-USP – Cirurgia Anatomia, <sup>3</sup>FCM-UNICAMP – Farmacologia, <sup>4</sup>EERP-USP – Enfermagem Geral e Especializada, <sup>5</sup>FMRP-USP – Farmacologia, <sup>6</sup>FCFRP-USP – Toxicologia, <sup>7</sup>EERP-USP – Farmacologia

**06.005**

Effect of quercetin on diabetic nephropathy in hypercholesterolemic mice. Gomes IBS<sup>1</sup>, Santos, MCLFS<sup>2</sup>, Ricardo KFS<sup>3</sup>, Meyrelles SS<sup>4</sup>, Vasquez EC<sup>5</sup> <sup>1</sup>UFES – Pharmaceutical Sciences, <sup>2</sup>UFES – Pathology, <sup>3</sup>FAESA, <sup>4</sup>UFES – Physiological Sciences, <sup>5</sup>UFES-EMESCAM – Physiological Sciences

**06.006**

Characterization of the hypertensive mechanism of ethanolic extract of *L. ericoides*. de Paula DCC<sup>1</sup>, Souza ACM<sup>1</sup>, Guzzo LS<sup>1</sup>, Guimarães HN<sup>2</sup>, Saúde-Guimarães DA<sup>1</sup>, Grabe-Guimarães, A<sup>1</sup> <sup>1</sup>DEFAR-UFOP, <sup>2</sup>UFMG – Engenharia Elétrica

**06.007**

Vasodilatory activity and antihypertensive profile of a new N-acylhydrazone derivative: LASSBio-1027. Leal CM<sup>1</sup>, Kummerle AE<sup>2</sup>, Leal DM<sup>3</sup>, Barreiro EJ<sup>2</sup>, Fraga CAM<sup>2</sup>, Sudo RT<sup>5</sup>, Zapata-Sudo G<sup>5</sup> <sup>1</sup>UFRJ – Farmacologia Básica e Clínica, <sup>2</sup>FF-UFRJ – LASSBio, <sup>3</sup>UFRJ – Farmacologia, <sup>4</sup>UFRJ – LASSBio, UFRJ, <sup>5</sup>UFRJ

**06.008**

Analysis of the mechanisms underlying the vasorelaxant action of THE Kaurane acid 16-metoxicauran-19-oic in the isolated rat aorta. Palazzin NB<sup>1</sup>, Bonaventura D<sup>2</sup>, Ambrósio SR<sup>3</sup>, Hipólito UV<sup>4</sup>, Tirapelli CR<sup>5</sup> – <sup>1</sup>EPCH-EERP-USP, <sup>2</sup>UFMG, <sup>3</sup>UNIFRAN – Bioprospecção e Biotransformação, <sup>4</sup>FMRP-USP – Farmacologia, <sup>5</sup>EERP-USP – Farmacologia

**06.009**

Effects of chronic ethanol consumption on the reactivity and adrenomedullin mRNA levels of components of this system in the rat mesenteric bed. <sup>1</sup>Rocha JT, <sup>3</sup>Hipólito UV, <sup>2</sup>Tirapelli DP, <sup>2</sup>Jacob-Ferreira AL, <sup>1</sup>Batalhão ME, <sup>2</sup>Tanus-Santos JE, <sup>1</sup>Carnio EC, <sup>1</sup>Tirapelli CR, <sup>1</sup>EERP-USP, <sup>2</sup>FMRP-USP, <sup>3</sup>EERP-USP / FMRP-USP

**06.010**

Characterization of L-arginine-NO-cGMP pathway in spontaneously hypertensive rat platelets: the effects of pregnancy. Ognibene DT, Bello PHP, Moss MB, Soares de Moura R, Brunini T, Mendes Ribeiro AC, Resende AC UERJ – Farmacologia e Psicobiologia

**06.011**

Effects of intermittent hypoxia on biochemical parameters of rats fed with different diets. Simões RR<sup>1</sup>, Dutra AL<sup>1</sup>, França RT<sup>2</sup>, Lopes STA<sup>2</sup>, Portela LOC<sup>3</sup>, Zanchet EM<sup>1</sup> <sup>1</sup>UFMS – Fisiologia e Farmacologia, <sup>2</sup>UFMS – Clínica de Pequenos Animais, <sup>3</sup>UFMS – Educação Física e Desportos

**06.012**

Effects of intermittent hypoxia on oxidative parameters of rats fed with different diets.

Simões RR<sup>1</sup>, Dutra AL<sup>1</sup>, Finamor IA<sup>1</sup>, Pavanato MA<sup>1</sup>, Portela LOC<sup>2</sup>, Zanchet EM<sup>1</sup> <sup>1</sup>UFMS – Fisiologia e Farmacologia, <sup>2</sup>UFMS – Educação Física e Desportos

**06.013**

Role of renin-angiotensin system and oxidative status on the maternal cardiovascular regulation in spontaneously hypertensive rats. Bello PHP, Ognibene DT, Carvalho LCRM, Costa CA, Soares de Moura R, Resende AC UERJ – Farmacologia e Psicobiologia

**06.014**

Molecular mechanisms involved in the dual blockade of the renin angiotensin system (RAS) on the left ventricular remodeling in renal hypertensive rats (2K-1C). Corrêa JWN<sup>1</sup>, Callera GE<sup>2</sup>, Yogi A.<sup>2</sup>, He Y<sup>2</sup>, Araújo AV<sup>1</sup>, Vercesi JA<sup>3</sup>, Riul ME<sup>4</sup>, Prado CM<sup>4</sup>, Rossi MA<sup>4</sup>, Touyz RM<sup>2</sup>, Bendhack LM<sup>3</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>University of Ottawa – Kidney Research, <sup>3</sup>FCFRP-USP – Física e Química, <sup>4</sup>FMRP-USP – Patologia

**06.015**

Renovascular hypertension alters the contribution of alternative pathway to ACE in the renal vascular response in isolated kidney. Sivieri-Jr DO<sup>1</sup>, Pereira HJV<sup>2</sup>, Oliveira EB<sup>2</sup>, Salgado MCO<sup>3</sup> <sup>1</sup>UFVJM – Farmácia, <sup>2</sup>FMRP-USP – Bioquímica e Imunologia, <sup>3</sup>FMRP-USP – Farmacologia

**06.016**

The disruption of intracellular Ca<sup>2+</sup> homeostasis is associated with a change of heart function in rats chronically malnourished. Silva DB<sup>1</sup>, Mendes LVP<sup>1</sup>, Nascimento JHM<sup>2</sup>, Einicker-Lamas M<sup>2</sup>, Vieyra A<sup>2</sup>, Cunha VMN<sup>1</sup>, Lara Morcillo LS<sup>1</sup> <sup>1</sup>UFRJ – Farmacologia Celular e Molecular, <sup>2</sup>IBCCF-UFRJ

**06.017**

Endothelial oxidative stress induced by diabetes mellitus I increases maximum contraction evoked by angiotensin II in rat carotid artery.

Pernomian L<sup>1</sup>, Gomes MS<sup>2</sup>, Oliveira AM<sup>2</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>FCF-USP – Física e Química

**06.018**

Hypercholesterolemia and aging: deleterious effects on renal function. Balarini CM<sup>1</sup>, Gava AL<sup>1</sup>, Pereira TMC<sup>1</sup>, Vasquez EC<sup>2</sup>, Meyrelles SS<sup>1</sup> <sup>1</sup>UFES – Ciências Fisiológicas, <sup>2</sup>EMESCAM-UFES – Ciências Fisiológicas

**06.019**

Impact of kidney ischemia-reperfusion on primary active Na<sup>+</sup> transporters and its modulation by lysophosphatidic acid. Gonzalez SR<sup>1</sup>, Verdoorn KS<sup>2</sup>, Beiral HJV<sup>2</sup>, Vieyra A<sup>2</sup>, Einicker-Lamas M<sup>2</sup>, Lara Morcillo LS<sup>1</sup> <sup>1</sup>ICB-UFRJ – Farmacologia Celular e Molecular, <sup>2</sup>IBCCF-UFRJ

**06.020**

Antihypertensive profile of a novel N-acylhydrazone derivative (LASSBio-1289) in spontaneously hypertensive rats. Pereira SL<sup>1</sup>, Oliveira LGT<sup>1</sup>, Kummerle AE<sup>2</sup>, Fraga CAM<sup>2</sup>, Barreiro EJ<sup>2</sup>, Sudo RT<sup>1</sup>, Zapata-Sudo G<sup>1</sup> <sup>1</sup>UFRJ – Desenvolvimento de Fármacos, <sup>2</sup>FF-UFRJ – LASSBio

**06.021**

Increased circulating cell-free DNA levels in preeclampsia and gestational hypertension. Amaral LM<sup>1</sup>, Palei ACT<sup>2</sup>, Sandrim VC<sup>3</sup>, Cavalli RC<sup>4</sup>, Tanus-Santos JE<sup>1</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>FCM-UNICAMP – Farmacologia, <sup>3</sup>Santa Casa de Belo Horizonte, <sup>4</sup>FMRP-USP – Ginecologia e Obstetrícia

**06.022**

Alveolar bone healing process of upper incisor in spontaneously hypertensive rats (SHR) subjected to treatment with  $\beta$ -adrenergic antagonist. a histomorphometric and immunohistochemistry study. Cursino NM<sup>1</sup>, Pereira CCS<sup>2</sup>, Garcia LMG<sup>3</sup>, Micaroni S<sup>4</sup>, Okamoto R<sup>2</sup>, Carvalho AAF<sup>5</sup>, Perri SHV<sup>6</sup>, Luvizuto EL<sup>2</sup>, Antoniali C<sup>4</sup> <sup>1</sup>FOA-UNESP – Odontologia Infantil e Social, <sup>2</sup>FOA-UNESP – Cirurgia e Clínica Integrada, <sup>3</sup>FORP-USP – Materiais Dentários e Prótese, <sup>4</sup>FOA-UNESP – Ciências Básicas, <sup>5</sup>FOA-UNESP – Patologia e Propedêutica Clínica, <sup>6</sup>FOA-UNESP – Apoio, Produção e Saúde Animal

**06.023**

Endothelium contributes to the vascular relaxation induced by C-type natriuretic peptide (CNP) in aortas from renal hypertensive rats. Pernomian L<sup>1</sup>, Bendhack LM<sup>2</sup> <sup>1</sup>FMRP-USP – Pharmacology, <sup>2</sup>FCF-USP – Physics and Chemistry

**06.024**

Cellular mechanisms involved in the venodilation induced by nitric oxide donors. Paulo M, Vercesi JA, Biazzotto JC, Silva RS, Bendhack LM FCF-USP – Physics and Chemistry



## 06.025

Vasorelaxant effects to the essential oil of *Aniba canellilla* in isolated mesenteric artery rings from spontaneously hypertensive rats. Interaminense LFL<sup>1</sup>, Ramos-Alves FE<sup>1</sup>, Xavier FE<sup>1</sup>, Pinto Duarte G<sup>1</sup>, Magalhães PJC<sup>2</sup>, da Silva JK<sup>6</sup>, Sousa PJC<sup>4</sup>, Leal-Cardoso JH<sup>5</sup>, Maia JGS<sup>3</sup>, Lahlou S<sup>5</sup> <sup>1</sup>UFPE – Fisiologia e Farmacologia, <sup>2</sup>UFC – Fisiologia e Farmacologia, <sup>3</sup>UFPA – Engenharia Química, <sup>4</sup>UFPA – Farmácia, <sup>5</sup>UECE – Ciências Biomédicas

## 06.026

Maternal diabetes induces endothelial dysfunction in an age-dependent manner in resistance vessels from male offspring rats: identification of possible mechanisms involved. Ramos-Alves FE, Queiroz DB, Pinto Duarte G, Xavier FE UFPE – Fisiologia e Farmacologia

## 09. Natural Products and Toxinology

### 09.001

Leukotrienes, but not bradykinin and nitric oxide, are involved in paw edema induced by batroxase, a PI metalloproteinase isolated from *Bothrops atrox* snake venom. de Toni LGB<sup>1</sup>, Figueiredo MJ<sup>2</sup>, Sartim MA<sup>1</sup>, Franco JJ<sup>1</sup>, Cintra ACO<sup>1</sup>, Souza GEP<sup>3</sup>, Sampaio SV<sup>1</sup> <sup>1</sup>FCFRP-USP – Análises Clínicas, Toxicológicas e Bromatológicas, <sup>2</sup>FMRP-USP – Farmacologia, <sup>3</sup>FCFRP-USP – Física e Química

### 09.002

Pharmacological characterization of a metalloproteinase from *Bothrops leucurus* snake venom. Gomes MSR<sup>1</sup>, Queiroz MR<sup>2</sup>, Mendes MM<sup>2</sup>, Mamede CCN<sup>2</sup>, Vieira SAPB<sup>2</sup>, Gimenes SNC<sup>2</sup>, Oliveira F<sup>2</sup>, Rodrigues VM<sup>2</sup> <sup>1</sup>UESB – Química e Exatas, <sup>2</sup>UFU – Genética e Bioquímica

### 09.003

Evaluation of the anti-hypernociceptive effect of the essential oil extracted from leaves of *Ugni myricoides* on inflammatory and neuropathic models of pain in mice. Rocha LR<sup>1</sup>, Silva GF<sup>1</sup>, Antonialli CS<sup>1</sup>, Cechinel Filho V<sup>2</sup>, Quintão NLM<sup>1</sup>, Ciccio, JF<sup>3</sup> <sup>1</sup>UNIVALI – Ciências Farmacêuticas, <sup>2</sup>NIQFAR-UNIVALI – Ciências Farmacêuticas, <sup>3</sup>Universidad de Costa Rica – Productos Naturales

### 09.004

Antidepressant-like effect of a supercritical carbon dioxide *Valeriana glechomifolia* extract. Müller LG<sup>1</sup>, Salles LA<sup>1</sup>, Betti AH<sup>1</sup>, Stein AC<sup>1</sup>, Sakamoto S<sup>2</sup>, Quintas LEM<sup>3</sup>, Bettero GM<sup>3</sup>, Figueira R<sup>3</sup>, Noel F<sup>3</sup>, Von Poser GL<sup>1</sup>, Rates SMK<sup>1</sup> <sup>1</sup>UFRGS – Ciências Farmacêuticas, <sup>2</sup>UFRGS – Farmácia, <sup>3</sup>UFRJ – Farmacologia

### 09.005

Effects of dietary supplementation with a multimixture composed of oat bran, flaxseed, sesame and sunflower seed on renal function of diabetic rats. Damasceno DCF<sup>1</sup>, Almeida IP<sup>1</sup>,

Sales ALCC<sup>2</sup>, Teixeira JMR<sup>1</sup>, Soares LFM<sup>1</sup>, Santos Júnior JC<sup>1</sup>, Cunha FVM<sup>3</sup>, Soares MA<sup>4</sup>, Martins MCC<sup>1</sup> <sup>1</sup>UFPI – Biophysics and Physiology, <sup>2</sup>UFPI – Nutrition, <sup>3</sup>Health, Human Science and Technologies Faculty – Physiotherapy, <sup>4</sup>UFPI – Biochemistry and Pharmacology

### 09.006

Dextran sulfate protected isolated rat heart from the cardiotoxic activity of *Bothrops jararacussu* venom. Martins VV, Ricardo HD, Machado MM, Tomaz MA, El-Kik CZ, Cons BL, Melo PA UFRJ – Farmacologia Básica e Clínica

### 09.007

Angiotensin-converting enzyme inhibition is involved in artemetin induced hypotension in rats. de Souza P<sup>1</sup>, Gasparotto Júnior A<sup>1</sup>, Crestani S<sup>1</sup>, Silva RCMVAFda<sup>1</sup>, Stefanello MEA<sup>2</sup>, Marques MCA<sup>1</sup>, da Silva-Santos JE<sup>3</sup>, Kassuya CAL<sup>4</sup> UFPR – Farmacologia, <sup>2</sup>UFPR – Química, <sup>3</sup>UFSC – Farmacologia, <sup>4</sup>UFGD – Ciências da Saúde

### 09.008

Antinociceptive effect of uliginosin B is mediated by the activation of dopaminergic and opioid systems. Stolz ED<sup>1</sup>, Viana AF<sup>2</sup>, Haas JS<sup>2</sup>, Hasse DR<sup>2</sup>, Von Poser GL<sup>2</sup>, Costentin J<sup>3</sup>, Do Rego JC<sup>3</sup>, Rates SMK<sup>2</sup> <sup>1</sup>UFRGS – Neurociências, <sup>2</sup>UFRGS – Farmácia, <sup>3</sup>Université de Rouen – Neuro-psychopharmacologie Expérimentale

### 09.009

Phytochemical analysis of ethanolic extract from *Terminalia cattapa* L. leaves and its correlation with gastroprotection. Silva LP<sup>1</sup>, Angelis CD<sup>1</sup>, Rinaldo D<sup>2</sup>, Vilegas W<sup>2</sup>, Hiruma-Lima CA<sup>3</sup>, Toma W<sup>4</sup> <sup>1</sup>UNESP-Botucatu – Fisiologia, <sup>2</sup>UNESP-Araraquara – Química Orgânica, <sup>3</sup>UNESP-Botucatu, <sup>4</sup>UNISANTA – Farmácia

### 09.010

Anti-inflammatory effects of aqueous extract *Echinodorus macrophyllus* in mice air pouch model. Silva GP, Pinto FA, Vigliano MV, Leal NRF, Marques PR, Sabino KCC, Coelho MGP UERJ – Bioquímica

### 09.011

Anxiolytic effect of the hydroalcoholic extract of *Lafoensia pacari* A. ST.-HIL. stem bark in mice. Galdino PM<sup>1</sup>, Nascimento MVM<sup>1</sup>, Sousa BF<sup>1</sup>, de Paula JR<sup>2</sup>, Costa EA<sup>2</sup> <sup>1</sup>UFG – Ciências Fisiológicas, <sup>2</sup>UFG – Farmácia

### 09.012

Effects of the hydroalcoholic extract of *Euterpe oleracea* Mart (açai) on oxidative stress and endothelial dysfunction associated with 2-kidney, 1-clip hypertension. Costa CA<sup>1</sup>, Oliveira PRB<sup>1</sup>, Emiliano da Silva AF<sup>1</sup>, Ognibene DT<sup>1</sup>, Carvalho LCRM<sup>1</sup>, Amaral TAS<sup>1</sup>, Cordeiro VSC<sup>1</sup>, Valença SS<sup>2</sup>, Soares de Moura R<sup>1</sup>, Resende AC<sup>1</sup> <sup>1</sup>UERJ – Farmacologia e Psicobiologia, <sup>2</sup>UFRJ – Farmacologia

**09.013**

Gastroprotective effects of the trichloroethane fraction of *Piper tuberculatum* in rats. Burci LM<sup>1</sup>, Pereira IT<sup>1</sup>, da Silva LM<sup>1</sup>, Baggio CH<sup>1</sup>, Facundo VA<sup>2</sup>, Rodrigues RV<sup>2</sup>, Santos ARS<sup>3</sup>, Marques MCA<sup>1</sup>, Werner MFP<sup>1</sup> <sup>1</sup>UFPR – Farmacologia, <sup>2</sup>UNIR – Química, <sup>3</sup>UFSC – Ciências Fisiológicas

**09.014**

Analgesic and anti-inflammatory activity of *Anadenanthera macrocarpa* brenan. Silva, KO<sup>1</sup>, Duarte JC<sup>1</sup>, Souza EP<sup>1</sup>, Cruz MP<sup>1</sup>, Marques LM<sup>1</sup>, Andrade MF<sup>1</sup>, Dórea RSDM<sup>1</sup>, Meireles VS<sup>1</sup>, Yatsuda R<sup>1</sup>, Napimoga MH<sup>2</sup>, Clemente-Napimoga JT<sup>2</sup> <sup>1</sup>UFBA – Saúde, <sup>2</sup>UNIUBE – Saúde

**09.015**

Substances from the leaves of *Derris urucu* inhibit alpha-glucosidase. Pereira AC<sup>1</sup>, Arruda MSP<sup>2</sup>, Lemos VS<sup>3</sup>, Côrtes SF<sup>1</sup> <sup>1</sup>UFMG – Farmacologia, <sup>2</sup>UFPA – Química, <sup>3</sup>UFMG – Fisiologia e Biofísica

**09.016**

Effects of an extract obtained from fruits of *Euterpe oleracea* mart. (Açaí) on experimental metabolic syndrome in C57BL/6 mice. Oliveira PRB<sup>1</sup>, Costa CA<sup>1</sup>, Bem GF<sup>2</sup>, Cordeiro VSC<sup>3</sup>, Carvalho LCRM<sup>5</sup>, Souza MAV<sup>5</sup>, Lemos Neto M<sup>5</sup>, Soares de Moura R<sup>2</sup>, Resende AC<sup>1</sup> <sup>1</sup>UERJ – Farmacologia e Psicobiologia, <sup>2</sup>UERJ – Farmacologia, <sup>3</sup>UERJ

**09.017**

The antinociceptive effect of triterpene 3beta, 6beta, 16beta-trihydroxylup-20(29)-ene against acute and chronic pain in mice: the involvement of glutamatergic system. Longhi-Balbinot DT<sup>1</sup>, Lanznaster D<sup>1</sup>, Martins DF<sup>1</sup>, Villarinho JG<sup>2</sup>, Ferreira J<sup>2</sup>, Facundo VA<sup>3</sup>, Santos ARS<sup>1</sup> <sup>1</sup>UFSC – Ciências Fisiológicas, <sup>2</sup>UFSC – Química, <sup>3</sup>UNIR – Química

**09.018**

Antiproliferative activity of extracts from leaves of fruit trees. Begnami AF<sup>1</sup>, Figueira GM<sup>2</sup>, Pereira B.<sup>2</sup>, Ruiz ALTG<sup>2</sup>, Carvalho JE<sup>2</sup>, Rehder VLG<sup>2</sup> <sup>1</sup>FOP-UNICAMP, <sup>2</sup>CPQBA-UNICAMP

**09.019**

Gastric antisecretory activity of an ethanolic extract of *Arctium lappa* L. in rats. da Silva LM<sup>1</sup>, Pereira IT<sup>1</sup>, Mendes DAGB<sup>1</sup>, Pizzolatti MG<sup>2</sup>, Werner MFP<sup>3</sup>, Andre E<sup>4</sup>, Marques MCA<sup>1</sup> <sup>1</sup>UFPR – Farmacologia, <sup>2</sup>UFSC – Química, <sup>3</sup>UFSC – Farmacologia, <sup>4</sup>UFRN – Biofísica e Farmacologia

**09.020**

Gastroprotective and antioxidant effects of ethanolic extract of *Arctium lappa* L. on acetic acid-induced ulcers in rats. da Silva LM<sup>1</sup>, Crestani S<sup>1</sup>, Burci LM<sup>1</sup>, Pizzolatti MG<sup>2</sup>, Werner MFP<sup>1</sup>, Andre E<sup>3</sup>, Marques MCA<sup>1</sup> <sup>1</sup>UFPR – Farmacologia, <sup>2</sup>UFSC – Química, <sup>3</sup>UFRN – Biofísica e Farmacologia

**09.021**

*Crotalus durissus terrificus*: hepatic effects of snake venom in rats. da Silva JG<sup>1</sup>, Soley BS<sup>1</sup>, Gris V.<sup>1</sup>, Rocio AAP<sup>2</sup>, Cadena SMSC<sup>2</sup>, Eler GJ<sup>3</sup>, Bracht A<sup>3</sup>, Dalsenter PR<sup>1</sup>, Acco A<sup>1</sup> <sup>1</sup>UFPR – Farmacologia, <sup>2</sup>UFPR – Bioquímica e Biologia Molecular, <sup>3</sup>UEM – Bioquímica

**09.022**

*Lonomia obliqua* venom-induced pro-inflammatory profile in endothelial cell *in vitro* and increased leukocyte trafficking *in vivo*. Nascimento-Silva V<sup>1</sup>, Rodrigues GS<sup>1</sup>, Moraes JA<sup>1</sup>, Cyrino FZ<sup>2</sup>, Bouskela E<sup>2</sup>, Guimarães JA<sup>3</sup>, Barja Fidalgo TC<sup>1</sup> <sup>1</sup>UERJ – Farmacologia, <sup>2</sup>UERJ – Fisiologia, <sup>3</sup>UFRGS – Farmacologia

**09.023**

Gastroprotective effect of *Terminalia fagifolia* ethanolic extract. Soares GFS, Sousa OT, Souza AES, Oliveira AC, Nunes PHM, Martins MCC UFPI – Biofísica e Fisiologia

**09.024**

Biological activity of hidroalcoholic fraction of *Herissantia crispa* (L.) Brizicky. Dias GEN, Mota KSL<sup>1</sup>, Lima IO<sup>1</sup>, Pereira, FO<sup>1</sup>, Viana WP<sup>1</sup>, Teles YCF<sup>1</sup>, Lima EO<sup>1</sup>, Diniz MFFM<sup>1</sup>, Souza MFV<sup>1</sup>, Batista LM<sup>1</sup> <sup>1</sup>DCF-UFPPB

**09.025**

Effect of methanolic extract and fractions from *Davilla elliptica* leaves (Dilleniaceae) on MMPs in *Bothrops jararaca* envenomation and inflammation. Nishijima CM<sup>1</sup>, Delella FK<sup>2</sup>, Bruni FM<sup>3</sup>, Rodrigues CM<sup>4</sup>, Vilegas W<sup>4</sup>, Lopes-Ferreira M<sup>5</sup>, Felisbino S<sup>6</sup>, Hiruma-Lima CA<sup>7</sup> <sup>1</sup>UNESP-Botucatu – Fisiologia, <sup>2</sup>UNESP-Botucatu – Morfologia, <sup>3</sup>IBu – Toxinologia Aplicada, <sup>4</sup>IQ-UNESP-Araraquara – Química Orgânica, <sup>5</sup>IBu – Imunopatologia, <sup>6</sup>UNESP, <sup>7</sup>UNESP-Botucatu

**09.026**

Evaluation of anti-inflammatory activity of butanolic fraction from *Dioscorea scabra* Humb. & Bonpl. ex Willd. Hank A<sup>1</sup>, Beduschi MG<sup>1</sup>, Darmarco ED<sup>2</sup>, Sousa JMB<sup>1</sup>, Magina MDA<sup>3</sup>, Guimarães CL<sup>5</sup> <sup>1</sup>FURB – Medicina, <sup>2</sup>FURB – Farmácia, <sup>3</sup>FURB – Ciências Farmacêuticas

**09.027**

Antibacterial activity of the *Byrsonima gardneriana* A. Juss. Dias GEN, Leite ATJ, Pereira FO, Rolim TL, Lima EO, Tavares JF, Batista LM DCF-UFPPB

**09.028**

Effect of sub-chronic treatment with psychollatine in the mice light/dark paradigm. Passos CS<sup>1</sup>, Both FL<sup>1</sup>, Steffen VM<sup>1</sup>, Kerber VA<sup>2</sup>, Henriques AT<sup>1</sup> <sup>1</sup>UFRGS – Ciências Farmacêuticas, <sup>2</sup>UFPR – Farmácia

**09.029**

Mechanisms underlying the diuretic effects of isoquercitrin – an active flavonoid of *Tropaeolum majus* L. Gasparotto Júnior A<sup>1</sup>, Gasparotto, FM<sup>2</sup>, Leme TSV<sup>2</sup>, Lourenço EL<sup>1</sup>, Stefanello MEA<sup>3</sup>, Silva

Santos, JE<sup>4</sup>, Kassuya CAL<sup>5</sup>, Marques MCA<sup>6</sup>  
<sup>1</sup>UNIPAR/UFPR - Farmacologia, <sup>2</sup>UNIPAR -  
Farmacologia, <sup>3</sup>UFPR - Química, <sup>4</sup>UFSC -  
Farmacologia, <sup>5</sup>UFGD - Farmacologia, <sup>6</sup>UFPR -  
Farmacologia

#### 09.030

Anti-nociceptive and antiedematogenic effect of *Argyrovernonia harleyi* (H. Rob) Macleish hydroalcoholic extract on writhing test. Silva, AAR<sup>1</sup>, Val DR<sup>2</sup>, Souza RB<sup>2</sup>, Araújo EB<sup>2</sup>, Ribeiro KA<sup>2</sup>, Brayner MMB<sup>3</sup>, Chaves HV<sup>4</sup>, Maia MBS<sup>5</sup>  
<sup>1</sup>UFC-Sobral - Odontologia, <sup>2</sup>UFC-Sobral, <sup>3</sup>UFC - Fisiologia e Farmacologia, <sup>4</sup>UFC, <sup>5</sup>UFPE - Fisiologia e Farmacologia

#### 09.031

Modulation of T lymphocyte and eosinophil functions *in vitro* by natural tetranortriterpenoids isolated from *Carapa guianensis* Aublet. Ferraris FK<sup>1</sup>, Rodrigues R<sup>2</sup>, Silva VP<sup>2</sup>, Figueiredo MR<sup>2</sup>, Penido C<sup>1</sup>, Henriques MGMO<sup>1</sup> - <sup>1</sup>Farmanguinhos-FIOCRUZ - Farmacologia Aplicada, <sup>2</sup>Farmanguinhos-FIOCRUZ - Química de Produtos Naturais

#### 09.032

Evaluation of the antiulcer activity of the extract obtained from rhizomes of *Typha domingensis* Pers (Typhaceae). Molina L<sup>1</sup>, Ornelas FGI<sup>1</sup>, Toma W<sup>1</sup> <sup>1</sup>UNISANTA - Farmácia

#### 09.033

Comparative study of different portions and extract from *Byrsonima intermedia* (leaves) A. Juss against disturbances gastrointestinal in rodents. dos Santos RC<sup>1</sup>, Sannomiya M<sup>2</sup>, Rodrigues CM<sup>2</sup>, Vilegas W<sup>2</sup>, Hiruma-Lima CA<sup>1</sup> <sup>1</sup>IB-UNESP-Botucatu - Fisiologia, <sup>2</sup>IQ-UNESP-Araraquara - Química Orgânica

#### 09.034

*Croton grewoides* Baill. shows antidiarrhoeal activity in mice. Silva ADS<sup>1</sup>, Silva, KM<sup>1</sup>, Lima LO<sup>1</sup>, Silva-Junior V<sup>2</sup>, Silva PCB<sup>3</sup>, Medeiros VM<sup>3</sup>, Costa VCO<sup>3</sup>, Tavares JF<sup>3</sup>, Silva MS<sup>4</sup>, Cavalcante FA<sup>1</sup> <sup>1</sup>ICBS-UFAL, <sup>2</sup>UFAL - Nutrição, <sup>3</sup>LTF-UFPB, <sup>4</sup>UFPB - Química

#### 09.035

Evaluation of the toxicity and gastroprotective activity of the ethanolic extract from leaves of *Xylopia langsdorffiana* A. St.-Hil. & Tul. (Annonaceae). Montenegro CA, Lima GRM, Pessoa DR, Viana WP, Castello Branco MVS, Tavares JF, Batista LM LTF-DCF-UFPB

### 11. Clinical Pharmacology, Pharmacokinetics, Pharmacogenomics and Preclinical Toxicology

#### 11.001

The proper use of self medication and risks and consequences in the health area of universities. Naime ACA, Reis LM, Garcia JAD, Soares EA, Loyola YCS UNIFENAS - Farmácia

#### 11.002

A functional matrix metalloproteinase (MMP)-9 polymorphism modifies plasma MMP-9 levels in subjects environmentally exposed to mercury. Jacob Ferreira ALB<sup>1</sup>, Barbosa Jr F<sup>2</sup>, Gerlach RF<sup>3</sup>, Tanus-Santos JE<sup>4</sup> <sup>1</sup>FCM-UNICAMP - Farmacologia, <sup>2</sup>FCFRP-USP - Toxicologia, <sup>3</sup>FORP-USP - Morfologia, <sup>4</sup>FMRP-USP - Farmacologia

#### 11.003

Endothelial nitric oxide synthase gene haplotypes affect nitrite levels in black subjects. Metzger IF<sup>1</sup>, Ishizawa MH<sup>1</sup>, Rios-Santos F<sup>2</sup>, Carvalho WA<sup>3</sup>, Tanus-Santos JE<sup>1</sup> <sup>1</sup>FMRP-USP - Farmacologia, <sup>2</sup>UESC - Saúde, <sup>3</sup>HSR - Patologia Clínica e Toxicologia

#### 11.004

Interethnic diversity of NAT2 polymorphisms in Brazilian admixed populations. Talbot J<sup>1</sup>, Magno LA<sup>1</sup>, Santana CVN<sup>1</sup>, Souza SMB<sup>1</sup>, Melo PRS<sup>1</sup>, Corrêa RX<sup>1</sup>, Di Pietro G<sup>2</sup>, Rios-Santos F<sup>2</sup> <sup>1</sup>DCB-UESC, <sup>2</sup>DCS-UESC

#### 11.005

Pharmacokinetic evaluation of the anticancer candidate LaSOM 65 in rats. Torres B<sup>1</sup>, Uchoa FDT<sup>2</sup>, Canto RFS<sup>1</sup>, Crestani A<sup>3</sup>, Russowsky D<sup>4</sup>, Eifler-Lima VL<sup>1</sup>, Dalla Costa T<sup>1</sup> <sup>1</sup>UFRGS - Ciências Farmacêuticas, <sup>2</sup>FF-UFRGS - Medicamentos, <sup>3</sup>FF-UFRGS - Síntese Orgânica Medicinal, <sup>4</sup>UFRGS - Química

#### 11.006

Pharmacoepidemiological evaluation of analgesic use for children and adolescents from a public school. Alves DS<sup>1</sup>, Lacerda JSJ<sup>1</sup>, Matias TC<sup>1</sup>, Borlini PG<sup>1</sup>, Brito BG<sup>1</sup>, Almeida JM<sup>1</sup>, Beijamini V<sup>2</sup> <sup>1</sup>UFES - Ciências da Saúde, <sup>2</sup>UFES - Ciências Farmacêuticas

#### 11.007

Imbalanced matrix metalloproteinases levels in women with polycystic ovary. Gomes VA<sup>1</sup>, Jacob Ferreira ALB<sup>2</sup>, Belo VA<sup>2</sup>, Vieira, CS<sup>3</sup>, Fernandes JBF<sup>3</sup>, Soares GM<sup>3</sup>, Ferriani R<sup>3</sup>, Tanus-Santos JE<sup>4</sup> <sup>1</sup>FCM-UNICAMP, <sup>2</sup>FCM-UNICAMP - Farmacologia, <sup>3</sup>FMRP-USP - Ginecologia e Obstetria, <sup>4</sup>FMRP-USP - Farmacologia

#### 11.008

Histological changes in different tissues of non-pregnant and pregnant rats and their fetuses treated with statins. Oliveira LP, Ikeda CM, Maciel LIS, Pereira DA, Ferreira TMI, Melo R, Braga-Vilela AS UNIFENAS - Ciências Biomédicas

#### 11.009

Influence of isotretinoin in liver transaminases and triglycerides plasma levels. Vieira AS<sup>1</sup>, Beijamini V<sup>2</sup>, Melchioris, AC<sup>1</sup> <sup>1</sup>UFES - Ciências da Saúde, <sup>2</sup>UFES - Ciências Farmacêuticas

**11.010**

Matrix metalloproteinase 9 gene polymorphisms affect left ventricular hypertrophy in hypertensive patients. Lacchini R<sup>1</sup>, Jacob Ferreira ALB<sup>2</sup>, Luizon MR<sup>1</sup>, Coeli FB<sup>3</sup>, Izidoro-Toledo TC<sup>1</sup>, Gasparini G<sup>4</sup>, Ferreira-Sae MC<sup>4</sup>, Schreiber R<sup>4</sup>, Nadruz Filho W<sup>5</sup>, Tanus-Santos JE<sup>1</sup> <sup>1</sup>FMRP-USP - Farmacologia, <sup>2</sup>FCM-UNICAMP - Farmacologia, <sup>3</sup>FMRP-USP - Endocrinologia, <sup>4</sup>FCM-UNICAMP - Patologia, <sup>5</sup>FCM-UNICAMP - Clínica Médica

**11.011**

Endothelial nitric oxide synthase (ENOS) haplotypes associated with aura in women with migraine. Gonçalves FM<sup>1</sup>, Oliveira AM<sup>2</sup>, Speciali JG<sup>3</sup>, Izidoro-Toledo TC<sup>4</sup>, Silva PS<sup>1</sup>, Dach F<sup>3</sup>, Tanus-Santos JE<sup>4</sup> <sup>1</sup>UNICAMP - Farmacologia, <sup>2</sup>USP - Farmacologia, <sup>3</sup>FMRP - Neurologia, <sup>4</sup>FMRP-USP - Farmacologia

01. Cellular and Molecular Pharmacology

**01.014**

Modulation of VEGF effects by a synthetic analogue of 15-epi-lipoxins: involvement of the enzyme heme oxygenase-1. Vieira AM<sup>1</sup>, Barja Fidalgo TC<sup>2</sup>, Fierro IM<sup>2</sup> <sup>1</sup>DFP-UERJ, <sup>2</sup>UERJ – Farmacologia

**01.015**

ATL-1, a synthetic analog of 15-epi-lipoxin A4, modulates foam cells activation: a novel potential tool for atherosclerosis treatment. Niconi-de-Almeida Y<sup>1</sup>, Simões RL<sup>1</sup>, Barja Fidalgo TC<sup>2</sup>, Fierro IM<sup>2</sup> <sup>1</sup>UERJ – Farmacologia e Psicobiologia, <sup>2</sup>UERJ – Farmacologia

**01.016**

Characterization of the antimuscarinic effect of LASSBio-767 in HT-29 cells. Gambôa NF<sup>1</sup>, Pimentel LSB<sup>1</sup>, Fraga CAM<sup>2</sup>, Barreiro EJ<sup>2</sup>, Bolzani V<sup>3</sup>, Castro NG<sup>1</sup> <sup>1</sup>ICB-UFRJ Farmacologia Molecular, <sup>2</sup>FF-UFRJ – LASSBio, <sup>3</sup>UFRJ – LASSBio, UFRJ, <sup>3</sup>NuBBE-UNESP-Araraquara – Química Orgânica

**01.017**

*In vitro* characterization of six new 1,4-benzodiazepines compounds. Thibaut JPB<sup>1</sup>, Vieira RO<sup>1</sup>, Menezes CMS<sup>2</sup>, Barreiro EJ<sup>2</sup>, Lima LM<sup>2</sup>, Noel F<sup>1</sup> <sup>1</sup>UFRJ – Farmacologia Básica e Clínica, <sup>2</sup>FF-UFRJ – LASSBio

**01.018**

Signaling function of Na/K-ATPase in ouabain-induced a decrease in LPS inflammation model *in vivo*. Kinoshita PF<sup>1</sup>, Yshii LM<sup>1</sup>, Sa Lima L<sup>1</sup>, Davel APC<sup>2</sup>, Rossoni LV<sup>2</sup>, Kawamoto EM<sup>1</sup>, Scavone C<sup>1</sup> <sup>1</sup>ICB-USP – Farmacologia, <sup>2</sup>ICB-USP – Fisiologia e Biofísica

**01.019**

Protective effects of resveratrol on hepatotoxicity induced by antituberculosis drugs. Nicoletti NF<sup>1</sup>, Santos Jr AA<sup>2</sup>, Rodrigues-Junior VS<sup>2</sup>, Campos MM<sup>3</sup>, Leite CE<sup>4</sup>, Basso LA<sup>2</sup>, Santos DS<sup>5</sup>, Souto AA<sup>6</sup> <sup>1</sup>INCTTB-PUCRS – Biologia Molecular e Funcional, <sup>2</sup>INCTB-PUCRS, <sup>3</sup>PUCRS, <sup>4</sup>PUCRS – Toxicologia, <sup>5</sup>PUCRS – Farmácia, <sup>6</sup>PUCRS – Química

**01.020**

The time-points of *Bothrops lanceolatus* venom molecular effects on rat gastrocnemius. Barbosa-Souza V<sup>1</sup>, Contin DK<sup>1</sup>, Bonventi W<sup>2</sup>, Lôbo de Araújo A<sup>1</sup>, Irazusta SP<sup>1</sup>, Cruz-Höfling MA<sup>3</sup> <sup>1</sup>UNICAMP – Farmacologia, <sup>2</sup>CEETEPS, <sup>3</sup>IB-UNICAMP – Biologia Celular e Estrutural

**01.021**

An autocrine/paracrine role for relaxin system in testis: Sertoli cell proliferation via activation of ERK1/2 pathway and a possible role in early steps of spermatogenesis. Nascimento AR,

Pimenta MT, Royer C, Lucas TFG, Porto CS, Lazari MFM UNIFESP – Farmacologia

**01.022**

$\beta$ -adrenoceptor modulates skeletal muscle contraction by coupling to both Gs and Gi proteins: a new concept to cAMP signaling pathway. Rodrigues FSM, Bergantin LB, Pires-Oliveira M, Andrade-Lopes AL, Godinho RO UNIFESP – Farmacologia

**01.023**

Role of P2X<sub>7</sub> receptor during *Mycobacterium tuberculosis*-infection in mice. Santos Jr AA<sup>1</sup>, Rodrigues-Junior VS<sup>2</sup>, Coutinho R<sup>3</sup>, Santos DS<sup>2</sup>, Campos MM<sup>4</sup>, Morrone FB<sup>1</sup> <sup>1</sup>PUCRS – Biologia Celular e Molecular, <sup>2</sup>INCTTb-PUCRS – Biologia Molecular e Funcional, <sup>3</sup>IBCCF-UFRJ, <sup>4</sup>PUCRS – Odontologia

**01.024**

Creb response after caloric restriction in a LPS inflammation model in rat hippocampus. Vasconcelos AR, Sá Lima L, Kawamoto EM, Scavone C ICB-USP – Farmacologia

**01.025**

Ovariectomy does not modulate chronic unpredictable stress (CUS) potentiation of lipopolysaccharide-induced NF- $\kappa$ B activity in striatum of female Wistar rats. Sá Lima L<sup>1</sup>, Porto CS<sup>2</sup>, Scavone C<sup>1</sup>, Carolina DM<sup>1</sup> <sup>1</sup>ICB-USP – Farmacologia, <sup>2</sup>UNIFESP – Farmacologia

**01.026**

Effect of N<sup>1</sup>-acetyl-N-formyl-5-methoxykynuramine (AFMK) on the production nitric oxide by cultured endothelial cells. Freitas AH, Tamura EK, Markus RP IB-USP – Fisiologia

**01.027**

Reactivity of endothelial cells in culture is conditioned by nocturnal melatonin surge in donor rats. Marçola M, Tamura EK, Fernandes PACM, Markus RP IB-USP – Fisiologia

02. Neuropharmacology

**02.023**

The selective A-type K<sup>+</sup> current blocker Tx3-1 rescues memory of mice submitted to a model of Alzheimer's disease. Gomes GM<sup>1</sup>, Dalmolin GD<sup>2</sup>, Ferreira J<sup>1</sup>, Gomez MV<sup>2</sup>, Rubin MA<sup>1</sup> <sup>1</sup>UFMSM – Química, <sup>2</sup>UFMG – Farmacologia

**02.024**

Ketamine/fentanyl administration in infant rats induces anxiolysis until adult life. Medeiros LF<sup>1</sup>, Souza A<sup>1</sup>, Rozisky JR<sup>1</sup>, Santos VS<sup>1</sup>, Netto CA<sup>2</sup>, Battastini AMO<sup>2</sup>, Torres ILS<sup>1</sup> <sup>1</sup>UFRGS – Farmacologia, <sup>2</sup>UFRGS – Bioquímica

**02.025**

Kinin B2 receptor can play a neuroprotective role in Alzheimer's disease. Caetano AL<sup>1</sup>, Amaral FA<sup>1</sup>,

Dong KE<sup>1</sup>, Baraldi T<sup>2</sup>, Viel TA<sup>2</sup>, Buck HS<sup>1</sup>  
<sup>1</sup>FCMSCSP – Ciências Fisiológicas, <sup>2</sup>EACH-USP

#### **02.026**

Medial prefrontal cortex muscarinic receptors modulate the expression of contextual fear conditioning. Fedoce AG, Ferreira Junior NC, Reis DG, Corrêa FMA, Resstel LBM FMRP-USP – Farmacologia

#### **02.027**

Morphological changes in rat skeletal muscle during atrophy caused by amyotrophic lateral sclerosis. Figueiredo LB, Barnabe GF, Mello LE, Godinho RO UNIFESP – Farmacologia, <sup>2</sup>UNIFESP – Fisiologia

#### **02.028**

“Anxious” and “non-anxious” subgroups of rats selected in the elevated plus maze do not differ in the density of [<sup>3</sup>H]-flunitrazepam binding in the hippocampus and limbic cortex. Carvalho JGB, Venditti MAC UNIFESP – Psicobiologia

#### **02.029**

Binding of [<sup>3</sup>H]-flunitrazepam and [<sup>3</sup>H]-MK-801 in brain regions of rats with different sensitivity to the convulsant effect of a benzodiazepine inverse agonist. Conto MB<sup>1</sup>, Carvalho JGB, Venditti MAC UNIFESP – Psicobiologia

#### **02.030**

The paraventricular nucleus of the hypothalamus mediates pressor response to acute restraint stress in rats. Busnardo C<sup>1</sup>, Tavares RF<sup>1</sup>, Resstel LBM<sup>1</sup>, Elias LLK<sup>2</sup>, Corrêa FMA<sup>1</sup> <sup>1</sup>FMRP-USP – Pharmacology, <sup>2</sup>FMRP-USP – Physiology

#### **02.031**

Pre-synaptic nicotinic cholinergic receptor increases neurotransmitter release in cultured cells from the medulla oblongata. Matsumoto JPP, Martins EAC, Fior-Chadi DR IB-USP – Physiology

#### **02.032**

Facilitation of endocannabinoid-mediated neurotransmission in the dorsal hippocampus induces anxiolytic effects in rats submitted to the Vogel conflict test. Nejo P, Lisboa SF, Resstel LBM, Guimarães FS FMRP-USP

#### **02.033**

Possible role of the angiotensin (1-7) in the hippocampus in a model of epilepsy. Pereira MGAG<sup>1</sup>, Souza LL<sup>1</sup>, Becari C<sup>2</sup>, Camacho F<sup>1</sup>, Oliveira JAC<sup>3</sup>, Salgado MCO<sup>2</sup>, Garcia-Cairasco N<sup>3</sup>, Costa-Neto CM<sup>1</sup> <sup>1</sup>FMRP-USP – Biochemistry and Immunology, <sup>2</sup>FMRP-USP – Pharmacology, <sup>3</sup>FMRP-USP – Physiology

#### **02.034**

Enriched environment stimulus improves spatial and aversive-related memory performance in an animal model of severe Alzheimer's disease. Schowe NM<sup>1</sup>, Oliveira EM<sup>1</sup>, Souza LHJ<sup>1</sup>, Sousa AMA<sup>2</sup>, Amaral FA<sup>2</sup>, Lopes ASA<sup>2</sup>, Caetano AL<sup>2</sup>,

Rocha MN<sup>3</sup>, Buck HS<sup>2</sup>, Viel TA<sup>1</sup> <sup>1</sup>EACH-USP, <sup>2</sup>FCMSCSP – Ciências Fisiológicas, <sup>3</sup>FCMSCSP – Medicina Molecular

#### **02.035**

Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease. Barbiero JK, Santiago RM, Lima MMS, Ariza D, Morais LH, Andreatini R, Vital MABF UFPR – Farmacologia

#### **02.036**

The noradrenergic neurotransmission in the MeA modulates the cardiovascular responses to acute restraint stress in rats. Fortaleza EAT, Scopinho AA, Corrêa FMA FMRP-USP

#### **02.037**

Inhibition of spinal c-Jun-N-terminal kinase (JNK) after spinal cord injury improves locomotor performance. Martini AC<sup>1</sup>, Forner S<sup>1</sup>, Koepf J<sup>2</sup>, Rae GA<sup>1</sup> <sup>1</sup>UFSC – Pharmacology, <sup>2</sup>UFSC – Chemical and Food Engineering

#### **02.038**

Medial prefrontal cortex NMDA-Nitric oxide pathway modulates anxiety-behavior in rats submitted to the Vogel conflict test. Resstel LBM, Lisboa SF, Guimarães FS FMRP-USP

#### **02.039**

Aged and young rats respond differently to permanent, 3-stage 4-vessel occlusion: An analysis of learning, neurodegeneration and  $\beta$ -APP expression. Ferreira EDF<sup>1</sup>, Romanini CV<sup>2</sup>, Albertin M<sup>1</sup>, Mori MA<sup>3</sup>, Oliveira RMW<sup>1</sup>, Milani H<sup>1</sup> <sup>1</sup>UEM – Farmácia e Farmacologia, <sup>2</sup>UEL – Farmácia e Farmacologia, <sup>3</sup>UEM – Ciências Biológicas

#### **02.040**

Alpha2-adrenoceptors in the lateral septal area modulates cardiovascular responses evoked by restraint stress in rats. Scopinho AA, Reis DG, Resstel LBM, Corrêa FMA FMRP-USP

#### **02.041**

Involvement of glutamate AMPA receptors in the hypothalamic mechanisms triggered by paracetamol on the suppression of LPS-induced fever. Campos EMB<sup>1</sup>, Moraes TP<sup>1</sup>, Kanashiro A<sup>2</sup>, Malvar DC<sup>3</sup>, Souza GEP<sup>2</sup>, Iyomasa MM<sup>1</sup>, Rosa ML<sup>1</sup> <sup>1</sup>FAMECA-FIPA – Neurociências, <sup>2</sup>FCF-USP – Física e Química, <sup>3</sup>UFRRJ – Ciências Fisiológicas

#### **02.042**

Comparison of cognitive stimulation during lifetime and during the elderly: effects on spatial memory and on neuroplasticity of mice. Baraldi T<sup>1</sup>, Amaral FA<sup>2</sup>, Caetano AL<sup>2</sup>, Albuquerque MS<sup>1</sup>, Buck HS<sup>1</sup>, Viel TA<sup>1</sup> <sup>1</sup>EACH-USP, <sup>2</sup>FCMSCSP – Ciências Fisiológicas

#### **02.043**

Characterization of glycinamide as a co-agonist of NMDA receptors. Montenegro VM<sup>1</sup>, Setti-

Perdigão P, Guimarães MZP, Castro NG ICB-UFRJ – Farmacologia Molecular

#### 02.044

The expression of mRNA encoding flip and flop isoforms of GLUR1 is increased in hippocampus of isolated young adult rats. Pereira MTR<sup>1</sup>, Tonso VM<sup>2</sup>, Limonte FH<sup>2</sup>, Oliveira FS<sup>3</sup>, Iyomasa MM<sup>1</sup>, Rosa ML<sup>1</sup> <sup>1</sup>FAMECA-FIPA – Neurociências, <sup>2</sup>FAMECA-FIPA – Bioquímica, <sup>3</sup>USP – Farmacologia

### 03. Psychopharmacology

#### 03.013

Effect of transient reversible inactivation of the ventral hippocampus in rats submitted to the forced swimming test. Diniz CRAF, Casarotto PC, Joca SRL FCFRP-USP – Física e Química

#### 03.014

Involvement of local insular cortex neurotransmission on contextual fear conditioning. Alves FHF<sup>1</sup>, Reis DG<sup>2</sup>, Crestani CC<sup>2</sup>, Corrêa FMA<sup>3</sup>, Resstel LBM<sup>3</sup> <sup>1</sup>FMRP-USP – Farmacologia

#### 03.015

DNA demethylating agents: new antidepressant drugs? Sales AJ<sup>1</sup>, Biojone C<sup>2</sup>, Gomes MVM<sup>3</sup>, Joca SRL<sup>1</sup> <sup>1</sup>FCFRP-USP – Física e Química, <sup>2</sup>FMRP-USP – Farmacologia, <sup>3</sup>UNOPAR – Genética

#### 03.016

New *N*-phenylpiperazine derivatives with antipsychotic-like activity in rodents bind to  $\alpha_{1a}$  and  $\alpha_{1b}$  receptors. Betti AH<sup>1</sup>, Antonio CB<sup>1</sup>, HASSE DR<sup>2</sup>, Vieira RO<sup>3</sup>, Martins TS<sup>4</sup>, Barreiro EJ<sup>4</sup>, Fraga CAM<sup>4</sup>, Noel F<sup>5</sup>, Rates SMK<sup>1</sup> <sup>1</sup>UFRGS – Ciências Farmacêuticas, <sup>2</sup>UFRGS – Psicofarmacologia Experimental, <sup>3</sup>UFRJ – Farmacologia Celular e Molecular, <sup>4</sup>FF-UFRJ – LASSBio, <sup>5</sup>UFRJ – Farmacologia Básica e Clínica

#### 03.017

Acute MDMA (Ecstasy) treatment induces a persistent leukocyte distribution change and enhances susceptibility to infection. Ferraz-de-Paula V<sup>1</sup>, Ribeiro A<sup>1</sup>, Souza-Queiroz J<sup>2</sup>, Torello CO<sup>3</sup>, Queiroz MLS<sup>4</sup>, Moreau RLM<sup>5</sup>, Palermo-Neto J<sup>6</sup> <sup>1</sup>FMVZ-USP – Patologia, <sup>2</sup>IP-USP, <sup>3</sup>UNICAMP – Farmacologia, <sup>4</sup>UNICAMP – Farmacologia / Hemocentro, <sup>5</sup>FCF-USP – Análises Clínicas e Toxicológicas, <sup>6</sup>FMZV-USP – Neuroimunomodulation

#### 03.018

Evaluation of the antinociceptive effect of ethanolic extract of *Sida galheirensis* (Malvaceae). Salgado PRR, Fonsêca DV, Carvalho FL, Torres PA, Lima MRV, Morais LCSL, Almeida RN, Souza MFV UFPB – Pharmaceutical Technology

#### 03.019

Evaluation of central activity of essential oil *Lippia microphylla* (Verbenaceae) in mice. Monte LO, Mota VG, Pinheiro LS, Timóteo RNP, Tavares JF, Morais LCSL, Alencar JL, Almeida RN UFPB – Pharmaceutical Technology

#### 03.020

Restraint stress changes temporal patterns of adenine nucleotides hydrolysis in rat's blood serum. Souza A<sup>1</sup>, Detanico BC<sup>1</sup>, Rozisky JR<sup>1</sup>, Medeiros LF<sup>2</sup>, Caumo W<sup>2</sup>, Hidalgo MP<sup>3</sup>, Battastini AMO<sup>4</sup>, Torres ILS<sup>2</sup> <sup>1</sup>UFRGS – Farmacologia, <sup>2</sup>UFRGS – Anestesia, <sup>3</sup>UFRGS – Psiquiatria, <sup>4</sup>UFRGS – Bioquímica

#### 03.021

Behavioral syndromes in experimental autoimmune encephalomyelitis. Rodrigues DH<sup>1</sup>, Sousa LFC<sup>1</sup>, Miranda AS<sup>1</sup>, Lacerda-Queiroz N<sup>1</sup>, Vilela MC<sup>1</sup>, Campos RDL, Teixeira MM<sup>1</sup>, Reis HJ<sup>2</sup>, Teixeira AL<sup>1</sup> <sup>1</sup>UFMG – Imunofarmacologia, <sup>2</sup>UFMG – Neurofarmacologia

#### 03.022

Chronic administration of medroxyprogesterone or clomifene, anti-estrogenic drugs, does not reproduce the antimanic-like effect of tamoxifen in an animal model of mania. Pereira M<sup>1</sup>, Siba IP<sup>1</sup>, Martynhak BJ<sup>1</sup>, Correia D<sup>1</sup>, Baretta IP<sup>2</sup>, Andreatini R<sup>1</sup> <sup>1</sup>UFPR – Pharmacology, <sup>2</sup>UNIPar

#### 03.023

Anxiolytic-like effect of benzodiazepine flurazepam is oestrous cycle-dependent. Silva Medeiros AG, Muniz GD, Figueiredo Neto JL, Arruda Junior WB, Costa RD, Carvalho MS, de Paula Soares V UFRN – Biofísica e Farmacologia

#### 03.024

Role of median raphe nucleus 5-HT<sub>1a</sub> receptors on behavioral despair. Trovo MC, Almeida PVG, Pereira DHS, Padovan CM FFCLRP-USP – Psicologia e Educação

### 04. Inflammation

#### 04.047

Effect of repeated treatment with enalapril on the hepatotoxicity induced by acetaminophen in mice. Betto MRB<sup>1</sup>, Lazarotto LF<sup>2</sup>, Leite CE<sup>3</sup>, Watanabe TTN<sup>4</sup>, Driemeier D<sup>5</sup>, Campos MM<sup>6</sup> <sup>1</sup>PUCRS – Biologia Celular e Molecular, <sup>2</sup>PUCRS – Farmácia, <sup>3</sup>PUCRS – Toxicologia, <sup>4</sup>UFRGS – Patologia e Clínica Veterinária, <sup>5</sup>UFRGS – Veterinária, <sup>6</sup>PUCRS – Cirurgia-Odontologia

#### 04.048

A pharmacological approach to food allergy in mice: novel therapeutic targets. Pereira-Silva PEM, Amaral SS, Noviello MLM, Menezes GB, Cara DC ICB-UFMG – Morfologia

#### 04.049

Quercetin inhibits neutrophil recruitment *in vivo* and *in vitro*: inhibition of actin polymerization. Zarpelon AC<sup>1</sup>, Souto FO<sup>2</sup>, Staurengo-Ferrari L<sup>1</sup>,

Fattori V<sup>1</sup>, Casagrande R<sup>1</sup>, Fonseca MJ<sup>3</sup>, Cunha TM<sup>2</sup>, Ferreira SH<sup>2</sup>, Cunha FQ<sup>2</sup>, Verri Jr WA<sup>1</sup>  
<sup>1</sup>UEL - Ciências Patológicas, <sup>2</sup>FMRP-USP - Farmacologia, <sup>3</sup>FCFRP-USP - Ciências Farmacêuticas

#### 04.050

Effects of mangiferin on allergic inflammation induced by ovalbumin in A/J mice. Coelho LP, Jurgilas PB, Serra MF, Pires ALA, Cruz CCD, Cordeiro RSB, Silva PMR, Martins MA IOC-FIOCRUZ - Fisiologia e Farmacodinâmica

#### 04.051

Inhibition heme oxygenase increases neutrophil migration to the bronchoalveolar spaces and attenuates pulmonary mechanics changes during severe sepsis induced by pneumonia. Czaikoski PG<sup>1</sup>, Nascimento DCB<sup>2</sup>, Spiller F<sup>1</sup>, Rocco PRM<sup>3</sup>, Cunha FQ<sup>1</sup> <sup>1</sup>FMRP-USP - Pharmacology, <sup>2</sup>FMRP-USP - Immunology, <sup>3</sup>UFRJ Investigaç o Pulmonar

#### 04.052

Effect of thoracic lymphatic duct ligation on the release of lung inflammatory mediators in the model of gut trauma in rats. Breithaupt-Faloppa AC, Vitoretto LB, de Assis Ramos MM, Cavriani G, Sudo-Hayashi LS, Oliveira-Filho RM, Vargaftig BB, Tavares de Lima W ICB-USP - Farmacologia

#### 04.053

Eosinophils as novel cell source of prostaglandin D<sub>2</sub>: autocrine activity and allergy-driven synthesis. Luna-Gomes T<sup>1</sup>, Magalhães KG<sup>2</sup>, Mesquita-Santos FP<sup>2</sup>, Bakker-Abreu I<sup>1</sup>, Samico RF<sup>1</sup>, Bozza PT<sup>2</sup>, Diaz BL<sup>1</sup>, Bandeira-Melo C<sup>1</sup> <sup>1</sup>IBCCF-UFRJ, <sup>2</sup>IOC-FIOCRUZ

#### 04.054

Kinetics of tissue response to orthodontic forces in mice: mechanical stimulation leads to bone remodeling through differential expression of osteoclast and osteoblast related factors. Garlet TP<sup>1</sup>, Tadei SR<sup>2</sup>, Silva TA<sup>3</sup>, Garlet GP<sup>4</sup>, Cunha FQ<sup>1</sup> <sup>1</sup>FMRP-USP, <sup>2</sup>ICB-UFGM, <sup>3</sup>UFGM - Patologia, <sup>4</sup>FOB-USP

#### 04.055

Signaling transduction pathway involved in LPS-induced suppression of melatonin production by rat pineal gland. Cruz-Machado SS<sup>1</sup>, Pinato, L<sup>2</sup>, Carvalho-Sousa CE<sup>1</sup>, Tamura EK<sup>1</sup>, Ferreira ZS<sup>1</sup>, Markus RP<sup>1</sup> <sup>1</sup>IB-USP - Fisiologia, <sup>2</sup>UNESP - Fonoaudiologia

#### 04.056

Enhanced airway smooth muscle reactivity to cholinergic provocation is associated to mast cells in A/J mice. Anjos-Valotta EA, Farias-Filho FA, Serra MF, Cordeiro RSB, Silva PMR, Martins MA FIOCRUZ - Inflamaç o

#### 04.057

Prior exposure to staphylococcal enterotoxin type B (SEB) potentiates the pulmonary eosinophil

infiltration of allergic mice. Squebola Cola DM<sup>1</sup>, Mello GC<sup>1</sup>, Schenka A<sup>2</sup>, Souza IA<sup>1</sup>, Antunes E<sup>1</sup> <sup>1</sup>FCM-UNICAMP - Farmacologia, <sup>2</sup>FCM-UNICAMP - Patologia

#### 04.058

Role of mast cells on the production of CINC-2, migration of neutrophils and bone resorption in SHR animals submitted to periodontal disease. Belini L<sup>1</sup>, Salzedas LMP<sup>2</sup>, Oliveira SHP<sup>1</sup> <sup>1</sup>FO-UNESP-Araçatuba - Ciências Básicas, <sup>2</sup>UNESP-Araçatuba - Radiologia

#### 04.059

Modulation of FCgR-mediated phagocytosis in macrophages by TLRs agonists: involvement of 5-LO products. Pinheiro CS<sup>1</sup>, Monteiro APT<sup>2</sup>, Benjamim CF<sup>3</sup>, Canetti C<sup>1</sup> <sup>1</sup>IBCCF-UFRJ, <sup>2</sup>UERJ - Farmacologia e Psicobiologia, <sup>3</sup>UFRJ - Farmacologia Básica e Clínica

#### 04.060

Odontoblasts stimulated by lipopolysaccharide express SCF and FGF-2 via p42/44, p38 and PI3K. Santos VAC<sup>1</sup>, Oliveira SHP<sup>2</sup> <sup>1</sup>FOA-UNESP - Odontologia Social e Preventiva e Ciências Básicas, <sup>2</sup>FOA-UNESP - Ciências Básicas

#### 04.061

Role of *GILZ* (*glucocorticoid-induced leucine zipper*) on resolution of inflammation. Nogueira CRC<sup>1</sup>, Tavares LP<sup>1</sup>, Silva JPV<sup>1</sup>, Queiroz ALL<sup>1</sup>, Silva DM<sup>1</sup>, Soriani FM<sup>1</sup>, Russo RC<sup>1</sup>, Garcia CC<sup>1</sup>, Lopes F<sup>2</sup>, Pinho V<sup>1</sup>, Teixeira MM<sup>1</sup>, Sousa LP<sup>3</sup> <sup>1</sup>UFGM - Bioquímica e Imunologia, <sup>2</sup>UFGM - Morfologia, <sup>3</sup>UFGM - Patologia Clínica - COLTEC

#### 04.062

Evaluation of the anti-inflammatory effect of mycophenolate mofetil in mice LPS-induced pleurisy. Beduschi MG<sup>1</sup>, Darmarco ED<sup>3</sup>, Frode TS<sup>2</sup>, Guimarães CL<sup>4</sup> <sup>1</sup>FURB - Medicina, <sup>2</sup>UFSC - Análises Clínicas, <sup>3</sup>FURB - Farmácia, <sup>4</sup>FURB - Ciências Farmacêuticas

#### 04.063

CC chemokine receptors play different roles in the pathogenesis of dengue virus infection in mice. Guabiraba R<sup>1</sup>, Pereira-Silva REM<sup>1</sup>, Besnard AG<sup>2</sup>, Souza DG<sup>3</sup>, Ryffel B<sup>2</sup>, Teixeira MM<sup>1</sup> <sup>1</sup>UFGM - Bioquímica e Imunologia, <sup>2</sup>CNRS-IEM, <sup>3</sup>UFGM - Microbiologia

#### 04.064

Inhibition of guanylyl cyclase restores neutrophil migration and maintains bactericidal activity increasing survival in sepsis. Amêndola R<sup>1</sup>, Neto H<sup>2</sup>, Souto FO<sup>3</sup>, Alves-Filho JC<sup>3</sup>, Spiller F<sup>3</sup>, Freitas A<sup>3</sup>, Cunha FQ<sup>3</sup>, Barja Fidalgo TC<sup>2</sup> <sup>1</sup>UERJ - Farmacologia e Psicobiologia, <sup>2</sup>UERJ - Farmacologia, <sup>3</sup>USP - Farmacologia e Dor

#### 04.065

Anti-inflammatory effects of lovastatin on the tests of formalin and dextran-induced paw edema. Siqueira RMP<sup>1</sup>, Gonçalves DO<sup>1</sup>, Calou



IBF<sup>2</sup>, Olinda TM<sup>1</sup>, Figueiredo IST<sup>1</sup>, Pinheiro CN<sup>4</sup>, Melo TS<sup>1</sup>, Cavalcante, ALC<sup>5</sup>, Viana GSB<sup>1</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>UFC – Análises Clínicas, <sup>4</sup>FATECI – Biomedicina, <sup>5</sup>UFC – Ciências Médicas

#### 04.066

Effect of the crude extract and the aerial parts fractions of *Sesbania virgata* on the inflammatory response in animals. Arruda LLM<sup>1</sup>, Bonfim, N. M.<sup>2</sup>, Kummer R<sup>1</sup>, Souza, M. C.<sup>3</sup>, Sarragioto MH<sup>2</sup>, Baroni S<sup>1</sup>, Grespan R<sup>1</sup>, Bersani-Amado CA<sup>1</sup> <sup>1</sup>UEM – Farmácia e Farmacologia, <sup>2</sup>UEM – Química, <sup>3</sup>UEM – Biologia

#### 04.067

Effects of resveratrol in the acute and chronic models of inflammation in rats. Silva RBM<sup>1</sup>, Maciel IS<sup>2</sup>, Souto AA<sup>3</sup>, Morrone FB<sup>4</sup>, Campos MM<sup>5</sup> <sup>1</sup>PUCRS – Farmacologia Aplicada, <sup>2</sup>PUCRS – Farmacologia, <sup>3</sup>PUCRS – Química, <sup>4</sup>PUCRS – Farmácia, <sup>5</sup>PUCRS – Cirurgia-Odontologia

#### 04.068

Inflammatory response induced by carvacrol, a *Thymus vulgaris* essential oil constituent. Fachini FC, Kummer R, Ritter AMV, Anteguera AAC, Domiciano TP, Bersani-Amado CA, Cuman RKN UEM – Farmácia e Farmacologia

#### 04.069

LTB4 as chemoattractant factor in the regulatory T cells migration. Pecli CP<sup>1</sup>, Molinaro RC<sup>2</sup>, Peters-Golden M<sup>3</sup>, Kunkel SL<sup>4</sup>, Canetti C<sup>5</sup>, Benjamim CF<sup>1</sup> <sup>1</sup>ICB-UERJ, <sup>2</sup>IOC-FIOCRUZ, <sup>3</sup>University of Michigan – Pulmonary and Critical Care Medicine, <sup>4</sup>University of Michigan – Pathology <sup>5</sup>IBCCF-UFRJ

#### 04.070

Nti-pyretic effect of dipyrone is not related with the hypothalamic PGE2 synthesis inhibition in rats. Malvar DC, Figueiredo MM, Martins JM, Pessini AC, Soares DM, Souza GEP FCFRP-USP – Física e Química

#### 04.071

The role of acid-induced laminin polymer in splenic dendritic cells. Ladislau L<sup>1</sup>, Da-Fe AR<sup>2</sup>, Coelho-Sampaio TL<sup>3</sup>, Kunkel SL<sup>4</sup>, Benjamim CF<sup>5</sup> <sup>1</sup>ICB-UFRJ, <sup>2</sup>UERJ – Farmacologia e Psicobiologia, <sup>3</sup>UFRJ – Histologia, <sup>4</sup>University of Michigan – Pathology, <sup>5</sup>UFRJ – Farmacologia Básica e Clínica

#### 04.072

Clinical evaluation of the anti-inflammatory effect of *Baccharis dracunculifolia* propolis gel (patent PI 0904121-4) on cervicitis. Paulino N<sup>1</sup>, Scremin Paulino A<sup>2</sup>, Marcucci MC<sup>1</sup>, Vautier P<sup>1</sup> <sup>1</sup>UNIBAN – Farmácia, <sup>2</sup>UFSC – Farmácia

#### 04.073

Activation of TLR9 in circulating neutrophils inhibits their migration to inflammatory site. Trevelin SC<sup>1</sup>, Alves-Filho JC<sup>1</sup>, Sônego F<sup>1</sup>, Souto FO<sup>2</sup>, Nascimento DCB<sup>2</sup>, Turato W<sup>2</sup>, Cunha TM<sup>1</sup>,

Gazzinelli RT<sup>2</sup>, Cunha FQ<sup>1</sup> <sup>1</sup>FMRP-USP – Pharmacology, <sup>2</sup>FMRP-USP, Immunology and Biochemistry

#### 04.074

Effects of eotaxin in the peritoneal migration of eosinophils and neutrophils, dependent on 5-lipoxygenase products. Lages PM<sup>1</sup>, Arcanjo LCG<sup>2</sup>, Lopes RS<sup>1</sup>, Silva CLCA<sup>1</sup>, Luz RA<sup>3</sup>, Elsas PPX<sup>4</sup>, Elsas MICG<sup>5</sup> <sup>1</sup>IMPPG-UFRJ, <sup>2</sup>IFF-FIOCRUZ, <sup>3</sup>IFF-FIOCRUZ – Pediatria, <sup>4</sup>UFRJ, <sup>5</sup>FIOCRUZ

#### 04.075

Adenosine and adenosine-monophosphate present into the *Phlebotomus papatasi* saliva block dendritic cell function and ameliorate collagen-induced arthritis. Carregaro V<sup>1</sup>, Sá-Nunes, A<sup>2</sup>, Cunha, TM<sup>3</sup>, Grespan R<sup>4</sup>, Oliveira CJ<sup>1</sup>, Lima-Jr DS<sup>5</sup>, Costa DL<sup>1</sup>, Milanezi CM<sup>1</sup>, Verri Jr WA<sup>5</sup>, Valenzuela JG<sup>6</sup>, Silva JS<sup>1</sup>, Ribeiro JM<sup>6</sup>, Cunha FQ<sup>3</sup> <sup>1</sup>FMRP-USP – Biochemistry and Immunology, <sup>2</sup>ICB-USP – Immunology, <sup>3</sup>FMRP-USP – Pharmacology, <sup>4</sup>UEM – Farmácia e Farmacologia, <sup>5</sup>UEL – Pathology and Pharmacology, <sup>6</sup>NIAID/NIH – Vector Biology

#### 04.076

Anti-inflammatory activity of crude extract and of flowers fractions from *Palicourea rigida* in mice. Arruda LLM<sup>1</sup>, Rosa EA<sup>2</sup>, Oliveira CMA<sup>3</sup>, Fachini RF<sup>2</sup>, Silva CC<sup>2</sup>, Baroni S<sup>1</sup>, Grespan R<sup>1</sup>, Bersani-Amado CA<sup>1</sup> <sup>1</sup>UEM – Farmácia e Farmacologia, <sup>2</sup>UEM Química, <sup>3</sup>UFGO – Química

#### 04.077

Short chain-fatty acid effects on acute gout: importance in induction and resolution of inflammatory responses. Vieira AT<sup>1</sup>, Shim D<sup>2</sup>, De-Leon E<sup>2</sup>, Schilter HC<sup>2</sup>, Amaral FA<sup>3</sup>, Arruda MCC<sup>3</sup>, Maslowski KM<sup>2</sup>, Fagundes CT<sup>3</sup>, Nicoli JR<sup>4</sup>, Teixeira MM<sup>3</sup>, Mackay CR<sup>2</sup> <sup>1</sup>Garvan Institute of Medical Research/UFMG – Arthritis and inflammation / Bioquímica e Imunologia, <sup>2</sup>Garvan Institute of Medical Research – Arthritis and Inflammation, <sup>3</sup>UFMG – Bioquímica e Imunologia, <sup>4</sup>UFMG – Microbiologia

#### 04.078

*In vivo* hydroquinone exposure affects leukocyte recruitment and adhesion molecules expression on LPS inflamed lung. Ribeiro ALT<sup>1</sup>, Shimada ALB<sup>1</sup>, Hebeda CB<sup>1</sup>, Bolonheis SM<sup>1</sup>, Tavares de Lima W<sup>2</sup>, Farsky S<sup>1</sup> <sup>1</sup>USP-Clinical and Toxicological Analyses, <sup>2</sup>ICB-USP – Pharmacology

#### 04.079

Exogenous leptin modulates acute lung inflammation induced by LPS in mice. Landgraf MA<sup>1</sup>, Silva RC<sup>2</sup>, Hiyane M<sup>3</sup>, Cunha CS<sup>3</sup>, Vieira PMM<sup>3</sup>, Cenedeze MA<sup>2</sup>, Keller AC<sup>4</sup>, Pacheco-Silva A<sup>4</sup>, Araújo RC<sup>6</sup>, Câmara NOS<sup>1</sup>, Landgraf RG<sup>4</sup> <sup>1</sup>ICB-USP, <sup>2</sup>UNIFESP – Nefrologia, <sup>3</sup>ICB-USP – Imunologia, <sup>4</sup>UNIFESP-Diadema – Ciências Biológicas, <sup>6</sup>UNIFESP – Biofísica

**04.080**

Gastroprotection and healing activities of the seeds oil from *Carapa guianensis* Aubl. in mice. Gonçalves DO<sup>1</sup>, Figueiredo IST<sup>1</sup>, Osório CBH<sup>1</sup>, Siqueira RMP<sup>1</sup>, Oliveira RSB<sup>2</sup>, Freitas LBN<sup>1</sup>, Vieira IR<sup>1</sup>, Vasconcelos MAM<sup>3</sup>, Alencar NMN<sup>1</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>UFC – Bioquímica e Biologia Molecular, <sup>3</sup>EMBRAPA – Agroindústria

**04.081**

ADP effect on skin wound healing on diabetic mice. Branco AMC<sup>1</sup>, Brogliato AR<sup>1</sup>, Figueiredo JB<sup>2</sup>, Melo PA<sup>3</sup>, Benjamim CF<sup>3</sup> <sup>1</sup>UFRJ – Farmacologia, <sup>2</sup>ICB-UFRJ, <sup>3</sup>UFRJ – Farmacologia Básica e Clínica

**04.082**

Inflammasome activation and IL-1b and IL-18 production are essential for host resistance to dengue virus primary infection. Fagundes CT<sup>1</sup>, Ávila TV<sup>2</sup>, Costa VV<sup>2</sup>, Silveira KD<sup>3</sup>, Cisalpino D<sup>2</sup>, Valadão DF<sup>2</sup>, Tavares LD<sup>2</sup>, Morcatty TQ<sup>2</sup>, Santos AG<sup>2</sup>, Souza RS<sup>2</sup>, Vieira LQ<sup>3</sup>, Zamboni DS<sup>4</sup>, Souza DG<sup>2</sup> Teixeira MM<sup>3</sup> <sup>1</sup>UFMG – Bioquímica e Imunologia/Microbiologia, <sup>2</sup>UFMG – Microbiologia, <sup>3</sup>UFMG – Bioquímica e Imunologia, <sup>4</sup>FMRP-USP – Biologia Celular, Molecular e Bioagentes Patogênicos

**04.083**

Membrane TNF- $\alpha$  is essential for the pathogenesis of gouty arthritis. Tavares LD<sup>1</sup>, Amaral FA<sup>1</sup>, Costa VV<sup>1</sup>, Fagundes CT<sup>2</sup>, Quesniaux V<sup>3</sup>, Ryffel B<sup>4</sup>, Teixeira MM<sup>2</sup>, Souza DG<sup>1</sup> <sup>1</sup>UFMG – Microbiologia, <sup>2</sup>UFMG – Bioquímica e Imunologia, <sup>3</sup>CNRS – Molecular Immunology and Embryology, <sup>4</sup>IEM-CNRS

**04.084**

ATL-1, a synthetic analog of 15-Epi-lipoxin A4, promotes changes in dendritic cells phenotype and function. Da-Fe AR<sup>1</sup>, Ladislau L<sup>2</sup>, Kunkel SL<sup>3</sup>, Benjamim CF<sup>4</sup>, Fierro IM<sup>5</sup> <sup>1</sup>UERJ – Farmacologia e Psicobiologia, <sup>2</sup>ICB-UFRJ, <sup>3</sup>University of Michigan – Pathology, <sup>4</sup>UFRJ – Farmacologia Básica e Clínica, <sup>5</sup>UERJ – Farmacologia

**04.085**

Platelet-Activating Factor (PAF) contributes to the neuroinflammatory process involved in the *Plasmodium berghei* ANKA infection. Lacerda-Queiroz N<sup>1</sup>, Rodrigues DH<sup>1</sup>, Miranda AS<sup>2</sup>, Vilela MC<sup>3</sup>, Teixeira MM<sup>4</sup>, Teixeira AL<sup>5</sup> <sup>1</sup>UFMG – Biologia Celular, <sup>2</sup>UFMG – Medicina Tropical, <sup>3</sup>UFMG – Neurociências, <sup>4</sup>UFMG, <sup>5</sup>UFMG – Medicina

**04.086**

iNOS-derived nitric oxide modulates bone loss from ligature induced periodontitis by inhibiting osteoclast differentiation and activity. Herrera BS<sup>1</sup>, Martins Porto R<sup>2</sup>, Costa SKP<sup>2</sup>, Spolidório LC<sup>1</sup>, Van Dyke TE<sup>3</sup>, Gyurko R<sup>3</sup>, Muscará MN<sup>2</sup> <sup>1</sup>FOAR-UNESP – Physiology and Pathology, <sup>2</sup>ICB-

USP – Pharmacology, <sup>3</sup>Boston University – Periodontology and Oral Biology

**04.087**

HQ impairs nitric oxide synthesis in neutrophils via post transcriptional modifications. Hebeda CB<sup>1</sup>, Bolonheis SM<sup>1</sup>, Pinedo F<sup>1</sup>, Teixeira SA<sup>2</sup>, Muscará MN<sup>2</sup>, Farsky S<sup>1</sup> <sup>1</sup>USP – Análises Clínicas e Toxicológicas, <sup>2</sup>USP – Farmacologia

**04.088**

Melatonin inhibits adhesion of neutrophils induced by lipopolysaccharide (LPS) in endothelial cells culture. Abrantes-Lima KD, Tamura EK, Markus RP IB-USP – Fisiologia

**04.089**

Interaction of the anti-inflammatory annexin A1 protein and tacrolimus immunosuppressant in the renal function of rats. Truzzi RR<sup>1</sup>, Araújo LP<sup>2</sup>, Oliani SM<sup>1</sup> <sup>1</sup>UNESP – Biology, <sup>2</sup>UNIFESP – Morphology

**04.090**

Crosstalk of TLR2/CD36 with PPAR $\gamma$  in lipid metabolism and inflammatory response during infection by *Mycobacterium bovis* BCG: role of rafts. Almeida PE<sup>1</sup>, Antunes KM<sup>2</sup>, Maya-Monteiro CM<sup>1</sup>, Almeida CJ<sup>1</sup>, Silva AR<sup>1</sup>, Castro-Faria-Neto HC<sup>1</sup>, Bozza PT<sup>1</sup> <sup>1</sup>FIOCRUZ – Fisiologia Farmacodinâmica, <sup>2</sup>FIOCRUZ – Microbiologia

**04.091**

Role of PPAR $\gamma$  in macrophage activation but not in neutrophil recruitment during *Mycobacterium bovis* BCG infection *in vivo*. Sette-Martins R, Almeida PE, Roque NR, Bozza PT IOC-FIOCRUZ – Imunofarmacologia

**04.092**

Role of substance P in different endogenous pyrogen-induced fever. Brito HO, Reis RC, Zampronio AR UFPR – Farmacologia

**05. Pain and Nociception****05.027**

Resistance exercise induces antinociception in rats with participation of nitric oxide/ $c$ GMP/ $K_{ATP}$  pathway. Galdino GS, Silva GC, Almeida RT, Duarte ID, Perez AC UFMG – Farmacologia

**05.028**

Peripheral sensitization increases opioid receptor activation and expression in both dorsal root ganglia and nerve paw of rats. Zambelli VO<sup>1</sup>, Gutierrez VP<sup>1</sup>, Fernandes ACO<sup>1</sup>, Parada CA<sup>2</sup>, Cury Y<sup>1</sup> <sup>1</sup>Ibu – Dor e Sinalização, <sup>2</sup>UNICAMP – Farmacologia

**05.029**

The sesquiterpene lactone, budlein A, inhibits antigen induced-arthritis inflammation in mice. Zarpelon AC<sup>1</sup>, Pinto LG<sup>2</sup>, Souto FO<sup>2</sup>, Turato W<sup>3</sup>, Arakawa NS<sup>4</sup>, Da Costa FB<sup>4</sup>, Cunha TM<sup>2</sup>, Ferreira SH<sup>2</sup>, Cunha FQ<sup>2</sup>, Silva JS<sup>5</sup>, Verri Jr WA<sup>1</sup> <sup>1</sup>UEL – Ciências Patológicas, <sup>2</sup>FMRP-USP – Farmacologia, <sup>3</sup>FCFRP-USP – Análises Clínicas,

Toxicológicas e Bromatológicas, <sup>4</sup>FCFRP-USP, <sup>5</sup>FMRP-USP – Imunologia

#### 05.030

LASSBio-294 has partial agonist and antagonistic actions on TRPV1. Munaro DV<sup>1</sup>, Barreiro EJ<sup>2</sup>, Fraga CAM<sup>2</sup>, Castro NG<sup>3</sup>, Guimarães MZP<sup>4</sup> <sup>1</sup>UFRJ – Biofísica, <sup>2</sup>FF-UFRJ – LASSBio, UFRJ, <sup>3</sup>UFRJ – Farmacologia Molecular, <sup>4</sup>UFRJ – Farmacologia Básica e Clínica

#### 05.031

Study of anti-inflammatory and antinociceptive properties of new derivatives rationally designed as PPAR agonists. Santos BLR, Lima CKF, D'Andrea ED, Lima LM, Barreiro EJ, Miranda ALP FF-UFRJ – LASSBio

#### 05.032

Ketamine/fentanyl administration in infant rats promotes analgesia associated with increased hydrolysis of nucleotides. Medeiros LF<sup>1</sup>, Souza A<sup>2</sup>, Rozisky JR<sup>1</sup>, Santos VS<sup>1</sup>, Netto CA<sup>2</sup>, Battastini AMO<sup>2</sup>, Torres ILS<sup>1</sup> <sup>1</sup>UFRGS – Farmacologia, <sup>2</sup>UFRGS – Bioquímica

#### 05.033

Evaluation of some mechanisms involved in antinociceptive effect of (-)epicatechin obtained from *Combretum leprosum* Mart. & Eicher (Combretaceae) in models of acute pain. Lopes LS<sup>1</sup>, Pereira SS<sup>1</sup>, Marques RB<sup>1</sup>, Ayres MCC<sup>2</sup>, Chaves MH<sup>2</sup>, Almeida FRC<sup>3</sup> <sup>1</sup>NPPM-CCS-UFPI, <sup>2</sup>UFPI – Chemistry, <sup>3</sup>UFPI – Biochemistry and Pharmacology

#### 05.034

Preliminary studies of possible mechanisms involved in the antinociception presented by  $\alpha$ -terpineol, a major constituent of essential oil from *Protium heptaphyllum* March. resin. Marques RB<sup>1</sup>, Lopes LS<sup>1</sup>, Fernandes, HB<sup>1</sup>, Pereira SS<sup>1</sup>, Chaves MH<sup>2</sup>, Oliveira, FA<sup>1</sup>, Almeida FRC<sup>3</sup> <sup>1</sup>NPPM-CCS-UFPI, <sup>2</sup>UFPI – Chemistry, <sup>3</sup>UFPI – Biochemistry and Pharmacology

#### 05.035

Antinociceptive effect of (-) epicatechin obtained from *Combretum leprosum* Mart. & Eicher (Combretaceae) in models of acute pain. Lopes LS<sup>1</sup>, Fernandes, HB<sup>1</sup>, Pereira SS<sup>1</sup>, Marques, RB<sup>1</sup>, Ayres MCC<sup>2</sup>, Chaves MH<sup>2</sup>, Almeida FRC<sup>1</sup> <sup>1</sup>NPPM-CCS-UFPI, <sup>2</sup>CCN-UFPI – Química

#### 05.036

Antinociceptive activity of new isatin derivatives. Figueiredo GSM<sup>1</sup>, Zardo RS<sup>1</sup>, Silva BV<sup>2</sup>, Matheus ME<sup>1</sup>, Pinto AC<sup>3</sup>, Fernandes PD<sup>1</sup> <sup>1</sup>UFRJ – Farmacologia Básica e Clínica, <sup>2</sup>IQ-UFRJ – Química Orgânica, <sup>3</sup>UFRJ – Química

#### 05.037

Involvement of adenosinergic system in the antinociceptive effect of ethanolic extract of *Cipura paludosa* Aubl. in mice. Macedo Junior SJ<sup>1</sup>, Lucena GMRS<sup>2</sup>, Nascimento FP<sup>3</sup>, Cerutti M<sup>3</sup>,

Santos ARS<sup>1</sup> <sup>1</sup>UFSC – Ciências Fisiológicas, <sup>2</sup>UnB – Ciências da Saúde, <sup>3</sup>UFSC – Farmacologia

#### 05.038

Direct blockade of inflammatory hypernociception by peripheral activation of the A1 adenosine receptor: involvement of the NO/cGMP/PKG/KATP signaling pathway. Cunha TM<sup>1</sup>, Lima FO<sup>1</sup>, Souza GR<sup>1</sup>, Verri Jr WA<sup>2</sup>, Parada CA<sup>3</sup>, Ferreira SH<sup>1</sup>, Cunha FQ<sup>1</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>UEL – Ciências Patológicas, <sup>3</sup>UNICAMP – Farmacologia, <sup>5</sup>FMRP-USP

#### 05.039

Ropivacaine gel for topical anesthesia: *in vitro* permeation skin and cytotoxic effects. Stoco SM<sup>1</sup>, Grillo R<sup>2</sup>, Mello NFS<sup>2</sup>, Guilherme VA<sup>1</sup>, Franz-Montan M<sup>1</sup>, Tófoli GR<sup>3</sup>, Fraceto LF<sup>2</sup>, de Paula E<sup>1</sup>, de Araújo DR<sup>4</sup> <sup>1</sup>UNICAMP – Bioquímica, <sup>2</sup>UNESP – Engenharia Ambiental, <sup>3</sup>UNIFAG – Farmacologia Clínica, <sup>4</sup>CCNH-UFABC – Farmacologia

#### 05.040

The armed spider toxin TX3-3 restores the analgesic effect of morphine in neuropathic and opioid-tolerant mice. Dalmolin GD<sup>1</sup>, Rigo FK<sup>1</sup>, Silva CR<sup>2</sup>, Gomez MV<sup>1</sup>, Ferreira J<sup>2</sup> <sup>1</sup>UFMG – Farmacologia, <sup>2</sup>UFMS – Química

#### 05.041

Celecoxib induces analgesia by release of B-Endorphin in rat paws. Paiva-Lima P<sup>1</sup>, Queiroz Junior CM<sup>1</sup>, Rezende RM<sup>2</sup>, Machado-Silva LDF<sup>2</sup>, Caliaro MV<sup>3</sup>, Bakhle YS<sup>4</sup>, Francischi JN<sup>1</sup> <sup>1</sup>UFMG – Farmacologia, <sup>2</sup>UFMG – Fisiologia e Farmacologia, <sup>3</sup>UFMG – Patologia, <sup>4</sup>Imperial College – Leukocyte Biology

#### 05.042

Antinociceptive and anti-inflammatory effect of electroacupuncture in zymosan-induced arthritis in the rat temporomandibular joint. Gondim DV<sup>1</sup>, Chaves, HV<sup>1</sup>, Costa JL<sup>2</sup>, Rocha SS<sup>2</sup>, Brito GAC<sup>3</sup>, Vale ML<sup>2</sup> <sup>1</sup>UFC – Medicina Clínica, <sup>2</sup>UFC – Fisiologia e Farmacologia, <sup>3</sup>UFC – Morfologia

#### 05.043

Macrophage Migration Inhibitory Factor (MIF) is involved in a cascade of events leading to inflammatory hypernociception in mice. Costa VV<sup>1</sup>, Amaral FA<sup>2</sup>, Sachs D<sup>3</sup>, Tavares LD<sup>4</sup>, Scopa IP<sup>2</sup>, Morcatty TQ<sup>1</sup>, Teixeira MM<sup>1</sup>, Souza DG<sup>2</sup> <sup>1</sup>UFMG – Bioquímica e Imunologia, <sup>2</sup>UFMG – Microbiologia, <sup>3</sup>FMRP-USP – Farmacologia, <sup>4</sup>UFMG – Fisiologia e Farmacologia

#### 05.044

Role of TRPV1 and NK1 receptors on nociception and edema induced by monosodium urate crystals in rats (MSU). Trevisan G, Rossato M, Hoffmeister C, Ferreira J UFSM – Química

**05.045**

The antinociception observed during glycogen-induced inflammation in rat paws is mediated by neutrophil migration and is independent of opioid peptides. Nogueira TO<sup>1</sup>, Spadacci-Morena DD<sup>1</sup>, Santoro ML<sup>1</sup>, Pagano RL<sup>2</sup>, Giorgi R<sup>1</sup> <sup>1</sup>Ibu – Fisiopatologia, <sup>2</sup>IEP-HSL

**05.046**

Ropivacaine gel for topical anesthesia: *in vitro* permeation skin and cytotoxic effects. Stoco SM<sup>1</sup>, Grillo R<sup>2</sup>, Mello NFS<sup>2</sup>, Guilherme VA<sup>1</sup>, Franz-Montan M<sup>1</sup>, Tófoli GR<sup>3</sup>, Fraceto LF<sup>2</sup>, de Paula E<sup>1</sup>, de Araújo DR<sup>4</sup> – <sup>1</sup>UNICAMP – Bioquímica, <sup>2</sup>UNESP – Engenharia Ambiental, <sup>3</sup>UNIFAG – Farmacologia, <sup>4</sup>CCNH-UFABC – Farmacologia

**05.047**

Cannabinoid and opioid receptors activation induces peripheral antinociception by noradrenaline release and  $\alpha_{2C}$  adrenoceptor interaction. Romero TRL<sup>1</sup>, Duarte IDG<sup>2</sup> <sup>1</sup>UFMG – Fisiologia e Farmacologia, <sup>2</sup>UFMG – Farmacologia

**05.048**

Antinociceptive effects of *Parkia platycephala* Benth in diabetic rats. Amorim VR<sup>1</sup>, Brito SRMC<sup>2</sup>, Sales Filho HLA<sup>3</sup>, Piauilino, CA<sup>4</sup>, Chaves MH<sup>5</sup>, Bezerra RDS<sup>5</sup> <sup>1</sup>UFPI – Farmacologia, <sup>2</sup>UFPI – Bioquímica e Farmacologia, <sup>3</sup>UFPI – Farmacologia, <sup>4</sup>UFPI-NPPM-UFPI, <sup>5</sup>UFPI – Química

**05.049**

Effects of thalamic nucleus submedius inhibition on the stimulation-induced antinociception in rats Reis GM, Rossaneis AC, Fais RS, Prado WA FMRP-USP – Farmacologia

**05.050**

Amitriptyline increases the duration of the antinociceptive effect produced by 2 Hz electroacupuncture in rats. Fais RS, Reis GM<sup>2</sup>, Dias QM<sup>1</sup>, Silveira JWS<sup>1</sup>, Prado WA<sup>3</sup> FMRP-USP – Farmacologia

**05.051**

Role of IL-33 / ST2 in carrageenin-induced innate inflammatory hypernociception in mice. Zarpelon AC<sup>1</sup>, Cunha, TM<sup>2</sup>, Xu D<sup>3</sup>, Alves-Filho JC<sup>3</sup>, Liew FY<sup>3</sup>, Ferreira SH<sup>2</sup>, Cunha FQ<sup>2</sup>, Verri Jr WA<sup>1</sup> <sup>1</sup>UEL – Patologia, <sup>2</sup>FMRP-USP – Pharmacology, <sup>3</sup>University of Glasgow – Immunology, Infection and Inflammation

**05.052**

Antinociceptive property of selenothiazolidines administered by oral route in mice. Frasson NR<sup>1</sup>, Donato F<sup>1</sup>, Schneider PH<sup>2</sup>, Savegnago L<sup>1</sup> <sup>1</sup>UNIPAMPA – Farmacologia e Toxicologia, <sup>2</sup>UFRGS – Química

**06. Cardiovascular and Renal Pharmacology****06.027**

Cardiac dysfunction in experimental sepsis as assessed by the isolated and perfused mouse heart. Bóf ER, DalBó S, Ramos GC, Assreuy J UFSC – Pharmacology

**06.028**

Sepsis-induced renal impairment to a second renal insult. Portella VG<sup>1</sup>, Silva-Filho JL<sup>1</sup>, de Rico TB<sup>2</sup>, Landgraf SS<sup>1</sup>, Vieira MAR<sup>3</sup>, Takiya CM<sup>4</sup>, Benjamim CF<sup>2</sup>, Canetti C<sup>1</sup>, Pinheiro AAS<sup>1</sup>, Caruso-Neves C<sup>1</sup> <sup>1</sup>IBCCF-UFRJ – Ciências da Saúde, <sup>2</sup>ICB-UFRJ – Farmacologia, <sup>3</sup>ICB-UFMG – Fisiologia e Biofísica, <sup>4</sup>ICB-UFRJ – Anatomia e Histologia

**06.029**

Effects of antioxidants treatment on cardiac dysfunction and MMP-2 levels in renovascular hypertension. Rizzi E<sup>1</sup>, Castro MM<sup>1</sup>, Ceron CS<sup>1</sup>, Neto-Neves EM<sup>1</sup>, Tanus-Santos JE<sup>1</sup>, Gerlach RF<sup>2</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>FORP-USP – Morfologia

**06.030**

Role of potassium channels in endothelium-dependent vasodilation in experimental periodontitis in rats. Olchanheski Junior LR<sup>1</sup>, Santos FA<sup>2</sup>, Fernandes D<sup>1</sup> <sup>1</sup>UEPG – Ciências Farmacêuticas, <sup>2</sup>UEPG – Odontologia

**06.031**

Inhibition of MMP-mediated vascular changes in 2K1C hypertension by doxycycline is dose-dependent. Guimarães DA<sup>1</sup>, Rizzi E<sup>1</sup>, Ceron CS<sup>1</sup>, Oliveira AM<sup>2</sup>, Marçal DMO<sup>5</sup>, Tirapelli CR<sup>5</sup>, Gerlach RF<sup>6</sup>, Tanus-Santos JE<sup>1</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>FCFRP-USP – Farmacologia, <sup>5</sup>EERP-USP – Farmacologia, <sup>6</sup>FORP-USP – Morfologia

**06.032**

New nitrite-pro-drug releases nitric oxide in a tissue and enzyme-dependent way. Pereira AC<sup>1</sup>, Lunardi CN<sup>2</sup>, Biazotto JC<sup>1</sup>, Silva RS<sup>1</sup>, Bendhack LM<sup>1</sup> <sup>1</sup>FCFRP-USP, <sup>2</sup>UnB

**06.033**

Effect of rosmarinic acid on the inhibition of angiotensin converting enzyme in normotensive and hypertensive rats. Ferreira LG, Celotto AC, Capellini VK, Albuquerque AAS, Evora PRB FMRP-USP – Cirurgia e Anatomia

**06.034**

Modulation of cardiac and renal P-type ATPases in diet-induced atherosclerosis. Balter AS, Marques EB<sup>1</sup>, Motta NAV<sup>1</sup>, Brito FCF<sup>1</sup>, Scaramello C<sup>1</sup> <sup>1</sup>UFF – Farmacologia Experimental

**06.035**

A new vasodilator compound (DCBPY-NO) presents cyclic activity in releasing nitric oxide by nitrite. Rodrigues GJ<sup>1</sup>, Cicillini SA<sup>2</sup>, Silva RS<sup>2</sup>, Bendhack LM<sup>2</sup> <sup>1</sup>FMRP USP - Farmacologia, <sup>2</sup>FCFRP-USP

**06.036**

The renal effects of l-amino acid oxidase from *Bothrops leucurus* venom in the rat perfused kidneys. Morais ICO<sup>1</sup>, Marinho AD<sup>2</sup>, Menezes RRPPB<sup>3</sup>, Dantas RT<sup>1</sup>, Torres AFC<sup>2</sup>, Lopes KS<sup>2</sup>, Meneses GC<sup>2</sup>, Costa MFB<sup>2</sup>, Jorge RJB<sup>1</sup>, Alves RS<sup>1</sup>, Toyama MH<sup>4</sup>, Monteiro HSA<sup>1</sup>, Martins AMC<sup>3</sup> <sup>1</sup>UFC - Fisiologia e Farmacologia, <sup>2</sup>UFC - Farmácia, <sup>3</sup>UFC - Análises Clínicas e Toxicológicas, <sup>4</sup>IB-UNICAMP

**06.037**

Tempol attenuates the hemodynamic changes associated with acute pulmonary embolism. Santos Sousa O<sup>1</sup>, Neto-Neves EM<sup>1</sup>, Ferraz KC<sup>2</sup>, Tanus-Santos JE<sup>1</sup> <sup>1</sup>FMRP-USP - Farmacologia, <sup>2</sup>UFJF - Farmacologia

**06.038**

Impaired cardiovascular responsiveness to isoprenaline in rats subjected to high-salt intake. Crestani S<sup>1</sup>, de Souza P<sup>1</sup>, Bóf ER<sup>2</sup>, Guarido KL<sup>2</sup>, Assreuy J<sup>2</sup>, Marques MCA<sup>1</sup>, da Silva-Santos JE<sup>2</sup> <sup>1</sup>UFPR - Farmacologia, <sup>2</sup>UFSC - Farmacologia

**06.039**

High salt-intake increases the activity of angiotensin-converting enzyme in rats. Crestani S<sup>1</sup>, Gasparotto Junior A<sup>2</sup>, Marques MCA<sup>1</sup>, da Silva-Santos JE<sup>3</sup> <sup>1</sup>UFPR - Farmacologia, <sup>2</sup>UNIPAR/UFPR - Farmacologia, <sup>3</sup>UFSC - Farmacologia

**06.040**

Quercetin produces beneficial effects in renovascular hypertension. Neto-Neves EM, Montenegro MF, Ceron CS, Dias-Junior CAC, Castro MM, Tanus-Santos JE FMRP-USP - Farmacologia

**06.041**

Neonatal hyperleptinaemia possibly modulates cardiac function. Marques EB<sup>1</sup>, Balter AS<sup>1</sup>, Pereira-Toste F<sup>2</sup>, Raimundo JM<sup>3</sup>, Sudo RT<sup>3</sup>, Zapata-Sudo G<sup>3</sup>, Marques SA<sup>4</sup>, Vieyra A<sup>5</sup>, Scaramello C<sup>1</sup> <sup>1</sup>UFF - Farmacologia Experimental, <sup>2</sup>UFF - Ciências do Exercício, <sup>3</sup>UFRJ - Farmacologia Básica e Clínica, <sup>4</sup>UFRJ - Histologia e Embriologia, <sup>5</sup>IBCCF-UFRJ

**06.042**

High-salt intake impairs the involvement of Rho-A/Rho-kinase and intracellular calcium in contractile responses of rat aortic rings. Crestani S<sup>1</sup>, Marques MCA<sup>1</sup>, da Silva-Santos JE<sup>2</sup> <sup>1</sup>UFPR - Farmacologia, <sup>2</sup>UFSC - Farmacologia

**06.043**

A sulfonamide compound attenuates vascular smooth muscle contraction and lowers arterial pressure of normotensive and spontaneously hypertensive rats. Pontes LB<sup>1</sup>, Raimundo JM<sup>1</sup>, Sudo RT<sup>1</sup>, Lima LM<sup>2</sup>, Barreiro EJ<sup>2</sup>, Zapata-Sudo G<sup>1</sup> <sup>1</sup>UFRJ - Farmacologia Básica e Clínica, <sup>2</sup>FF-UFRJ - LASSBio

**06.044**

New NO donor induces relaxation of mesenteric resistance arteries and reduces resistance of mesenteric bed of normotensive and 2K-1C hypertensive rats. Araújo AV<sup>1</sup>, Rodrigues GJ<sup>1</sup>, Vercesi JA<sup>2</sup>, Biazzotto JC<sup>2</sup>, Bonagamba LGH<sup>3</sup>, Machado BH<sup>3</sup>, Silva RS<sup>2</sup>, Bendhack LM<sup>2</sup> <sup>1</sup>FMRP-USP - Farmacologia, <sup>2</sup>FCFRP-USP - Física e Química, <sup>3</sup>FMRP-USP - Fisiologia

**06.045**

Vasodilation induced by atrial natriuretic peptide (ANP) involves K<sub>ATP</sub> channels activation in rat aorta. Andrade FA<sup>1</sup>, Bendhack LM<sup>2</sup> <sup>1</sup>FMRP-USP, <sup>2</sup>FCFRP-USP

**06.046**

Cardiovascular hyporesponsiveness in severe sepsis is related with augment of G-protein receptor kinase (GRK)-2 expression via a nitric oxide-dependent mechanism. Dal-Secco D<sup>1</sup>, Olivon VC<sup>2</sup>, Corrêa T<sup>1</sup>, Celes MRN<sup>3</sup>, Abreu A<sup>3</sup>, Rossi MA<sup>3</sup>, Oliveira AM<sup>2</sup>, Cunha FQ<sup>4</sup>, Assreuy J<sup>1</sup> <sup>1</sup>UFSC - Farmacologia, <sup>2</sup>FCFRP-USP - Física e Química, <sup>3</sup>FMRP-USP - Patologia, <sup>4</sup>FMRP-USP - Farmacologia

**06.047**

Vasorelaxant effect of Isotirumalin, a dihydroflavonol from *Derris urucu*, on rat aorta. Mendes LJ<sup>1</sup>, Capettini LSA<sup>2</sup>, Arruda MSP<sup>3</sup>, Lemos VS<sup>2</sup>, Côrtes SF<sup>1</sup> <sup>1</sup>UFMG - Farmacologia, <sup>2</sup>ICB-UFMG - Fisiologia e Biofísica, <sup>3</sup>UFPA - Química

**06.048**

Echocardiography aspects of structural changes in different morphological and functional models of hypertension in SHR. Pereira DJ<sup>1</sup>, Gazzoto AF<sup>1</sup>, Pires NF<sup>1</sup>, Moreira MM<sup>1</sup>, Santos RC<sup>1</sup>, Ludovico ND<sup>1</sup>, Quinaglia TSS<sup>1</sup>, Renno AL<sup>2</sup>, Figueiredo VN<sup>1</sup>, Moreno Junior H<sup>1</sup> <sup>1</sup>UNICAMP - Farmacologia cardiovascular, <sup>2</sup>UNICAMP - Farmacologia Bioquímica

**06.049**

Development and validation of analytical method for quantification of arsenic and antimony in liposomes. Reis PG, Souza J, Teixeira MC, Grabe-Guimarães A, Silva-Barcellos NM UFOP - Farmácia

**06.050**

Spontaneously hypertensive rats (SHR) under chronic treatment with sodium fluoride showed reduced fluoride and calcium concentrations in plasma and saliva. Picco DCR<sup>1</sup>, Delbem ACB<sup>1</sup>,

Antioniali C<sup>2</sup> <sup>1</sup>FOA-UNESP – Odontologia Infantil e Social, <sup>2</sup>UNESP-Araçatuba – Ciências Básicas

#### 06.051

H<sub>2</sub>O<sub>2</sub> -induced vasodilatation through neuronal nitric oxide synthase activation by a natural xanthone. Capettini LSA<sup>1</sup>, Silva JF<sup>1</sup>, Dos Santos MH<sup>2</sup>, Nagem TJ<sup>3</sup>, Côrtes SF<sup>4</sup>, Lemos VS<sup>1</sup> <sup>1</sup>ICB-UFMG Fisiologia e Biofísica, <sup>2</sup>UNIFAL-MG – Farmácia, <sup>3</sup>UFOP – Química, <sup>4</sup>UFMG – Farmacologia

#### 06.052

Consequences of acute or chronic stress on relaxation induced by angiotensin 1-7 in rat carotid. Banin TM<sup>1</sup>, Olivon VC<sup>1</sup>, Ramalho L<sup>2</sup>, de Oliveira AM<sup>1</sup> <sup>1</sup>USP – Física e Química, <sup>2</sup>USP – Patologia

### 09. Natural Products and Toxinology

#### 09.036

Investigation of gastroprotective effect and 50 lethal concentration of the ethanolic extract from *Combretum duarteianum cambess* (Combretaceae). Lima GRM, Montenegro CA, Almeida CLF, Pessoa DR, Moreira MMB, Castello Branco MVS, Tavares JF, Batista LM LTF-DCF-UFPB

#### 09.037

Mechanisms involved in the antinociceptive effect of the ethanolic extract from the leaves of *Celtis iguanaea* (jacq.) Sargent (Ulmaceae). Nascimento MVM<sup>1</sup>, Lino RC<sup>1</sup>, Sousa BF<sup>1</sup>, Florentino FI<sup>1</sup>, Galdino PM<sup>1</sup>, Couto, RO<sup>2</sup>, Paula JR<sup>2</sup>, Costa EA<sup>1</sup> <sup>1</sup>ICB-UFG, <sup>2</sup>UFG – Farmácia

#### 09.038

Effects of amblyomin-X on tumor growth, endothelial cell migration, adhesion and secretion. Dias RYS<sup>1</sup>, Drewes CC<sup>1</sup>, Hebeda CB<sup>1</sup>, Simons SM<sup>2</sup>, Chudzinski-Tavassi AM<sup>2</sup>, Farsky S<sup>1</sup> <sup>1</sup>FCF-USP Análises Clínicas e Toxicológicas, <sup>2</sup>IBU – Laboratório de Bioquímica

#### 09.039

Healing properties of bark extract of *Tabebuia avellanadae* in chronic gastric ulcer induced by acetic acid in rats. Pereira IT<sup>1</sup>, Burci LM<sup>1</sup>, da Silva LM<sup>1</sup>, Baggio CH<sup>1</sup>, Andre E<sup>2</sup>, Pizzolatti MG<sup>3</sup>, Marques MCA<sup>1</sup>, Werner MFP<sup>4</sup> <sup>1</sup>UFPR – Farmacologia, <sup>2</sup>UFRN – Farmacologia, <sup>3</sup>UFSC – Química, <sup>4</sup>UFSC – Farmacologia

#### 09.040

Subfraction of *Pterodon pubescens* seeds oil induces apoptosis of leukemic cells by inducing Apaf-1 gene expression. Martino T, Pereira MF, Dalmau SR, Silva MCC, Coelho MGP, Sabino KCC UERJ – Bioquímica

#### 09.041

Antinociceptive effects of (1→3),(1→6)-linked β-glucan isolated from *Pleurotus pulmonarius* in models of acute and neuropathic pain in mice. Baggio CH<sup>1</sup>, Freitas CS<sup>1</sup>, Werner MFP<sup>2</sup>, Martins

DF<sup>3</sup>, Mazzardo L<sup>3</sup>, Smiderle FR<sup>4</sup>, Sasaki GL<sup>4</sup>, Iacomini M<sup>4</sup>, Marques MCA<sup>1</sup>, Santos ARS<sup>5</sup> <sup>1</sup>UFPR – Farmacologia, <sup>2</sup>UFSC – Farmacologia, <sup>3</sup>UFSC – Fisiologia, <sup>4</sup>UFPR – Bioquímica, <sup>5</sup>UFSC – Ciências Fisiológicas

#### 09.042

Effect of p-cymene obtained from *Citrus latifolia* Tanaka essential oil on *in vitro* leukocytes chemotaxis. Kummer R<sup>1</sup>, Fachini FC<sup>1</sup>, Silva CFE<sup>1</sup>, Freitag A<sup>1</sup>, Silva EL<sup>2</sup>, Grespan R<sup>1</sup>, Bersani-Amado CA<sup>1</sup>, Cuman RKN<sup>1</sup> <sup>1</sup>UEM – Farmácia e Farmacologia, <sup>2</sup>UEM – Química

#### 09.043

Effect of eugenol treatment on renal parameters after renal ischemia and reperfusion in mice. Damião MJ<sup>1</sup>, Victor ML<sup>1</sup>, Fonseca JP<sup>1</sup>, Bersani-Amado CA<sup>1</sup>, Rilson JP<sup>1</sup>, Giannocco G<sup>2</sup>, Câmara NOS<sup>3</sup>, Cuman RKN<sup>1</sup> <sup>1</sup>UEM – Farmácia e Farmacologia, <sup>2</sup>UNIFESP – Endocrinologia, <sup>3</sup>ICB-USP

#### 09.044

Cardiovascular activity *Hancornia speciosa* ethanolic extract in a model of hypertension induced by nitric oxide synthesis inhibition in rats. Silva MDA<sup>1</sup>, Serra CP<sup>2</sup>, Grabe-Guimarães A<sup>2</sup>, Guimarães HN<sup>3</sup>, Braga FC<sup>4</sup> <sup>1</sup>CiPharma-UFOP, <sup>2</sup>DEFAR-UFOP, <sup>3</sup>UFMG – Engenharia Elétrica, <sup>4</sup>FaFar -UFMG

#### 09.045

Investigation of toxic and antidiarrhoeal activities of ethanol extract of aerial parts from *Xylopija langsdorffiana* A. St. Hil. & Tul. (Annonaceae) in mice. Silva KM<sup>1</sup>, Silva ADS<sup>1</sup>, Lima LO<sup>1</sup>, Clementino-Neto J<sup>1</sup>, Silva PCB<sup>2</sup>, Medeiros VM<sup>2</sup>, Costa VCO<sup>2</sup>, Tavares JF<sup>2</sup>, Silva MS<sup>2</sup>, Cavalcante FA<sup>1</sup> <sup>1</sup>ICBS-UFAL, <sup>2</sup>LTF-UFPB

#### 09.046

Investigation of topical anti-inflammatory activity of *Vochysia bifalcata*. Silva CD<sup>1</sup>, Mendes DAGB<sup>1</sup>, Soley BS<sup>1</sup>, Ferreira BGA<sup>2</sup>, Zuffellato-Ribas KC<sup>2</sup>, Otuki MF<sup>1</sup>, Cabrini DA<sup>1</sup> <sup>1</sup>UFPR – Farmacologia, <sup>2</sup>UFPR – Botânica

#### 09.047

Anti-inflammatory effect of latex proteins (LP) isolated from *calotropis procera* in 5-fluorouracil-induced oral mucositis in hamsters. Freitas APF<sup>1</sup>, Almeida RA<sup>2</sup>, Cerqueira GS<sup>2</sup>, Alencar NMN<sup>2</sup>, Brito GAC<sup>3</sup>, Ribeiro RA<sup>2</sup>, Ramos MV<sup>4</sup>, Vale ML<sup>2</sup> <sup>1</sup>UFC – Medicina Clínica, <sup>2</sup>UFC – Fisiologia e Farmacologia, <sup>3</sup>UFC – Morfologia, <sup>4</sup>UFC – Bioquímica

#### 09.048

Evaluation of antimicrobial activity and preliminary phytochemical profile of *Hyptis suaveolens* L. Poit. Jesus NZT<sup>1</sup>, Mota FD<sup>2</sup>, Silva Junior IF<sup>3</sup>, Tavares JF<sup>4</sup>, Batista LM<sup>5</sup> <sup>1</sup>UNIC-UFPB-LTF, <sup>2</sup>UNIC – Farmácia, <sup>3</sup>UFMT – Farmacologia, <sup>4</sup>UFPB – Tecnologia Farmacêutica, <sup>5</sup>UFPB – Ciências Farmacêuticas

**09.049**

Acute toxicity and gastric cytoprotective effect of *Argyrovernonia harleyi* (H. ROB) Macleish in mice. Silva AAR<sup>1</sup>, Bezerra MM<sup>3</sup>, Aguiar, JA<sup>2</sup>, Chaves, HV<sup>4</sup>, Ribeiro, KA<sup>5</sup>, Pereira, KMA<sup>4</sup>, Maia, MBS<sup>6</sup> <sup>1</sup>UFC – Pharmacology Laboratory, <sup>2</sup>UFC – Medicine, <sup>3</sup>UFC – Biotechnology, <sup>4</sup>UFC – Pharmacology Laboratory, <sup>5</sup>UVA – Pharmacology, <sup>6</sup>UFPE – Pharmacology and Toxicology of Bioactive Products

**09.050**

(+)-cordiaquinone J triggers both death receptor-dependent apoptosis and necrosis by oxidative stress pathway in leukemia cells. Marinho-Filho JDB<sup>1</sup>, Araújo AJ<sup>1</sup>, Bezerra DP<sup>2</sup>, Montenegro RC<sup>3</sup>, Pessoa C<sup>1</sup>, Diniz J<sup>3</sup>, Viana FA<sup>4</sup>, Pessoa ODL<sup>4</sup>, Silveira ER<sup>4</sup>, Moraes MO<sup>1</sup>, Costa-Lotufo LV<sup>1</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>UFAL, <sup>3</sup>UERN – Química, <sup>4</sup>UFC – Química Orgânica e Inorgânica

**09.051**

Anti-inflammatory activity of anethole obtained from *Foeniculum vulgare* Miller var. *vulgare* Miller essential oil. Domiciano TP<sup>1</sup>, Ritter AMV<sup>1</sup>, Silva EL<sup>2</sup>, Dantas JA<sup>1</sup>, Caparroz-Assef SM<sup>3</sup>, Cuman RKN<sup>1</sup>, Bersani-Amado CA<sup>1</sup> <sup>1</sup>UEM – Farmácia e Farmacologia, <sup>2</sup>UEM – Química, <sup>3</sup>UEM – Inflamação

**09.052**

Evaluation of antimicrobial activity of ethanol extract of the aerial parts of *Nanuzia plicata* (Mart.) L. B. Smith & Ayensu. Tenório JAB<sup>1</sup>, Mendes JM<sup>1</sup>, Falcão HS<sup>1</sup>, Lima EO<sup>2</sup>, Marculino DMM<sup>1</sup>, Tavares JF<sup>1</sup>, Batista LM<sup>1</sup>, Montes RC<sup>1</sup> <sup>1</sup>UFPPB – Ciências Farmacêuticas, <sup>2</sup>UFPPB – Micologia

**09.053**

Evaluation of the effects of jatobá juice concentrating on the glucemic control, lipid profile and liver function of diabetic rats. Almeida IP<sup>1</sup>, Damasceno DCF<sup>1</sup>, Sales ALCC<sup>2</sup>, Teixeira JMR<sup>1</sup>, Soares LFM<sup>1</sup>, Santos Júnior JC<sup>1</sup>, Amorim VR<sup>3</sup>, Silva AFS<sup>3</sup>, Assis RC<sup>3</sup>, Martins MCC<sup>1</sup> <sup>1</sup>UFPI – Biophysics and Physiology, <sup>2</sup>UFPI – Nutrition, <sup>3</sup>UFPI – Biochemistry and Pharmacology

**09.054**

Inhibitory effects of ginger (*Zingiber officinale* Roscoe) essential oil on *in vivo* and *in vitro* leukocytes migration. Grespan R, Nogueira de Melo GA, Fonseca JP, Farinha TO, Dantas JA, Miranda CR, Bersani-Amado CA, Cuman RKN UEM – Pharmacy and Pharmacology

**09.055**

Hypoglycemic effect of *Terminalia catappa* Linn. in alloxan-induced diabetic rats. Ferreira AKB<sup>1</sup>, Costa DL<sup>2</sup>, Tenório EP<sup>1</sup>, Oliveira DA<sup>1</sup>, Santana AEG<sup>2</sup>, Humberto MMS<sup>2</sup>, Grillo LAM<sup>1</sup>, Ribeiro EAN<sup>1</sup> <sup>1</sup>ESENFAR-UFAL, <sup>2</sup>IQB-UFAL

**09.056**

Fraction from *Calotropis procera* Latex shows anti-inflammatory effects on the pathogenesis of irinotecan-induced intestinal mucositis in mice. Alverne SM<sup>1</sup>, Bitencourt FS<sup>1</sup>, Figueiredo JG<sup>2</sup>, Luz PB<sup>1</sup>, Lima-Júnior RCP<sup>1</sup>, Ramos MV<sup>3</sup>, Cunha FQ<sup>4</sup>, Ribeiro RA<sup>1</sup>, Alencar NMN<sup>1</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>UFC – Bioquímica e Biologia Molecular, <sup>3</sup>UFC – Bioquímica, <sup>4</sup>FMRP-USP

**09.057**

Ability of fucosylated chondroitin sulfate to inhibit muscle damage induced by *Bothrops jararacussu* crude snake venom. Machado MM<sup>1</sup>, Strauch MA<sup>1</sup>, Tomaz MA<sup>1</sup>, Cons BL<sup>1</sup>, Branco AMC<sup>1</sup>, Martins VV<sup>1</sup>, Mourão PAS<sup>2</sup>, Melo PA<sup>1</sup> <sup>1</sup>UFRJ – Farmacologia Básica e Clínica, <sup>2</sup>UFRJ – Bioquímica Médica

**09.058**

Evaluation of the toxicity of the ethanol extract of aerial parts of *Nanuzia plicata* (Mart.) L. B. Smith & Ayensu. Tenório JAB<sup>1</sup>, Falcão HS<sup>1</sup>, Viana WP<sup>2</sup>, Dias GEN<sup>1</sup>, Batista LM<sup>1</sup>, Diniz MFFM<sup>1</sup>, Tavares JF<sup>1</sup> <sup>1</sup>LTF-UFPPB – Ciências Farmacêuticas, <sup>2</sup>UFPPB – Ciências da Saúde

**09.059**

Fish oil supplementation on motor and cognitive side effects of typical antipsychotics in psychiatric patients. Bürger ME<sup>1</sup>, Cardoso PM<sup>2</sup>, Reckziegel P<sup>2</sup>, Pase CS<sup>2</sup>, Emanuelli, T<sup>3</sup>, Santos DB<sup>4</sup>, Cunha A<sup>5</sup>, Rocha JBT<sup>4</sup> <sup>1</sup>UFMS – Farmacologia, <sup>2</sup>UFMS – Fisiologia e Farmacologia, <sup>3</sup>UFMS – Tecnologia e Ciência dos Alimentos, <sup>4</sup>UFMS – Química, <sup>5</sup>UFMS – Neuropsiquiatria

**09.060**

Anti-inflammatory activity of the hydroalcoholic extract and fractions from *Gochnatia polymorpha ssp floccosa* in mouse air pouch model. Piornedo RR<sup>1</sup>, Kassuya CAL<sup>2</sup>, Zampronio AR<sup>1</sup>, Stefanello MEA<sup>3</sup>, Strapasson RLB<sup>3</sup> <sup>1</sup>UFPR – Farmacologia, <sup>2</sup>UFGD – Ciências da Saúde, <sup>3</sup>UFPR – Química

**09.061**

*In vitro* chlorogenic acid inhibits adhesion molecules expression and inflammatory mediators secretion in neutrophils. Bolonheis SM<sup>1</sup>, Hebeda CB<sup>1</sup>, Belinati KD<sup>1</sup>, Lopes NP<sup>2</sup>, Farsky S<sup>1</sup> <sup>1</sup>FCF-USP – Análises Clínicas e Toxicológicas, <sup>2</sup>FCFRP-USP – Física e Química

**09.062**

Topical effect of crude hydroalcoholic extract from *Psychotria nuda* (Cham. & Schldtl.) Wawra leaves in skin inflammation model. Mendes DAGB<sup>1</sup>, Soley BS<sup>1</sup>, Ferreira BGA<sup>2</sup>, Zuffellato-Ribas KC<sup>2</sup>, Otuki MF<sup>1</sup>, Cabrini DA<sup>1</sup> <sup>1</sup>UFPR – Farmacologia, <sup>2</sup>UFPR – Botânica

**09.063**

Ethanol crude extract of *Erythroxylum caatingae* induces relaxant effect in the guinea-pig trachea. Santos HAS<sup>1</sup>, Oliveira SL<sup>2</sup>, Tavares JF<sup>2</sup>, Ribeiro LAA<sup>3</sup>, Lima JT<sup>3</sup> <sup>1</sup>UNIVASF – Medicina, <sup>2</sup>UFPPB –

Tecnologia Farmacêutica, <sup>3</sup>UNIVASF – Ciências Farmacêuticas

#### 09.064

Effect of LED treatment on muscular edema and mionecrose induced by *Bothrops jararaca* venom. Bulgarelli<sup>1</sup>, Barbosa AM<sup>2</sup>, Lima CJ<sup>3</sup>, Zamuner SR<sup>4</sup> <sup>1</sup>UNIVAP – Fisiologia e Inflamação, <sup>2</sup>UNIVAP – Pesquisa e Desenvolvimento, <sup>3</sup>UNICASTELO – Instrumentação Optobiomédica, <sup>4</sup>UNINOVE – Ciências da Reabilitação

#### 09.065

Modulation of gene expression in melanoma cells by treatment with crotonamine. Moura AB<sup>1</sup>, Yonamine CM<sup>1</sup>, Pellegrino R<sup>2</sup>, Oliveira EB<sup>3</sup>, Yamane T<sup>4</sup>, Lapa AJ<sup>1</sup>, Hayashi MA<sup>1</sup> <sup>1</sup>UNIFESP – Farmacologia, <sup>2</sup>UNIFESP – Psicobiologia, <sup>3</sup>FMRP-USP – Biochemistry and Immunology, <sup>4</sup>CBA – Bioquímica e Biologia Molecular

#### 09.066

Preliminary biochemical and pharmacological characterizations of *Rhinela icterica* toad venom. Pesamosca ME, Freitas TC, Franco JL, Dal Belo CA UNIPAMPA

#### 09.067

Evaluation of antinociceptive property of ethanolic extract of *Sidastrum micranthum* (A. St.-Hil.) Fryxell. Villa JKD<sup>1</sup>, Marinho DG<sup>2</sup>, Dias DM<sup>1</sup>, Ramiro JB<sup>1</sup>, Scherrer JV<sup>1</sup>, Faccim AG<sup>1</sup>, Almança CCJ<sup>3</sup>, Marinho BG<sup>1</sup> <sup>1</sup>UFES – Medicina Veterinária, <sup>2</sup>ICB-UFRJ – Farmacologia e Química Medicinal, <sup>3</sup>FAFIA – Farmácia

#### 09.068

Endothelium-dependent and independent relaxation of rat aortic ring by crude extracts and fractions from *Scutia buxifolia*. Silva RCMVAF<sup>1</sup>, Crestani S<sup>1</sup>, Boligon AA<sup>2</sup>, Athayde ML<sup>2</sup>, Santos ARS<sup>3</sup>, Marques MCA<sup>1</sup>, Kassuya CAL<sup>1</sup>, da Silva-Santos JE<sup>4</sup> <sup>1</sup>UFPR – Farmacologia, <sup>2</sup>UFMS – Farmácia Industrial, <sup>3</sup>UFSC – Ciências Fisiológicas, <sup>4</sup>UFPA – Farmacologia Experimental e Pré-clínica

#### 09.069

Anti-inflammatory and antinociceptive activity of the ethanolic extract from *Sinningia leucotricha*. Botelho A<sup>1</sup>, Verdán ML<sup>2</sup>, Stefanello MEA<sup>2</sup>, Kassuya CAL<sup>3</sup>, Zampronio AR<sup>1</sup> <sup>1</sup>UFPR – Farmacologia, <sup>2</sup>UFPR – Química, <sup>3</sup>UFGD – Ciências da Saúde

#### 09.070

Preliminary evaluation of wound healing activity of the aqueous extract from stem bark of *Bowdichia virgilioides*. Agra IKR, Santos TC, Smaniotto S, Barreto E UFAL – Biologia Celular

11. Clinical Pharmacology, Pharmacokinetics, Pharmacogenomics and Preclinical Toxicology

#### 11.012

Efficacy evaluation of the therapeutic protocols used to treatment of TMDR patients in a respiratory diseases reference centre, in Salvador, Bahia, Brazil. Pitanga QML<sup>1</sup>, Santos CBS<sup>1</sup>, Pitta LB<sup>1</sup>, Pinheiro CG<sup>1</sup>, Carvalho JSM.<sup>2</sup>, Carvalho FLDQ<sup>1</sup> <sup>1</sup>UNEB – Ciências da Vida, <sup>2</sup>UNIJORGE – Saúde

#### 11.013

Quantification of cyproheptadine in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry in a bioequivalence study. Arruda AMM<sup>1</sup>, Mendes GD<sup>1</sup>, Chen LS<sup>2</sup>, Nucci G<sup>1</sup> <sup>1</sup>FCM-UNICAMP – Farmacologia/FCM, <sup>2</sup>Galeno Research Unit – Bioequivalence

#### 11.014

Multi-drug resistance tuberculosis: association between comorbidities, drug resistance and treatment. Santos CBS<sup>1</sup>, Pitanga QML<sup>1</sup>, Pitta LB<sup>2</sup>, Pinheiro CG<sup>2</sup>, Carvalho JSM<sup>2</sup>, Carvalho FLDQ<sup>1</sup> <sup>1</sup>UNEB – Ciências da Vida, <sup>2</sup>UNIJORGE – Saúde

#### 11.015

Specific matrix metalloproteinase-9 (MMP-9) genotype and haplotype in obese children and adolescents. Belo VA<sup>1</sup>, Souza-Costa DC<sup>2</sup>, Carneiro PC<sup>3</sup>, Lanna CM<sup>4</sup>, Izidoro-Toledo TC<sup>3</sup>, Gerlach RF<sup>5</sup>, Tanus-Santos JE<sup>3</sup> <sup>1</sup>UNICAMP – Farmacologia, <sup>2</sup>UFJF – Farmacologia, <sup>3</sup>FMRP-USP – Farmacologia, <sup>4</sup>UFJF – Fisiologia, <sup>5</sup>FORP-USP – Morfologia

#### 11.016

Adverse reactions to chemotherapy for breast cancer: influence of clinical and histopathologic variables. Índio-do-Brasil V<sup>1</sup>, Telles C<sup>1</sup>, Vianna-Jorge R<sup>2</sup>, Koifman S<sup>3</sup> <sup>1</sup>INCa – Farmacologia, <sup>2</sup>UFRJ – Farmacologia Básica e Clínica, <sup>3</sup>ENSP-FIOCRUZ – Saúde Pública e Meio Ambiente

#### 11.017

Evaluation of the toxicity of the ethanolic extract of *Gracilaria ferox* J. Agardh (Gracilariaceae) leaves. Almeida CLF, Falcão HS, Montenegro CA, Lima GRM, Ramirez RRA, Souza MFV, Batista LM LTF-DCF-UFPB

#### 11.018

Adverse reactions to chemotherapy for breast cancer and impact of genetic polymorphisms. Martins CL<sup>1</sup>, Índio-do-Brasil V<sup>1</sup>, Telles C<sup>1</sup>, Vianna-Jorge R<sup>2</sup>, Koifman S<sup>3</sup> <sup>1</sup>INCa – Farmacologia, <sup>2</sup>UFRJ – Farmacologia Básica e Clínica <sup>3</sup>ENSP-FIOCRUZ –Saúde Pública e Meio Ambiente



**11.019**

Pre-clinical pharmacokinetic study of LASSBio-468: a new achiral thalidomide analogue. Kaiser M<sup>1</sup>, Haas SE<sup>2</sup>, Azeredo FJ<sup>2</sup>, Torres B<sup>2</sup>, Brum Junior L<sup>2</sup>, Uchôa FDT<sup>1</sup>, Contri, RV<sup>2</sup>, Lima LM<sup>3</sup>, Barreiro EJ<sup>3</sup>, Dalla Costa T<sup>2</sup> <sup>1</sup>UFRGS – Medicamentos, <sup>2</sup>UFRGS – Ciências Farmacêuticas, <sup>3</sup>UFRJ – LASSBio

**11.020**

Assessment of the pharmaceutical equivalence of captopril and propranolol hydrochloride tablets sold in the popular pharmacy program in Brazil. Pontes AV, Pimenta Costa CS, Nascimento DF, Leite ALAS, Capistrano Júnior VL, Rocha MBS, Moraes RA, Frota Bezerra FA, Moraes MEA, Moraes MO UFC – Fisiologia e Farmacologia

**11.021**

Reduction of nitric oxide levels after intervention with sitagliptin in type 2 diabetic patients. Capistrano Júnior VL<sup>1</sup>, Tagliapietra JI<sup>1</sup>, Oliveira JC<sup>1</sup>, Pimenta Costa CS<sup>1</sup>, Souza MHL<sup>1</sup>, Montenegro Jr RM<sup>2</sup>, Leite ALAS<sup>1</sup>, Frota Bezerra FA<sup>1</sup>, Vale OC<sup>1</sup>, Moraes MEA<sup>1</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>HU-UFC – Endocrinologia e Metabologia

**11.022**

Learning and teaching pharmacology: a case study in Rio de Janeiro, Brazil. Fidalgo-Neto AA, Lopes RM, Alves LA IOC-FIOCRUZ – Comunicação Celular

01. Cellular and Molecular Pharmacology

**01.028**

The C-Rel subunit from nuclear factor kappa B (NFkB) family may play a differential role in peripheral melatonin synthesis. Lapa MAPC, Ferreira ZS, Markus RP <sup>1</sup>IB-USP – Fisiologia

**01.029**

NADPH oxidase mediates heme-induced cytoskeletal alterations, endothelial permeability and increased expression of adhesion molecules in HUVEC. Nascimento-Silva V<sup>1</sup>, Morandi V<sup>2</sup>, Barja Fidalgo TC<sup>1</sup>, Arruda MA<sup>3</sup> <sup>1</sup>UERJ – Farmacologia, <sup>2</sup>UERJ – Biologia Celular, <sup>3</sup>FIOCRUZ – Farmanguinhos

**01.030**

Testosterone induces VSMC proliferation via P38-COX2-dependent, NFkB- independent pathways. Chignalia AZ<sup>1</sup>, Munhoz CD<sup>1</sup>, Yogi A<sup>1</sup>, Camargo LL<sup>1</sup>, Oliveira MA<sup>1</sup>, Lopes LR<sup>1</sup>, Rossoni LV<sup>2</sup>, Carvalho MHC<sup>1</sup>, Fortes ZB<sup>1</sup>, Tostes RCA<sup>1</sup> <sup>1</sup>ICB-USP – Farmacologia, <sup>2</sup>ICB-USP – Fisiologia e Biofísica

**01.031**

Modulation of gastrointestinal epithelial cells activation by heme. Barcellos-de-Souza P<sup>1</sup>, Nasciutti LE<sup>2</sup>, Barja Fidalgo TC<sup>1</sup>, Arruda MA<sup>3</sup> <sup>1</sup>UERJ – Farmacologia, <sup>2</sup>UFRJ – Histologia e Embriologia, <sup>3</sup>FIOCRUZ – Farmanguinhos

**01.032**

Schild analysis of the self cancelling effects of tricyclic antidepressants on alpha-1 adrenoceptor mediated responses. Nojimoto FD, Pupo AS UNESP – Farmacologia

**01.033**

MicroRNA *let-7b* targets AKT-1 and regulates skeletal muscle atrophy in diabetic rats. Sousa TA<sup>1</sup>, Kato M<sup>2</sup>, Paula-Gomes, S.<sup>1</sup>, Silva VAO<sup>1</sup>, Tragante V<sup>1</sup>, Zanon NM<sup>1</sup>, Wang M<sup>2</sup>, Kettelhut IC<sup>1</sup>, Natarajan R<sup>2</sup>, De Lucca FL<sup>1</sup> <sup>1</sup>FMRP-USP – Biochemistry and Immunology, <sup>2</sup>Beckman Research Institute – Gonda Diabetes Center

**01.034**

Expression of MicroRNAs in skeletal muscle atrophy induced by fasting in rats. Tragante V, Sousa TA, Silva VAO, Zanon NM, Kettelhut IC, De Lucca FL FMRP-USP – Biochemistry and Immunology

**01.035**

Evidence of a regulatory role of dystrophin on the release of acetylcholine (ACh) in the mouse brain. Della Colleta E, Nogueira FM, Campos DV, Lima-Landman MTR, Lapa AJ, Souccar C UNIFESP – Farmacologia

**01.036**

Facilitatory action of a quaternary derivate of l-hyoscyamine on acetylcholine (ACh) release in

rat cortex synaptosomes. Analysis of the mechanisms involved. Nogueira FM, Della Colleta E, Lima-Landman MTR, Lapa AJ, Souccar C UNIFESP/EPM – Farmacologia

**01.037**

Treatment effect of acute *in vivo* ethanol on adrenergic neurotransmission in the smooth muscle of periadolescent rats vas deferens. Silva Junior ED, Jurkiewicz A, Jurkiewicz NH UNIFESP – Farmacologia

**01.038**

Characterization of signaling pathways of Angiotensin I-converting enzyme in mesangial cells of spontaneously hypertensive rats (SHR). Reis RI<sup>1</sup>, Parreiras-e-Silva LT<sup>2</sup>, Becari C<sup>3</sup>, De Andrade MCC<sup>4</sup>, Salgado MCO<sup>3</sup>, Costa-Neto CM<sup>2</sup>, Casarini DE<sup>5</sup> <sup>1</sup>UNIFESP – Rim e Hormônios, <sup>2</sup>FMRP-USP – Bioquímica e Imunologia, <sup>3</sup>FMRP-USP – Farmacologia, <sup>4</sup>UNIFESP – Nefrologia, <sup>5</sup>UNIFESP – Medicina

**01.039**

Estrogen attenuates cellular death induced by H<sub>2</sub>O<sub>2</sub> in C6 cells: a role for ESR and GPER receptors. Franco LAM, Yshii LM, Lopes DCF, Sá Lima L, Scavone C, Munhoz CD ICB-USP – Farmacologia

**01.040**

P2Y1 receptors stimulation on rat pineal glands: effects on nuclear factor kappa B pathway (NFkB) and inducible nitric oxide synthase (iNOS). Petrilli CL, Carvalho-Sousa CE, Muxel SM, Markus RP, Ferreira ZS IB-USP – Fisiologia

02. Neuropharmacology

**2.045**

Imipramine facilitates adaptation to chronic stress in animals with lesions of serotonergic neurons of the median raphe nucleus. Silva K, Padovan D, Padovan CM FFCLRP-USP – Psicologia e Educação

**02.046**

Allopregnanolone antidepressive and stress activity evaluation after nucleus *accumbens* administration in rats. Ferri MK<sup>1</sup>, Dalpra WL<sup>1</sup>, Azeredo LA<sup>1</sup>, Couto-Pereira N<sup>2</sup>, Nin MS<sup>1</sup>, Gomez R<sup>1</sup>, Barros HMT<sup>1</sup> <sup>1</sup>UFCSA – Farmacologia, <sup>2</sup>UFCSA – Ciências Fisiológicas

**02.047**

The expression of mRNAs encoding the flip isoforms of GLuR1 and GLuR2 are decreased in hippocampus of rats reared in isolation from weaning. Trindade LB<sup>1</sup>, Sestito RS<sup>1</sup>, Kerbauy LN<sup>1</sup>, de Souza RG<sup>1</sup>, Limonte FH<sup>1</sup>, Iyomasa MM<sup>2</sup>, Rosa ML<sup>2</sup> <sup>1</sup>FAMECA – Bioquímica, <sup>2</sup>FAMECA-FIPA – Neurociências

**02.048**

Neuroprotective effect of propofol in model of hippocampal ischemia in rats. Binda NS<sup>1</sup>, Pessoa FLC<sup>2</sup>, Pinheiro ACN<sup>1</sup>, Silva JF<sup>3</sup>, Lavor MSL<sup>4</sup>, Gomez RS<sup>6</sup>, Gomez MV<sup>3</sup> <sup>1</sup>UFMG – Farmacologia, <sup>2</sup>UFMG – Medicina, <sup>3</sup>UFMG – Farmacologia Bioquímica e Molecular, <sup>4</sup>UFMG – Clínica e Cirurgia Veterinária, <sup>5</sup>UFMG – Cirurgia

**02.049**

Glial cells are important in protecting neurons after ischemia induced by glucose deprivation. Lopes DCF, Matsubara CS, Franco LAM, Sá Lima L, Scavone C, Munhoz CD ICB-USP – Farmacologia

**02.050**

Interaction between 5-HT<sub>1A</sub> receptor and a nitric oxide donor, sin-1, ON locomotor activity of rats. Gualda LBS<sup>1</sup>, Martins GG<sup>2</sup>, Guimarães FS<sup>3</sup>, Oliveira RMMW<sup>1</sup> <sup>1</sup>UEL – Farmácia e Farmacologia, <sup>2</sup>UEM – Farmácia e Farmacologia, <sup>3</sup>FMRP-USP

**02.051**

Glutamatergic neurotransmission within the hypothalamic paraventricular nucleus is involved in the cardiovascular response evoked by noradrenaline microinjected into the dorsal periaqueductal gray area of rats. Pelosi GG<sup>1</sup>, Busnardo C<sup>2</sup>, Tavares RF<sup>2</sup>, Corrêa FMA<sup>2</sup> <sup>1</sup>UEL – Farmacologia, <sup>2</sup>FMRP-USP – Farmacologia

**02.052**

Relationship of long-term memory evocation and cholinergic markers in hippocampus, along the aging process of rats. Oliveira EM<sup>1</sup>, Souza LHJ<sup>1</sup>, Schowe NM<sup>1</sup>, Albuquerque MS<sup>1</sup>, Baraldi T<sup>1</sup>, Chamberg FS<sup>1</sup>, Pina dos Santos VP<sup>2</sup>, Araújo MS<sup>2</sup>, Buck HS<sup>3</sup>, Viel TA<sup>1</sup> <sup>1</sup>EACH-USP, <sup>2</sup>UNIFESP – Bioquímica, <sup>3</sup>FCMSCSP – Ciências Fisiológicas

**02.053**

Effects of isolation rearing on the expression of B-amyloid precursor proteins, isoforms 695 and 751/770, in rat hippocampus. Kerbauy LN<sup>1</sup>, de Souza RG<sup>2</sup>, Trindade LB<sup>1</sup>, Sestito RS<sup>1</sup>, Limonte FH<sup>2</sup>, Iyomasa MM<sup>2</sup>, Rosa ML<sup>2</sup> <sup>1</sup>FAMECA-FIPA – Bioquímica, <sup>2</sup>FAMECA-FIPA Neurociências

**02.054**

Influence of glucocorticoids in the increase of CRF<sub>2</sub> mRNA levels in the lateral septal nucleus of rats submitted to chronic unpredictable stress. Malta MB<sup>1</sup>, Sita LV<sup>2</sup>, Silva JM<sup>2</sup>, Bittencourt JC<sup>2</sup>, Scavone C<sup>1</sup>, Munhoz CD<sup>1</sup> <sup>1</sup>ICB-USP – Farmacologia, <sup>2</sup>ICB-USP – Anatomia

**02.055**

Overactive bladder induced by spinal cord injury: implication of TRPA1 receptor. Andrade EL<sup>1</sup>, Forner S<sup>1</sup>, Bento AF<sup>1</sup>, Leite DFP<sup>1</sup>, Dias MA<sup>2</sup>, Leal PC<sup>3</sup>, Koepf J<sup>4</sup>, Calixto JB<sup>1</sup> <sup>1</sup>UFSC – Farmacologia, <sup>2</sup>ISCAL – Neurocirurgia, <sup>3</sup>UFSC – Química, <sup>4</sup>UFSC – Engenharia Química

**02.056**

Neonatal morphine exposure alters E-NTPDase activity and gene expression pattern in spinal cord and cerebral cortex of rats. Rozisky JR<sup>1</sup>, Silva, RS<sup>2</sup>, Adachi LNS<sup>1</sup>, Bogo MR<sup>2</sup>, Bonan CD<sup>2</sup>, Torres ILS<sup>1</sup> <sup>1</sup>UFRGS – Farmacologia, <sup>2</sup>PUCRS – Biologia Celular e Molecular

**02.057**

Fish oil prevents orofacial dyskinesia, memory loss and lipid peroxidation induced by haloperidol in rats. Bürger ME<sup>1</sup>, Barcelos RCS<sup>2</sup>, Benvegnú DM<sup>1</sup>, Müller LG<sup>2</sup>, Reckziegel P<sup>2</sup>, Pase C<sup>2</sup>, Emanuelli T<sup>3</sup>, Bouffleur N<sup>2</sup> <sup>1</sup>UFMS – Farmacologia, <sup>2</sup>UFMS – Fisiologia e Farmacologia, <sup>3</sup>UFMS – Tecnologia dos Alimentos

**03. Psychopharmacology****03.025**

Nitric oxide modulates glutamatergic control of sensorimotor gating in rats. Henriques-Santos NF<sup>1</sup>, Brosco MC<sup>1</sup>, Del Bel EA<sup>2</sup>, Salum C<sup>1</sup> <sup>1</sup>UFABC – Matemática, Computação e Cognição, <sup>2</sup>FORP-USP – Morfologia, Estomatologia e Fisiologia

**03.026**

Effects of nNOS Inhibition on forced swimming-induced FOS expression in the rat brain. Silva M, Aguiar DC, Guimarães FS, Joca SRL FMRP-USP – Farmacologia

**03.027**

Antidepressant-like activity of *Hypericum caprifoliatum* Cham. & Schltdl (Guttiferae) is not due to NMDA receptor activation neither to neuronal glutamate transport. Centurião FB<sup>1</sup>, Stein AC<sup>1</sup>, Gay BM<sup>2</sup>, Prigol M<sup>2</sup>, Viana AF<sup>3</sup>, Nogueira CW<sup>2</sup>, Rates SMK<sup>3</sup> <sup>1</sup>UFRGS – Farmácia, <sup>2</sup>UFMS – Química, <sup>3</sup>UFRGS – Ciências Fisiológicas

**03.028**

Repeated morphine administration in early life promotes anxiolytic effect on elevated plus-maze. Nonose Y<sup>1</sup>, Rozisky JR<sup>1</sup>, Santos VS<sup>1</sup>, Medeiros LF<sup>1</sup>, Souza A<sup>2</sup>, Caumo W<sup>3</sup>, Torres ILS<sup>1</sup> <sup>1</sup>UFRGS – Farmacologia, <sup>2</sup>UFRGS – Bioquímica, <sup>3</sup>UFRGS – Anestesia

**03.029**

Evaluation of intestinal motility tolerance after repeated diethylpropion administration in rats. Dalpra WL<sup>1</sup>, Caletti, G<sup>1</sup>, Olguins, DB<sup>2</sup>, Barros HMT<sup>1</sup>, Gomez, R<sup>1</sup> <sup>1</sup>UFCSA – Farmacologia, <sup>2</sup>IPA – Farmacologia

**03.030**

Blockade of glutamate NMDA receptors in the rat ventromedial prefrontal cortex (vMPFC) induces antidepressant-like effects. Pereira VS<sup>1</sup>, Joca SRL<sup>2</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>FCFRP-USP – Física e Química

**03.031**

Ayahuasca repeated treatment inhibits behavioral sensitization previously developed to ethanol in mice. Marinho EAV<sup>1</sup>, Gerardi-Junior CA<sup>2</sup>, Santos R<sup>3</sup>, Baldaia MA<sup>4</sup>, Oliveira-Lima AJ<sup>5</sup>, Wuo-Silva R<sup>6</sup>, Hollais AW<sup>7</sup>, Malpezzi-Marinho ELA<sup>2</sup>, Fernandes HA<sup>8</sup>, Frussa-Filho R<sup>5</sup>  
<sup>1</sup>UBC/UNIFESP - Ciências da Saúde / Farmacologia, <sup>2</sup>UBC - Ciências da Saúde, <sup>3</sup>UBC - Farmácia, <sup>4</sup>UBC/UNIFESP - Farmacologia, <sup>5</sup>UNIFESP - Farmacologia, <sup>6</sup>UBC - Fisiologia

**03.032**

Acute effect of *Dioclea violacea* M. (aqueous extract) on general activity observed in the rats on elevated plusmaze and its dyskinetics movements. Gemignani S, Silva FO, Biscaro MDA, Santos NSS, Rassam E, Gonçalves RB, Pedroso-Mariani SR FMJ - Farmacologia

**03.033**

Role of L-arginine-nitric oxide pathway and possible implications for cardiovascular disease in depressed patients. Pinto VLM<sup>1</sup>, Fontoura PCS<sup>1</sup>, Brunini T<sup>2</sup>, Mendes Ribeiro AC<sup>1</sup> <sup>1</sup>UERJ - Farmacologia e Psicobiologia, <sup>2</sup>UERJ - Farmacologia

**03.034**

Chronic imipramine treatment enhances the panicolytic-like effect caused by the stimulation of 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors in the dorsomedial hypothalamic nucleus. de Bortoli VC, Zangrossi Jr H FMRP-USP - Farmacologia

**03.035**

Bipolar disorder and cardiovascular disease. Fontoura PCS<sup>1</sup>, Pinto VLM<sup>1</sup>, Cheniaux Jr E<sup>2</sup>, da Silva O<sup>1</sup>, Brunini T<sup>3</sup>, Mendes Ribeiro AC<sup>1</sup> <sup>1</sup>UERJ - Farmacologia e Psicobiologia, <sup>2</sup>IPUB-UFRJ - Psiquiatria, <sup>3</sup>UERJ - Farmacologia

**03.036**

Memory impairment is associated with inflammatory changes in the hippocampus of DENV-3 infected mice. Campos RDL<sup>1</sup>, Amaral DCG<sup>2</sup>, Cisalpino D<sup>3</sup>, Vilela MC<sup>4</sup>, Rodrigues DH<sup>5</sup>, Miranda AS<sup>1</sup>, Lacerda-Queiroz N<sup>5</sup>, Souza KPR<sup>3</sup>, Kroon EG<sup>3</sup>, Reis HJ<sup>6</sup>, Teixeira, AL<sup>2</sup> <sup>1</sup>UFMG - Bioquímica e Imunologia, <sup>2</sup>UFMG - Clínica Médica, <sup>3</sup>UFMG - Microbiologia, <sup>4</sup>UFMG - Neurociências, <sup>5</sup>UFMG - Biologia Celular, <sup>6</sup>ICB-UFMG - Farmacologia

## 04. Inflammation

**04.093**

Pineal gland is instrumented to be an integral player of innate immune response. Carvalho-Sousa CE<sup>1</sup>, Cruz-Machado SS<sup>1</sup>, Fernandes PACM<sup>1</sup>, Tamura EK<sup>1</sup>, Pinato, L<sup>2</sup>, Petrilli CL<sup>1</sup>, Markus RP<sup>1</sup> <sup>1</sup>IB-USP - Fisiologia, <sup>2</sup>UNESP - Fonoaudiologia

**04.094**

The intestinal ischemia/reperfusion in rats promotes changes in the lung depending on the time of reperfusion. Vitoretto LB, Breithaupt-Faloppa AC, Gimenes-Junior JA, Domingos HV, Sudo-Hayashi LS, Oliveira-Filho RM, Tavares de Lima W ICB-USP - Pharmacology

**04.095**

*Saccharomyces boulardii* prevents the inflammatory response in intestinal mucositis induced by 5-fluorouracil in mice. Justino PFC<sup>1</sup>, Silva LMN<sup>1</sup>, Melo LFM<sup>1</sup>, Costa JVG<sup>1</sup>, Nogueira AF<sup>1</sup>, Ribeiro RA<sup>1</sup>, Souza MHL<sup>1</sup>, Soares PMG<sup>2</sup> <sup>1</sup>UFC - Fisiologia e Farmacologia, <sup>2</sup>UFC - Morfologia

**04.096**

Effect of protease-activated receptor-2 activating peptide on B1 cell spreading and its modulation by the C-terminus of the calcium binding protein S100A9. Moraes NF<sup>1</sup>, Sampaio SC<sup>1</sup>, Freitas JD<sup>1</sup>, Pagano RL<sup>2</sup>, Giorgi R<sup>1</sup> <sup>1</sup>IBU - Fisiopatologia, <sup>2</sup>IEP - Neuromodulação e Dor Experimental

**04.097**

Effects of the treatment with an inhibitor of CCL2 synthesis, in acute diet-induced adiposity in mice. Lima RL<sup>1</sup>, Menezes Z<sup>1</sup>, Santos MCC<sup>1</sup>, Guglielmotti A<sup>2</sup>, Teixeira MM<sup>3</sup>, Ferreira AVM<sup>4</sup>, Souza DG<sup>1</sup> <sup>1</sup>UFMG - Microbiologia, <sup>2</sup>ACRAF - Pharmacology, <sup>3</sup>UFMG - Imunofarmacologia, <sup>4</sup>UFMG - Enfermagem Básica

**04.098**

Hydrogen sulfide and antioxidant enzyme activities in allergic mice lungs. Campos D<sup>1</sup>, Benetti LR<sup>1</sup>, Nogueira JS<sup>1</sup>, Gurgueira SA<sup>2</sup>, Vercesi AE<sup>3</sup>, Ferreira HHA<sup>1</sup> <sup>1</sup>USF - Inflamação, <sup>2</sup>FCM-UNICAMP - Bioenergética, <sup>3</sup>FCM-UNICAMP - Patologia Clínica

**04.099**

Expression of adhesion molecules in vessels of the microcirculation affected by different metalloproteases isolated from *Bothrops* venoms. Zychar BC<sup>1</sup>, Baldo C<sup>2</sup>, Clissa, PB<sup>2</sup>, Alves AS<sup>3</sup>, Britto LRG<sup>3</sup> <sup>1</sup>IBU - Fisiopatologia, <sup>2</sup>IBU - Imunopatologia, <sup>3</sup>USP - Fisiologia e Biofísica

**04.100**

Effects of the cystein proteinase obtained from *C. candamarcensis* P1G10-treatment on eosinophil recruitment in allergic mice pleurisy. Miwa MY<sup>1</sup>, Lopes MTP<sup>1</sup>, Ferreira RG<sup>2</sup>, Gomides LF<sup>1</sup>, Salas CE<sup>3</sup>, Klein A<sup>2</sup> <sup>1</sup>UFMG - Farmacologia, <sup>2</sup>UFMG - Fisiologia/Farmacologia, <sup>3</sup>UFMG - Bioquímica e Imunologia

**04.101**

Aprotinin potentiates carrageneen edema formation: evidences for prostaglandin participation. Ferreira RG<sup>1</sup>, Godin AM<sup>2</sup>, Matsui TC<sup>3</sup>, Coelho MM<sup>4</sup>, Klein A<sup>3</sup> <sup>1</sup>UFMG - Fisiologia/Farmacologia, <sup>2</sup>FF-UFMG - Produtos Farmacêuticos, <sup>3</sup>UFMG - Farmacologia, <sup>4</sup>UFMG

**04.102**

Methotrexate effects on systemic and adipose tissue alterations induced by obesity in mice. De Oliveira CC, Acedo SC, Gotardo EMF, Gambero A USF – Farmacologia e Gastroenterologia

**04.103**

Crohn's experimental model decreased the mechanical inflammatory hypernociception in rats- role of NO/cGMP/ KATP pathway. Barbosa ALR<sup>1</sup>, Sousa RB<sup>2</sup>, Torres JNL<sup>2</sup>, Lucetti LT<sup>2</sup>, Cunha, TM<sup>3</sup>, Cunha FQ<sup>3</sup>, Ribeiro RA<sup>2</sup>, Vale ML<sup>2</sup>, Souza MHL<sup>2</sup> <sup>1</sup>UFPI – Fisiologia e Farmacologia / UFC, <sup>2</sup>UFC – Fisiologia e Farmacologia, <sup>3</sup>FMRP-USP

**04.104**

Effects of hydrogen sulfide on leukocyte migration and protein tyrosine nitration in airways of allergic mice. Benetti LR<sup>1</sup>, Teixeira SA<sup>2</sup>, Campos D<sup>3</sup>, Silva AA<sup>3</sup>, Costa SKP<sup>2</sup>, Muscará MN<sup>2</sup>, Ferreira HHA<sup>3</sup> <sup>1</sup>USF – Farmacologia, <sup>2</sup>USP – Farmacologia, <sup>3</sup>USF – Inflamação

**04.105**

Characterization of allergic lung inflammation in genetically obese mice. Lintomen L, Calixto MC, Schenka A, Antunes E UNICAMP – Farmacologia

**04.106**

*Mycobacterium bovis* BCG infection activates a rapamycin-sensitive mTOR pathway: involvement in the lipid body formation and inflammatory response. D'Ávila H<sup>1</sup>, Lage SL<sup>2</sup>, Roque NR<sup>3</sup>, Maya-Monteiro CM<sup>3</sup>, Almeida PE<sup>3</sup>, Melo RCN<sup>4</sup>, Castro-Faria-Neto HC<sup>3</sup>, Bozza PT<sup>3</sup> <sup>1</sup>UFJF – Biologia Celular, <sup>2</sup>USP – Imunologia, <sup>3</sup>FIOCRUZ – Imunofarmacologia, <sup>4</sup>FIOCRUZ – Biologia Celular

**04.107**

Contribution of reactive-oxygen species to the enhancement of platelet aggregation in high-fat fed rats. Monteiro PF<sup>1</sup>, Prada Morganti R<sup>1</sup>, Delbin MA<sup>2</sup>, Pires MEL<sup>1</sup>, Priviero FBM<sup>1</sup>, Marcondes S<sup>1</sup>, Zanesco A<sup>2</sup>, Antunes E<sup>1</sup> <sup>1</sup>UNICAMP – Farmacologia, <sup>2</sup>UNESP – Educação Física

**04.108**

Staphylococcal enterotoxin A (SEA) inhibits human eosinophil migration *in vitro*. Mello GC, Squebola Cola DM, Souza IA, Antunes E FCM-UNICAMP – Farmacologia

**04.109**

Effect of a combination of medium chain triglycerides, linoleic acid, soy lecithin and vitamins A and E on wound healing in rats. Magalhães MS<sup>1</sup>, Moraes MEA<sup>1</sup>, Fechine FV<sup>1</sup>, Nascimento DF<sup>1</sup>, Macedo RN<sup>1</sup>, Monteiro DLS<sup>2</sup>, Oliveira CC<sup>1</sup>, Linhares JH<sup>3</sup>, Leite ALAS<sup>1</sup>, Moraes MO<sup>1</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>FAMED-UFC – Fisiologia e Farmacologia, <sup>3</sup>UFC – Cirurgia

**04.110**

Leukotriene B4 mediates  $\gamma\delta$  T lymphocyte migration in response to diverse stimuli. Souza-Martins R<sup>1</sup>, Costa MFS<sup>1</sup>, Souza M<sup>1</sup>, Piva B<sup>1</sup>, Diaz BL<sup>3</sup>, Peters-Golden M<sup>4</sup>, Henriques MGMO<sup>1</sup>, Canetti C<sup>1</sup>, Penido C<sup>1</sup> <sup>1</sup>Farmanguinhos-FIOCRUZ – Farmacologia Aplicada, <sup>2</sup>IBCCF-UFRJ, <sup>3</sup>IBCCF-UFRJ – Imunobiologia, <sup>4</sup>University of Michigan – Pulmonary and Critical Care Medicine

**04.111**

Adhesion molecules and chemokines receptor expression in bone marrow eosinophils of obese mice. Calixto MC<sup>1</sup>, Lintomen L<sup>1</sup>, Thomé R<sup>2</sup>, Tamashiro WMSC<sup>2</sup>, Antunes E<sup>2</sup> <sup>1</sup>UNICAMP – Farmacologia, <sup>2</sup>UNICAMP – Imunologia e Microbiologia

**04.112**

Antinociceptive and anti-inflammatory effect of heme oxygenase-1 / biliverdin / carbon monoxide pathways in temporomandibular joint arthritis induced by zymosan. Chaves HV<sup>1</sup>, Filgueira AA<sup>2</sup>, Ribeiro KA<sup>3</sup>, Silva AAR<sup>2</sup>, Souza MHL<sup>4</sup>, Ribeiro RA<sup>4</sup>, Bezerra MM<sup>5</sup>, Brito GAC<sup>6</sup> <sup>1</sup>UFC – Ciências Médicas, <sup>2</sup>UFC-Sobral – Odontologia, <sup>3</sup>UVA – Biologia, <sup>4</sup>UFC – Fisiologia e Farmacologia, <sup>5</sup>UFC-Sobral – Medicina, <sup>6</sup>UFC – Morfologia

**04.113**

Antipruritic activity of the ethanol extract from *Lecythis pisonis* Camb. (Lecythidaceae) leaves in mice. Silva LL<sup>1</sup>, Gomes BS<sup>1</sup>, Silva AMS<sup>1</sup>, Oliveira JPC<sup>2</sup>, Chaves MH<sup>2</sup>, Oliveira FA<sup>1</sup> <sup>1</sup>UFPI – NPPM, <sup>2</sup>UFPI – Química

**04.114**

Effects of acute treatment with 1-(3-chlorophenyl) piperazine (mCPP) in the leukocyte traffic in rats. Lombardi L, Hebeda CB, Farsky S, Moreau RLM USP – Análises Clínicas e Toxicológicas

**04.115**

Lipoxin A4 plays a protective role in experimental dengue disease. Cisalpino D<sup>1</sup>, Fagundes CT<sup>2</sup>, Costa VV<sup>2</sup>, Guabiraba R<sup>2</sup>, Souza DG<sup>1</sup>, Teixeira MM<sup>2</sup> <sup>1</sup>UFMG – Microbiologia, <sup>2</sup>UFMG – Bioquímica e Imunologia

**04.116**

Lipopolysaccharide *in vivo* increases the production of reactive oxygen species in rat platelet mainly through activation of NADPH-oxidase system. Pires MEL, Cardelli NJA, Anhé GF, Antunes E, Marcondes S UNICAMP – Farmacologia

**04.117**

Synthesis and evaluation of activity of 4-antihypernociceptive aminochalcones. Sonza DR, Buzzi FC, Rodrigues C, Corrêa R, Souza PS, Quintão NLM <sup>1</sup>NIQFAR-UNIVALI – Farmacêuticas

**04.118**

Mechanisms of the inflammatory response induced by topical application of cinnamaldehyde in mice. Silva CR<sup>1</sup>, Oliveira SM<sup>1</sup>, Rossato MF<sup>1</sup>, Guerra GP<sup>1</sup>, Dalmolin GD<sup>2</sup>, Prudente AS<sup>3</sup>, Cabrini DA<sup>3</sup>, Otuki MF<sup>3</sup>, Ferreira J<sup>1</sup> <sup>1</sup>UFMSM – Química, <sup>2</sup>UFMG – Farmacologia, <sup>3</sup>UFPR – Farmacologia

**04.119**

IFN-g limits antigen-induced arthritis severity by inducing IDO/GCN2 kinase pathway. Lemos HP<sup>1</sup>, Mellor AL<sup>2</sup>, Chandler PR<sup>3</sup>, Vieira SM<sup>4</sup>, Grespan R<sup>5</sup>, Cunha FQ<sup>1</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>Medical College of Georgia – Molecular Medicine and Genetics, <sup>3</sup>Medical College of Georgia – Immunotherapy, <sup>4</sup>COPE-INPA, <sup>5</sup>UEM – Farmácia e Farmacologia

**04.120**

IL-1 receptor antagonist (IL-1RA) Prevents hemorrhage, inflammation, nociception and bladder dysfunction in ifosfamide-induced hemorrhagic cystitis. Leite CAVG<sup>1</sup>, Alencar VTL<sup>1</sup>, Lima-Júnior RCP<sup>1</sup>, Mourão LTC<sup>1</sup>, Wong DVT<sup>1</sup>, Melo DLR<sup>1</sup>, Magalhães PJC<sup>1</sup>, Santos AA<sup>1</sup>, Brito GAC<sup>2</sup>, Cunha FQ<sup>3</sup>, Ribeiro RA<sup>1</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>UFC – Morfologia, <sup>3</sup>FMRP-USP

**04.121**

Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation. Leite CAVG<sup>1</sup>, Lima-Júnior RCP<sup>1</sup>, Wong DVT<sup>1</sup>, Oriá RB<sup>2</sup>, Brito GAC<sup>2</sup>, Souza MHL<sup>1</sup>, Cunha FQ<sup>3</sup>, Ribeiro RA<sup>1</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>UFC – Morfologia, <sup>3</sup>FMRP-USP

**04.122**

IL-6/ IL-23/ IL-17/ IL-22 axis mediates the inflammatory response in antigen-induced arthritis in mice. Pinto LG<sup>1</sup>, Talbot J<sup>1</sup>, Vieira SM<sup>2</sup>, Verri Jr WA<sup>3</sup>, Cunha, TM<sup>1</sup>, Cunha FQ<sup>1</sup>, Ferreira SH<sup>1</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>COPE-INPA, <sup>3</sup>UEL – Pathology and Pharmacology

**04.123**

Nitric oxide, carbon monoxide and guanylate cyclase modulate remote ischemic preconditioning: participation of adhesion molecules in inhibition of neutrophils migration. Simão AFL<sup>1</sup>, Souza-Filho MVP<sup>2</sup>, Souto FO<sup>3</sup>, Simão AAL<sup>4</sup>, Cunha FQ<sup>5</sup>, Ribeiro RA<sup>5</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>UFC – Cirurgia, <sup>3</sup>FMRP-USP – Surgery and Anatomy, <sup>4</sup>UFC – Farmacologia, <sup>5</sup>FMRP-USP

**04.124**

Lipid droplet in pulmonary dendritic cells during severe sepsis. Molinaro RC<sup>1</sup>, Vieira-de-Abreu A<sup>1</sup>, Silva AR<sup>1</sup>, Castro-Faria-Neto HC<sup>1</sup>, Benjamim CF<sup>2</sup>, Bozza PT<sup>1</sup> <sup>1</sup>DFF-FIOCRUZ, <sup>2</sup>UFRJ – Farmacologia Básica e Clínica

**04.125**

Intraperitoneal injection of *S. aureus* induces fever accompanied by an increase of prostaglandin E2 (PGE2) in the CSF and hypothalamus in rats. Martins JM<sup>1</sup>, Soares DM<sup>2</sup>, Malvar DC<sup>1</sup>, Figueiredo MJ<sup>1</sup>, Souza GEP<sup>2</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>FCFRP-USP – Física e Química

**04.126**

Reduction of the expression of membrane CXCR2 and BLT1 receptors on neutrophils related to increased mortality of septic patients in emergency department. Sousa RB<sup>1</sup>, Souto FO<sup>2</sup>, Spiller F<sup>2</sup>, Turato W<sup>3</sup>, Lobo RR<sup>1</sup>, Mendonça PR<sup>1</sup>, Cunha FQ<sup>2</sup>, Pazin A<sup>1</sup> <sup>1</sup>FMRP-USP – Clínica Médica, <sup>2</sup>FMRP-USP – Pharmacology, <sup>3</sup>FCFRP-USP – Análises Clínicas, Toxicológicas e Bromatológicas

**04.127**

JM 25-1, a non anesthetic lidocaine derivative, decreased the expression of transcription factor GATA-3 in a murine model of acute allergic inflammation. Couto GC<sup>1</sup>, Serra MF<sup>1</sup>, Cotias AC<sup>1</sup>, Anjos-Valotta EA<sup>2</sup>, Jurgilas PB<sup>1</sup>, Ferreira TPT<sup>1</sup>, Costa JCS<sup>1</sup>, Pires ALA<sup>1</sup>, Cordeiro RSB<sup>1</sup>, Silva PMR<sup>1</sup>, Martins MA<sup>1</sup> <sup>1</sup>IOC-FIOCRUZ – Fisiologia e Farmacodinâmica, <sup>2</sup>ICB-USP

**04.128**

Lidocaine inhibits airway inflammation, peribronchial fibrosis and mucus production in a murine model of asthma. Serra MF<sup>1</sup>, Cotias AC<sup>1</sup>, Anjos-Valotta EA<sup>2</sup>, Couto GC<sup>1</sup>, Pão CRR<sup>1</sup>, Jurgilas PB<sup>1</sup>, Ferreira TPT<sup>1</sup>, Pires ALA<sup>1</sup>, Arantes ACS<sup>1</sup>, Cordeiro RSB<sup>1</sup>, Silva PMR<sup>1</sup>, Martins MA<sup>1</sup> <sup>1</sup>FIOCRUZ – Fisiologia e Farmacodinâmica, <sup>2</sup>ICB-USP

**04.129**

Role of arylhydrocarbon Receptor (AhR) in antigen-induced arthritis. Talbot J<sup>1</sup>, Pinto LG<sup>1</sup>, Alves-Filho JC<sup>2</sup>, Vieira SM<sup>3</sup>, Ferreira SH<sup>1</sup>, Cunha TM<sup>1</sup>, Louzada Jr P<sup>4</sup>, Cunha FQ<sup>1</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>University of Glasgow – Immunology, Infection and Inflammation, <sup>3</sup>COPE-INPA, <sup>4</sup>FMRP-USP – Clínica Médica

**04.130**

Chemokine decoy receptor D6 deficiency protects against bleomycin-induced pulmonary inflammation and fibrosis in mice. Russo RC<sup>1</sup>, Savino B<sup>1</sup>, Mirolo M<sup>1</sup>, Buracchi C<sup>2</sup>, Anselmo A<sup>2</sup>, Zammataro L<sup>2</sup>, Pasqualini F<sup>2</sup>, Germano G<sup>2</sup>, Nebuloni M<sup>3</sup>, Mantovani A<sup>3</sup>, Teixeira MM<sup>1</sup>, Locati M<sup>2</sup> <sup>1</sup>UFMG – Bioquímica e Imunologia, <sup>2</sup>Istituto Clinico Humanitas, Leukocyte Biology, <sup>3</sup>University of Milan – Pathology

**04.131**

Early-lifetime exposure to 1,2-naphthoquinone (1,2-NQ) interact to increase asthma susceptibility and behavior changes in juvenile mice. Florenzano J, Santos KT, Teixeira SA,

Barreto MAA, Muscará MN, Camarini R, Costa SKP ICB-USP – Farmacologia

#### 04.132

Pharmacological blockade of the CXCL-ELR+ chemokine / receptor cxcr2 axis accelerates wound closure in mice. Castro TBR<sup>1</sup>, Canesso MCC<sup>1</sup>, Almeida BG<sup>1</sup>, Colotta F<sup>2</sup>, Bertini R<sup>2</sup>, Proudfoot AEI<sup>3</sup>, Andrade SP<sup>1</sup>, Teixeira MM<sup>4</sup>, Barcelos L<sup>1</sup> <sup>1</sup>ICB-UFGM – Physiology and Biophysics, <sup>2</sup>Dompé Research and Development, <sup>3</sup>Serono Pharmaceutical Research Institute, <sup>4</sup>ICB-UFGM – Biochemistry and Immunology

#### 04.133

Absence of P2X<sub>7</sub> purinergic receptors in the hemorrhagic cystitis induced by cyclophosphamide in mice. Martins JP<sup>1</sup>, Silva RBM<sup>2</sup>, Santos Jr AA<sup>3</sup>, Coutinho R<sup>4</sup>, Battastini AMO<sup>5</sup>, Santos DS<sup>6</sup>, Morrone FB<sup>6</sup>, Campos MM<sup>7</sup> <sup>1</sup>PUCRS – Medicina, <sup>2</sup>PUCRS – Farmacologia Aplicada, <sup>3</sup>INCTb-PUCRS – Biologia Molecular e Funcional, <sup>4</sup>IBCCF-UFRJ, <sup>5</sup>UFRGS – Bioquímica, <sup>6</sup>PUCRS – Farmácia, <sup>7</sup>PUCRS – Cirurgia-Odontologia

#### 04.134

Characterization of the inflammatory process in epididymal fat tissues in mice submitted to a palatable diet. Bernardes PTT<sup>1</sup>, Rezende B<sup>2</sup>, Castor MGM<sup>3</sup>, Ferreira AVM<sup>4</sup>, Teixeira MM<sup>5</sup>, Pinho V<sup>5</sup> <sup>1</sup>UFGM – Morfologia e Bioquímica, <sup>2</sup>UFGM – Bioquímica e Imunologia e Morfologia, <sup>3</sup>UFGM – Fisiologia e Farmacologia, <sup>4</sup>UFGM – Fisiologia e Biofísica, <sup>5</sup>UFGM – Bioquímica e Imunologia

#### 04.135

*In vitro*-differentiated mouse eosinophils as a new tool for the study of eosinophil biology. Samico RF<sup>1</sup>, Luna-Gomes T<sup>1</sup>, Mesquita-Santos FP<sup>2</sup>, Bakker-Abreu I<sup>1</sup>, Diaz BL<sup>3</sup>, Bandeira-Melo C<sup>2</sup> <sup>1</sup>IBCCF-UFRJ, <sup>2</sup>FIOCRUZ – Fisiologia e Farmacodinâmica, <sup>3</sup>IBCCF-UFRJ – Imunobiologia

#### 04.136

Behavioral changes are associated with central nervous system inflammation in an experimental model of malaria. Miranda AS<sup>1</sup>, Lacerda-Queiroz N<sup>2</sup>, Vilela MC<sup>3</sup>, Rodrigues DH<sup>2</sup>, Reis HJ<sup>4</sup>, Teixeira MM<sup>1</sup>, Rachid M<sup>6</sup>, Teixeira AL<sup>7</sup> <sup>1</sup>UFGM – Bioquímica e Imunologia, <sup>2</sup>UFGM – Biologia Celular, <sup>3</sup>UFGM – Neurociências, <sup>4</sup>UFGM – Farmacologia, <sup>6</sup>UFGM – Patologia, <sup>7</sup>UFGM – Clínica Médica

#### 04.137

Hydrogen Peroxide is associated to neutrophil clearance in model of arthritis induced in mice. Lopes F<sup>1</sup>, Sousa LP<sup>2</sup>, Coelho FM<sup>3</sup>, Costa VV<sup>3</sup>, Gonçalves W<sup>1</sup>, Teixeira MM<sup>3</sup>, Pinho V<sup>3</sup> <sup>1</sup>UFGM – Morfologia, <sup>2</sup>UFGM – Patologia Clínica e Bioquímica e Imunologia, <sup>3</sup>UFGM – Bioquímica e Imunologia

#### 04.138

Role of transient receptor potential vanilloid 4 (TRPV4) in joint inflammation. Denadai-Souza A<sup>1</sup>, Vergnolle N<sup>2</sup>, Martin L<sup>2</sup>, Muscará MN<sup>1</sup>, Cenac N<sup>2</sup> <sup>1</sup>ICB-USP – Pharmacology, <sup>2</sup>INSERM

### 05. Pain and Nociception

#### 05.053

Evaluation of the antinociceptive profile of a series of *N*-acylhydrazones derivatives modified from the prototype LASSBio-294. Veloso RR, Nogueira MCO, Maia RC, Lima ML, Barreiro EJ, Miranda ALP FF-UFRJ- LASSBio

#### 05.054

Effects of methysergide injected into the anterior pretectal nucleus on the stimulation-induced antinociception from the retrosplenial cortex. Rossaneis AC, Reis GM, Prado WA FMRP USP – Farmacologia

#### 05.055

Crotalpine induces a long-lasting and opioid-mediated antinociceptive effect in an experimental model of bone cancer pain. Gutierrez VP<sup>2</sup>, Brigatte P<sup>1</sup>, Zambelli VO<sup>2</sup>, Carvalho JS<sup>2</sup>, Picolo G<sup>2</sup>, Radin A<sup>3</sup>, Marques FLN<sup>3</sup>, Cury Y<sup>2</sup> <sup>1</sup>CEIS-UNESP, <sup>2</sup>IBU – Pain and Signaling, <sup>3</sup>FM-USP – Oncology

#### 05.056

Aspirin-triggered resolvin d1, AT-RVD1, and its precursor, possess anti-hyperalgesic properties in a model of arthritis in rats. Lima-Garcia JF<sup>1</sup>, Motta EM<sup>1</sup>, Campos MM<sup>2</sup>, Calixto JB<sup>1</sup> <sup>1</sup>UFSC – Farmacologia, <sup>2</sup>PUCRS – Cirurgia-Odontologia

#### 05.057

Endothelin-1 induces both itch and pain in the mouse cheek. Oliveira L, Hara DB, Rae GA UFSC – Farmacologia

#### 05.058

The involvement of the transient receptor potential A1 (TRPA1) on norepinephrine-induced nociception in neuropathic mice. Pinheiro FV<sup>1</sup>, Silva CR<sup>2</sup>, Oliveira SM<sup>2</sup>, Villarinho JG<sup>3</sup>, Andre E<sup>3</sup>, Ferreira J<sup>2</sup> <sup>1</sup>UFSC – Fisiologia e Farmacologia, <sup>2</sup>UFSC – Química, <sup>3</sup>UFRN – Biofísica e Farmacologia

#### 05.059

Peripheral antinociceptive effect of inosine depends of the A1 adenosine receptor but not of receptors A2A and A3. Cerutti ML<sup>1</sup>, Nascimento FP<sup>2</sup>, Macedo Junior SJ<sup>1</sup>, Santos ARS<sup>1</sup> <sup>1</sup>UFSC – Ciências Fisiológicas, <sup>2</sup>UFSC – Farmacologia

#### 05.060

Analgesic effects of ethanolic extract from *Sinningia aggregata* tubers and from the isolated compound 3-prenyl-4-oxo-3'-methyl-naphtho [1,2b] oxepin-1,3'(4H)-diol. Simas AS<sup>1</sup>, Verdan ML<sup>2</sup>, Kassuya CAL<sup>3</sup>, Stefanello MEA<sup>2</sup>, Zamprônio AR<sup>1</sup> <sup>1</sup>UFPR – Farmacologia, <sup>2</sup>UFPR – Química, <sup>3</sup>UFGD – Ciências da Saúde

**05.061**

Cytokines and chemokines participate in the genesis of post-incisional pain. Carreira EU, Cunha FQ, Ferreira SH, Cunha TM FMRP-USP – Farmacologia

**05.062**

Effect of Oligopeptidases B from *Trypanosoma cruzi* and *Trypanosoma brucei* in an experimental model of pain in mice. Abrahão RQ<sup>1</sup>, Juliano MA<sup>2</sup>, Juliano L<sup>2</sup>, Giorgi R<sup>3</sup>, Dale CS<sup>4</sup> <sup>1</sup>UNIFESP – Biofísica, <sup>2</sup>UNIFESP – Farmacologia, <sup>3</sup>IBu – Fisiopatologia, <sup>4</sup>IEP-HSL

**05.063**

Central antinociceptive effects of ethanolic extract from the bark of *Pithecellobium cochliocarpum* on mice. Souza IA<sup>1</sup>, Jesus RPF<sup>2</sup>, Bastos IVGA<sup>2</sup>, Rodrigues GCR<sup>2</sup> <sup>1</sup>UFPE – Antibióticos

**05.064**

Role of NMDA receptors in carrageenin-induced hypernociception in rat temporomandibular joint: magnesium chloride modulator effect. Cavalcante ALC<sup>1</sup>, Siqueira RMP<sup>2</sup>, Colares MT<sup>1</sup>, Chaves HV<sup>1</sup>, Vale ML<sup>2</sup> <sup>1</sup>UFC – Ciências Médicas, <sup>2</sup>UFC – Fisiologia e Farmacologia

**05.065**

Involvement of B1 and B2 kinin receptors in painful neuropathy induced by paclitaxel in mice. Tamiozzo LLR<sup>1</sup>, Dalmolin GD<sup>2</sup>, Rigo FK<sup>2</sup>, Ferreira J<sup>1</sup> <sup>1</sup>UFMS – Química, <sup>2</sup>UFMG – Farmacologia

**05.066**

Mechanism of peripheral antinociceptive effect of 15D-PGJ<sub>2</sub> on rheumatoid arthritis into the TMJ of rats. Quintero MS<sup>1</sup>, Napimoga MH<sup>2</sup>, Clemente-Napimoga JT<sup>1</sup> <sup>1</sup>UNIUBE – Biologia Molecular, <sup>2</sup>UNIUBE – Biologia Celular e Molecular

**05.067**

Involvement of kinin receptors in pronociceptive action of dynorphin A (1-17) in a mouse model of orofacial neuropathy. Schroeder SD<sup>1</sup>, Luiz AP<sup>2</sup>, Chichorro JG<sup>3</sup>, Rae GA<sup>1</sup> <sup>1</sup>UFSC – Farmacologia, <sup>2</sup>UFSC – Ciências Fisiológicas, <sup>3</sup>UFPR – Farmacologia

**05.068**

Analgesic effect of a novel allosteric antagonist of C5a receptors. Carneiro VL<sup>1</sup>, Bertini R<sup>2</sup>, Cunha FQ<sup>1</sup>, Ferreira SH<sup>1</sup>, Teixeira MM<sup>5</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>Dompé Research and Development

**05.069**

Hyponociceptive effect of H1 and H2 receptors in a model of articular inflammation induced by formalin. Souza-Silva E, Mascarin LZ, Eto C, Oliveira D, Tonussi CR UFSC – Farmacologia

**05.070**

Role of nitric oxide in nociception, edema and plasma leakage induced by intra-articular

formalin. Eto C, Souza-Silva E, Mascarin LZ, Tonussi CR UFSC – Farmacologia

**05.071**

Cafestol evokes peripheral antinociception via activation of  $\alpha_{2C}$  adrenoceptors. Guzzo LS, Perez AC, Duarte IDG UFMG – Farmacologia

**05.072**

Antinociceptive and anti-inflammatory activity of ethanol extract of *Polygala sabulosa* in mice. Borges FR, Pierosan L, Silva MD, Córdova MM, Santos ARS CFS-UFSC

**05.073**

Visceral antinociceptive effect of HC-030031, an antagonist of TRPA1 ion channel, is independent of inflammatory cells and nitric oxide. Pereira LMS<sup>1</sup>, Sá LG<sup>1</sup>, Wong DVT<sup>1</sup>, Callado RB<sup>1</sup>, Teixeira CCG<sup>1</sup>, Bem AXC<sup>1</sup>, Larsen GR<sup>2</sup>, Lima-Júnior RCP<sup>1</sup>, Ribeiro RA<sup>1</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>Hydra Biosciences Biopharmaceutical Co – Biopharmacology

**05.074**

Synthesis and evaluation of antihyperalgesic activity of benzofuranone derived of xanthoxylin: hypothesis of the possible mechanism of action. Souza JP<sup>1</sup>, Quintão NLM<sup>1</sup>, Sonza DR<sup>2</sup>, De Campos-Buzzi F<sup>2</sup>, Niero R<sup>2</sup> <sup>1</sup>UNIVALI – Ciências Farmacêuticas, <sup>2</sup>NIQFAR-CCS-UNIVALI

**05.075**

Evaluation of antinociceptive spinal activity of TX3-4, a toxin peptide purified from the spider *Phoneutria nigriventer* venom, in mice. Silva JF<sup>1</sup>, Fontanini CEM<sup>2</sup>, Lavor, MSL<sup>3</sup>, de Souza AH<sup>4</sup>, Pessoa FLC<sup>2</sup>, Pinheiro ACN<sup>4</sup>, Binda NS<sup>4</sup>, Ferreira J<sup>5</sup>, Gomez MV<sup>4</sup> <sup>1</sup>UFMG – Farmacologia Bioquímica e Molecular, <sup>2</sup>UFMG – Medicina, <sup>3</sup>UFMG – Clínica e Cirúrgica Veterinária, <sup>4</sup>UFMG – Farmacologia, <sup>5</sup>UFMS – Química

**05.076**

Is there an involvement of endocannabinoid system in the peripheral antinociception of NSAID? Resende LC, Duarte IDG UFMG – Farmacologia

**05.077**

Antinociceptive effect of Riparin II in mice. Carvalho AMR<sup>1</sup>, Leite CP<sup>1</sup>, Moura BA<sup>3</sup>, Vasconcelos LF<sup>1</sup>, Melo TV<sup>1</sup>, Bastos MVR<sup>1</sup>, Barbosa Filho JM<sup>2</sup>, Sousa FCF<sup>2</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>UFPB – Tecnologia Farmacêutica

**05.078**

Crotalphine reduces peripheral sensitization evoked by activation of TRPV1 receptor in mice. Motta EM<sup>1</sup>, Machado FC<sup>2</sup>, Gutierrez VP<sup>2</sup>, Lira<sup>2</sup>, Gandra<sup>2</sup>, Picolo G<sup>3</sup>, Cury Y<sup>3</sup> <sup>1</sup>UFSC – Dor e Sinalização, <sup>2</sup>IBu – Dor e Sinalização, <sup>3</sup>IBu – Laboratório de Fisiopatologia



**05.079**

Evidence for the Involvement of kinin B<sub>1</sub> and B<sub>2</sub> receptors in the neuropathic pain-like behavior after treatment with paclitaxel in mice. Motta EM<sup>1</sup>, Costa R<sup>2</sup>, Manjavachi MN<sup>3</sup>, Dutra RC<sup>2</sup>, Pesquero JB<sup>3</sup>, Calixto JB<sup>2</sup> <sup>1</sup>UFSC – Dor e Sinalização, <sup>2</sup>UFSC – Farmacologia, <sup>3</sup>UNIFESP – Biofísica

**06. Cardiovascular and Renal Pharmacology****06.053**

Study of the cytotoxic effect of *Bothrops pauloensis* on MDCK cells. Jorge RJB<sup>1</sup>, Marinho AD<sup>2</sup>, Barbosa JPC<sup>3</sup>, Abreu ML<sup>1</sup>, Morais ICO<sup>1</sup>, Menezes RRPPB<sup>4</sup>, Lima Filho CF<sup>5</sup>, Pessoa AWP<sup>6</sup>, Santos LFL<sup>6</sup>, Alves CD<sup>3</sup>, Toyama MH<sup>7</sup>, Martins AMC<sup>4</sup>, Evangelista JSAM<sup>6</sup>, Monteiro HSA<sup>1</sup>, Moraes GB<sup>6</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>UFC – Farmácia, <sup>3</sup>UNIFOR – Fisiologia e Farmacologia, <sup>4</sup>UFC – Análises Clínicas e Toxicológicas, <sup>5</sup>UECE – Ciências Fisiológicas, <sup>6</sup>UECE – Veterinária, <sup>7</sup>IB-UNICAMP

**06.054**

Important changes in hematologic and cardiovascular parameters produced by chronic treatment with etoricoxib in normotensive and spontaneously hypertensive rats. Baracho NCV FMIT – Farmacologia e Bioquímica

**06.055**

Hypotensive and diuretic effect of *Achillea millefolium* L. (Asteraceae) in rats. de Souza P<sup>1</sup>, Gasparotto Junior A<sup>2</sup>, Boffo MA<sup>3</sup>, Lourenço EL<sup>4</sup>, Stefanello MEA<sup>5</sup>, Marques MCA<sup>1</sup>, da Silva-Santos JE<sup>6</sup>, Kassuya CAL<sup>7</sup> <sup>1</sup>UFPR – Farmacologia, <sup>2</sup>UNIPAR/UFPR – Farmacologia, <sup>3</sup>UNIPAR – Farmacologia, <sup>4</sup>USP – Toxicologia e Análises Toxicológicas., <sup>5</sup>UFPR – Química, <sup>6</sup>UFPA – Farmacologia Experimental e Pré-clínica, <sup>7</sup>UFGD – Ciências da Saúde

**06.056**

Involvement of L-arginine/NO pathway on the vascular adaptive response of high fat-diet rats exposed or not to chronic stress. Bruder-Nascimento T<sup>7</sup>, Campos DHJ<sup>2</sup>, Cicogna AC<sup>2</sup>, Cordellini S<sup>1</sup> <sup>1</sup>UNESP – Farmacologia, <sup>2</sup>UNESP – Clínica Médica

**06.057**

Comparative study of effects hemodynamic of diabetic cardiomyopathy is induced by L-name in rats. Gazzoto AF<sup>1</sup>, Pereira DJ<sup>1</sup>, Pires NF<sup>1</sup>, Moreira MM<sup>2</sup>, Santos RC<sup>1</sup>, Figueiredo VN<sup>2</sup>, Renno AL<sup>3</sup>, Quinaglia TSS<sup>2</sup>, Ludovico ND<sup>2</sup>, Moreno Junior H<sup>4</sup> <sup>1</sup>UNICAMP – Farmacologia, <sup>2</sup>UNICAMP – Farmacologia cardiovascular, <sup>3</sup>UNICAMP – Farmacologia Bioquímica, <sup>4</sup>UNICAMP

**06.058**

Effect of potassium-sparing diuretics on rat corpus cavernosum smooth muscle reactivity. Claudino MA<sup>1</sup>, Silva FH<sup>1</sup>, Franco-Penteado CF<sup>2</sup>, Takeshi FI<sup>1</sup>, Lopes AG<sup>3</sup>, Antunes E<sup>1</sup>, Nucci G<sup>1</sup>

<sup>1</sup>UNICAMP – Pharmacology, <sup>2</sup>UNICAMP – Hemocentro, <sup>3</sup>IBCCF-UFRJ – Fisiologia Renal

**06.059**

Cytotoxic effect of *Bothrops pirajai* on MDCK cells. Marinho AD<sup>1</sup>, Jorge RJB<sup>2</sup>, Barbosa JPC<sup>3</sup>, Abreu ML<sup>3</sup>, Rocha VHP<sup>1</sup>, Morais ICO<sup>2</sup>, Menezes RRPPB<sup>4</sup>, Morais GB<sup>5</sup>, Sampaio AM<sup>8</sup>, Alves RS<sup>2</sup>, Jorge ARC<sup>2</sup>, Ximenes RM<sup>2</sup>, Toyama MH<sup>6</sup>, Martins AMC<sup>4</sup>, Evangelista JSAM<sup>7</sup>, Monteiro HSA<sup>2</sup> <sup>1</sup>UFC – Farmácia, <sup>2</sup>UFC – Fisiologia e Farmacologia, <sup>3</sup>UNIFOR – Fisiologia e Farmacologia, <sup>4</sup>UFC – Análises Clínicas e Toxicológicas, <sup>5</sup>UECE – Faculdade de Veterinária, <sup>6</sup>UNICAMP – Instituto de Biologia

**06.060**

Inhibition of MMP decreases mortality and right ventricular damage caused by acute pulmonary embolism in rats. Cau SBA<sup>1</sup>, Barato RC<sup>1</sup>, Gerlach RF<sup>2</sup>, Tanus-Santos JE<sup>1</sup> – <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>FORP-USP – Morfologia

**06.061**

Angiotensin (1-12) metabolism in cardiac perfusate of Wistar and spontaneously hypertensive rats. Becari C<sup>1</sup>, Pereira HJV<sup>2</sup>, Mesquita Jr O<sup>1</sup>, Oliveira EB<sup>1</sup>, Salgado MCO<sup>1</sup> <sup>1</sup>FMRP-USP – Pharmacology, <sup>2</sup>FMRP-USP – Biochemistry and Immunology

**06.062**

Impaired Rho-A/Rho-kinase pathway contributes to vascular dysfunction in endotoxemic mouse. Corrêa T, da Silva-Santos JE UFSC – Farmacologia

**06.063**

Protein Disulfide Isomerase regulation of NADPH oxidase activity in vascular smooth muscle cells: effects on Angiotensin II redox signaling in hypertension. Camargo LL<sup>1</sup>, Androwiki ACD<sup>1</sup>, Ceravolo GS<sup>1</sup>, Denadai-Souza A<sup>1</sup>, Muscará MN<sup>1</sup>, Carvalho MHC<sup>1</sup>, Fortes ZB<sup>1</sup>, Janiszewski M<sup>2</sup>, Lopes LR<sup>1</sup> <sup>1</sup>USP – Farmacologia, <sup>2</sup>Hospital Israelita Albert Einstein – IEP

**06.064**

Endothelium potentiates vasodilator effect of nitric oxide donor with gold nanoparticles in aortas from normotensive but not from renal hypertensive rats. Silva BR<sup>1</sup>, Vercesi J. A<sup>2</sup>, Moraes JB<sup>2</sup>, Silva RS<sup>2</sup>, Bendhack LM<sup>2</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>FCFRP-USP – Física e Química

**06.065**

Vascular response in acute lung injury induced by paraquat. Aires RD<sup>1</sup>, Capettini LSA<sup>1</sup>, Pinho JF<sup>2</sup>, Côrtes SF<sup>3</sup>, Pinho V<sup>4</sup>, Lemos VS<sup>1</sup> <sup>1</sup>UFMG – Fisiologia e Biofísica, <sup>2</sup>UFMG – Fisiologia e Farmacologia, <sup>3</sup>UFMG – Farmacologia, <sup>4</sup>UFMG – Bioquímica e Imunologia

**06.066**

Expression of protein disulfide isomerase is associated with increased reactive oxygen

species generation in target organs in hypertension: possible interaction with NADPH oxidase. Androwiki ACD<sup>1</sup>, Camargo LL<sup>1</sup>, Dias AA<sup>1</sup>, Janiszewski M<sup>2</sup>, Lopes LR<sup>1</sup> <sup>1</sup>ICB-USP – Farmacologia, <sup>2</sup>Hospital Israelita Albert Einstein – IEP

#### 06.067

Comparison of the action mechanisms of sodium nitroprusside and [Ru(terpy)(bdq)NO<sup>+</sup>]<sup>3+</sup> in normotensive and hypertensive rats (SHR). Munhoz, FC<sup>1</sup>, Pereira AC<sup>2</sup>, Bonaventura D<sup>2</sup>, Bendhack LM<sup>2</sup>, Antoniali C<sup>1</sup> <sup>1</sup>FOA-UNESP – Ciências Básicas, <sup>2</sup>FCFRP-USP – Física e Química

#### 06.068

Protein disulfide isomerase regulates reactive oxygen species generation and vascular reactivity to angiotensin II in rat aorta. Dias AA<sup>1</sup>, Camargo LL<sup>2</sup>, Ceravolo GS<sup>1</sup>, Androwiki ACD<sup>1</sup>, Carvalho, MHC<sup>1</sup>, Laurindo FRM<sup>2</sup>, Janiszewski M<sup>3</sup>, Lopes LR<sup>1</sup> <sup>1</sup>ICB-USP – Farmacologia, <sup>2</sup>InCor-HC-FMUSP, <sup>3</sup>Hospital Israelita Albert Einstein – IEP

#### 06.069

Pharmacological characterization of the contractile response of the dorsal penile vein. Carioletti GH<sup>1</sup>, Linder AE<sup>2</sup> <sup>1</sup>UFSC – Farmacologia, Centro de Ciências Biológicas, <sup>2</sup>UFSC – Farmacologia

#### 06.070

The contribution of endothelial factors to serotonin-induced contraction in the rat jugular vein. Costa EB, Linder AE <sup>1</sup>UFSC – Farmacologia

#### 06.071

Hypothalamic obese and non-obese rats express a similar functional muscarinic M<sub>3</sub> subtype in the conductance artery. Scolaro LL<sup>1</sup>, Oliveira JC<sup>2</sup>, Ambiel CR<sup>3</sup>, Mathias PC<sup>2</sup>, Alves-do-Prado W<sup>1</sup> <sup>1</sup>UEM – Farmacologia, <sup>2</sup>UEM – Biologia Celular e Genética, <sup>3</sup>UEM – Ciências Fisiológicas

#### 06.072

Phenylephrine relaxes rat jugular vein. De Prá MA, Linder AE UFSC – Farmacologia

#### 06.073

Blood renin activity and vasoactive peptides concentrations in rats with different angiotensin I converting enzyme (ACE) phenotypes. Peixoto HS, da Silva RM, Tanæ MM, Souccar C, Lapa AJ, Lima-Landman MTR UNIFESP – Farmacologia

#### 06.074

Atorvastatin seems inhibit the MMP-9 expression more pronouncedly than simvastatin in human endothelial cell culture. Izidoro-Toledo TC<sup>1</sup>, Guimarães DA<sup>1</sup>, Gerlach RF<sup>2</sup>, Tanus-Santos JE<sup>1</sup> <sup>1</sup>FMRP-USP – Pharmacology, <sup>2</sup>FORP-USP – Morphology

#### 06.075

Hydrogen sulfide improves vascular hyporesponsiveness and survival in severe polymicrobial sepsis in mice. Balsanelli LS, Dal-Secco D, Assreuy J UFSC – Farmacologia

#### 06.076

Changes in rat's vascular reactivity in response to neonatal induced hyperleptinaemia. Motta NAV<sup>1</sup>, Marques EB<sup>1</sup>, Louback LS<sup>2</sup>, Miranda ALP<sup>2</sup>, Scaramello C<sup>1</sup>, Brito FCF<sup>1</sup> – <sup>1</sup>UFF – Fisiologia e Farmacologia, <sup>2</sup>FF-UFRJ – LASSBio

#### 06.077

Temporal evaluation of 2K1C model of renovascular hypertension: metalloproteinases and oxidative stress. Ceron CS<sup>1</sup>, Rizzi E<sup>1</sup>, Oliveira AM<sup>3</sup>, Guimarães DA<sup>1</sup>, Cau SBA<sup>1</sup>, Marçal DMO<sup>1</sup>, Gerlach RF<sup>1</sup>, Tanus-Santos JE<sup>1</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>FORP-USP – Morfologia

#### 06.078

Evaluation of cilostazol effects in hypercholesterolemic diet fed rats. Motta NAV<sup>1</sup>, Canal PF<sup>1</sup>, Amorim LEO<sup>1</sup>, Reis RC<sup>1</sup>, Miranda ALP<sup>2</sup>, Brito FCF<sup>1</sup> – <sup>1</sup>UFF – Fisiologia e Farmacologia, <sup>2</sup>FF-UFRJ – LASSBio

#### 06.079

Cardiovascular and neuroendocrine changes after blood volume expansion with hydroxyethyl starch 450/0.7 during experimental septic shock induced by cecal ligation and perforation (CLP). Santiago MB<sup>1</sup>, Andrade CAF<sup>1</sup>, Antunes-Rodrigues J<sup>2</sup>, Giusti-Paiva A<sup>1</sup> <sup>1</sup>UNIFAL – Ciências Biológicas, <sup>2</sup>FMRP-USP – Fisiologia

#### 06.080

Pharmacological characterization of a new steroidal cardiotonic isolated from *Physalis angulata* leafs. Gomes VM<sup>1</sup>, Pessoa ODL<sup>2</sup>, Santos CF<sup>3</sup>, Fonteles MC<sup>4</sup>, Lessa LMA<sup>5</sup>, Nascimento NRF<sup>6</sup> <sup>1</sup>UECE – Fisiologia, <sup>2</sup>UFC – Química Orgânica, <sup>3</sup>UECE – Medicina, <sup>4</sup>Mackenzie – Fisiologia e Farmacologia, <sup>5</sup>ISCB-UECE, <sup>6</sup>UECE – Medicina Veterinária

#### 06.081

Blood arterial pressure and vasoactive peptides concentration after nephrectomy in rats with different ace phenotypes. da Silva RM, Tanæ MM, Peixoto HS, Souccar C, Lapa AJ, Lima-Landman MTR UNIFESP – Farmacologia

#### 06.082

Cardiovascular responses to bothropstoxin. Rodrigues MAP, Dias L, Smaal A, Rennó AL, da Silva DA, Lorenzetti R, Hyslop S, Hyslop S UNICAMP – Farmacologia

#### 06.083

Cardiovascular alterations caused by *Bothrops alternatus* snake venom in anesthetized dogs. Rodrigues MAP<sup>1</sup>, Dias L<sup>1</sup>, Smaal A<sup>1</sup>, Rennó AL<sup>1</sup>, Moreno Junior H<sup>2</sup>, Mello SM<sup>3</sup>, Hyslop S<sup>1</sup> <sup>1</sup>UNICAMP – Farmacologia, <sup>2</sup>UNICAMP, <sup>3</sup>UNICAMP – Controle de Intoxicações

**06.084**

The participation of AT<sub>1</sub> receptor in the Ang II-increased contraction in the contralateral carotid artery after balloon catheter injury. Olivon VC<sup>1</sup>, Mestriner FL<sup>2</sup>, Cunha FQ<sup>2</sup>, de Oliveira AM<sup>1</sup> <sup>1</sup>FCF-USP – Física e Química, <sup>2</sup>FMRP-USP

**06.085**

Renin inhibition with aliskiren did not prevent the vascular remodeling found in 2K1C hypertension. Oliveira AM<sup>1</sup>, Castro MM<sup>1</sup>, Marçal DMO<sup>1</sup>, Rizzi E<sup>1</sup>, Ceron CS<sup>1</sup>, Guimarães DA<sup>1</sup>, Gerlach RF<sup>2</sup>, Tanus-Santos JE<sup>1</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>FORP-USP – Morfologia

**06.086**

Renal cyclooxygenase expression in rats treated with *Bothrops alternatus* venom. Rennó AL<sup>1</sup>, Penteadó CF<sup>2</sup>, Linardi A<sup>1</sup>, Hyslop S<sup>1</sup> <sup>1</sup>UNICAMP – Farmacologia, <sup>2</sup>UNICAMP – Hemocentro

**06.087**

Effects of high-fat diet during six week on biochemical parameters and arterial blood pressure of Wistar rats. Milet-Morais MM<sup>1</sup>, Silva OA<sup>1</sup>, Figueiredo TG<sup>2</sup>, Guedes GS<sup>2</sup>, Xavier FE<sup>3</sup>, Rabelo LA<sup>2</sup>, Pinto Duarte G<sup>1</sup> <sup>1</sup>UFPE – Fisiologia e Farmacologia, <sup>2</sup>UFAL – Fisiologia e Farmacologia, <sup>3</sup>UFES – Fisiologia

**06.088**

Cardiovascular effects produced by chronic treatment with L-arginine in hypertensive rats. Baracho NCV<sup>1</sup>, Silva GF<sup>2</sup>, Bernardes DSV<sup>1</sup>, Oliveira RCS<sup>1</sup> <sup>1</sup>FMIT – Farmacologia e Bioquímica, <sup>2</sup>FMIT

**06.089**

Cardiovascular effects produced by chronic treatment of sodium cyclamate in hypertensive rats. Pereira AC, Zaroni ACE, Tavares JD, Furtado GS, Baracho NCV, Irulegui RSC FMIT

**07. Endocrine and Gastrointestinal Pharmacology****07.001**

Role of the cholinergic/NO pathway in delayed gastric emptying of liquids induced by α-terpineol in awake rats. Bento-Silva MT<sup>1</sup>, Marques RB<sup>2</sup>, Oliveira FGV<sup>1</sup>, Silva LL<sup>2</sup>, Piauilino CA<sup>2</sup>, Oliveira IS<sup>2</sup>, Pinheiro, ADN<sup>1</sup>, Santos AA<sup>3</sup>, Oliveira FA<sup>2</sup>, Almeida FRC<sup>4</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>NPPM-CCS-UFPI, <sup>3</sup>UFC – Medicina, <sup>4</sup>UFPI – Bioquímica e Farmacologia

**07.002**

Characterization of neuro-humoral pathways in increased gastric retention of liquids due to mechanical right atrium stretch in awake rats. Palheta Junior RC<sup>1</sup>, Okoba W<sup>1</sup>, Bento-Silva MT<sup>1</sup>, Pinheiro ADN<sup>1</sup>, Oliveira, FGV<sup>1</sup>, Elias LLK<sup>2</sup>, Rodrigues JA<sup>2</sup>, Santos AA<sup>1</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>FMRP-USP – Fisiologia

**07.003**

Hypoglycemic activity of new derivatives sulfonilhidrazonic in the animal model of type 1 diabetes. Oliveira LGT<sup>1</sup>, Kartnaller MA<sup>1</sup>, D'Andrea ED<sup>2</sup>, Lima ML<sup>2</sup>, Barreiro EJ<sup>2</sup>, Sudo RT<sup>1</sup>, Zapata-Sudo G<sup>1</sup> <sup>1</sup>UFRJ – Desenvolvimento de Fármacos, <sup>2</sup>FF-UFRJ

**07.004**

Antiulcerogenic activity of ethanolic and aqueous extracts of the bark of *Terminalia catappa* in gastric ulcer induced by ethanol in *Rattus norvegicus*. Viana VSL, Brito-Júnior EC, Rabelo RS, Nunes-Filho DM, Maia EP, Martins MCC, Nunes PHM UFPI – Biofísica e Fisiologia

**07.005**

Nitric oxide (NO) pathway influence the gastroprotection induced by carbon monoxide (CO) against ethanol-induced gastric damage in mice. Lucetti LT, Medeiros J-VR, Gomes AS, Santana APM, Soares PMG, Ribeiro RA, Souza MHLP UFC – Fisiologia e Farmacologia

**07.006**

Role of nitric oxide synthase (NOS) in the gastroprotective effect of hydrogen sulphide (H<sub>2</sub>S) in ethanol-induced gastric damage in mice. Lucetti LT<sup>1</sup>, Medeiros J-VR<sup>2</sup>, Gomes AS<sup>1</sup>, Santana APM<sup>1</sup>, Barbosa ALR<sup>1</sup>, Soares PMG<sup>3</sup>, Cunha FQ<sup>4</sup>, Ribeiro RA<sup>1</sup>, Souza MHLP<sup>1</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>UFPI – Biologia, <sup>3</sup>UFC – Morfologia, <sup>4</sup>FMRP-USP

**07.007**

A possible role of leptin and adiponectin during differentiation of monocyte in macrophage *in vitro*. Acedo SC<sup>1</sup>, Gambero S<sup>2</sup>, Cunha FGP<sup>2</sup>, Lorand-Metze I<sup>2</sup>, Gambero A<sup>1</sup> <sup>1</sup>UNIFAG-USF, <sup>2</sup>UNICAMP – Hemocentro

**07.008**

Gastroprotective effect of nitrosyl-ruthenium against the ethanol-induced gastric damage in mice. Santana APM<sup>1</sup>, Torres JNL<sup>1</sup>, Medeiros J-VR<sup>2</sup>, Lucetti LT<sup>1</sup>, Soares PMG<sup>3</sup>, Wong DVT<sup>1</sup>, Tavares BM<sup>1</sup>, Saraiva MIR<sup>1</sup>, Lopes LGF<sup>4</sup>, Souza MHLP<sup>1</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>UFPI – Biologia, <sup>3</sup>UFC – Morfologia, <sup>4</sup>UFC – Química Orgânica e Inorgânica

**07.009**

Perinodal adipose tissue and mesenteric lymph node cells interactions during inflammatory intestinal response: adipocytokine and polyunsaturated fatty acids profile. Gotardo EMF<sup>1</sup>, Acedo SC<sup>1</sup>, De Oliveira CC<sup>1</sup>, Carvalho, PO<sup>2</sup>, Gambero A<sup>1</sup> <sup>1</sup>UNIFAG-USF, <sup>2</sup>USF – Multidisciplinar

**07.010**

*Saccharomyces boulardii* ameliorates gastric dysmotility and inflammation presents in intestinal mucositis induced by 5-fluorouracil in mice. Justino PFC<sup>1</sup>, SILVA LM<sup>1</sup>, Melo LFM<sup>1</sup>, Costa JVG<sup>1</sup>, Nogueira AF<sup>1</sup>, Lucetti LT<sup>1</sup>, Ribeiro RA<sup>1</sup>, Souza MHLP<sup>1</sup>, Soares PMG<sup>2</sup> <sup>1</sup>UFC –

Fisiologia e Farmacologia, <sup>2</sup>UFC –  
Morfologia/Fisiologia e Farmacologia

#### 07.011

Intestinal permeability test as a useful tool to discriminate patterns of diarrhea due to cancer chemotherapy agents. Wong DVT<sup>1</sup>, Bem AXC<sup>1</sup>, Nunes LG<sup>1</sup>, Leite LL<sup>1</sup>, Noronha FJD<sup>1</sup>, Barbosa CRN<sup>1</sup>, Brito GAC<sup>2</sup>, Souza MHL<sup>1</sup>, Lima AAM<sup>1</sup>, Lima-Júnior RCP<sup>1</sup>, Ribeiro RA<sup>1</sup> <sup>1</sup>UFC – Physiology and Pharmacology, <sup>2</sup>UFC – Morphology

#### 07.012

Mechanisms involved in delayed gastric emptying induced by thermogenic supplement in female ovariectomized mice. Sousa, LN<sup>1</sup>, Santos, RGS<sup>1</sup>, Oliveira, FGV<sup>2</sup>, Silveira, GL<sup>2</sup>, Bento-Silva MT<sup>2</sup>, Monteiro FMF<sup>1</sup> Santos AA<sup>2</sup>, Palheta Junior RC<sup>1</sup> <sup>1</sup>UNIVASF – Veterinary Medicine, <sup>2</sup>UFC – Physiology and Pharmacology

#### 07.013

Metyrapone reverses effects of LPS on neuroendocrine response and maternal behavior of lactating female rats. Vilela FC, Melo CM, Andrade CAF, Giusti-Paiva A ICB-UNIFAL

### 08. Respiratory, Urinary and Reproductive

#### 08.001

NO association between vitamin D Receptor haplotype and preeclampsia in a Brazilian population. de Rezende V<sup>1</sup>, Sandrim VC<sup>1</sup>, Palei ACT<sup>2</sup>, Cavalli RC<sup>2</sup>, Luizon MR<sup>1</sup>, Tanus-Santos JE<sup>1</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>FMRP-USP – Ginecologia e Obstetrícia

#### 08.002

Effect of intrauterine undernutrition in rat vas deferens: altered Ca<sup>2+</sup> homeostasis and implications in male fertility. Muzi-Filho H<sup>1</sup>, Souza AM<sup>1</sup>, Bezerra CGP<sup>1</sup>, Boldrini LC<sup>2</sup>, Takiya CM<sup>2</sup>, Oliveira FL<sup>2</sup>, El-Cheikh MC<sup>2</sup>, Einicker-Lamas M<sup>3</sup>, Vieyra A<sup>3</sup>, Lara Morcillo LS<sup>1</sup>, Cunha VMN<sup>1</sup> <sup>1</sup>ICB-UFRJ – Farmacologia Celular e Molecular, <sup>2</sup>ICB-UFRJ – Ciências Morfológicas, <sup>3</sup>IBCCF-UFRJ – Instituto de Biofísica Carlos Chagas Filho

#### 08.003

Functional characterization of erectile dysfunction in middle-aged rats. Silva FH, Monica FZT, Priviero FBM, Flores Toque HA, Antunes E UNICAMP – Pharmacology

#### 08.004

Pre-clinical evaluation of the isoniazid-derived compounds IQG-607 and IQG-639 in a mouse model of tuberculosis. Rodrigues-Junior VS<sup>1</sup>, Santos Jr AA<sup>1</sup>, Jader ABS<sup>1</sup>, Souto AA<sup>1</sup>, Calixto JB<sup>2</sup>, Basso LA<sup>1</sup>, Santos DS<sup>1</sup>, Campos MM<sup>1</sup> <sup>1</sup>INCTTB-PUCRS, <sup>2</sup>UFSC – Farmacologia

#### 08.005

Effect of chronic undernutrition in rat vas deferens: altered Ca<sup>2+</sup> homeostasis and

implications in male fertility. Muzi-Filho H<sup>1</sup>, Bezerra CGP<sup>1</sup>, Souza AM<sup>1</sup>, Boldrini LC<sup>2</sup>, Takiya CM<sup>2</sup>, Oliveira FL<sup>2</sup>, El-Cheikh MC<sup>2</sup>, Einicker-Lamas M<sup>3</sup>, Vieyra A<sup>3</sup>, Lara Morcillo LS<sup>1</sup>, Cunha VMN<sup>1</sup> – <sup>1</sup>ICB-UFRJ – Farmacologia Celular e Molecular, <sup>2</sup>ICB-UFRJ – Ciências Morfológicas, <sup>3</sup>IBCCF-UFRJ

#### 08.006

Functional, molecular and morphological characterization of bladder dysfunction in diabetic mice. Leiria LOS<sup>1</sup>, Carvalho FDGF<sup>1</sup>, Franco-Penteado CF<sup>2</sup>, Monica FZT<sup>1</sup>, Claudino MA<sup>1</sup>, Schenka A<sup>1</sup>, Nucci G<sup>1</sup>, Antunes E<sup>1</sup> <sup>1</sup>UNICAMP – Farmacologia, <sup>2</sup>UNICAMP – Hemocentro

#### 08.007

Relaxation of airways smooth muscle induced by glucagon is dependent of epithelial-derived factor. Insuela DBR, Coelho LP, Cruz CCD, Serra MF, Cordeiro RSB, Silva PMR, Martins MA, Carvalho VF IOC-FIOCRUZ – Fisiologia e Farmacodinâmica

#### 08.008

Role of CXCR2 in a model of pulmonary infection with *Klebsiella pneumoniae*. Paula TP<sup>1</sup>, Arifa RDN<sup>1</sup>, Ávila TV<sup>2</sup>, Fagundes CT<sup>3</sup>, Cruz RC<sup>1</sup>, Werneck SMC<sup>1</sup>, Karklin YC<sup>1</sup>, Baltazar LM<sup>1</sup>, Madeira MFM<sup>1</sup>, Campi PS<sup>1</sup>, Pinho V<sup>3</sup>, Teixeira MM<sup>3</sup>, Souza DG<sup>3</sup> <sup>1</sup>UFMG – Microbiologia, <sup>2</sup>UFPR – Farmacologia, <sup>3</sup>UFMG – Bioquímica e Imunologia

#### 08.009

Alpha-1 adrenoceptor mediated contractions of the rat bladder neck. Pacini ESA, Pupo AS UNESP Botucatu – Farmacologia

### 09. Natural Products and Toxinology

#### 09.071

Antioxidant activity of dichloromethane fraction of *Baccharis trimera* and its effects on murine macrophages. Freitas GM, Gayer CRM, Coelho MGP, Sabino KCC UERJ – Bioquímica

#### 09.072

Pulsed therapeutic ultrasound effects on skeletal muscle damage induced by *Bothrops jararacussu* snake venom. Tomaz MA<sup>1</sup>, Saturnino-Oliveira J<sup>2</sup>, Machado MM<sup>1</sup>, Cons BL<sup>1</sup>, Calil-Elias S<sup>3</sup>, Martinez AMB<sup>4</sup>, Melo PA<sup>1</sup> <sup>1</sup>UFRJ – Farmacologia Básica e Clínica, <sup>2</sup>UESC – Microscopia Eletrônica, <sup>3</sup>UFF – Farmácia e Administração Farmacêutica, <sup>4</sup>UFRJ – Embriologia e Histologia

#### 09.073

Study of the neuropharmacological activity of the compound GB-2a obtained from *Rheedia gardneriana*. Santos ECS<sup>1</sup>, Marques de Carvalho RS<sup>1</sup>, Cechinel-Filho V<sup>2</sup>, De Lima TCM<sup>1</sup> <sup>1</sup>UFSC – Farmacologia, <sup>2</sup>NIQFAR-UNIVALI

**09.074**

Effects of chronic treatment with aqueous extract of *Cuphea balsamona* L. on the lipid profile of rats submitted to a high-cholesterol diet. Baracho NCV<sup>1</sup>, Brügger PG<sup>2</sup>, Camanducaia DSM<sup>2</sup>, Sanches AIF<sup>2</sup>, Sanches RS<sup>2</sup> <sup>1</sup>FMIT – Farmacologia e Bioquímica, <sup>2</sup>FMIT – Medicina

**09.075**

Evaluation of antinociceptive property of ethanolic extract of *Buddleja brasiliensis*. Cavallini OF<sup>1</sup>, Marinho DG<sup>2</sup>, Freitas GA<sup>1</sup>, Carneiro LU<sup>1</sup>, Contarato KS<sup>1</sup>, Almança CCJ<sup>3</sup>, Marinho BG<sup>1</sup> <sup>1</sup>UFES – Medicina Veterinária, <sup>2</sup>ICB-UFRJ – Farmacologia e Química Medicinal, <sup>3</sup>FAFIA – Farmácia

**09.076**

Antidiarrheic activity of hidroalcoholic extract from barks of *Astronium fraxinifolium* schott in mice. Serikava SMO<sup>1</sup>, Kushima H<sup>1</sup>, Hiruma-Lima CA<sup>1</sup>, da Silva VC<sup>2</sup>, Vilegas W<sup>3</sup> <sup>1</sup>IB-UNESP-Botucatu – Fisiologia, <sup>2</sup>IQ-UNESP – Química Orgânica, <sup>3</sup>UNESP-Araraquara – Química Orgânica

**09.077**

Evaluation of the anti inflammatory cutaneous effect of *Croton brasiliensis*. Silva MO<sup>1</sup>, Prudente AS<sup>1</sup>, Conserva LM<sup>2</sup>, Cabrini DA<sup>1</sup>, Otuki MF<sup>3</sup> <sup>1</sup>UFPR – Farmacologia, <sup>2</sup>IQB-UFAL, <sup>3</sup>UEPG – Ciências Farmacêuticas

**09.078**

Crotoxin modifies intracellular signaling involved in phagocytosis by neutrophils. Lima TS<sup>1</sup>, Sampaio SC<sup>1</sup>, Della-Casa MS<sup>2</sup>, Cirillo MC<sup>1</sup> <sup>1</sup>IBu – Fisiopatologia, <sup>2</sup>IBu – Imunopatologia

**09.079**

Anxiogenic-like effect of repeated administration of *Passiflora alata* aqueous extract in rodents in the elevated plus maze. Braga A<sup>1</sup>, Fenner R<sup>1</sup>, Betti AH<sup>1</sup>, Stolz ED<sup>2</sup>, Hasse DR<sup>3</sup>, Gosmann G<sup>1</sup>, Rates SMK<sup>1</sup> <sup>1</sup>UFRGS – Ciências Farmacêuticas, <sup>2</sup>UFRGS – Neurociências, <sup>3</sup>UFRGS – Psicofarmacologia Experimental, <sup>6</sup>UFRGS – Ciências Farmacêuticas

**09.080**

Bioassay-guided fractionation of the marine sponge *Polymastia janeirensis* for anticancer and anticoagulant activity. Biegelmeier R<sup>1</sup>, da Frota Jr. MLC<sup>2</sup>, Andrade JMM<sup>1</sup>, Carraro JLF<sup>3</sup>, Zanutto-Filho A<sup>2</sup>, Lorenzi R<sup>2</sup>, Mothes B<sup>3</sup>, Moreira JCF<sup>2</sup>, Henriques AT<sup>1</sup> <sup>1</sup>UFRGS – Farmacognosia, <sup>2</sup>UFRGS – Bioquímica, <sup>3</sup>Fundação Zoobotânica – Ciências Naturais

**09.081**

Biomonitoring of *Coutarea hexandra* in topic model of inflammation in mice. Prudente AS<sup>1</sup>, Lima SF<sup>2</sup>, Conserva LM<sup>2</sup>, Cabrini DA<sup>1</sup>, Otuki MF<sup>3</sup> <sup>1</sup>UFPR – Farmacologia, <sup>2</sup>IQB-UFAL, <sup>3</sup>UEPG – Ciências Farmacêuticas

**09.082**

Preliminary investigation on the pharmacological activities of *Araucaria angustifolia* hidroalcoholic extract in insects. Lucho APB<sup>1</sup>, Corrêa MS<sup>2</sup>, Franco J<sup>3</sup>, Dal Belo CA<sup>1</sup> <sup>1</sup>UNIPAMPA – Toxinologia, <sup>2</sup>UNIPAMPA – Química, <sup>3</sup>UNIPAMPA – Bioquímica

**09.083**

Amblyomin-X impairs VEGF-induced new vessels formation by altering endothelial cell functions. Drewes CC<sup>1</sup>, Dias RYS<sup>1</sup>, Hebeda CB<sup>1</sup>, Simons SM<sup>2</sup>, Chudzinski-Tavassi AM<sup>2</sup>, Farsky S<sup>1</sup> <sup>1</sup>FCF-USP – Análises Clínicas e Toxicológicas, <sup>2</sup>IBu – Bioquímica

**09.084**

Ability of suramin to antagonize permeability alterations induced by honey bee venom. El-Kik CZ, Fernandes FFA, Fonseca TF, Gaban GA, Branco AMC, Silva CLM, Melo PA UFRJ – Farmacologia Básica e Clínica

**09.085**

Purification and characterization of hyaluronidase from venom of the Brazilian spider *Vitalius dubius* (Araneae, Theraphosidae). Sutti R, Tamascia ML, Hyslop S UNICAMP – Farmacologia

**09.086**

Effect of oral treatment with crude extract of *Plectranthus neochilus* in models of nociception and injury of the stomach mucosa. Calheiros AS<sup>1</sup>, Souza<sup>1</sup>, Azeredo JA<sup>2</sup>, Castro-Faria-Neto HC<sup>2</sup>, Frutuoso VS<sup>2</sup> <sup>1</sup>FIOCRUZ – Imunofarmacologia, <sup>2</sup>FIOCRUZ – Fisiologia e Farmacodinâmica

**09.087**

Hecogenin-induced gastroprotection against acute gastric lesions: role of prostaglandins and K<sup>+</sup>-channels. Neves KRT<sup>1</sup>, Cerqueira GS<sup>1</sup>, Siqueira RMP<sup>1</sup>, Rocha NFM<sup>1</sup>, Freitas APF<sup>2</sup>, Vasconcelos SMM<sup>1</sup>, Leal LKAM<sup>3</sup>, Rios ERV<sup>1</sup>, Macedo DS<sup>1</sup>, Viana GSB<sup>1</sup>, Moura BA<sup>1</sup>, Sampaio LRL<sup>1</sup>, <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>UFC – Ciências Médica, <sup>3</sup>UFC – Farmácia

**09.088**

Antinociceptive effect of the hidroalcoholic extract of *Salvia officinalis* in mice. Rodrigues MRA<sup>1</sup>, Kanazawa LKS<sup>1</sup>, dos Santos FC<sup>1</sup>, Neves TLM<sup>1</sup>, Pereira IT<sup>1</sup>, Burci LM<sup>1</sup>, Santos ARS<sup>2</sup>, Pizzolatti GM<sup>3</sup>, Baggio CH<sup>1</sup>, Werner MFP<sup>1</sup> <sup>1</sup>UFPR – Farmacologia, <sup>2</sup>UFSC – Ciências Fisiológicas, <sup>3</sup>UFSC – Química

**09.089**

Antiophidic activity of the Amazon plant *Humirianthera ampla* and its compounds lupeol and sitosterol. Strauch MA<sup>1</sup>, Azevedo SM<sup>2</sup>, Ricardo HD<sup>3</sup>, Lemos BC<sup>3</sup>, Tomaz MA<sup>1</sup>, Machado MM<sup>3</sup>, Melo PA<sup>1</sup> <sup>1</sup>UFRJ – Farmacologia Básica e Clínica, <sup>2</sup>UNIR – Química Orgânica, <sup>3</sup>UFRJ – Farmacologia e Química Medicinal

**09.090**

Evaluation of anti-inflammatory activity of crude extract from *Sapium glandulatum* (Vell.). Soley BS<sup>1</sup>, Mendes DAGB<sup>1</sup>, Ferreira BGA<sup>2</sup>, Zuffellato-Ribas KC<sup>2</sup>, Otuki MF<sup>3</sup>, Cabrini DA<sup>1</sup> <sup>1</sup>UFPR – Farmacologia, <sup>2</sup>UFPR – Botânica, <sup>3</sup>UEPG – Ciências Farmacêuticas

**09.091**

*Hypericum polyanthemum* and its main phloroglucinol derivative uliginosin B present synergistic effect with different antidepressant drugs in the forced swimming test in mice. Stein AC<sup>1</sup>, Centurião FB<sup>1</sup>, Haas JS<sup>1</sup>, Viana AF<sup>2</sup>, Do Rego JC<sup>3</sup>, Costentin J<sup>3</sup>, Von Poser GL<sup>2</sup>, Rates SMK<sup>2</sup> <sup>1</sup>UFRJ – Farmácia, <sup>2</sup>UFRGS – Ciências Farmacêuticas, <sup>3</sup>Université de Rouen – Neuropsychopharmacologie Expérimentale

**09.092**

Cardiovascular effects of *Syzygium cumini* L. Skeels fruit extract in rats. Tenório EP<sup>1</sup>, Ferreira AKB<sup>1</sup>, Oliveira DA<sup>1</sup>, Aquino PGV<sup>2</sup>, Araújo-Júnior JX<sup>1</sup>, Santana AEG<sup>2</sup>, Ribeiro EAN<sup>1</sup> <sup>1</sup>ESENFAR-UFAL, <sup>2</sup>UFAL – Química e Biotecnologia

**09.093**

Subchronic toxicity of a proteolytic fraction from *C. candamarcensis* latex: qualitative histopathological analysis. Villalba MIC<sup>1</sup>, Bilheiro RP<sup>2</sup>, Salas CE<sup>3</sup>, Cassali, G. D.<sup>4</sup>, Vasconcelos A<sup>4</sup>, Tagliati CA<sup>5</sup>, Lopes MTP<sup>2</sup> <sup>1</sup>UFMG – Fisiologia e Farmacologia, <sup>2</sup>UFMG – Farmacologia, <sup>3</sup>UFMG – Bioquímica e Imunologia, <sup>4</sup>UFMG – Patologia Geral, <sup>5</sup>UFMG – Farmácia

**09.094**

Effect of salvia (*Salvia officinalis*) hydroalcoholic extract on the topic anti-inflammatory response in mice. Lopes VM, Fonseca JP, Melo GAN, Damião JM, Freitag A, Amado CAB, Cuman RKN UEM – Farmácia e Farmacologia

**09.095**

Spasmolytic action of *Solanum agrarium* sendtner (Solanaceae) involves blockade of L-type calcium channels on guinea-pig ileum. Oliveira GA<sup>1</sup>, Correia ACC<sup>1</sup>, Santos RF<sup>1</sup>, Agra MF<sup>1</sup>, Silva TMS<sup>2</sup>, Silva BA<sup>1</sup> <sup>1</sup>LTF-CCS-UFPB – Ciências Farmacêuticas, <sup>2</sup>DQ-UFRPE

**09.096**

Hydroxydihydrocarvone, a monoterpene derivative, decreases carrageenan-induced inflammation in rodents. Camargo E, de Souza DP UFS – Fisiologia

**09.097**

Evaluation of anethole obtained from *Foeniculum vulgare* Mill essential oil on renal ischemia and reperfusion in mice. Fonseca JP<sup>1</sup>, Lopes VM<sup>1</sup>, Damião MJ<sup>1</sup>, Pinheiro RJ<sup>1</sup>, Giannocco G<sup>2</sup>, Bersani-Amado CA<sup>1</sup>, Cuman RKN<sup>1</sup> <sup>1</sup>UEM – Farmácia e Farmacologia, <sup>2</sup>USP – Fisiologia e Biofísica

**09.098**

Inhibitory effects of *Combretum leprosum* Mart. & Eicher, *Protium heptaphyllum* March and *Copernicia prunifera* on glycosylated hemoglobin. Piauilino CA<sup>1</sup>, Sales Filho HLA<sup>1</sup>, Sousa VR<sup>1</sup>, Ayres MCC<sup>2</sup>, Carvalho AA<sup>2</sup>, Chaves MH<sup>2</sup>, Brito SMRC<sup>1</sup> <sup>1</sup>NPPM-UFPI, <sup>2</sup>UFPI – Química

**09.099**

Involvement of potassium channels and cyclic nucleotides in the tocolytic action of Labdane-302 on rat uterus. Travassos RA, Macedo CL, Santos RF, Oliveira GA, Silva ACL, Carreiro JN, Ferreira TF, Tavares JF, Silva BA LTF-UFPB – Ciências Farmacêuticas

**09.100**

Involvement of K<sup>+</sup> channels on spasmolytic effect of the fraction of the total alkaloids from *Solanum paludosum* Moric. root bark on guinea-pig ileum. Silva ACL<sup>1</sup>, Monteiro FS<sup>1</sup>, Martins IRR<sup>2</sup>, Travassos RA<sup>4</sup>, Santos RF<sup>2</sup>, Agra MF<sup>1</sup>, Basílio IJLD<sup>2</sup>, Bhattacharyya J<sup>2</sup>, Silva BA<sup>1</sup>, <sup>1</sup>LTF-UFPB – Ciências Farmacêuticas, <sup>2</sup>LTF-CCS-UFPB

**09.101**

Evaluation of the activity of the crude extract, fractions and isolated compounds obtained from the leaves of *Chrysophyllum cainito* against sensory changes present in experimental models of clinical pain in rodents. Meira NA<sup>1</sup>, Quintão NLM<sup>1</sup>, Cechinel Filho V<sup>1</sup>, Klein Jr LC<sup>2</sup>, Martin Z<sup>3</sup>, Rodriguez LMP<sup>3</sup> <sup>1</sup>NIQFAR-UNIVALI – Ciências Farmacêuticas, <sup>2</sup>UNIVALI – Produtos Naturais e Substâncias Bioativas, <sup>3</sup>CICY – Biotecnologia

**09.102**

Gastroprotective activity of chloroform and aqueous fractions obtained of hydroalcoholic extracts of *Brassica oleracea* L. var. *acephala* DC. Lemos M, Santin JR, Oliveira AP, Klein LC, Niero R, Andrade SF NIQFAR-CCS-UNIVALI

**09.103**

Antinociceptive effects of *Rheedia longifolia* Planch & Triana aqueous extract and its fractions. Nascimento DD<sup>1</sup>, Siqueira AM<sup>1</sup>, Costa NF<sup>1</sup>, Bérenger ALR<sup>2</sup>, Castro-Faria-Neto HC<sup>1</sup>, Figueiredo MR<sup>2</sup>, Frutuoso VS<sup>1</sup> <sup>1</sup>IOC-FIOCRUZ – Imunofarmacologia, <sup>2</sup>Farmanguinhos-FIOCRUZ – Produtos Naturais

**09.104**

Hypertension and oxidative stress associated with development of fetal programming: influence of extract from *Vitis vinifera* grape skin. Emiliano da Silva AF<sup>1</sup>, Costa CA<sup>2</sup>, Bem G<sup>2</sup>, Carvalho LCRM<sup>3</sup>, Boaventura GT<sup>4</sup>, Soares de Moura R<sup>3</sup>, Resende AC<sup>1</sup> <sup>1</sup>UERJ – Farmacologia e Psicobiologia, <sup>2</sup>UERJ – Farmacologia e Psicobiologia, <sup>3</sup>UERJ – Farmacologia, <sup>4</sup>UFF – Nutrição Dietética

**09.105**

Comparative study between the effect of aqueous extract of *Bixa orellana* L. and simvastatin on

lipidic profile and blood pressure of hypertensive rats and submitted to a high-cholesterol diet. Reis MLA, Baracho NCV, Ferreira MRC FMIT

#### 09.106

Study of the acute toxicity of *Eugenia brasiliensis* Lamarck and *Eugenia beaurepaireana* (Kiaerskou) Legrand extracts on mice. Lemes EV<sup>1</sup>, Cabrini DA<sup>2</sup>, Otuki MF<sup>2</sup>, Pizzolatti MG<sup>3</sup>, Brighente IMC<sup>3</sup>, Magina MDA<sup>4</sup>, Beirith A<sup>5</sup> <sup>1</sup>FURB – Physiotherapy, <sup>2</sup>UFPR – Pharmacology, <sup>3</sup>UFSC – Chemistry, <sup>4</sup>FURB – Pharmaceutical Sciences, <sup>5</sup>FURB – Natural Sciences

#### 09.107

Evaluation of the anti-inflammatory and antinociceptive activities of the leaf and stem of *Costus spiralis* (Jacq.) Roscoe (Costaceae). Campesatto-Mella E<sup>1</sup>, Araújo MV<sup>1</sup>, Silva AKD<sup>1</sup>, Santos DLF<sup>1</sup>, Delatorre P<sup>2</sup>, Rocha BAM<sup>3</sup> <sup>1</sup>UFAL - Farmacologia, <sup>2</sup>UFPB - Biologia Celular, <sup>3</sup>UFC – Bioquímica.

### 10. Cancer and Cell Proliferation

#### 10.001

Obesity and cancer development: effect of metformin. Fonseca EAI<sup>1</sup>, Oliveira, M. A.<sup>1</sup>, Tostes RCA<sup>1</sup>, Colquhoun A<sup>2</sup>, Carvalho MHC<sup>1</sup>, Zyngier SZ<sup>1</sup>, Fortes ZB<sup>1</sup> <sup>1</sup>ICB-USP – Farmacologia, <sup>2</sup>ICB-USP – Biologia Tecidual e do Desenvolvimento

#### 10.002

Effects of P2X<sub>7</sub> receptor agonists on cell proliferation of human glioma cell lines U138-MG and M059J. Gehring MP<sup>1</sup>, Campos MM<sup>2</sup>, Battastini AMO<sup>3</sup>, Morrone FB<sup>4</sup> <sup>1</sup>PUCRS – Farmacologia Aplicada, <sup>2</sup>PUCRS – Cirurgia-Odontologia, <sup>3</sup>UFRGS – Bioquímica, <sup>4</sup>PUCRS – Farmácia

#### 10.003

Evaluation of butyrate and aqueous extract of the *Ilex paraguariensis* enemas in reducing the levels of malondialdehyde in exclusion of colitis. Silva CMG, Lameiro TMM, Marques LHS, Almeida MG, Cunha FL, Martinez CAR – Sao Francisco University – Cancer and cell proliferation

#### 10.004

Glucose starvation induces melanogenesis in B16F10 murine melanoma cells through oxidative stress. Piva B<sup>1</sup>, Diaz BL<sup>2</sup> IBCCF-UFRJ – Programa de Imunobiologia

#### 10.005

Structure-related activity of a series of chalcones derived from quinoxaline on *in vitro* oral squamous cell carcinoma proliferation. Mielcke TR<sup>1</sup>, Mascarello A<sup>2</sup>, Calixto JB<sup>3</sup>, Yunes RA<sup>2</sup>, Leal PC<sup>2</sup>, Morrone FB<sup>4</sup>, Campos MM<sup>5</sup> <sup>1</sup>PUCRS – Farmacologia, <sup>2</sup>UFSC – Química, <sup>3</sup>UFSC – Farmacologia, <sup>4</sup>PUCRS – Farmácia, <sup>5</sup>PUCRS – Cirurgia-Odontologia

#### 10.006

Stress-related neurohormonal mediators influence the human oral cancer cells behavior. Bernabé DG<sup>1</sup>, Tamae AC<sup>1</sup>, Miyahara GI<sup>2</sup>, Biasoli ER<sup>2</sup>, Oliveira SHP<sup>1</sup> <sup>1</sup>FOA-UNESP – Ciências Básicas, <sup>2</sup>FOA-UNESP – Ciências Básicas, <sup>3</sup>FOA-UNESP – Oncologia Bucal

#### 10.007

Anticancer Activities of 2,2-Dimethyl-3-(3-nitrophenylamino)-2,3-dihydro-naphtho[1,2-b]furan-4,5-dione (1): Oxidative Stress based-apoptosis. Araújo AJ<sup>1</sup>, Marinho-Filho JDB<sup>1</sup>, Silva-Junior EN<sup>2</sup>, Moura MABF<sup>3</sup>, Goulart MOF<sup>4</sup>, Ferreira VF<sup>2</sup>, Pessoa C<sup>1</sup>, Moraes MO<sup>1</sup>, Costa-Lotufo LV<sup>1</sup>, Montenegro RC<sup>1</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>UFF – Química Orgânica, <sup>3</sup>UFAL – Química, <sup>4</sup>UFAL – Química e Biotecnologia

#### 10.008

Effect of crotoxin, the main toxin of the rattlesnake *C.d. terrificus* venom, on secretory activity of peritoneal macrophages during tumor progression. Studies *in vivo* and *in vitro*. Costa ES<sup>1</sup>, Faiad OJ<sup>1</sup>, Curi R<sup>2</sup>, Cury Y<sup>1</sup>, Sampaio SC<sup>1</sup> <sup>1</sup>Ibu – Fisiopatologia, <sup>2</sup>ICB-USP – Fisiologia e Biofísica

#### 10.009

Cytotoxic activity of benzothiazole analogues. Vieira GC<sup>1</sup>, Araújo AJ<sup>1</sup>, Vasconcelos, TRA<sup>2</sup>, Ferreira VF<sup>2</sup>, Nogueira, AF<sup>2</sup>, Pessoa CO<sup>1</sup>, Costa-Lotufo LV<sup>1</sup>, Montenegro RC<sup>1</sup>, Moraes MO<sup>1</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>UFF – Química Orgânica

#### 10.010

Assessment of the cytotoxic, antiproliferative, genotoxic, mutagenic and pro-apoptotic activities of indirubin, directed for its use as an anticancer substance. Fogaça MV<sup>1</sup>, Cardoso PF<sup>1</sup>, Cândido PM<sup>1</sup>, Varanda EA<sup>2</sup>, Calvo TR<sup>3</sup>, Vilegas W<sup>3</sup>, Cólus, IMS<sup>1</sup> <sup>1</sup>UEL– Biologia Geral, <sup>2</sup>FCFAR-UNESP – Ciências Biológicas, <sup>3</sup>IQ-UNESP – Química

#### 10.011

Characterization of cytotoxic activity induced by phospholipase A2 (PLA-LYS49) isolated from *Bothrops jararacussu* snake venom. Lino CNR<sup>1</sup>, Sorigi CA<sup>2</sup>, Cintra ACO<sup>2</sup>, Sampaio SV<sup>2</sup>, Faccioli LH<sup>2</sup>, Nomizo A<sup>2</sup> <sup>1</sup>FFCLRP-USP – Biologia, <sup>2</sup>FCFRP-USP – Análises Clínicas, Toxicológicas e Bromatológicas

#### 10.012

Involvement of the kinin B1 receptor in melanoma progression. Maria AG<sup>1</sup>, Reis RI<sup>1</sup>, Dillenburg-Pilla P<sup>1</sup>, Pesquero JB<sup>2</sup>, Costa-Neto CM<sup>1</sup> <sup>1</sup>FMRP-USP – Bioquímica e Imunologia, <sup>2</sup>UNIFESP – Biofísica

#### 10.013

Overexpression of platelet-derived growth factor receptor- $\alpha$  in basal-like triple-negative breast cancer. Melo-Filho AF<sup>1</sup>, Ribeiro RA<sup>2</sup>, Rodrigues EJM<sup>2</sup>, Magalhães HO<sup>1</sup>, Soares FA<sup>3</sup>, Chagas DWN<sup>2</sup>, Lima VCC<sup>4</sup> – <sup>1</sup>ICC – Mastologia, <sup>2</sup>UFC –

Fisiologia e Farmacologia, <sup>3</sup>HCANC – Anatomia Patológica, <sup>4</sup>HCANC – Oncologia Clínica

#### 10.014

Leptin activates the mTOR pathway in epithelial cells: roles in lipid metabolism, inflammatory mediator production and cell proliferation. Fazolini NPB FIOCRUZ – Fisiologia e Farmacodinâmica. Fazolini NPB<sup>1</sup>, Viola JPB<sup>2</sup>, Maya-Monteiro CM<sup>1</sup>, Bozza PT<sup>1</sup>. <sup>1</sup>IOC-FIOCRUZ – Imunofarmacologia, <sup>2</sup>INCa – Cellular Biology

#### 10.015

Investigation of cytotoxicity of 4-nerolidilcaterol and its synthetic derivatives. Cunha CRM<sup>1</sup>, Menegatti R<sup>2</sup>, Valadares MC<sup>2</sup> <sup>1</sup>UFG – Farmacologia e Toxicologia Celular, <sup>2</sup>UFG – Química Medicinal

#### 10.016

Effects of tumor-derived extracellular matrix on endothelial cell functions: implications to tumor-associated angiogenesis. Brandão-Costa RM<sup>1</sup>, Saldanha-Gama RF<sup>2</sup>, Helal Neto E<sup>2</sup>, Morandi V<sup>3</sup>, Barja Fidalgo TC<sup>1</sup> <sup>1</sup>UERJ – Farmacologia, <sup>2</sup>UERJ – Farmacologia e Psicobiologia, <sup>3</sup>UERJ – Biologia Celular e Genética

#### 10.017

Withaphysalin F induces apoptosis and necrosis in HER-2 overexpression breast cell line. Montenegro RC<sup>1</sup>, Rocha DD<sup>1</sup>, Rodrigues FAR<sup>1</sup>, Lima PDL<sup>4</sup>, Pessoa CO<sup>2</sup>, Maia I<sup>3</sup>, Pessoa ODL<sup>3</sup>, Moraes MO<sup>1</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>UFC – Oncologia Experimental, <sup>3</sup>UFC – Química Orgânica, <sup>4</sup>UEPA – CCBS

#### 10.018

5-hydroxy-2-(4-methylphenylthio)-1,4-naphthoquinone, a juglone derivative, induces apoptosis and necrosis in hl-60 cell line. Araújo AJ<sup>1</sup>, Montenegro RC<sup>1</sup>, Marinho-Filho JDB<sup>1</sup>, Rocha DR<sup>2</sup>, Souza ACG<sup>3</sup>, Pessoa C<sup>1</sup>, Costa-Lotufo LV<sup>1</sup>, Ferreira VF<sup>3</sup>, Santos WC<sup>4</sup>, Moraes MO<sup>1</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>UFF – Instituto de Química, <sup>3</sup>UFF – Química Orgânica, <sup>4</sup>UFF – Farmácia e Administração Farmacêutica

11. Clinical Pharmacology, Pharmacokinetics, Pharmacogenomics and Preclinical Toxicology

#### 11.023

Plasma levels of matrix metalloproteinases -8 and -9 and their endogenous inhibitors TIMP-1 and TIMP-2 in untreated hypertensive patients. Fontana V<sup>1</sup>, Silva PS<sup>2</sup>, Belo VA<sup>2</sup>, Biagi C<sup>3</sup>, Tanus-Santos JE<sup>1</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>FCM-UNICAMP – Farmacologia, <sup>3</sup>Santa Casa de Araçatuba – Cardiologia

#### 11.024

Efficacy and safety of the *Mentha crispa* in the treatment of trichomonas infections: a randomized, open and parallel study. Pimenta Costa CS, Cavalcanti PP, Cunha GH, Pontes AV,

Fechine FV, Oliveira JC, Andrade WS, Moraes RA, Camarão GC, Moraes MEA UFC – Fisiologia e Farmacologia

#### 11.025

Effects of sitagliptin on visual alterations diagnosed by visual evoked potential in type 2 diabetic patients. Capistrano Júnior, VL<sup>1</sup>, Tagliapietra JI<sup>1</sup>, Pontes AV<sup>1</sup>, Cunha GH<sup>1</sup>, Rocha MBS.<sup>1</sup>, Frota Bezerra FA<sup>1</sup>, Vale OC<sup>1</sup>, Fernandes VO<sup>2</sup>, Montenegro Jr RM<sup>2</sup>, Moraes MEA<sup>1</sup> <sup>1</sup>UFC – Fisiologia e Farmacologia, <sup>2</sup>HU-UFC – Endocrinologia e Diabetes, <sup>4</sup>HU-UFC – Endocrinologia e Metabolologia

#### 11.026

NAT2, GSTT1 and GSTM1 genotypes and predisposition to adverse drug reaction (ADR) in tuberculosis patients. Costa GNO<sup>1</sup>, Santana CVN<sup>2</sup>, Konstantinovas C<sup>1</sup>, Magno LA<sup>3</sup>, Bastos-Rodrigues L<sup>3</sup>, Miranda DM<sup>4</sup>, Romano-Silva M<sup>3</sup>, Marco LAC<sup>5</sup>, Di Pietro G<sup>1</sup>, Rios-Santos F<sup>1</sup> <sup>1</sup>LAFEM-UESC – Ciências da Saúde, <sup>2</sup>LAFEM-UESC – Ciências Biológicas, <sup>3</sup>UFMG – Saúde Mental, <sup>4</sup>UFMG – Pediatria, <sup>5</sup>UFMG – Cirurgia

#### 11.027

Sulfadiazine determination in human plasma by high-performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS-MS): application to pharmacokinetic study. Nascimento DF, Oliveira JC, Pimenta Costa CS, Rocha MBS., Moraes RA, Cunha GH, Magalhães MS, Uchoa CRA, Moraes MO, Moraes MEA UFC – Fisiologia e Farmacologia

#### 11.028

Susceptible NOS3 (endothelial nitric oxide synthase) gene haplotypes in hypertension and resistant hypertension. Luizon MR<sup>1</sup>, Sandrim VC<sup>2</sup>, Izidoro-Toledo TC<sup>1</sup>, Coelho EB<sup>3</sup>, Tanus-Santos JE<sup>1</sup> <sup>1</sup>FMRP-USP – Farmacologia, <sup>2</sup>Santa Casa de Belo Horizonte, <sup>3</sup>FMRP-USP – Clínica Médica

#### 11.030

New educational strategies to improve pharmacology teaching: a interdisciplinary approach. Fidalgo-Neto AA, Lopes RM, Alves LA<sup>2</sup> IOC-FIOCRUZ Laboratório de Comunicação Celular

#### 11.031

Interference of matrix metalloproteinase (MMP)-9 genotypes and haplotypes in the responsiveness to antihypertensive therapy of patients with preeclampsia or gestational hypertension. Palei ACT<sup>1</sup>, Sandrim VC<sup>2</sup>, Cavalli RC<sup>3</sup>, Gerlach RF<sup>4</sup>, Tanus-Santos JE<sup>5</sup> <sup>1</sup>FCM – UNICAMP – Farmacologia, <sup>2</sup>Santa Casa de Belo Horizonte – Farmacologia, <sup>3</sup>FMRP-USP – Ginecologia e Obstetria, <sup>4</sup>FORP-USP – Morfologia, <sup>5</sup>FMRP-USP – Farmacologia



**11.032**

Comorbidities and medication use in elderly women with vestibular disorders. Prezotto AO, Paulino CA, Onishi ET UNIBAN

**11.033**

Serum cortisol and IL-10 levels increase in chronic renal failure patients with cognitive deficit. Degaspari D<sup>1</sup>, Stein G<sup>2</sup>, Munhoz CD<sup>1</sup>, Martins JPB<sup>2</sup>, Ribeiro Junior E<sup>2</sup>, Sá Lima L<sup>1</sup>, Tzanno-Martins CB<sup>1</sup>, Scavone C<sup>1</sup>, Kawamoto EM<sup>1</sup> <sup>1</sup>ICB-USP – Farmacologia, <sup>2</sup>CEHUS-CINE

**11.034**

Changes in cardiovascular and biochemical parameters produced by chronic treatment with celecoxib in normotensive rats. Figueiredo LF, Baracho NCV FMIT

## Conferences

**Ligand-directed signaling bias and its potential for new therapeutics.**

Roger J. Summers (Monash Institute, Australia).

Ligand-directed signaling bias describes the reversal of efficacy and/or potency observed for different signaling pathways by certain drugs acting at G protein-coupled receptors. Current evidence suggests that it may be explained in terms of the production or selection of unique receptor conformations by particular drugs. Several key factors have emerged for the identification of signaling bias. The bioassay critically affects the type and magnitude of drug efficacy observed and many drugs are now known that behave as classical antagonists for one signaling pathway and agonists at another. Efficacy therefore depends on the assay being used and a drug may be described as an antagonist for cAMP accumulation but an agonist for Erk1/2 phosphorylation, an effect termed pluridimensional efficacy (Galandrin & Bouvier, 2006). Recent studies with  $\beta_1$ - $\beta_2$ - and  $\beta_3$ -ARs have shown that many compounds originally classified as antagonists for cAMP signaling have quite different efficacy at other signaling pathways and can act as agonists, neutral or inverse antagonists for MAP kinase signaling (Galandrin & Bouvier, 2006; Baker *et al.*, 2003; Sato *et al.*, 2007; Sato *et al.*, 2008; Galandrin *et al.*, 2008) raising the possibility that further development of these compounds will allow the selection of a profile which is useful therapeutically. This work is supported by a project grant 491190 (to R.J. Summers and B.A. Evans) and program grant 519461 (to P.M. Sexton, A. Christopoulos and R.J. Summers) from the National Health and Medical Research Council of Australia. Baker JG *et*

*al.*, (2003) *Mol Pharmacol* 64, 1357-1369; Galandrin S & Bouvier M (2006) *Mol Pharmacol* 70, 1575-1584; Galandrin S *et al.*, (2008) *Mol Pharmacol* 74, 162-172; Sato M *et al.*, (2007) *Mol Pharmacol* 72, 1359-1368; Sato M *et al.*, (2008) *Mol Pharmacol* 74, 1417-1428

**Anti-inflammatory GPCRs as targets for novel therapeutics.**

Mauro Perretti (Queen Mary University of London, London, UK).

Cell trafficking in inflammation is tightly controlled by endogenous anti-inflammatory mediators. Their properties are mediated by specific GPCRs which activate anti-inflammatory circuits limiting leukocyte extravasation in a space and time-dependent fashion. Our work focuses on some of these GPCRs, namely FPR2, a receptor activated by annexin A1 (AnxA1) and lipoxin A4, as well as MC3, a receptor activated by natural and synthetic melanocortin peptides (e.g. ACTH). Our approach is, at the beginning, pharmacological, so that the properties of specific ligands (often peptides, more recently also NCEs) as assessed in models of acute inflammation. Then, antagonists and/or transgenic mouse colonies are used to pinpoint the receptor target(s) responsible for these anti-inflammatory effects. Such an approach is then expanded by determining, on one hand, the molecular events and cellular responses regulated by FPR2 activation (in the case of Annexin A1) and, on the other hand, the pathophysiological relevance of a given receptor. The latter aspect is addressed by using transgenic colonies, and it requires the study of the full time course: we use the mouse paw oedema as a prototype of an acute model of inflammation and the K/BxN inflammatory arthritis, to monitor the relevance of these pathways in more prolonged (chronic?) inflammatory experimental conditions. Exqui-

site control of the process of blood-borne cell extravasation is achieved by activation of these receptors, associated with multiple proresolving actions on other processes including osteoclastogenesis, chondrocyte activation and phagocytosis of apoptotic leukocytes. Novel concepts in the field are linked to modulation of the expression of anti-inflammatory GPCRs and to the exploitation of this approach for innovative drug discovery programs. Determining how FPR2 (and MC3) expression changes during an on-going inflammatory reaction can allow prediction of efficacy of new selective agonists for these receptors. Similarly, monitoring their expression in human cells and tissue samples would predict efficacy in human chronic inflammatory conditions. We are working on samples taken from patients suffering from rheumatoid arthritis and giant cell arteritis. In either case, treatment of patients with glucocorticoids, at doses able to control disease progression, would augment expression of FPR2 in circulating PMN and monocytes. Finally, the overall aim of this research is to develop selective agonists to either FPR2 or MC3 as novel anti-inflammatory therapeutics. We propose that these new drugs would produce very little, if any, side effects, as they will be operating in the same way our body disposes of an inflammatory episode. Such novel anti-inflammatory therapeutics would represent a fresh change to the drug discovery programs applied, and developed, so far in the pharmaceutical world. Selected References: Perretti M, Chiang N, *et al.* Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activates the lipoxin A4 receptor. *Nature Med* 8: 1296-1302, 2002. Serhan CN, *et al.* Resolution of inflammation: state of the art, definitions and

terms. *FASEB J* 21:325-32, 2007. Perretti M, D'Acquisto. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. *Nat Rev Immunol* 9: 62-70, 2009.

### **Toll-like receptors: emerging roles in reproductive physiology and therapeutics.**

Mark Hedger (Monash Institute, Australia)

Interactions between the immune and reproductive systems have important consequences for fertility and reproductive health. There is increasing evidence that many of these interactions involve pattern recognition receptors, such as the Toll-like receptors (TLRs), which recognize microbial products or "danger" signals, called pathogen associated molecular patterns. Although abundantly expressed by macrophages, TLRs are also widely distributed, particularly in epithelia. The TLRs are important in providing protection against infection in the reproductive tract, but there is increasing evidence for involvement of these receptors in more basic pathology and physiology. In the female, TLRs have been implicated in normal ovarian, endometrial and placental function, as well as in ovarian cancer, pelvic inflammatory disease, intrauterine growth restriction, pre-eclampsia and pre-term birth. In the male, TLRs appear to play a role in prostatitis and prostatic cancer, but also in the control of testicular steroidogenesis and spermatogenesis. Spermatogenesis is a complex, organized and highly regulated process involving intimate interactions between the developing germ cells and their supporting Sertoli cells. Sertoli cells express several TLRs and respond to TLR ligands by producing a number of inflammatory cytokines and mediators. These products regulate spermatogonial / spermatocyte development and many critical supportive functions of the Sertoli cells, and their production varies across the cycle of the seminiferous epithelium,

with significant changes in expression coinciding with key events within the cycle. Such relationships between inflammatory signaling and spermatogenesis provide a potential mechanism to account for the link between infection/inflammation and testicular dysfunction. At least some of the negative effects of inflammation on spermatogenesis may be attributed to elevated production of inflammatory mediators that may exert disruptive effects on germ cell development and survival, as well as Sertoli cells support. Further investigation of these interactions may be applicable to improving fertility in men with disordered spermatogenesis. Finally, it is also expected that these studies may create new opportunities for modulating fertility by targeting spermatogonial renewal and meiosis as a safe, effective and reversible male contraceptive. This work has been supported by grants from the National Health and Medical Research Council and the Australian Research Council.

### **Indoleamine 2,3 dioxygenase (IDO) inhibitors: from bench to bedside.**

Andrew L Mellor Immunotherapy Center, Medical College of Georgia, Augusta GA. USA  
Indoleamine 2,3 dioxygenase (IDO) is an intracellular enzyme that catabolizes tryptophan (1). IDO is induced in settings of chronic inflammation associated with many diseases including cancer and infectious diseases. In 1998 we reported that pharmacologic inhibition of IDO during pregnancy induced rejection of fetal tissues by maternal T cells (2). This pioneering study identified IDO as a pivotal regulator of adaptive immunity, and suggested that IDO inhibitors might be effective as immune modulators to treat clinical syndromes in which immune system hyporeactivity contributed to disease progression. Immune hypo-reactivity is the hallmark of tumors and pathogens that cause persistent infections. IDO

activity at sites of tumor growth and infection creates immune privilege, allowing these agents of disease to persist (3). Consistent with this notion IDO inhibitors – especially when combined with methods to incite immunity - enhance immunity to tumors and infected cells (4-6). In my presentation I will describe the current state of knowledge regarding the role of IDO in cancer and infectious diseases, and summarize progress in testing IDO inhibitors as cancer vaccine adjuvants in ongoing experimental clinical trials. This research is funded by grants from the NIH (AI063402, AI075165, AI083005). References: 1. Huang L, Baban B, Johnson BA, & Mellor AL (2010) Dendritic cells, IDO and acquired immune privilege. *Int. Rev. of Immunology* 29:133-155. 2. Munn DH, *et al.* (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. *Science* 281:1191-1193. 3. Mellor AL & Munn DH (2008) Creating immune privilege: active local suppression that benefits friends, but protects foes. *Nat Rev Immunol* 8:74-80. 4. Muller AJ, *et al.* (2005) Inhibition of IDO, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. *Nat Med* 11:312-319. 5. Potula R, *et al.* (2005) Inhibition of IDO enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. *Blood* 106:2382-2390. 6. van der Sluijs KF, *et al.* (2006) Influenza-induced expression of IDO enhances IL-10 production and bacterial outgrowth during secondary pneumococcal pneumonia. *J Infect Dis* 193:214-222.

### **The stressed CNS: when glucocorticoids aggravate inflammation.**

Javier R. Caso. Department of Biology, Stanford University, California-USA

Glucocorticoids (GCs) are hormones released during the stress response that are well known for their immune-suppressive and

anti-inflammatory properties; however, recent advances have uncovered situations wherein they have effects in the opposite direction, challenging the classic view of the GCs actions at a variety of levels. It was first observed that under some circumstances, acute GC exposure could have pro-inflammatory effects on the peripheral immune response. More recently, chronic exposure to GCs has been found to have pro-inflammatory effects on the specialized immune response to injury in the central nervous system. The central nervous system (CNS) is a particularly interesting example, both because of its unique immune environment, and because GCs affect immune responses differently in different brain regions. Thus, it has been shown that in some cases, glucocorticoids can increase pro-inflammatory cell migration, cytokine production, and even transcription factor activity in the brain. Here, we discuss the contexts wherein GCs increase CNS inflammation and point out directions for future investigation as well as the considerable clinical implications of these findings.

#### **Genetic modeling of PI3K inhibition.**

Emilio Hirsch (University of Turin, Italy)

Phosphoinositide 3-kinases (PI3K) are crucial elements needed for receptor-mediated signal transduction and modification of PI3K signaling is emerging as a key element in cancer, inflammation, metabolic disorders and cardiovascular diseases. PI3K consist of heterodimers of a 110 kD catalytic (p110) as well as a regulatory/adaptor subunit and are required for the production of a membrane bound phosphorylated lipid (PIP3) that acts as a critical secondary messenger molecule. Class I p110s (p110 $\alpha$ ,  $\beta$ ,  $\gamma$  and  $\delta$ ) share significant homology but studies using genetically engineered mice show that they all play non-redundant roles. Interestingly, modeling by

genetic means of PI3K inhibition revealed that different isoforms can be distinctly involved in different pathologies. For example, we recently demonstrated that, while PI3K $\gamma$  is crucially involved in the establishment of inflammatory responses, PI3K $\beta$  is a key determinant in the development of ErbB2-driven mammary gland cancer. In addition, we also recently found that PI3K $\gamma$  signaling also occurs in the heart where it can modulate the contractile response and contribute to the development of heart failure. While these genetic studies recently provided support for PI3K catalytic activity as a promising drug target they also unexpectedly revealed that these proteins not only work as kinases but also as scaffolds for protein-protein interactions. Despite this complex regulation, genetic modeling of PI3K inhibition clearly supports that selective targeting of different PI3K isoforms can represent a promising strategy to improve efficacy and reduce side effects. Efforts to produce and test such drugs are under way and clinical trials are foreseen for the next future. This work is supported by Regione Piemonte, AIRC, Leducq Foundation, European Union FP6.

#### **Chemokines and their receptors: the Nexus of neurobiology and immunobiology**

Richard Ransohoff (Cleveland Clinic, USA)

Chemokines comprise a family of peptides that act through G protein-couple receptors (GPCRs) to regulate leukocyte migration throughout all tissues, in an exquisitely specific and flexible fashion. Initial studies related to neuroinflammation asked how chemokines and chemokine receptors governed inflammatory cell recruitment to the CNS during immune-mediated or virus-induced inflammation. More recently, it has become clear that the CNS complement of constitutive chemokines supports developmental and neurophysiological functions as well as regulating the behavior of

both macroglia and microglia. Inflammation of the central nervous system (CNS) entails the activation of resident microglia and macroglia, as well as canonical events including recruitment of hematogenous leukocytes and degradation of blood-brain barrier function. Thus defined, inflammation accompanies most neurological disorders, including multiple sclerosis (MS), stroke, neoplasia, trauma and HIV-1-associated dementia, as well as Alzheimer's disease and other primary neurodegenerations. Because GPCRs can serve as drug targets, these results have implications for the understanding and treatment of disease by neurologists and neuroscientists.

#### **Courses**

##### **Pharmacology of learning and memory formation.**

Hudson de Sousa Buck (FCMSCSP)

Memory is the ability of humans and other animals to retain and subsequently retrieve information. Basically, the mnemonic process comprises three main stages: Encoding or registration (processing and combining of received information); Storage (creation of a permanent record of the encoded information), and; Retrieval or recall (calling back the stored information in response to some cue for use in a process or activity). Another important component of the mnemonic process that may occur is the forgetting of the information. This is a normal process that occurs all the time, but age, stress, emotions, anxiety, high blood pressure are examples of conditions that may lead to abnormal memory loss, resulting in manifestation of dementias like Alzheimer's disease. The neural mechanisms of memory are not totally determined. It is considered that the information is stored in several cortical areas (motor memory/motor cortex; visual memory/visual cortex; etc), hippocampus, dorsal striatum, parahippocampal region,

basal forebrain and cerebellum. The hippocampus is located deep inside the temporal lobe, and it receives inputs from virtually all association areas in the neocortex, including those in the parietal, temporal and frontal lobes, via the adjacent parahippocampal gyrus and entorhinal cortex. Additional inputs come from the amygdala and via a separate pathway, from the cholinergic and other regulatory systems. The dorsal striatum plays a vital role not only in learning new response strategies but also in the inhibition of pre-existing strategies when a shift in strategy is required. This system is called as a declarative or relational memory system and appears to be essential for processing information about flexible utilization of the relationship between multiple external cues and events. The dorsal striatum is necessary for the mediation of stimulus response learning. The parahippocampal region receives inputs from widespread secondary or "association" cortical regions and provides the major conduct for hippocampal outputs to the same cortical association areas. This region can play a critical role in recognition memory. Various ions, neurotransmitters and messengers are associated with memory. The ion calcium participates in control of the formation and development of neural structures. Temporal and spatial control of calcium signaling through the neural circuitry involved in learning and memory are fundamental for cognitive capacities. The ion potassium can contribute to learning and memory through the slow after hyperpolarization (sAHP) and A-type potassium channel modification in hippocampal pyramidal neurons. The sAHP amplitude in hippocampal pyramidal neurons can be reduced by signaling pathways triggered by a variety of neurotransmitters, like Acetylcholine which have been implicated in learning and memory. Several findings showed that the

neurotransmitters glutamate,  $\gamma$ -aminobutyric acid (GABA), acetylcholine, serotonin and dopamine can play a key role in the mnemonic process alone or by association among them. Glutamate, the major excitatory neurotransmitter in the brain, is associated to the modulation of cognitive process by acting on metabotropic glutamate (mGlu) receptors. Also, the positive modulation of AMPA ( $\alpha$ -amino-3-hydroxyl-5-methyl-4-isoxazole-propionic acid)-type glutamate receptors can potentially enhance cognition by decrease the losses of glutamatergic synapses, promoting synaptic plasticity and increasing the production of tropic factors. Induction of long term potentiation (LTP), a presumed substrate of memory, requires intense depolarization of spine heads which could be induced by the activation of AMPA receptors. The  $\gamma$ -aminobutyric acid (GABA) is a central inhibitory neurotransmitter and the GABA system is a target for a variety of central pharmacological agents including sedatives, analgesics and anticonvulsants. Studies suggest that GABAergic drugs might impair memory formation through effects on cholinergic systems. Conversely, other findings showed that the GABA receptor agonists muscimol and baclofen enhance memory. Pharmacological data showed that the activation of muscarinic and nicotinic acetylcholine receptors have a role in the encoding of new memories. Acetylcholine might enhance the encoding of memory by increasing glutamate neurotransmission and, in this way, stimulating the LTP. Formation of LTP requires a persistent increase in neuronal stimulation with gene transcription and formation of new proteins, which leads to increases in post synaptic density. Acetylcholine might also enhance encoding through its role in increasing theta rhythm oscillations within the hippocampal formation. Learning is enhanced when sti-

mul are presented during periods of theta rhythmicity. Serotonin (5-HT) is another neurotransmitter that affects neuronal communication in hippocampus. 5-HT exerts a direct hyperpolarizing influence on principal cells, via 5-HT<sub>1</sub> receptors, and indirectly, it facilitates GABA release from local interneurons through 5-HT<sub>3</sub> receptors. Dopamine also has a great impact on cognitive processes. In the field of memory and learning studies the mesolimbic dopaminergic and especially the mesolimbic system clearly have received most of the scientific attention. These areas are known to play a crucial role in various cognitive processes. D<sub>1</sub>, D<sub>2</sub>, D<sub>3</sub> and D<sub>4</sub> receptors are all implicated in learning and consolidation of memory. Together with these neurotransmitters, a great variety of neuromodulators are implicated in memory formation. According to this, various attempts to characterize a proper memory pharmacology that could reverse memory decline have been done. The efficacy of memory therapeutics, however, depends on our understanding of the basic mechanisms that characterize memory itself, once memories are thought to be due to lasting synaptic modifications in the brain. Suggested literature: Roberto Lent, Cem Bilhões de Neurônios, 2005; *The Internet J of Pharmacol* 7(1), 2009.

### **Neuropharmacological changes along the aging process.**

Tânia Araújo Viel USP

Memory is the capacity of learn, consolidate and retrieve information that are acquired along life-time. The biological basis for memory formation requires proteins that are common to many living species. What really makes the difference between individuals is all experiences that one lives and which mobilizes those proteins to create memory traces that are unique to each individual. During the aging process (since conception until elderly) the central nervous system develops in such a manner that

until a determined moment, the organism can increase neuroplasticity with great strength and velocity. After a point (still not determined, and that surely is different among persons), these features declines and the capacity of learning new information as well as the recall of consolidated memory starts to decline. However, there are certain types of memory that show no apparent deficit during normal aging. For example, normal elderly do not forget how to write, drive a car, or make a cup of tea, and vocabulary actually increases throughout life. There are some theories that try to explain these phenomena and these theories are related to formation of long term potentiation (LTP). LTP is a specific form of plasticity that normally leftovers for a long time, but there is large evidence showing that manipulations to disrupt LTP interfere with memory process and, in this way, it is reasonable to accept that age-related deficits in LTP would contribute to memory deficits along aging. LTP induced neuroplasticity depends on the integrity of neurons rather than their quantity. There is a common misconception that a significant neuronal loss is associated with aging. In fact, careful anatomical studies in humans, monkeys, rats and mice showed that there is no significant loss in the hippocampus areas during normal aging. So, the loss in neuroplasticity is likely to be related to the decline in functionality of LTP. Formation and maintenance of LTP requires cellular and molecular events resulting in induction, expression and consolidation of neuronal plasticity. Induction requires cell depolarization that can be reproduced experimentally using theta burst stimulation (TBS, 100 Hz pulses separated by 200 ms intervals). This depolarization engages proteins from the cytoskeleton such as the integrin-actin system. Alterations in actin cytoskeleton modify spine and postsynaptic

density. A constant release event would result in stable changes of the cytoskeleton (consolidation), viewed as cross-linking of actin filaments. After that, increases in receptors densities or mobilization of receptors from extra-synaptic areas occur (mainly glutamate receptors). As a result, a stability of excitatory postsynaptic currents is installed. Actin network is constantly modulated by endogenous factors that positively or negatively affect production and maintenance of stable LTP. Among the positive modulators are the neurotrophins brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) and also some neurotransmitters such as serotonin, endorphins, cannabinoids, corticosteroids, and acetylcholine, which also plays a direct role in the formation of memory. In opposite, adenosine was described as a potent negative modulator of LTP. In the elderly, the functionality of LTP can be disrupted as a result of interferences in the induction, expression or consolidation of the process and also as a result in decline of positive modulators or increase in negative modulators. However, there is no defined mechanism for these neuropharmacological changes. For instance, a decline in the clearance of extracellular adenosine was observed in aged rats which could account for the decline in LTP. Moreover, there is no consensus in the literature about the maintenance or the decrease in the quantity of the neurotrophins BDNF and NGF in the aged brain. In the same way, alteration in neurotransmitter or neuromodulator systems can also influence LTP maintenance. In a recent work we observed an increase in memory retention together with an increase in the density of  $\alpha 7$  nicotinic acetylcholine receptors in hippocampus of rats with 6 and 12 months old, when compared to 3 month-old animals. In addition, decreases in memory and in density of those receptors were

observed in 18 and 22 month-old rats. Once these receptors are involved with LTP in the hippocampus, these results also suggest an involvement of the cholinergic system with the modulation of memory along the aging process. The degree of LTP disruption during elderly can also be influenced by the quantity and quality of stimulus that is applied to the brain during aging process. In fact, people that are submitted to intellectual activities during their life have less probability to develop dementias. In the same way, young animals that are submitted to environmental enrichment present significant morphological and functional changes in the central nervous system. According to this, in another set of experiments we showed that C57Bl/6 mice submitted to environmental enrichment (boxes containing toys, activity wheels, wood objects, etc) during 15 months (from 2 to 17 months of age) showed increase in spatial memory evaluated in Barnes maze, when compared with their age-matched control. Surprisingly, mice submitted to the same protocol, but only in more advanced age (from 15 to 17 months of age), also presented improve in spatial memory when compared to non-stimulated aged-matched animals. These observations suggest that the stimulus applied during elderly is as significant and effective as those applied during the youth. Moreover, we can propose that deficits in LTP functionality, i.e., alterations in LTP and its positive or negative modulators, can be reversed by improving life quality with increases in social interactions, physical practices and changes in nutritional intake. Suggested literature: *Experiment Gerontol* 38: 61-9, 2003; *Ageing Res Rev* 5:255-80, 2006; *The Internet J of Pharmacol* 7(1), 2009; *J Neurosci* 29(35):10883-9, 2009

## Pharmacological modulation of memory process in neurodegenerative diseases.

Marielza Andrade Nunes (FCMSCSP)

Along aging, the cognitive processes naturally suffer impairments, varying from mild to aggressive forms.

The neurodegenerative diseases have some common symptoms like motor and memory deficits. In general, there are no diagnostic tests that could clarify the presence, absence or the type of the degenerative disease and frequently, the diagnoses are based on clinical symptoms. In addition, brain pathological lesions that could be characteristic for certain diagnosis can be found in different syndromes with cognitive and motor alterations related to elderly. As an example, one of the pathological characteristics of the Alzheimer's disease (AD), the senile plaques, can also be found in Parkinson's disease, although both pathological features have distinct components. In the same way, the presence of Lewy's bodies (consisted of  $\alpha$ -synucleins) can be found in Parkinson's disease and also in another kind of dementia (dementia of Lewy's bodies). So, different types of neurodegenerative diseases may show similar histopathological characteristics.

From all the dementias, AD is surely one of the most devastating. The basic ultra-structural lesions of Alzheimer's disease are amyloid- $\beta$  ( $A\beta$ ) aggregates around the neuronal cell bodies and neurofibrillary tangles inside the cell bodies.  $A\beta$  peptide derives from amyloid precursor protein which starts an amyloid cascade leading to biochemical alterations that promote the aggregates. Inflammation and glial reaction follows those deposits and also alterations in calcium homeostasis, activation of the glycogen synthase kinase-3 (GSK3)  $\alpha$  and  $\beta$  and finally inhibition of cell growth and neuronal death. Some recent works also describe a subsequent acti-

vation of caspases and apoptosis and also oxidative stress. Chemical shifts initiated by ultrastructural alterations in brains of AD patients leads to a significant loss in cholinergic neurons. In this way, concentration of the neurotransmitter acetylcholine and also function of cholinergic receptors (even muscarinic and nicotinic) are markedly decreased in AD, which has serious consequences to stability of long term potentiation (LTP) and, in this way, to maintenance of memory. Glutamate receptors, which are essential for LTP, are superactivated in this situation because of the low retrieval of glutamate by glial cells at the synaptic gap.

Parkinson's disease is the second more common neurodegenerative illness and is characterized by rest muscle tremor and rigidity. There are losses of dopaminergic neurons in the substantia nigra and the presence of Lewy's bodies in those neurons. There is also loss in the density of presenilin, a transmembrane protein, alteration in glutamate release and alteration in intracellular calcium metabolism.

Other common dementias in the elderly include: Huntington's disease, where an error in DNA replication results in hyper excitability of glutamate transmission and neuronal death; Frontotemporal dementia, where mutations in the tau protein linked to chromosome 17 leads to neurofibrillary tangles inside neurons and glial cells with no senile plaques; Degenerative disease of Purkinje cells that produce antibodies for cdr2 cytoplasmatic protein, resulting in cellular death; Diffuse disease of Lewy's bodies, where these Lewy's bodies are widely expressed in subpopulations of cortical neurons and lead to the same alterations observed in Parkinson's disease.

Some researchers argued that neurodegenerative diseases characterized by abnormal deposits of proteins should be evaluated

together with a continuum of symptoms and not only as individualized entities, once there are common chemical reactions for cell death in these illnesses. In addition, the modified genes in neurodegenerative diseases codify mutant proteins that lead to molecular and physiological abnormalities or discrete but progressive structural alterations that can disrupt the transmission in the neuronal circuitry, increasing the vulnerability of neuronal cells.

A better knowledge of the consequences of the chemical alterations for memory and other cognitive functions, in these diseases, may contribute to a more precise diagnosis and to the development of more specific and effective therapies. Suggested literature: Roberto Lent, Cem Bihões de Neurônios, 2005; *J Alzheimer's Dis.* 2009;18(2):381-400.

## Writing a Scientific Paper: theory and practice.

Y. S. Bakhle (Imperial College, UK)

Good scientific results deserve and need good communication. Scientific research has always depended on telling others about your results and you basing experiments on the results of others. So presenting your results in a form that makes them more readily acceptable to Journals and their readers is an essential part of advancing scientific knowledge.

This Course starts with a lecture on scientific writing which is the "Theory" followed by "practical" sessions. In these, MSS supplied by the "students" are discussed in some detail in terms of each component (Title, Abstract, Introduction, Figures), applying the principles and methods outlined in the lecture. I show the scripts marked up with the edits so it is clear what has been changed and then explain and comment on the edit (why was it necessary and how it is "corrected").

These practical sessions *must* be interactive. Students are en-

couraged and *need* to ask questions about the points raised, the stylistic and language editing and the editing of Figures and Tables. The MSS should be in an advanced state of preparation, i.e. ready to be submitted and some, on past occasions, have been submitted and already rejected. The latter class of MS together with the reviewers' comments can provide an excellent basis of discussing "what went wrong" with the MS. Even factual / data "errors and deficits" can be generated by inadequate explanation or description of experimental work. The topics of the MSS are not important in this context - good communication is as important for explaining ecstasy-induced hyperthermia as it is for relating CYP polymorphism to efficacy of anti-cancer drugs. The support of the British Pharmacological Society is gratefully acknowledged.

### **Quantitative and qualitative analysis of drug-receptor interactions.**

André Sampaio Pupo (UNESP-Botucatu)

Pharmacologists are constantly required to present in understandable terms the effects of drugs on physiologic systems. This is usually accomplished by applying relatively simple mathematical transformations of drug's doses/concentrations and effects, and confronting them against theoretical backgrounds. The non compliance of the experimental findings to these theoretical backgrounds has led to important advances in the understanding of both the mechanisms of actions of drugs and the physiologic systems upon which the effects of these drugs are investigated. In this context, drugs are valuable tools to elucidate physiologic processes, provided that the effects of these drugs are appropriately interpreted and that all possible mechanisms of actions of these drugs are known. Therefore, misinterpretation of drugs effects or the incomplete knowledge of

its mechanisms of actions may be deceiving.

The first class of this course will address theoretical and practical aspects of dose-response curves plotting, such as curve adjustment, requirements of dependent and independent variables, raw versus transformed data and its statistical analysis.

The second class of the course will discuss the actions of competitive antagonists focusing on the importance of the Schild analysis for the appropriate study of this class of drugs. Special attention will be dedicated to the fundamental criteria that must be fulfilled in the construction of Schild's plots and also to operational aspects of the calculation of the slope parameter. In addition, the pharmacological interpretation of slope values different from the predicted theoretical unity will be discussed in light of experimental results.

The final class of the course will focus on the functional analysis of dose-response curves in complex contexts where the pharmacological responses result from multiple mechanisms of actions and its consequences on the estimates of curves slopes and drug's potencies and efficacies.

### **The proteins kinase and their role in the cellular immune response.**

Aristóboło M. Silva (UFMG)

Protein kinases are enzymes that phosphorylate certain amino acid residues in specific proteins. They are key regulators of cell function by driving the activity, physical interaction and cellular localization of many proteins. The activity of protein kinases is tightly regulated by a number of molecular events such as the turning on or off by phosphorylation, and binding of activator proteins or small molecules. Protein kinases are involved in a myriad of cellular processes, including the immune cell function. In this module, I will present the basic concepts in the protein kinases such as the phosphorylation of amino

acids and proteins by protein kinases, how does phosphorylation regulate activity of proteins, and how the domains within protein structures regulate cell function. Yet, considerable attention will be given to specific protein kinases or groups constituted by them whose activities will determine the major outcomes in the cellular immune response. Activation of immune cells in the immune response is triggered upon detection of stress stimuli that the organism receives. The outcome of these stimuli will be the activation of specific signaling pathways that control the expression regulation of inflammatory genes that are critical to cellular immune response. Therefore, protein kinases are essential cellular components required to modulate these pathways. Among these include the one which leads to the activation of the kinases responsible for nuclear factor kB (NF-kB) transcription factor activity regulation. This pathway involves the formation of NF-kB dimmers as a result of phosphorylation-induced proteolysis mediated by the kinase responsible for NF-kB activation, I $\kappa$ B kinase (IKK). Other important protein kinases constitute a group called a mitogen-activated protein kinases (MAPKs). MAPK pathway is classically composed by a cascade of three kinases: (1) a MAPK that is responsible for the effector functions, (2) the kinase that activates the MAPK by phosphorylation (MAP2K or MKK), and (3) the kinase that activates the MKK (MAP3K or MEKK), which provides specificity in response to cell surface receptors upon stress recognition. Within the MAPKs family, the stress-activated protein kinase (SAPK) group has been defined as a group of kinases that are activated by stimuli that cause cell stress such as inflammation. SAPKs control the expression of some proinflammatory genes such as those encoding cytokines. Finally, the function of a protein kinase with



a role in viral immune responses will also be presented. Recently, emerging role for this protein kinase has been observed in bacterial and parasitic infections. The double-stranded RNA dependent protein kinase PKR is a host defense enzyme whose expression is up-regulated in response to Interferons (IFNs) and during viral infections. Increased levels of PKR result in its activation by auto-phosphorylation, which in turn phosphorylates the alpha-subunit of eukaryotic translation initiation factor 2 (eIF2-alpha) resulting in the inhibition of global cellular protein synthesis. In summary, the basic concepts in the protein kinases and what is currently known about the kinases aforementioned in their overall contribution to the immune response will be discussed.

### **Pi3kinase and inflammation.**

Remo de Castro Russo (UFMG) Phosphorylated lipids are produced at cellular membranes during signaling events and contribute to the recruitment and activation of various signaling components. The role of phosphoinositide 3-kinase (PI3K) is to catalyze the production of phosphatidylinositol-3,4,5-trisphosphate in cell survival pathways, regulating gene expression, cell metabolism and highlighting cytoskeletal rearrangements. The PI3K pathway is implicated in human pathophysiology including chronic inflammatory diseases and cancer; understanding the intricacies of this pathway may provide new direction for therapeutic intervention.

Based on their primary sequences, the PI3K family is divided into three classes, in which the class I PI3K has been studied most extensively and is the focus of this course. The expression patterns and mode of regulation of class II and III PI3Ks are less understood mechanisms of regulation and substrate specificities. Inside the class I PI3K, class IA subtypes are heterodimers that consist of

a catalytic subunit (p110) and a regulatory subunit (p85). These subtypes are thought to be the major *in vivo* source of PIP3 upon activation of the receptors possessing protein-tyrosine kinase activity or the receptors coupling to Src-type protein-tyrosine kinases.

In mammals, there are multiple isoforms of class IA PI3K. Different genes encode class IA catalytic subunits, referred to as p110 $\alpha$ , p110 $\beta$  and p110 $\delta$ , while other genes encode the associated regulatory subunits, referred to as p85, represented by five species (p85 $\alpha$ , p85 $\beta$ , p55 $\alpha$ , p55 $\gamma$  and p50 $\alpha$ ). p85 has two Src homology 2 (SH2) domains, which link the p85-p110 PI3K enzyme complex to tyrosine kinase signaling pathways. Class IA PI3K is activated by most receptors that trigger tyrosine kinase activity. In lymphocytes, this includes antigen receptors, co-stimulatory molecules, adhesion molecules, Toll-like receptors and cytokine receptors. By contrast, the class IB catalytic subunit p110 $\gamma$  binds to one of the two non-p85 regulatory subunits, called p101 and p84, and mediates PI3K activity upon G protein-coupled receptors (GPCRs) stimulation. Class IB PI3K is activated by GPCRs including chemokine receptors, bradykinin receptors and sphingosine-1-phosphate (S1P) receptors.

The acute phosphorylation of Phosphatidylinositol lipids at inositol ring D-3 position in response to cell stimulation by growth factors, hormones and chemokines sets in motion a coordinated set of events leading to cell cycle entry, growth, migration and survival. How does lipid phosphorylation coordinate such complex behavior? Various signaling proteins, including the mitogen-transducing signal proteins (protein kinase C, phosphoinositide-dependent kinases, small G-proteins, MAP-kinase, mitogen activated protein-kinases), are activated either via their interaction with lipid prod-

ucts of PI3K as through PI3K-dependent phosphorylation of proteins, which have domains that specifically bind to D-3 phosphorylated phosphoinositides. These proteins are located in the cytosol of unstimulated cells, but in response to lipid phosphorylation, accumulate at the plasma membrane because of their ability to associate with the newly formed phosphoinositides. At the membrane, these proteins become activated and initiate various local responses, including polymerization of actin, assembly of signaling complexes and priming of protein kinase cascades.

Most PI3K subunits seem to have a broad tissue distribution, including endothelial cells, fibroblasts and tumor cells, with p110 $\gamma$  and p110 $\delta$  being highly enriched in leukocytes, playing important roles in chemotaxis, antigen recognition, leukocyte activation and survival. Many chronic inflammatory diseases are associated with deregulated intracellular signal transduction pathways. Resultant pathogenic interactions between immune and stromal cells lead to changes in cell activation, proliferation, migratory capacity and cell survival, contributing to inflammation. Increasing efforts are now being made in the design of novel therapeutic compounds to interfere with signaling pathways in inflammatory diseases like rheumatoid arthritis, asthma and cancer. Studies with focus on PI3Ks are providing new insights into the mechanisms and the extent of their involvement in innate immunity and chronic inflammatory diseases, highlighting new potential targets for therapeutic intervention using PI3K inhibitors, opening up potentially opportunities for these drugs.

### **NF $\kappa$ B and IRF3/7 signaling pathway in the innate immunity.**

Daniel Santos Mansur (UFMG) Production of pro-inflammatory mediators such as cytokines and chemokines is intimately depen-

dant on certain transcription factors that are activated after the recognition of pathogens and danger signals. Here we will focus on the kinases involved in signal transduction and activation of the main transcription factors involved in initiating an immune response in an intracellular level: NF- $\kappa$ B and IRFs 3/7.

Recognition of micro-organisms and danger signals by pathogen recognition receptors (PRRs) leading to transcription of pro-inflammatory cytokines and chemokines and other genes is arguably one of the most important features of innate immunity and is responsible for immediate response to infection and orchestration of an efficient adaptative immune response. Playing a central role in this process is NF- $\kappa$ B (nuclear factor kappa-light-chain-enhancer of activated B cells). First related to B cells development, NF- $\kappa$ B is a heterodimer consisted of p50 and p65 that shuttles from cytoplasm to nucleus in its inactive form, bound to the repressor I $\kappa$ B $\alpha$ .

Let's use the example of one of the most studied PRRs, TLR4, to detail the activation process of NF- $\kappa$ B. LPS is a main component of gram-negative bacterial cell wall and it is the best described PAMP (pathogen associated molecular pattern) that activates TLR4. After TLR4 activation by LPS, mediated by CD14 and MD2, a complex of adaptor molecules is recruited to the plasma membrane, amongst them MyD88 that binds TLR4 through its TIR domain. This recruits IRAKs and the scaffold protein TRAF6 that ultimately activates the master kinase TAK1. TAK1 phosphorylates another kinase, IKK $\gamma$  (NEMO) that on its turn phosphorylates IKK $\beta$ , in the same complex called I $\kappa$ B kinase (IKK) complex.

Activation of IKK $\beta$  through NEMO is considered the canonical pathway of NF- $\kappa$ B activation. IKK $\beta$  phosphorylates I $\kappa$ B $\alpha$  that is ubiquitinated, and hence de-

graded by 26S proteasome. The degradation of the repressor I $\kappa$ B $\alpha$  leads to the exposition of a NLS (nuclear localization signal) and leave NF- $\kappa$ B able to bind DNA and play its role in gene transcription.

Another important transcription factor involved in starting innate immunity is IRF3 (interferon regulatory factor 3). IRF3 is activated after the ligation of LPS into the CD14/MD-2/TLR4 as well, or after cytosolic recognition of nucleic acids. The differences from the NF- $\kappa$ B to IRF3 activation start on the adaptor that is recruited to the TIR domain after ligation of LPS to the receptor. TRIF and TRAM are adaptors that are engaged to TLR4 and recruit TRAF3 that complexes two main kinases, IKK $\epsilon$  and TBK-1, that are required for IRF3 phosphorylation, dimerization and translocation to the nucleus, where it will regulated transcription of many genes, amongst them type 1 interferons.

During cytosolic nucleic acid recognition different kinds of receptors are recruit and the pathways involved in signal transduction are being studied, but most of them, like RIG-I, that recognizes 5'pRNA use IKK $\epsilon$  or TBK-1 to activate gene transcription mediated through IRF3.

Nucleic acid recognition can engage other transcription factors depending on the cell that is being activated. Importantly, when dendritic cells recognize nucleic acid through TLR7/8 or 9, they are able to induce the dimerization, mediated by MyD88 and IRAKs, of IRF7, that is a potent transcriptional factor for type 1 interferon production. Coordinated those two families of transcription factors are of great importance to immediate response to viruses and bacteria and to orchestration of an efficient adaptative immune response.

## Symposia

### **Roles of GRKs and beta-arrestins activities in the regulation of $\beta$ 2 adrenergic signaling.**

Jamil Assreuy (UFSC)

Introduction: Sepsis is a systemic inflammatory response resulting from the inability of the host to restrict local infection. From the cardiovascular point of view, septic shock is characterized by cardiac collapse and decreased peripheral resistance due to dilatation of systemic resistance vessels induced by nitric oxide (NO) production from inducible NO synthase (NOS-2). G protein-coupled receptor (GPCR) kinases (GRKs) are specific kinases interacting with GPCR proteins, inducing receptor phosphorylation and thereby desensitization of GPCR desensitization even in the agonist presence. Therefore, it is conceivable that increased expression of GRKs could increased adrenergic receptor desensitization and in turn reduces cardiovascular responses. Therefore, we hypothesized that the hyporesponsiveness observed in sepsis could result from signal receptor desensitization mediated by a NO-induced GRK increased activity. Methods: Female C57Bl/6 mice were submitted to cecal ligation and puncture (CLP). Vascular responsiveness was evaluated in endothelium-bearing aorta rings contracted with phenylephrine (1  $\mu$ M). Cardiac responsiveness was evaluated in isolated contracted with isoproterenol (1  $\mu$ M). Aortic and ventricle responsiveness was evaluated 6, 12 and 24 h after CLP surgery in the presence or absence of a selective NOS-2 inhibitor 1400W (100  $\mu$ M). GRK2 expression was analyzed on heart and aorta harvested from sham and CLP treated or not with 1400W (1 mg/kg) 6, 12 and 24 h after CLP by immunofluorescence analysis. All procedures have been approved by the institutional Animal Ethics Committee (Proto-

col PP003/CEUA). Results: The vascular response to phenylephrine was significantly reduced in aorta rings from septic mice evaluated 6 (55% reduction compared to the response of sham-operated animals), 12 (57%) and 24 (78%) h after CLP. Incubation with 1400W reverted vascular hyporesponsiveness 6 and 12 h after CLP. The cardiac responsiveness to isoproterenol was significantly reduced in ventricles from septic mice evaluated 12 (73%) and 24 (88%) h after CLP. Conversely, the 1400W treatment prevented the cardiac hyporesponsiveness 12 (70% reduction compared to the response of sham-operated animals) and 24 (80%) h after CLP. Moreover, high expression of GRK2 was detected in aorta 6 (65%), 12 (70%) and 24 (88%) h, and heart of septic mice 12 (52%) and 24 (63%) h after CLP. The treatment of septic mice with 1400W reduced the GRK2 high expression on aorta (75%) and heart (79%). Finally, the pre and post-treatment with 1400W enhanced significantly the survival rate of the septic mice (55%). Discussion: Our findings show that NO, produced mainly by NOS-2 during sepsis seems to activate GRK2, which induces adrenergic receptor desensitization. Increased in the GRK expression is associated with impairment vascular response, contributing to severe cardiovascular hyporesponsiveness observed during septic shock. Moreover, NO synthesis inhibition improves output cardiovascular, and as consequence, enhances the survival of septic mice. Therefore, the results suggest that GRK2 could be a new potential target to sepsis pharmacotherapy. Financial support: CNPq, CAPES, FAPESC.

#### **Therapeutic potential of block-ing PI3Kg in inflammation.**

Danielle G. Souza, Erica L. Martin, Fernando Q. Cunha, Emilio Hirsch, V. Marco Ranieri, Mauro M. Teixeira

Rationale: Sepsis is a leading cause of ICU-death, character-

ized by a systemic inflammatory response (SIRS) and bacterial infection, which can often induce multi-organ damage and failure. Leukocyte recruitment, required to limit bacterial spread, depends on PI3Kg signaling *in vitro*; however the role of this enzyme in polymicrobial sepsis has remained unclear. Objective: This study aimed to determine the specific role of the kinase activity of PI3Kg in the pathogenesis of sepsis and multi-organ damage. Methods: PI3Kg wild-type, knockout and kinase-dead mice were exposed to cecal ligation and perforation-induced sepsis and assessed for survival, pulmonary, hepatic and cardiovascular damage, coagulation derangements, systemic inflammation, bacterial spread and neutrophil recruitment. Additionally, wild-type mice were treated either before or after the onset of sepsis with a PI3Kg inhibitor and assessed for survival, neutrophil recruitment and bacterial spread. Measurements and Main Results: Both genetic and pharmaceutical PI3Kg inhibition significantly improved survival, reduced multiorgan damage and limited bacterial decompartmentalization, while modestly effecting systemic inflammation (SIRS). Protection resulted from both neutrophil-independent mechanisms, involving improved cardiovascular function, and neutrophil-dependent mechanisms, through reduced susceptibility to neutrophil migration failure during severe sepsis by maintaining neutrophil surface expression of the chemokine receptor, CXCR2. Furthermore, PI3Kg pharmacological inhibition significantly decreased mortality, improved neutrophil migration and bacterial control, even when administered during established septic shock. Conclusions: This study establishes PI3Kg as a key molecule in the pathogenesis of septic infection and the transition from SIRS to organ damage, and identifies it as a novel possible therapeutic target.

#### **Antioxidants as anti-inflammatory agents.**

Juliano Ferreira (UFSM)

A vast amount of circumstantial evidence implicates reactive oxygen species (ROS) as mediators of inflammation. ROS activate cellular redox-sensitive proteins in target cells involved in mediating inflammatory responses, such as the transcription factor NF- $\kappa$ B that regulates the expression of numerous genes that encode pro-inflammatory molecules, such as some cytokines, adhesion molecules and cyclooxygenase-2. Antioxidants can scavenge ROS and have long been advocated for the treatment of inflammatory diseases. However, the value of antioxidants in the prevention and treatment of such diseases has been questioned. We will review the anti-inflammatory effect of antioxidants in pre-clinical models of inflammation and in clinical setting, focusing their potential use in arthritis treatment.

#### **Can antioxidants prevent dyskinesia?**

Roberto Frussa-Filho (UNIFESP)

The clinical symptoms, the epidemiology and the risk factors of tardive dyskinesia will be briefly characterized. Afterwards, the first pathophysiological hypothesis of the disease – the dopaminergic supersensitivity hypothesis – will be discussed. The pitfalls of the supersensitivity hypothesis and the proposal of the oxidative stress pathophysiological hypothesis will be detailed and followed by both preclinical and clinical evidence supporting the later hypothesis. Finally the potential use of antioxidant agents to prevent tardive dyskinesia and the antioxidant properties of atypical neuroleptics will be discussed.

#### **Quimiocinas e inflamação no sistema nervoso central.**

Antonio Lúcio Teixeira (UFMG)

As quimiocinas constituem uma grande família de citocinas responsáveis pelo recrutamento de leucócitos, incluindo a migração dos mesmos para locais de inflamação tecidual a partir da

circulação sanguínea. As quimiocinas são polipeptídios de 8 a 12 kDa, sendo classificadas nas subfamílias XC, CC, CXC e CX3C conforme o número e a localização dos resíduos de cisteína N-terminais. Nosso grupo de pesquisa vem investigando ativamente os níveis circulantes de quimiocinas e outras moléculas relacionadas com a resposta imune/inflamatória em várias doenças cerebrais humanas, procurando correlacioná-las com parâmetros clínicos. Essa estratégia, além de contribuir para o estudo do envolvimento de moléculas inflamatórias nessas doenças, tem o potencial de identificar candidatos a biomarcadores diagnósticos e/ou prognósticos.

Estudamos os níveis séricos e no líquor de quimiocinas em crianças portadoras de coreia de Sydenham, a manifestação neurológica da febre reumática. Observamos que as quimiocinas MIG/CXCL9 e IP-10/CXCL10, envolvidas no recrutamento de linfócitos de perfil predominantemente Th1, encontravam-se elevadas no soro de pacientes com coreia aguda em relação a controles assintomáticos e pacientes com a forma persistente da coreia (Teixeira et al., 2004). Esses resultados corroboraram a natureza imune-mediada da coreia reumática, questionando se processos autoimunes estariam relacionados à persistência dos sintomas além da fase aguda. Investigamos o envolvimento das quimiocinas na esclerose múltipla, doença inflamatória desmielinizante do sistema nervoso central. De acordo com dados da literatura internacional, observamos que os pacientes em surto (ou seja, com sintomas agudos indicativos da presença de processo inflamatório em atividade) apresentavam simultaneamente níveis elevados de IP-10/CXCL10 e níveis diminuídos de MCP-1/CCL2 no líquor. Demonstramos ainda que, após o tratamento dos pacientes em surto com pulsoterapia com metilprednisolona, ocorria uma

queda dos níveis de IP-10/CXCL10 e uma elevação de MCP-1/CCL2 no líquor (Moreira et al., 2006). Sugerimos que essas duas quimiocinas poderiam ser utilizadas como marcadores da atividade ou surto da doença. Posteriormente, passamos a explorar o potencial das quimiocinas como biomarcadores em doenças infecto-parasitárias. Demonstramos, por exemplo, que pacientes com esquistossomose apresentavam níveis séricos elevados das quimiocinas MCP-1/CCL2, MIP-1 $\alpha$ /CCL3, eotaxina/CCL11 e eotaxina2/CCL24, todas envolvidas no recrutamento de células comprometidas com resposta de perfil predominantemente Th2. Quando o líquor de pacientes com esquistossomose medular foi analisado, não se observou aumento dos níveis de quimiocinas, contrariamente ao encontrado, por exemplo, na mielopatia associada ao HTLV-1 (HAM/TSP) (Sousa-Pereira et al., 2006). Interessantemente, observamos que os pacientes portadores de HAM/TSP apresentavam níveis séricos muito elevados das quimiocinas MIG/CXCL9 e IP-10/CXCL10 (envolvidas na resposta Th1) em relação às pacientes infectados com o vírus HTLV-1 sem a mielopatia (Guerreiro et al., 2006). Em contraste, os pacientes com HAM/TSP exibiam níveis circulantes menores de quimiocinas relacionadas ao recrutamento de células de perfil predominantemente Th2, como o MCP-1/CCL2. Em conjunto, esses dados sugerem que as quimiocinas poderiam auxiliar o diagnóstico diferencial das mielopatias e, eventualmente, prever a conversão de estado de infecção pelo HTLV para HAM/TSP.

Em conclusão, fenômenos inflamatórios estão direta ou indiretamente relacionados com uma série de doenças neurológicas. Assim, determinadas moléculas inflamatórias têm o potencial de serem relevantes biomarcadores dessas doenças. Referências bibliográficas: Guerreiro JB, San-

tos SB, Morgan DJ, Porto AF, Muniz AL, Ho JL, Teixeira AL, Teixeira MM, Carvalho EM. Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state. *Clin Exp Immunol.* 2006; 145: 296-301. Moreira MA, Tilbery CP, Monteiro LP, Teixeira MM, Teixeira AL. Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis. *Acta Neurol Scand.* 2006;114:109-113.

Sousa-Pereira SR, Teixeira AL, Silva LC, Souza AL, Antunes CM, Teixeira MM, Lambertucci JR. Serum and cerebral spinal fluid levels of chemokines and Th2 cytokines in *Schistosoma mansoni* myeloradiculopathy. *Parasite Immunol.* 2006; 28: 473-478. Teixeira AL, Cardoso F, Souza AL, Teixeira MM. Increased serum concentrations of monokine induced by interferon-gamma/CXCL9 and interferon-gamma-inducible protein 10/CXCL-10 in Sydenham's chorea patients. *J Neuroimmunol.* 2004;150:157-162.

### **Neurochemical and behavioral changes after systemic inflammation and sepsis.**

Felipe dal Pizzol (UNESC)

It has been demonstrated that septic present both acute and long-term central nervous system dysfunction, including alterations in memory, attention, concentration, and global loss of the cognitive function. However, the mechanisms associated to these alterations are still unclear. Using an animal model of cecal ligation and perforation (CLP) we demonstrated several behavioral changes, mainly memory impairment and depression-like symptoms, in rats. In addition, it was observed that animals submitted to CLP presented decreased mitochondrial respiratory chain activity associated with short-term oxidative

damage. In addition, during sepsis brain-produced cytokines and chemokines is an early event and seemed to participate both on CNS dysfunction and blood brain barrier permeability alterations, leading to neuronal death. All these alterations seemed to be implicated in the long-term behavioral changes and neurotransmitters alterations observed in sepsis animal models and septic humans. Supported by CNPq, INCT-Translacional Medicina, FA-PESC.

### **New vistas for an old friend: Lipoxin A4 as an allosteric endocannabinoid in the brain.**

Fabrcio Pamplona (UFSC)

Lipoxins and endocannabinoids are endogenous eicosanoids that are released on demand following neuronal stimulation or injury. Lipoxin A<sub>4</sub> (LXA<sub>4</sub>) activates ALX receptors and has an important role in the resolution of inflammation, but information about its effects on the central nervous system is scarce. The available evidence suggests that LXA<sub>4</sub> may influence brain function in a cannabinoid-like fashion, which would imply participation of CB<sub>1</sub> cannabinoid receptors. Although endocannabinoids and lipoxins share structural and functional similarities, the pharmacological relationship between them has not yet been described. Hence, this study aimed to investigate the participation of the endocannabinoid system in the central effects of LXA<sub>4</sub>.

As an initial behavioral characterization, mice were injected i.c.v. with LXA<sub>4</sub> or control evaluated in the cannabinoid tetrad test (catalepsy, locomotion, analgesia and rectal temperature), considered predictive for cannabimimetic activity. These responses were further investigated by injecting the CB<sub>1</sub> receptors antagonist SR141716A or the ALX receptor antagonist BOC-2 before i.c.v. injection of LXA<sub>4</sub>. LXA<sub>4</sub> induced catalepsy, hypolocomotion, analgesia and hypothermia in mice. These ef-

fects were antagonized by the CB<sub>1</sub> receptor antagonist SR141716A, but not by the ALX receptor antagonist BOC-2. The role of CB<sub>1</sub> receptors on LXA<sub>4</sub> effects was further confirmed in CB1 knockout mice.

Binding of LXA<sub>4</sub> to CB<sub>1</sub> receptors was tested in a competitive binding assay against [<sup>3</sup>H]SR141716A in mouse brain membranes. The putative pharmacological interaction between LXA<sub>4</sub> and the endocannabinoids was addressed by co-injecting sub-effective doses of anandamide (AEA) or 2-araquidonilglicerol (2-AG) and LXA<sub>4</sub>. Possible effects of LXA<sub>4</sub> on degradation of endocannabinoids were assessed by *in vitro* assays of the metabolic enzymes of AEA e 2-AG. LXA<sub>4</sub> virtually did not inhibit the binding of [<sup>3</sup>H]SR141716A, but enhanced the inhibition of [<sup>3</sup>H]SR141716A binding by AEA. LXA<sub>4</sub> potentiated the cataleptic effects of AEA, but not of 2-AG. There was no effect of LXA<sub>4</sub> on the endocannabinoid-degrading enzymes FAAH and MAGL.

The present results suggest that LXA<sub>4</sub> exerts central effects via CB<sub>1</sub> cannabinoid receptors and interacts positively with the endocannabinoid AEA. While we did not find any effect of LXA<sub>4</sub> on endocannabinoid metabolism, this study brings evidence that LXA<sub>4</sub> enhances the affinity of AEA for CB<sub>1</sub> receptors through a mechanism of positive allosteric modulation. This is a pioneer finding on the endocannabinoid pharmacology.

### **Stress and inflammation.**

Moises Evandro Bauer (PUCRS)

Cytokines have been implicated in the pathophysiology of a series of neuropsychiatric disorders, including major depression, bipolar disorder, schizophrenia, dementia and post-traumatic stress disorder (PTSD). There is growing evidence supporting the link between traumatic stress or depression to a pro-inflammatory profile, with increasing serum concentrations of C-reactive protein, TNF- $\alpha$ , IFN- $\gamma$ , IL-1 $\beta$  and IL-6. Recently, we observed that

depressed patients with PTSD symptoms had poor memory performance, negatively related to lower brain-derived neurotrophic factor (BDNF) plasma levels. Patients had also significant lower salivary cortisol and DHEAS across the day in parallel with blunted T-cell proliferation and lower IL-2 levels than controls. Patients had also lower RANTES but higher sTNF-R2 levels when compared to controls. The involvement of cytokines in the pathophysiology of depression may involve changes of synaptic transmission, especially in hippocampal-amygdala structures, influencing various aspects of memory related to traumatic memories. The phenomenon of low-grade inflammation could be also involved with increased morbidity in depression. Peripheral administration of pro-inflammatory cytokines or increased levels observed during infections has been associated with changes in patient's behavior known as "sickness behavior". The patient becomes irritable and exhibits increased sleep, depression, fatigue, decreased appetite and sexual drive. Pro-inflammatory cytokines have been implicated in this phenomenon. For instance, depression has been reported in up to 60% of patients with hepatitis C under treatment with IFN- $\alpha$ . The activity of the HPA axis is also enhanced by pro-inflammatory cytokines and may further contribute to pathophysiology of depression.

### **The impact of stress on body weight gain.**

Ruth B.S. Harris, Department of Physiology, Medical College of Georgia.

Stress induces a complex array of physiological, neurological and behavioral responses that allow an animal to respond to a change in its environment. These responses are initiated by corticotrophin releasing factor (CRF) and the urocortins. There are two major subtypes of CRF receptors (CRFR1 and CRFR2) that each mediate specific aspects of

the stress response. Stress may cause weight gain or weight loss, dependent upon the type and severity of stress and an individual's perception of the degree of stress. Humans may gain weight in response to chronic daily stress, but will lose weight in response to a traumatic event. Hamsters gain body fat in following exposure to social stress, whereas food intake and growth are decreased in rats, mice and monkeys living in a stressful environment. We have investigated a rat model in which 3 hours of restraint stress on each of 3 consecutive days results in a chronic down-regulation of body weight. The rats lose weight on the days of restraint and then gain weight at the same rate as their non-stressed controls, but do not compensate for the stress-induced weight loss. Five days after the end of restraint the stressed rats weigh approximately 10-15% less than controls and this weight difference is maintained for at least 90 days. Third ventricle infusions of a CRFR1 antagonist, antalarmin, immediately before restraint do not prevent weight loss on the days of restraint or stress-induced activation of the HPA axis, but do prevent the long-term down-regulation of body weight. There is no evidence of chronic activation of the CRF system in the post-stress period, but rats that have been restrained are hyper-responsive to subsequent mild stressors. We are investigating whether this is associated with a change in threshold or an exaggerated response to stress and whether the increased sensitivity to daily events contributes to the sustained reduction in body weight. (Supported by NIMH grant MH068281)

**High- or low-salt diet from weaning to adulthood: effect on body weight, food intake and energy balance in rats.**

Michella S. Coelho<sup>1</sup>, Mariana D. Passadore<sup>2</sup>, Alessandra L. Gasparetti<sup>3</sup>, Theo Bibancos<sup>4</sup>, Patricia O. Prada<sup>3</sup>, Luciene L. Furukawa<sup>1</sup>, Luzia N.S.

Furukawa<sup>1</sup>, Rosa T. Fukui<sup>1</sup>, Dulce E. Casarini<sup>c</sup>, Mario J.A. Saad<sup>3</sup>, Jacqueline Luz<sup>2</sup>, Silvana Chiavegatto<sup>4</sup>, Miriam S. Dolnikoff<sup>1</sup>, Joel C. Heimann<sup>1</sup>.  
<sup>1</sup>FM-USP - Nephrology,  
<sup>2</sup>UNIFESP - Physiology <sup>3</sup>FCM-UNICAMP <sup>4</sup>IPq-USP/InCor-HCFMUSP, <sup>5</sup>UNIFESP - Internal Medicine

Objective: To get some additional insight on the mechanisms of the effect of salt intake on body weight. Design and methods: Rats were fed a low (LSD), normal (NSD), or high (HSD) salt diet. In a first set, body weight, tail-cuff blood pressure, fasting plasma thyroid-stimulating hormone, triiodothyronine, L-thyroxine, glucose, insulin, and angiotensin II were measured. Angiotensin II content was determined in white and brown adipose tissues. Uncoupling protein 1 expression was measured in brown adipose tissue. In a second set, body weight, food intake, energy balance, and plasma leptin were determined. In a third set of rats, motor activity and body weight were evaluated. Results: Blood pressure increased on HSD. Body weight was similar among groups at weaning, but during adulthood it was lower on HSD and higher on LSD. Food intake, L-thyroxine concentration, uncoupling protein 1 expression and energy expenditure were higher in HSD rats, while non-fasting leptin concentration was lower in these groups compared to NSD and LSD animals. Plasma thyroid-stimulating hormone decreased on both HSD and LSD while plasma glucose and insulin were elevated only on LSD. A decrease in plasma angiotensin II was observed in HSD rats. On LSD, an increase in brown adipose tissue angiotensin II content was associated to decreased uncoupling protein 1 expression and energy expenditure. In this group, a low angiotensin II content in white adipose tissue was also found. Motor activity was not influenced by the dietary salt content. Con-

clusions: Chronic alteration in salt intake is associated with changes in body weight, food intake, hormonal profile, and energy expenditure and tissue angiotensin II content.

**Hypertension, kidney disease, and cardiovascular outcomes in childhood: is there a role for birth weight?**

Franco MCP and Sesso R. (UNIFESP)

Objectives: Low birth weight due to intrauterine growth retardation may be a risk factor for hypertension, renal impairment and cardiovascular disease in the adult life. Our purpose was to investigate whether alterations in C-reactive protein, homocysteine, leptin and NO are present in small for gestational age children and to determine if the levels of these plasma biomarkers are associated with birth weight, vascular function and blood pressure. In addition, we investigated levels of both cystatin C and creatinine, and to evaluate whether there was an association between reduced GFR estimated by these markers and low birth weight. Methods: In this cross-sectional study the concentrations of leptin, homocysteine, C-reactive protein, cystatin, creatinine and NO were measured in 71 children between 8 and 13 years of age. Results: Leptin and homocysteine levels were significantly elevated in children born small for gestational age compared to those with appropriate birth weight. Nevertheless, NO concentration was significantly reduced in small birth weight children and the levels of C-reactive protein remained unchanged. There was a significant association between the circulating levels of both NO and homocysteine with vascular function as well as with blood pressure levels in our population. In addition, no differences were found for serum creatinine or GFRcr levels in the birth weight quartiles. There was a significant linear trend of increasing cystatin C (decreasing GFRcys) in the

lower birth weight quartile groups. Systolic blood pressure correlated with plasma levels of cystatin C ( $r = 0.311$ ,  $p=0.008$ ) and GFR<sub>cys</sub> ( $r = - 0.261$ ,  $p=0.028$ ). Conclusion: As both homocysteine and NO are associated with a risk of cardiovascular disease, it is possible that part of the association of low birth weight with elevated risk for vascular and metabolic disease in later life is mediated by perturbation in pathways for these biomarkers. Moreover, lower birth weight is associated with reduced renal function in 10 yr. old children with adequate gestational age.

#### **Vascular reactivity of femoral arteries from diabetic trained rats.**

Angelina Zanesco (UNESP-Rio Claro)

The number of diabetic individuals is increasing in the world due to a number of factors such as population growth, increase of lifespan and elderly population as well as increased prevalence of obesity and sedentary lifestyle. Evidences have pointed out that a massive production of ROS is the basis to macro- and micro-vascular disease in diabetic patients that contributes to the loss of endothelial function which is the critical phase of all the vascular diabetes mellitus (DM) complications. Therefore, overproduction of ROS by oxidative stress in response to hyperglycemia in DM leads to severe endothelium dysfunction. A healthy lifestyle has been strongly associated with the practice of regular physical activity. Evidences have shown that physically active subjects have more longevity with reduction of morbidity and mortality. Physical exercise prevents or reduces the deleterious effects of pathological conditions such as arterial hypertension, coronary artery disease, atherosclerosis, and diabetes mellitus. This work was to evaluate the effect of exercise training and aminoguanidine treatment (AG) on the femoral vascular responsiveness

from diabetic rats. Methods: Male Wistar rats (180-200 g) were divided into: sedentary (C/SD); diabetic (DB/SD), diabetic trained (DB/TR), diabetic treated with AG (DB/SD-AG) and diabetic trained treated with AG (DB/TR-AG). Diabetes mellitus was induced by streptozotocin (60mg/Kg, i.p.) and run training (RT) consisted of 5 days/week, 60 minutes, 0.9 km/h and 0% grade during 8 weeks. The AG (1g/L) treatment was administrated in the drinking water. Concentration-response curves for acetylcholine (ACh), sodium nitroprusside (SNP), cromakalin (CRO), phenylephrine (PHE) and thromboxane A<sub>2</sub> analogue (U46619) were obtained in femoral artery. Blood glucose, glycated hemoglobin and  $\beta$ -ketone levels were measured. Results: Glucose was reduced in RT groups (8%) whereas glycated hemoglobin and  $\beta$ -ketone levels were not affected compared to DB/SD group. Both potency and E<sub>max</sub> for ACh were decreased in DB/SD (6.0±0.1; 62±2%) compared to C/SD (6.8±0.09; 76±2%) while RT or AG treatment partly restored this reduction in DB/TR (6.4±0.06; 68±3%) and DB/SD-AG (6.4±0.07; 69±4%). Combination of RT and AG treatment completely reversed this reduction (6.7±0.02; 74±3%). Neither potency nor E<sub>max</sub> were modified for SNP in all groups. Potency for CRO was decreased in all DB groups that it was not restored by RT or AG treatment. No changes were observed for PHE and U46619 in all groups. Conclusion: Endothelium-dependent relaxing responses in femoral artery were restored by combination of RT and AG treatment. Financial Support: FAPESP

#### **Potential application of flavonoids in the therapeutics of diabetes mellitus**

Gabriel Forato Anhê (UNICAMP)  
Aim/hypothesis: A low grade inflammatory response probably accounts for insulin resistance in Type 2 Diabetes Mellitus. Quercetin, a potent anti-inflam-

matory flavonoid, was described to increase glucose tolerance in streptozotocin-induced diabetic rodents but its benefits to insulin resistance have yielded contradictory results. The present study aimed to determine whether intraperitoneal quercetin treatment increases insulin sensitivity in ob/ob mice and reduces inflammatory response in the skeletal muscle. Methods: L6 myotubes were treated with palmitate or TNF $\alpha$  plus quercetin. Obese ob/ob mice were treated with quercetin for 10 weeks. Cells and muscles were processed for mRNA quantification of GLUT4, TNF $\alpha$  and iNOS and phosphorylation of JNK and I $\kappa$ K. Myotubes were assayed for glucose uptake and nuclear NF- $\kappa$ B translocation. Chromatin immunoprecipitation assessed NF- $\kappa$ B p50 binding to Slc2a4 promoter. Results: Quercetin increased whole body insulin sensitivity and increased GLUT4 expression and decreased JNK phosphorylation, and TNF $\alpha$  and iNOS expression in skeletal muscle. L6 myotubes exposure to quercetin suppressed palmitate-induced upregulation of TNF $\alpha$  and iNOS and restored normal levels of GLUT4. In parallel, quercetin suppressed both palmitate- and TNF $\alpha$ -induced reduction of glucose uptake in myotubes. Nuclear accumulation of NF- $\kappa$ B in myotubes and binding of NF- $\kappa$ B p50 to Slc2a4 promoter in muscle of ob/ob mice were also reduced by quercetin. Conclusions/interpretation: We demonstrate that intraperitoneal quercetin decreases the inflammatory status in skeletal muscle of obese mice, which was mimicked in L6 myotubes. These effects were followed by an improvement in insulin action, suggesting that quercetin is a putative strategy to manage insulin resistance in obesity.

## **Novel endogenous peptide agonists of cannabinoid receptors.**

Lakshmi A. Devi, Prahlad T. Ram<sup>Δ</sup>, Avi Ma'ayan, and Ivone Gomes Department of Pharmacology & Systems Therapeutics, Mount Sinai School of Medicine, New York, USA, <sup>Δ</sup>M. D, Anderson Cancer Center, Texas, U.S.A.

Hemopressin, a 9-residue  $\alpha$ -hemoglobin-derived peptide, was previously reported to function as a CB<sub>1</sub> cannabinoid receptor-selective ligand (Heimann et al., PNAS, 194:20588, 2007). Recent peptidomics analyses of mouse brain extracts using mass spectrometry identified N-terminally extended forms of hemopressin containing either three (Arg-Val-Asp) or two (Val-Asp) additional amino acids. Characterization of these 'longer hemopressins' revealed that they function as CB<sub>1</sub> cannabinoid receptor agonists, in contrast to the 9-residue hemopressin that functions as an antagonist (Gomes et al., FASEB J. 23:3020, 2009). We have recently found that longer hemopressins activate a signal transduction pathway that is distinct from that of classical CB<sub>1</sub>R agonists. For example, the longer hemopressins activate G<sub>α<sub>lpha</sub></sub> independent signaling leading to a robust mobilization of intracellular Ca<sup>+2</sup> levels whereas the classic CB<sub>1</sub>R agonists activate G<sub>α<sub>lpha</sub></sub>-mediated signaling leading to G-protein activation. To further explore this ligand-directed signaling, we used a combination of reverse phase protein array and graph theory- inspired network analysis. Data from these analyses confirm the notion that longer hemopressins activate a signaling network distinct from that of classic ligands. Further characterization of the longer hemopressin-activated signaling pathway revealed that a number of proteins involved in neurogenesis and neuronal survival are selectively activated indicating that this ligand-directed signaling expands the functional repertoire of CB<sub>1</sub>R. Taken together, these results

suggest that CB<sub>1</sub> receptors are involved in the integration of signals from both lipid- and peptide-derived endocannabinoids. Furthermore, the fact that longer hemopressins possess unique agonistic activity at CB<sub>1</sub> receptors provides additional tools to understand how the endocannabinoid system is modulated as well as novel candidates to be developed as therapeutics in the treatment of pathologies involving cannabinoid receptors. Supported by NIH grants DA01952; DA08863 (to LAD) and GM071558 (to AM and LAD).

## **Therapeutic potential and mechanisms of non-psychoactive cannabinoids.**

Francisco Silveira Guimarães (USP)

$\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC) is usually recognized as the major component of *Cannabis sativa*, responsible for its behavioral and physiological effects. However, the Cannabis plant contains several other cannabinoids with potential therapeutic effects, including Cannabidiol (CBD). Unlike  $\Delta^9$ -THC, CBD is devoid of the typical psychotomimetic effects of the plant. Systemic administration of CBD can produce several neuropharmacological effects such as anticonvulsant, neuroprotective, antipsychotic and anxiolytic. Antipsychotic effects have been shown in animal models and in pilot studies with schizophrenic or Parkinson patients with L-Dopa-induced psychosis. Regarding the anxiolytic properties of CBD, they have been demonstrated by several pre-clinical studies which employed animal models such as the Vogel conflict test, the elevated plus- and T-maze, aversive electrical stimulation and conditioned emotional response. Similar to the data obtained in animal models, results from studies in healthy volunteers strongly suggested that CBD has an anxiolytic action. Moreover, CBD is able to attenuate the anxiogenic effects induced by high doses of

$\Delta^9$ -THC in humans. We have recently shown that CBD also possess antidepressant and anti-compulsive behavior properties. The mechanisms of these effects remain poorly understood due to the multiple pharmacological effects induced by CBD. Although the mechanisms of the antipsychotic effects are unknown, CBD produces a behavioral, clinical and cFos expression profile akin to atypical rather than typical antipsychotics. Recent results obtained in our laboratory suggest that the anxiolytic and antidepressant effects of CBD are mediated by activation of 5HT<sub>1A</sub> receptors in brain areas such as the dorsolateral periaqueductal gray, bed nucleus of the stria terminalis, hippocampus and the medial prefrontal cortex. However, the anti-compulsive effects of CBD seem to be mediated by facilitation of endocannabinoid-mediated neurotransmission. Financial support: FAPESP, CNPq, CAPES

## **Hemopressin: a new target for drug development.**

Camila Squarzon Dale (IEP-HSL)

Studies on cannabinoid receptors (CB) have raised a new perspective about the therapeutic potential of those receptors on different pathologies such as those with painful origin. In this aspect it has been demonstrated that agonists and antagonists of CB inhibit experimental pain in different models of nociception evaluation. Hemopressin (PVNFKFLSH) is a nonapeptide derived from the  $\alpha_1$  chain of hemoglobin (95-103 fragments) which acts as an inverse agonist of CB<sub>1</sub> receptors modulating the signaling mediated by this receptor. Data obtained by our group demonstrates that hemopressin induces antinociception in acute and chronic experimental models. Hemopressin acts by inhibiting nociceptive activation at spinal level, directly on sensory neurons and involves peripheral CB<sub>1</sub> receptors on acute models of nociception evaluation. More



interestingly, hemopressin is effective in inhibiting pain when administered by either intrathecal, intraplantar, or oral routes underscoring its therapeutic potential without affecting locomotor activity or sleeping time of animals indicating and absence of motor abnormalities or sedative effect. More recently we observed that hemopressin does not interfere with swimming time of animals demonstrating that hemopressin does not despair any depressant effects on Central Nervous System. These results represent a demonstration of a peptide ligand for CB1 cannabinoid receptors that also exhibits analgesic properties. These findings are likely to have a profound impact on the development of novel therapeutics targeting CB1 receptors.

**Inverse agonism in G-protein coupled receptors (GPCRs) seen in light of classical mechanisms of receptor activation.**

Laerte Oliveira (UNIFESP)

GPCRs may be activated constitutionally or by agonist binding thus becoming apt for signal transduction across their seven-trans-membrane (7TM) structure. Initiated at the extracellular side of the membrane, the signal can attain the receptor cytosolic domains thereby activating the G-protein system, the phosphorylation and the internalization of receptors. In both constitutional and agonist-mediated mechanisms, activation seems to result from an expansion of the receptor 7TM structure, so extensively that its cytosolic ends become accessible for coupling G-alpha chains and protein kinases. This theory has now been compellingly challenged by recent studies on mechanisms of action for inverse agonism. Identified by their action reverting the constitutive activation of receptors, inverse agonists have recently been shown to bind at the receptor agonist site at the same residue side-chains involved in agonist binding or even in agonist-me-

diated activation. In fact, inverse agonists should primarily be competitive antagonists of receptors but special features were added to these molecules transforming them into inverse agonists. Consistent interpretation of these findings may be hardly attained considering that the mechanism of GPCR activation is assumed to be generalized all over the receptor structure. Would the inverse agonism be also a reversion of this widespread effect or a parallel event simply annulling the activation? Thus, other hypotheses stressing the importance of interactions localized in the agonist site surroundings to trigger receptor activation, seem useful for discussion of these problems. These are derived from finding such as: (1) only the retinal-free opsin, with an extracellularly-located Lys-to-Glu mutation can activate transducin; (2) special features of agonists as aromatic rings may control the activation of GPCRs by binding of these molecules at the specific site.

**Computational chemistry underpinning carbohydrate drug discovery.**

Ivone Carvalho (USP)

Computational approaches have been progressively incorporated into the drug discovery process since several in silico methods are available, such as docking, pharmacophore modeling, QSAR (Quantitative Structure-Activity Relationship) and virtual screening. Computational chemistry and informatics can be used to integrate workflow and dataflow for optimum effectiveness in achieving project goals. This integration makes possible fast iterative virtual screening, to effectively prioritize targeted synthesis and screening efforts. In this context, the importance of selecting hit compounds with an appropriate scaffold is crucial for the successful in lead-optimization phase during drug discovery. The ideal scaffold should be both chemically and biologically stable and contain rigidity to enable the molecule to maintain

a controlled three-dimensional presentation of pharmacophores. The advantage of carbohydrates is that they provide a series of scaffolds, as well as mediate many biological processes (cell adhesion, differentiation and growth, signal transduction, protozoa, bacterial and virus infections, and immune response). Amongst the large array of enzymes as therapeutic targets, our group has focused the exploration of TcTS (*Trypanosoma cruzi* Trans-Sialidase) and  $\alpha$ -glucosidase enzymes. Concerning TcTS studies, short glycopeptide fragments based on *T. cruzi* mucin sequences (building blocks), potential drugs based on 1,4-disubstituted 1,2,3-triazole derivatives of galactose and cyclic pseudo-galactooligosaccharides were synthesized and tested, giving promising results. On the other hand, for studies involving  $\alpha$ -glucosidase, a 3D model was built and validated, and further used to perform docking simulations. In addition, pharmacophore modeling and molecular interaction fields were carried out in order to establish the most relevant structural features of both enzyme and inhibitors to drive the synthesis of more active compounds.

**Structure-based discovery of novel anti-inflammatory protein kinase inhibitors.**

Carlos Alberto Manssour Fraga (UFRJ)

Abstract: NF- $\kappa$ B is a member of a family of cellular transcription factors that are implicated in the inducible expression of various genes involved in immune responses, inflammation, cell survival and cancer. In unstimulated cells, NF- $\kappa$ B is kept in the cytoplasm through interaction with I $\kappa$ B inhibitory proteins. In response to specific external stimuli, including proinflammatory cytokines, viral infection, oxidants, phorbol esters and ultraviolet irradiation, the I $\kappa$ B component of the complex is phosphorylated and degraded, resulting in translocation of NF- $\kappa$ B into the nucleus and the in-

duction of target gene transcription. Two protein kinases, IKK- $\alpha$  and IKK- $\beta$ , phosphorylate I $\kappa$ B proteins and represent a convergence point for most signal transduction pathways leading to NF- $\kappa$ B activation. IKK- $\beta$  is a key regulator of keratinocyte and epidermal differentiation and suppresses skin cancer, being implicated in some of the anti-inflammatory properties of commercial drugs, such as aspirin and salicylates. These pharmacological effects indicate that an inhibitor of IKK- $\beta$  could effectively treat autoimmune and inflammatory disorders such as rheumatoid arthritis, lupus, Crohn's disease and multiple sclerosis.

The discovery and development of small molecule IKK- $\beta$  modulators is a significant area of research, and several classes of inhibitors have been previously reported. The majority of these inhibitors share a core heterocycle that mimics the adenosine ring of ATP, promoting additional interactions with the target protein.

In this study, we describe the rational design, molecular modeling and pharmacological profile of (*E*)-*N*-(4-nitrobenzylidene)-2-naphthohydrazide (LASSBio-1524), a novel small molecule inhibitor of I $\kappa$ B Kinase- $\beta$ . The design based on the IKK- $\beta$  active site, and a *privileged structure* template yielded a novel IKK- $\beta$  inhibitor scaffold with significant selectivity over IKK- $\alpha$  and CHK2, as assessed by a robust kinase assay. For a better understanding of the structural requirements of IKK- $\beta$  inhibition, molecular dynamics simulations of staurosporine and LASSBio-1524 were performed. The NAH derivative LASSBio-1524 was able to suppress arachidonic acid-induced edema formation in a dose-dependent manner, demonstrating an *in vivo* anti-inflammatory effect. The molecular architecture of this novel, low-molecular weight IKK- $\beta$  inhibitor is encouraging for further lead optimization toward the devel-

opment of innovative anti-inflammatory drug candidates. Financial support: This work was supported by grants and fellowships from INCT-INOFAR (573.564/2008-6), CNPq, FAPERJ and CAPES.

### **Atrofia muscular na Insuficiência cardíaca: efeito do treinamento físico aeróbico**

Patricia Chakur Brum EEFÉ-USP - Biodinâmica do Movimento do Corpo Humano

Apesar das alterações no tecido cardíaco serem causais e principais no desenvolvimento da insuficiência cardíaca (IC), vários estudos tem demonstrado que a limitação da capacidade funcional perante o agravamento da IC não está somente relacionada ao grau de disfunção ventricular. A intolerância ao esforço físico, que é amplamente observada em portadores de IC correlaciona-se principalmente às alterações morfo-funcionais da musculatura esquelética, que contribuem para a antecipação da fadiga nesses indivíduos. Dentre essas alterações musculares observase: a) redução da capacidade oxidativa, b) mudanças na composição dos tipos de fibras musculares em direção as fibras glicolíticas de contração rápida e c) atrofia muscular. Além disso, a perda excessiva de massa muscular (caquexia) conjuntamente com o consumo de oxigênio de pico em pacientes com IC grave eram preditores independentes de mortalidade.

Apesar dos avanços terapêuticos e progresso da farmacoterapia da IC, o prognóstico da síndrome ainda merece atenção, pois pacientes apresentam expectativa de vida média de seis anos após diagnóstico. Nesse sentido, terapias adjuvantes que melhorem a qualidade de vida do portador de IC são hoje imprescindíveis.

O treinamento físico aeróbico tem sido preconizado como adjuvante à terapia farmacológica da IC. Dentre seus benefícios destaca-se: a) redução da atividade nervosa simpática, b) melhora da tolerância aos esforços físicos e c) redução da atrofia

muscular e melhora da capacidade oxidativa muscular.

Na presente palestra daremos destaque aos benefícios do treinamento físico aeróbico sobre a função e o trofismo da musculatura esquelética em modelo experimental de IC e em pacientes com IC. Daremos destaque aos estudos em andamento do nosso grupo visando o efeito do treinamento físico aeróbico sobre a sinalização de vias proteolíticas como a das calpaínas e o sistema ubiquitina-proteassoma. Apoio financeiro dos estudos: FAPESP (06/61523-7) e CNPq (301519-2008-0)

### **Sympathetic actions on the skeletal muscle protein metabolism.**

Luiz Carlos Navegantes (USP) Skeletal muscle protein mass depends on the balance between synthesis and degradation. The main intracellular proteolytic systems in the skeletal muscles are the lysosomal, the Ca<sup>2+</sup>-dependent and the ubiquitin-proteasome system (UPS). The majority of intracellular proteins are degraded by the UPS. In all types of atrophying muscle, the UPS is activated, and catalyzes the degradation of the bulk of muscle proteins. In addition, there is a dramatic induction of two muscle-specific ubiquitin-ligases, Atrogin-1 and MuRF-1, whose induction occurs before the onset of muscle weight loss and which is necessary for rapid atrophy. The key mediators of this catabolic response during atrophy are the FoxO (Forkhead box O) family of transcription factors, whose activity is suppressed during growth by phosphorylation by AKT. We have been studying the mechanisms through which the rates of these different proteolytic components are regulated by hormonal, nutritional and neural factors. Among the factors that regulate proteolysis, the Sympathetic Nervous System (SNS) has an important physiological role. We have previously shown that SNS, through the activation of beta-2 and beta-3 adrenoceptors and

cAMP signaling cascade, exerts an anabolic effect on muscle protein metabolism by inhibiting the activity of the Ca<sup>2+</sup>-dependent proteolytic system. In the present study, we present evidences that the beta-2 adrenergic agonist clenbuterol (CB) *in vivo* induces hypertrophy and reduces UPS activity in skeletal muscles from normal rats. In addition, CB suppresses the transcriptional upregulation of the ubiquitin ligases Atrogin-1 and MuRF-1 in muscles from mice under atrophic conditions. This effect is independent of PGC-1 $\alpha$  (Proliferator-Activated Receptor- $\gamma$  Coactivator-1 $\alpha$ ) since it has been also observed in muscles from PGC-1 $\alpha$  muscle-specific knock-out animals. The CB-induced reduction of atrophy-related genes occurs through the activation of AKT, which leads to phosphorylation of FOXO3a. The anti-proteolytic effect of CB on UPS is probably mediated through the cAMP pathway since elevated cAMP levels induced by cAMP-phosphodiesterase inhibitors *in vitro* suppresses the UPS activity, the levels of ubiquitin-conjugated proteins and the mRNA and protein levels of Atrogin-1 transcripts in muscles from normal rats and in C2C12 myotubes treated with dexametasone. These data suggest that stimulation of beta-2 adrenoceptors, through the activation of cAMP and AKT signaling pathways, inhibit ubiquitin-proteasome proteolysis by increasing FOXO3a phosphorylation and suppressing Atrogin-1 mRNA expression in skeletal muscle from rodents. The understanding of the precise mechanisms by which endogenous catecholamines promote muscle anabolic effects may bring new perspectives for efficient treatment of muscle-wasting conditions.

#### **New function of the kallikrein-kinin system in the muscular atrophy.**

Parreiras-e-Silva, LT<sup>1</sup>, Pires-Oliveira M<sup>2</sup>, Lira EC<sup>3</sup>, Reis RI<sup>1</sup>, dos Santos GA<sup>1</sup>, Pesquero JB<sup>4</sup>, Ket-

telhut IC<sup>1</sup>, Navegantes LCC<sup>3</sup>, Gomes MD<sup>1</sup>, Godinho RO<sup>2</sup>, Costa-Neto CM<sup>1</sup> <sup>1</sup>FMRP-USP – Biochemistry and Immunology, <sup>2</sup>UNIFESP – Pharmacology, <sup>3</sup>FMRP-USP – Physiology, <sup>4</sup>UNIFESP – Biophysics

Introduction: Skeletal muscle fibers loose mass due to catabolic signals such as those driven by pro-inflammatory molecules and malnutrition. Ultimately those effects are mainly mediated by the ubiquitin-proteasome system (UPS), but also by other proteolytic systems. Muscle proteolysis is increased during several pathologies such as cancer, diabetes and sepsis, in some cases leading to severe muscular atrophy. Objective: Since the B<sub>1</sub> and B<sub>2</sub> kinin receptors are involved in inflammatory responses, we decided to analyze the participation of the kallikrein-kinin system (KKS) in three different *in vivo* models of muscle atrophy, and also *in vitro* using primary culture and C2C12 cells. Methods: Wistar rats, Balb-C mice and C57BL/6 wild-type and kinin B<sub>1</sub> receptor *knockout* mice were gonadectomized for 2, 7, 15 and 30 days to induce levator ani (LA) muscle atrophy. In another atrophy model, C57BL/6 mice were fasted for 2 days and gastrocnemius muscles were collected. In the third model, sepsis was induced in young Wistar rats by the cecal ligation and puncture (CLP) method, which afterwards also causes muscle atrophy. After processing, samples from different muscles were analyzed concerning the expression of transcripts for kinin B<sub>1</sub> and B<sub>2</sub> receptors, atrogin-1 and MuRF-1 (key enzymes of UPS), TNF- $\alpha$  and IL-6 (pro-inflammatory cytokines with known catabolic roles in muscular tissue), IGF-1 (an anabolic peptide), and LC3 and cathepsin L (involved in lysosomal proteolysis). All experiments were conducted in accordance with the local Animal Care and Use Committee (FMRP-USP 046/2006). Concerning the *in vitro* approach, to analyze the

molecular effects of activation of the KKS we treated cultured myotubes obtained from all the hindlimb muscles from young Wistar rats and developed from the murine C2C12 cell line, with the agonists of kinin receptors, bradykinin (BK) and des-Arg<sup>9</sup>-BK (DABK). After sample processing, the expression levels of targeted transcripts were analyzed by conventional or quantitative PCR, as well as western blotting analyses. RESULTS: We show that mRNA expression levels of atrogin-1 and MuRF-1 were increased in the muscles collected from animals submitted to the three *in vivo* models. The kinin B<sub>1</sub> receptor mRNA was also increased in the same muscles and the B<sub>2</sub> receptor mRNA was increased in the murine fasting model. Moreover, LA muscles from B<sub>1</sub> receptor *knockout* mice did not induce MuRF-1 transcript expression and exhibited a slight increase in relative mass. Expression of LC3 mRNA was induced to a lower extent when compared to the WT animals. Western blotting analyses showed an increase in ERK 1/2 phosphorylation in LA muscles from Balb-C mice treated with the kinin B<sub>2</sub> receptor antagonist HOE-140, suggesting a possible mechanism for KKS role in regulating muscle mass in physiological situations. *In vitro*, we showed that the treatment of C2C12 myotubes with the B<sub>1</sub> receptor agonist, DABK, induced a decrease in myotubes diameter after 12 to 48 hours (5 and 15%, respectively). Transcript expression analysis showed an increase of the inflammatory cytokines, TNF- $\alpha$  and IL-6, and the lysosomal protease cathepsin L. It was also shown a decrease in IGF-1 mRNA expression. In myotubes from primary culture of rat hindlimbs, activation of the B<sub>2</sub> receptor induced an increase in MuRF-1 mRNA and in atrogin-1 protein levels. Activation of both receptors induced an increase in reactive oxygen species (ROS) production until 1 hour following stimulus. DIS-

CUSSION: Our data evidence the participation of KKS in muscle mass control, and therefore its involvement in muscular atrophy, mainly via UPS and lysosomal proteolytic systems. Finally, our results also suggest possible mechanisms by which kinins regulate such process, as follows: *i*) activation of NF- $\kappa$ B, since B<sub>1</sub> receptor stimulation in cultures of myotubes induced an increase in inflammatory cytokines and ROS production, and B<sub>1</sub>-*knockout* mice did not induce MuRF-1 mRNA expression in LA of castrated animals; *ii*) regulation of MAPK pathway, since the antagonism of the B<sub>2</sub> receptor in mice induced an increase of ERK 1/2 phosphorylation levels in LA. Also, the increase of MuRF-1 and atrogin-1 levels in myotubes concomitantly with the increase of ROS production induced by BK, suggest a possible activation of p38 MAPK; *iii*) regulation of PI3K/Akt signaling pathway, since B<sub>1</sub>-*knockout* mice showed a lower increase in LC3 mRNA expression in LA muscle, and DABK decreased IGF-1 expression (which activates PI3K/Akt) in cultured myotubes, and finally because BK induced atrogin-1 protein expression in rat myotubes, which expression is known to be regulated by Akt/Foxo. Financial support: FAPESP, CAPES, CNPq, FAEPA.

#### **Excitation-secretion coupling in Leydig cells.**

Wamberto A. Varanda (USP)  
Leydig cells are responsible for the synthesis and secretion of testosterone, processes controlled by the hypophysis via the Luteinizing Hormone (LH). Binding of LH to a G Protein Coupled Receptor in the plasma membrane of Leydig cells, results in a primary increase in cAMP and in the intracellular calcium concentration ( $[Ca^{2+}]_i$ ). Both processes are known to be essential for testosterone production. The question we ask here is: how events occurring in the plasma membrane are linked to and to what extent determine changes in the intracellular cal-

cium concentration? Using the whole cell variation of the patch clamp technique we show the presence of T-type calcium currents which can be enhanced by treatment of the cells with LH. This effect is also evident when the cells are exposed to dibutyryl-cAMP. The electrophysiological properties of the currents and immunofluorescence experiments support the conclusion that the calcium currents are carried by Ca<sub>v</sub>3.2 ( $\alpha_{1H}$ ) channels. Measurements of intracellular calcium activity with the fluorescent dye Fluo3 and confocal microscopy, show that the changes in  $[Ca^{2+}]_i$  induced by LH require the presence of extracellular calcium and do not occur when Ca<sub>v</sub>3.2 are blocked by nickel. Using specific antibodies we show that Leydig cells express the three isoforms of both ryanodine receptors (RYRs) and inositol 1,4,5-trisphosphate receptors (IP3Rs). The RYRs and IP3Rs are functional, as judged both from their activation by caffeine and IP3 and block by ryanodine and 2-APB, respectively. Both types of receptors are involved in a calcium-induced calcium-release mechanism (CICR), which amplifies the initial Ca<sup>2+</sup> influx through plasma membrane T-type calcium channels. Nevertheless, our results show that RYRs are the principal players involved in the release of Ca<sup>2+</sup> from the endoplasmic reticulum. This assumption is supported mainly by the fact that the global Ca<sup>2+</sup> changes evoked by LH are readily blocked by 100  $\mu$ M ryanodine but not by 2-APB or xestospongin C. Both calcium currents and transients are predominantly modulated by PKA but PKC also participates in the process. Finally, we will show that blockage of the ryanodine receptors, but not IP3 receptors, inhibits both the hormone-induced  $[Ca^{2+}]_i$  transients and the subsequent testosterone production by the Leydig cells. These results not only broaden our understanding of the role played by calcium in Leydig cells

but also show, for the first time, that ryanodine receptors play a crucial role in determining testosterone secretion by the testis. Financial Support: FAPESP, CNPq, FAEPA.

#### **Nucleoplasmic calcium regulates cell through legumain**

Andrade VA<sup>‡</sup>, Guerra MT<sup>§</sup>, Jardim, CA<sup>†</sup>, Melo FM<sup>†</sup>, Silva Jr WA<sup>¶</sup>, Ortega MJ<sup>‡</sup> Robert ME<sup>\*</sup>, Nathanson MH<sup>§</sup>, Leite MF<sup>†,δ</sup>  
‡UFMG – Biochemistry and Immunology, †UFMG – Physiology and Biophysics, ¶FMRP-USP – Genetics and Center for Cell Based Therapy, \*Yale University – Pathology, §School of Medicine New Haven – Internal Medicine/Cell Biology, δHoward Hughes Medical Institute.

Nucleoplasmic Ca<sup>2+</sup> regulates cell growth, but the proteins through which this occurs are unknown. To investigate this, we used Rapid Subtraction Hybridization to subtract genes in SKHep1 liver cells expressing the Ca<sup>2+</sup> buffer protein parvalbumin (PV) targeted to the nucleus, from genes in cells expressing a mutated form of nuclear-targeted PV which has one of two Ca<sup>2+</sup>-binding site inactivated. The subtraction permitted selection of genes whose expression was affected by a small alteration in nuclear Ca<sup>2+</sup> concentration. The asparaginyl endopeptidase legumain (LGMN) was identified by this assay and differential expression of this gene was validated by Real Time-PCR. When Ca<sup>2+</sup> was buffered in the nucleus of SKHep1 cells, LGMN mRNA was decreased by 97%, and decreased expression at the protein level was observed by immunoblot and immunofluorescence. Knockdown of LGMN by siRNA decreased proliferation of SKHep1 cells by ~50% as measured both by BrdU uptake and mitotic index. A significant reduction in the fraction of cells in G2/M phase was seen as well. This was associated with increases in expression of cyclins A and E. Furthermore, LGMN expression was increased in hepatocellular carcinoma cells rel-

ative to normal hepatocytes in the same tissue specimens. These findings identify a new role for LGMN and provide evidence that nuclear  $\text{Ca}^{2+}$  signals regulate cell proliferation in part through modulation of LGMN expression, and suggest that increased expression of LGMN may be involved in carcinogenesis in the liver.

### **Physiological and pathological aspects of brain mitochondrial $\text{Ca}^{2+}$ transport.**

Roger Frigério Castilho (UNICAMP)

Changes in mitochondrial integrity, reactive oxygen species release and  $\text{Ca}^{2+}$  handling are proposed to be involved in the pathogenesis of many neurological disorders. In mitochondria,  $\text{Ca}^{2+}$  influx occurs electrophoretically in response to the internally negative membrane potential generated by the respiratory chain or ATP hydrolysis by the reverse activity of the mitochondrial ATP synthase. The channel that promotes mitochondrial  $\text{Ca}^{2+}$  uptake is inhibited by ruthenium red and has low affinity for  $\text{Ca}^{2+}$ , presenting a  $K_m$  of 10-30  $\mu\text{M}$ .  $\text{Ca}^{2+}$  efflux from mitochondria involves two pathways. The  $\text{Na}^+$ -dependent pathway, presented mainly in excitable tissue, which exchanges one  $\text{Ca}^{2+}$  ion for two  $\text{Na}^+$  ions; while the ubiquitous  $\text{Na}^+$ -independent pathway exchanges  $\text{Ca}^{2+}$  for  $2\text{H}^+$ . Under steady-state, mitochondrial  $\text{Ca}^{2+}$  uptake typically maintains extramitochondrial  $\text{Ca}^{2+}$  ions in the 0.5 to 1.0  $\mu\text{M}$  range. The main function of mitochondrial  $\text{Ca}^{2+}$  uptake appears to be the regulation of matrix  $\text{Ca}^{2+}$  concentrations, which stimulate the activity of regulatory enzymes of the Krebs cycle.

Energy metabolism defects in neurons cause increases in intracellular  $\text{Ca}^{2+}$  levels, either by directly impairing  $\text{Ca}^{2+}$  removal systems or due to *N*-methyl-D-aspartate (NMDA) receptor activation. Under these conditions, the mitochondrion is the main organelle responsible for  $\text{Ca}^{2+}$  sequestration, a required

step in NMDA-induced neurotoxicity. Excessive mitochondrial  $\text{Ca}^{2+}$  uptake and oxidative stress can cause non-selective inner mitochondrial membrane permeabilization, known as the permeability transition (MPT). MPT results in mitochondrial  $\text{Ca}^{2+}$  release, organellar swelling, release of mitochondrial apoptogenic factors such as cytochrome *c* and loss of inner membrane potential and ATP synthesis. MPT can result both in necrosis and apoptosis.

We have recently shown that the addition of the succinate dehydrogenase (SDH) inhibitor 3-nitropropionic (3NP) to  $\text{Ca}^{2+}$ -loaded brain mitochondria leads to MPT (Maciel et al., 2004). Brain and heart mitochondria were generally more sensitive to 3NP and  $\text{Ca}^{2+}$ -induced MPT than mitochondria from liver and kidney. In addition, 3NP resulted in more pronounced MPT in striatal mitochondria than in cortical or cerebellar organelles (Mirandola et al., 2010). We propose that the increased susceptibility of the striatum to 3NP-induced neurodegeneration in rats systemically treated with this toxin may be partially explained by its susceptibility to MPT.

The adenine nucleotides ADP and ATP are probably the most important endogenous inhibitors of MPT. We studied the inhibitory effects of adenine nucleotides on brain MPT (Saito and Castilho, 2010). We observed that ATP lost most of its inhibitory effects on MPT when the experiments were carried out in the presence of ATP-regenerating systems. These results indicate that MPT inhibition observed in the presence of added ATP could be mainly due to hydrolysis of ATP to ADP. From mitochondrial swelling measurements, half-maximal inhibitory values ( $K_i$ ) of 4.5  $\mu\text{M}$  and 98  $\mu\text{M}$  were obtained for ADP and ATP, respectively. In addition, a delayed mitochondrial swelling sensitive to higher ADP concentrations was observed. Mitochondrial anoxia / reoxygenation did not interfere

with the inhibitory effect of ADP on  $\text{Ca}^{2+}$ -induced MPT, but oxidative phosphorylation markedly decreased this effect. We conclude that ADP is a potent inhibitor of brain MPT. Our results suggest that ADP can have an important protective role against  $\text{Ca}^{2+}$ -induced MPT and tissue damage under conditions of brain ischemia and hypoglycemia. Maciel EN, Kowaltowski AJ, Schwalm FD, Rodrigues JM, Souza DO, Vercesi AE, Wajner M, Castilho RF (2004) Mitochondrial permeability transition in neuronal damage promoted by  $\text{Ca}^{2+}$  and respiratory chain complex II inhibition. *J Neurochem* 90: 1025-1035.

Mirandola SR, Melo DR, Saito A, Castilho RF (2010) 3-nitropropionic acid-induced mitochondrial permeability transition: comparative study of mitochondria from different tissues and brain regions. *J Neurosci Res* 88: 630-639. Saito A, Castilho RF (2010) Inhibitory effects of adenine nucleotides on brain mitochondrial permeability transition. *Neurochem Res* (in press). Supported by FAPESP and CNPq.

**Dopamine turnover following administration of 7-nitroindazole to rats with L-DOPA-induced dyskinesia.** E.A. Del Bel<sup>1,2</sup>, R.S. Szawka<sup>1</sup>, F.E. Padovan-Neto<sup>1,2</sup>, C.A. da-Silva<sup>1</sup>, J.A. Anselmo-Franci<sup>1</sup>. <sup>1</sup>FORP-MEF - Physiology and <sup>2</sup>FMRP- Neurology

Purpose of the study: Administration of L-3,4-dihydroxyphenylalanine (L-DOPA) enhances dopamine synthesis and release in dopamine-deafferented striatum leading to improvements in parkinsonian symptoms. Long-term use of L-DOPA leads to side-effects such as unwanted movements or dyskinesias. We have recently described that nitric oxide synthase inhibition is able to reduce L-DOPA-induced dyskinesias in experimental Parkinson (3). This result suggests that controlling nitric oxide production may be useful for the prevention of dyskinesias. Be-

cause the mechanism of this effect is poorly understood, it is of interest to determine whether nitric oxide synthase inhibitor 7-nitroindazole would affect neurochemical responses. Therefore, we determined the effects of 7-nitroindazole in striatal levels of catecholamines and indoleamines in 6-hydroxydopamine (6-OHDA) lesioned rats with L-DOPA induced dyskinesias. Methods. Male Wistar rats with unilateral 6-OHDA lesions of the medial forebrain bundle or sham animals (2, n=5-7/group) were treated chronically (21 days) with L-DOPA (30mg/kg) to induce abnormal involuntary movements (AIMs) (1). Comparisons between 6-OHDA lesioned (dyskinetic) and sham (non-dyskinetic) L-DOPA-treated rats, receiving either saline or 7-nitroindazole, were then carried out with regard to striatal levels of dopamine (DA), DOPAC (DA metabolite), serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA, a 5-HT metabolite), measured by HPLC analyses. Since it has been shown that the nigrostriatal DA system has functional and neurochemical asymmetry, the measurements were made separately in each side. Results: L-DOPA induced AIMs in all 6-OHDA lesioned rats, which was attenuated by 7-nitroindazole. 6-OHDA lesion induced a decrease in DA and DOPAC levels in the striatum ipsilateral to lesion (85.2 and 90%, respectively,  $F_{1,19}=87.3$   $p<0.001$ ); 7-nitroindazole treatment decreased DOPAC in both striatum (28-30%). 7-nitroindazole treatment per se increased DA level in sham-L-DOPA treated rats (42-60%). The content of 5-HT decreased in the ipsilateral striatum (28.2% of control); however 7-nitroindazole increased it in the contralateral one (24.5%). 5-HIAA decreased in the striatum ipsilateral to lesion (35.6%) and 7-nitroindazole treatment did not change lesion effect. DOPAC/DA ratio regarded as a measure of DA turnover, was significantly higher (391%,

$F_{1,19}=4.38$ ,  $p=0.05$ ) in the ipsilateral striatum of dyskinetic rats. This effects was prevented by 7-nitroindazole. 5HIAA/5HT ratio increased in the striatum ipsilateral (119%) but did not change after 7-nitroindazole treatment. Conclusion: Confirming previous results (3), treatment with 7-nitroindazole attenuated L-DOPA-induced dyskinesias in animals with unilateral striatal 6-OHDA lesions. Dyskinetic animals show an increase in dopamine metabolism as expressed by increased DOPAC/DA levels. This increase in dopamine turnover could serve to maintain dopamine levels in the dopamine-depleted striatum and may account for the therapeutic benefit of L-DOPA. However, it may also be related to the dyskinesias induced by this drug. Interestingly, 7-nitroindazole, a preferential neuronal nitric oxide synthase, was able to prevent both this turnover increase and attenuate the drug-induced dyskinesias. Together these results suggest that nitric oxide production could be important for the occurrence of L-DOPA-induced dyskinesias. Financial support: FAPESP, FAPESP/INSERM, CNPq, CAPES/COFECUB. Reference(s): (1) Cenci MA, Lee CS Björklund A (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA Eur J Neurosci 10: 2694-2706. (2) Gomes MZ, Raisman-Vozari R, Del Bel EA (2008) A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway Brain Res 1203:160-169. (3) Padovan-Neto FE, Echeverry MB, Tumas V, Del-Bel EA. (2009) Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease Neuroscience 159(3):927-935.

### **Brain in movement: the role of physical exercise in Parkinson's disease.**

Aderbal S. Aguiar-Jr. (UFSC) Parkinson's disease (PD) is considered a motor neurodegenerative disease, and its diagnosis is based on cardinal motor signs. In addition, subtle cognitive impairments are present even during the PD earlier phases that includes attentional and working memory deficits. Dopamine-replacement therapy has dominated the treatment of PD since the early 1960s and although the currently approved antiparkinsonian agents offer effective relief of the motor deficits, they have not been found to alleviate the underlying dopaminergic neuron degeneration, and drug efficacy is gradually lost. In addition, this approach did not shows modifying-disease effects to cognitive dysfunction. Thus, the management of non-motor symptoms of PD remains a challenge. A putative strategy is the physical exercise, because there are several evidences showing benefits to aged and diseased brain. Clinical studies have been inconsistent to show exercise-induced reverse PD symptoms, which can be largely attributed to methodological issues. On the other hand, recent findings have shown that exercise programs can present beneficial effects in neurotoxic rodent models of PD such as 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). However, no consistent evidence for the potential of exercise to prevent cognitive impairments in animal models of PD has to date been documented. Here, we evaluated the neuroprotective properties of exercise in ameliorate animal models of basal ganglia dysfunction, such as 6-OHDA-induced motor dysfunction and MPTP-induced olfactory and cognitive dysfunction. Five to 6-month-old male C57BL/6 mice were maintained under controlled environment (UFSC ethical board number

23080.019001/2009-27). Initially, mice were assigned to two groups: untrained and runners. Animals were exercised with a treadmill ergometer during 6 weeks, where blood lactate levels were weekly monitored to control exercise intensity. Five animals per groups were sacrificed 48h after the exercise program ending to analyze skeletal muscle mitochondrial function. Moreover, we separated animal in two additional groups: 6-OHDA and MPTP treated mice. The animals were treated with the neurotoxins 6-OHDA (4 µg), injected into the right midstriatum (anterior 0.4, lateral 1.8, ventral 3.5), or MPTP (65 mg/kg) that was administered intranasally (Prediger et al, *Neurotox Res*, 17, 114, 2010) or their respective vehicle 48 h after the end of physical program. Blood lactate levels of trained mice remained within the moderate levels of intensity effort. Moreover, the activity of citrate synthase and complex I of skeletal muscle isolated mitochondria were increased in relation to sedentary controls. In the striatal 6-OHDA model, apomorphine treatment (0.6 mg/kg, s.c.) induced a progressive rotation in sedentary animals, which was not observed in the 6-OHDA trained mice, suggesting a reduced dopamine receptors sensitization in trained mice. We assessed rota rod performance of mice and verified a per se effect in the exercised mice, while 6-OHDA sedentary mice presented poor latency to fall than saline treated animals. Moreover, exercise was also able to ameliorate the rota rod performance of exercised mice impaired by the 6-OHDA treatment. We also evaluated the role of physical exercise on basal ganglia-dependent stimulus-response learning and memory. The intranasally MPTP treatment induces poor freezing response retrieval in the tone fear conditioning tasks and the exercise presented not per se effect. However, we observed that 6 weeks of moderate running exercise ameliorate this

impairment in the exercise MPTP-treated group. Moreover, MPTP-treated groups also showed dopamine receptor sensitization as indicated by a marked increase in climbing behavior induced by a low dose of apomorphine (0.2 mg/kg, s.c.) that was prevented by exercise. Indeed, exercise prevented the catalepsy induced by haloperidol (0.32 mg/kg, i.p.) in MPTP-treated mice. These effects seem not be related to neuroprotective actions of exercise since it did not prevent the MPTP-induced reduction in the levels of dopamine and tyrosine hydroxylase enzyme in the striatum. However, exercised MPTP-treated mice presented decreased striatal DA turnover in comparison to sedentary MPTP-treated mice. Our evidences are coherent with this statement due to modifying-disease effects induced by exercise. Taken together, the present findings suggest that physical exercise can reduce behavioral alterations associated to dopamine receptors imbalance in neurotoxicant models of PD and that this response is an association between neuroprotection and post-synaptic changes. Financial support: FAPESC, CAPES and CNPq.

**Behavioral and neurochemical alterations induced by intranasal administration of MPTP, an experimental model of Parkinson's disease, in mice with genetic deletion of the heparin binding growth factors Pleiotrophin and Midkine.**

Rita Raisman-Vozari<sup>1</sup>, Argelia Esperanza Rojas-Mayorquin<sup>1</sup>, Elaine Del Bel<sup>2</sup>, Raymond Mongeau<sup>3</sup>, Laurence Lanfumey<sup>3</sup> Rui D. S. Prediger<sup>4</sup>. <sup>1</sup>INSERM-UMR, <sup>2</sup>FORP-USP, <sup>3</sup>INSERM - Neuropsychopharmacologie, <sup>4</sup>UFSC - Farmacologia  
The "olfactory vector hypothesis" postulates that Parkinson's disease (PD) may be caused or catalyzed by agents that enter the brain via the olfactory mucosa. We have recently demonstrated that rats treated with intranasal

(i.n.) infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin largely used to modeling PD in primates and rodents, suffer from progressive signs of PD that are correlated with time-dependent degeneration in dopaminergic neurons. On the other hand, previous studies have suggested that heparin binding growth factors, such as Midkine (Mdk), might play an important role in nigrostriatal system development and in the compensatory mechanisms that take place in PD. Here, we employed Mdk knock-out mice (Mdk-Ko) to evaluate the relevance of such heparin binding growth factor in the olfactory, emotional, learning and memory, and motor deficits induced by a single i.n. administration of MPTP (1 mg/nostril). Mimicking the clinical condition, mice exhibited an early disruption in olfactory discrimination ability and social recognition memory during the first two weeks after MPTP treatment. These responses were not due to locomotor impairments, since no behavioral alterations in the activity chambers were observed in the first post-treatment week. Interestingly, Mdk-Ko mice have a poorer performance in the olfactory discrimination and social recognition tests, but not in the elevated plus-maze, than wild-type controls. Of high importance, selective locomotor impairments evaluated in activity chambers were observed in Mdk-Ko mice at 3 weeks after i.n. MPTP infusion.

The present results suggest, for the first time, the role of Mdk in olfactory and short-term social memory processes in rodents. Moreover, our findings reinforce the involvement of Mdk in compensatory mechanisms in PD, indicating that the genetic deletion of Mdk confers increased susceptibility to behavioral deficits induced by MPTP in mice.

### **Molecular approaches to the study of natural products modulating nociception.**

Marilia Zaluar P. Guimarães (UFRJ)

Natural products have been fundamental tools in the understanding of how pain occurs and also served as medicines to treat pain for a long time. For instance, acetylsalicylic acid extracted from the willow bark was important to confirm the role of prostaglandins in sensitizing nociceptors. More recently, capsaicin, the pungent ingredient in chili peppers, was used to clone TRPV1, a channel responsible for the transduction of several painful stimuli. Upon activation by vanilloids, protons, endogenous lipids or high temperatures, TRPV1 causes nociceptor excitation via cation influx. In addition, TRPV1 has been linked to some toxins and venoms produced by animals and plants that act as repellents to predators, such as resiniferatoxin, spider toxins and jellyfish venom. Other toxins are likely to produce burning pain via activation of TRPV1. One good candidate is the bee venom, responsible for thousands envenomations a year in Brazil. Previous works have suggested that some of the bee venom-caused inflammatory hypersensitivity is of neurogenic origin. In particular, authors have suggested the involvement of TRPV1 channels in some of the bee venom effects. However, this was not clearly demonstrated on the molecular level. We decided to investigate this matter using *Xenopus* oocytes expressing TRPV1 and performing electrophysiology experiments. Preliminary data suggest that crude bee venom is able to activate TRPV1 channels. These initial experiments indicate that crude venom might contain a toxin or toxins capable of activating TRPV1. Further experiments will help clarify which constituents are responsible for modulating TRPV1 and cause burning pain sensation.

### **Cell and tissue responses to melittin and its antagonist.**

Camila El-Kik (UFRJ)

*Apis mellifera* bee venom is composed by a mixture of many components some as proteins with different molecular weight but the toxic effect of the venom is attributed mainly the presence of melittin. Venom components present pharmacologic and allergic effects producing located pain, edema and erythema caused by the increase of the vascular permeability. Melittin is a cytotoxic protein, that induces hemolysis, cardiotoxic and myotoxic effects because the property of decreased superficial tension of plasma membrane, acting like a natural detergent. This component has a potent destructive action on biological membranes mainly when acts synergic with the venom phospholipase A2 in the membrane phospholipids acting as diffusion factor. Recently studies have reported that suramin, a polysulfonated naphthylurea derivative, is an enzymatic inhibitor that prevents the effects produced by polications present in the snake venom and some isolated myotoxins that act like *A. mellifera* components. We evaluated the ability of suramin to antagonize the vascular permeability, edema and cytotoxicity in endothelial cells induced by *Apis mellifera* crude venom and by melittin.

The plasma extravasation was assessed by using a i.v. injection of a visual marker, Evans blue and measured the absorbance which was express in arbitrary units. Intradermal injection of bee venom or melittin induced intense plasma extravasation in the local injection and was compared with control animals that received only PSS injection. The effect of crude venom and melittin was reduced when was preincubated, pre and post treated with suramin. Paw edema induced by injection of bee venom or melittin was inhibited by suramin treatments. Primary cultures of microvascu-

lar endothelial cells were obtained from rat cremaster muscle microcirculation according to a method described previously. Cells culture were incubated per 1 hour with venom or melittin alone or with suramin. After incubation sobrenadant was collected and LDH measured. Data show that low concentrations of suramin inhibited completely the cytotoxic activity of bee venom and melittin effects. These data suggest that the toxic effect of bee venom is due the melittin action and that suramin has a protective effect against damage caused by bee venom components.



## Author Index

Abrahão RQ	05.062	Alves-do-Prado W	06.071
Abrantes-Lima KD	04.088	Amado CAB	09.094
Abreu A	06.046	Amaral DCG	03.036
Abreu LC	02.004	Amaral FA	02.013, 02.025,
Abreu ML	06.053, 06.059		02.034, 02.042,
Acco A	09.021		04.077, 04.083,
Accorsi-Mendonça D	02.002		05.043
Acedo SC	04.102, 07.007,	Amaral LM	06.021
	07.009	Amaral SS	04.048
Adachi LNS	02.056	Amaral TAS	09.012
Agra IKR	09.070	Ambiel CR	06.071
Agra MF	09.095, 09.100	Ambrósio SR	06.008
Aguiar DC	03.026	Amemiya RM	04.023, 04.040
Aguiar JA	05.008, 09.049	Amêndola R	04.064
Aguiar-Jr AS	02.005	Amorim LEO	06.078
Aido-Machado R	01.007	Amorim VR	05.048, 09.053
Aires RD	06.065	Andrade CAF	06.079, 07.013
Albertin M	02.039	Andrade EL	02.006, 02.055
Albuquerque AAS	06.033	Andrade FA	06.045
Albuquerque MS	02.042, 02.052	Andrade JMM	09.080
Albuquerque RAF	05.008	Andrade M F	09.014
Alencar JL	03.019	Andrade SF	09.102
Alencar NMN	04.080, 09.047,	Andrade SP	04.132
	09.056	Andrade WS	11.024
Alencar VTL	04.120	Andrade-Lopes AL	01.022
Alexandre-Moreira MS	05.015	Andre E	05.058, 09.019,
Almança CCJ	09.067, 09.075		09.020, 09.039
Almeida BG	04.132	Andreatini R	02.035, 03.022
Almeida CB	02.017	Androwiki ACD	06.063, 06.066,
Almeida CJ	04.090		06.068
Almeida CLF	09.036, 11.017	Angelis CD	09.009
Almeida FRC	05.033, 05.034,	Anhê GF	04.116
	05.035, 07.001	Anjos-Valotta EA	04.056, 04.127,
Almeida IP	09.005, 09.053		04.128
Almeida JM	11.006	Anselmo A	04.130
Almeida MG	10.003	Anteguera AAC	04.068
Almeida PE	04.090, 04.091,	Antoniali C	06.022, 06.050,
	04.106		06.067
Almeida PVG	03.024	Antoniali CS	09.003
Almeida RA	09.047	Antonio CB	02.011, 02.015,
Almeida RN	03.018, 03.019		03.016
Almeida RT	05.027	Antunes E	04.057, 04.105,
Almendra LR	04.013		04.107, 04.108,
Alvarez L	05.016		04.111, 04.116,
Alverne SM	09.056		06.058, 08.003,
Alves AS	04.099, 05.021		08.006
Alves CD	06.053	Antunes F	05.007
Alves DR	05.016	Antunes KM	04.090
Alves DS	11.006	Antunes-Rodrigues J	06.079
Alves FHF	02.008, 02.012,	Aquino PGV	09.092
	03.014	Arakawa NS	05.029
Alves Filho FC	06.001, 06.002	Arantes ACS	04.018, 04.128
Alves Filho JC	04.064, 04.073,	Araújo AJ	09.050, 10.007,
	04.129, 05.051		10.009, 10.018
Alves LA	11.022, 11.030	Araújo AV	06.014, 06.044
Alves R	02.010	Araújo EB	09.030
Alves RS	06.036, 06.059	Araújo Júnior JX	09.092

Araújo LP	04.089	Barbosa Jr F	11.002
Araújo MS	02.052	Barbosa Neto O	01.002
Araújo MV	09.107	Barbosa-Souza V	01.020
Araújo RC	04.079	Barcellos-de-Souza P	01.031
Araújo Souza PS	04.024	Barcelos L	04.132
Arcanjo LCG	04.074	Barcelos RCS	02.057
Arifa RDN	04.006, 08.008	Baretta IP	03.022
Ariza D	02.035	Barja Fidalgo TC	01.008, 01.014,
Arruda AMM	11.013		01.015, 01.029,
Arruda Junior WB	03.023		01.031, 04.064,
Arruda LLM	04.066, 04.076		09.022, 10.016
Arruda MA	01.029, 01.031	Barnabé GF	02.027
Arruda MCC	04.077	Baroni S	04.066, 04.076
Arruda MSP	06.047, 09.015	Barreiro EJ	01.009, 01.016,
Assis RC	09.053		01.017, 02.009,
Assreuy J	04.032, 04.042,		02.011, 03.016,
	06.027, 06.038,		05.007, 05.010,
	06.046, 06.075		05.015, 05.030,
Athayde ML	09.068		05.031, 05.053,
Athayde-Filho PF	03.003		06.007, 06.020,
Audi EA	02.017		06.043, 07.003,
Ávila RMD	05.023		11.019
Ávila TV	04.006, 04.011,	Barreto E	09.070
	04.044, 04.082,	Barreto LRF	01.005
	08.008	Barreto MAA	04.131
Ayres MCC	05.033, 05.035,	Barros HMT	02.046, 03.029
	09.098	Barroso LC	04.043
Azeredo FJ	11.019	Basílio IJLD	09.100
Azeredo JA	09.086	Basso LA	01.019, 08.004
Azeredo LA	02.046	Bastos GNT	04.029
Azevedo SM	09.089	Bastos IVGA	05.063
Baggio CH	09.013, 09.039,	Bastos MVR	05.077
	09.041, 09.088	Bastos NFP	10.014
Bakhle YS	05.041	Bastos-Rodrigues L	11.026
Bakker-Abreu I	04.014, 04.053,	Batalhão ME	06.004
	04.135	Batassini C	02.015
Balarini CM	06.018	Batista LM	09.024, 09.027,
Baldaia MA	03.031		09.035, 09.036,
Baldo C	04.099		09.048, 09.052,
Ballejo G	06.001, 06.002		09.058, 11.017
Balsanelli LS	06.075	Battastini AMO	02.024, 03.020,
Baltazar LM	08.008		04.133, 05.032,
Balter AS	06.034, 06.041		10.002
Bandeira-Melo C	04.014, 04.053,	Becari C	01.038, 02.033,
	04.135		06.061
Banin TM	06.052	Beduschi MG	04.062, 09.026
Baracho NCV	06.054, 06.088,	Begnami AF	09.018
	06.089, 09.074,	Beijamini V	11.006, 11.009
	09.105, 11.034	Beiral HJV	06.019
Baraldi T	02.025, 02.042,	Beirith A	09.106
	02.052	Belinati KD	09.061
Barato RC	06.060	Belini L	04.058
Barberato LC	01.004	Bello PHP	06.010, 06.013
Barbiero JK	02.035	Belo VA	11.007, 11.015,
Barbosa ALR	04.103, 07.006		11.023
Barbosa AM	09.064	Bem AXC	05.073, 07.011
Barbosa CRN	07.011	Bem G	09.104, 09.016
Barbosa Filho JM	05.077	Bendhack LM	06.014, 06.023,
Barbosa JPC	06.053, 06.059		06.024, 06.032,

	06.035, 06.044, 06.045, 06.064, 06.067	Bolonheis SM	04.037, 04.078, 04.087, 09.061
Benetti LR	04.098, 04.104	Bolzani V	01.016, 02.009
Benjamim CF	04.012, 04.013, 04.025, 04.059, 04.069, 04.071, 04.081, 04.084, 04.124, 06.028	Bonagamba LGH	02.002, 06.044
		Bonan CD	02.056
		Bonaventura D	06.003, 06.008, 06.067
Bento AF	02.006, 02.018, 02.055	Bonet IJM	05.001
Bento-Silva MT	07.001, 07.002, 07.012	Bonfim NM	04.066
Benvegnú DM	02.057	Bonventi W	01.020
Bérenger ALR	09.103	Borges FR	05.072
Bergantin LB	01.022	Borges RS	04.012
Bernabé DG	10.006	Borja GP	04.046
Bernardes DSV	06.088	Borlini PG	11.006
Bernardes PTT	04.010, 04.134	Borsoi M	02.015
Bersani-Amado CA	04.066, 04.068, 04.076, 09.042, 09.043, 09.051, 09.054, 09.097	Bortolatto CF	04.036
		Botelho A	09.069
		Both FL	09.028
Bertini R	04.132, 05.068	Bouffleur N	02.057
Bertoglio LJ	03.012	Bouskela E	09.022
Besnard AG	04.063	Bozza PT	04.014, 04.053, 04.090, 04.091, 04.106, 04.124
Bettero GM	09.004		
Betti AH	02.011, 02.015, 03.016, 09.004, 09.079	Bozzo TA	05.025
Betto MRB	04.047	Bracht A	09.021
Bezerra CGP	08.002, 08.005	Braedon B	01.013
Bezerra DP	09.050	Braga A	09.079
Bezerra MM	04.112, 05.008, 09.049	Braga FC	09.044
		Braga Neto MB	01.005
Bezerra RDS	05.048	Braga-Vilela AS	11.008
Bhattacharyya J	09.100	Branco AMC	04.013, 04.081, 09.057, 09.084
Biagi C	11.023	Brandão-Costa RM	10.016
Biasoli ER	10.006	Brayner MMB	09.030
Biazzotto JC	06.024, 06.032, 06.044	Breithaupt-Faloppa AC	04.040, 04.052, 04.094
Biegelmeyer R	09.080		
Bilheiro RP	09.093	Brigagão MRPL	04.001
Binda NS	02.048, 05.075	Brigatte P	05.055
Biojone C	03.005, 03.006, 03.015	Brighente IMC	09.106
		Brito BG	11.006
Biscaro MDA	03.032	Brito FCF	05.023, 06.034, 06.076, 06.078
Bispo Júnior W	05.015	Brito GAC	01.005, 04.112, 04.120, 04.121, 05.042, 07.011, 09.047
Bitencourt CS	04.008		
Bitencourt FS	09.056	Brito HO	04.092
Bittencourt JC	02.054	Brito SMRC	05.048, 09.098
Boaventura GT	09.104	Brito-Júnior EC	07.004
Boemer G	02.005	Britto LRG	04.099, 05.021
Bóf ER	06.027, 06.038	Brogliato AR	04.013, 04.081
Boffo MA	06.055	Brosco MC	03.025
Bogo MR	02.056	Bruder-Nascimento T	06.056
Boldrini LC	08.002, 08.005	Brügger PG	09.074
Boligon AA	09.068	Brum Junior L	11.019
		Bruni FM	09.025
		Brunini T	03.033, 03.035, 06.010

Buck HS	02.013, 02.025, 02.034, 02.042, 02.052	Candico LCM	04.019
Bürger ME	02.057, 09.059	Cândido PM	10.010
Bulgarelli	09.064	Canesso MCC	04.132
Buracchi C	04.130	Canetti C	04.025, 04.059, 04.069, 04.110, 06.028
Burci LM	09.013, 09.020, 09.039, 09.088	Canto RFS	11.005
Busnardo C	02.030, 02.051	Caparroz-Assef SM	09.051
Buzzi FC	04.117	Capellini VK	06.033
Cabrini DA	04.009, 04.118, 09.046, 09.062, 09.077, 09.081, 09.090, 09.106	Capettini LSA	06.047, 06.051, 06.065
Cáceres A	05.016	Capistrano Júnior VL	11.020, 11.021, 11.025
Cadena SMSC	09.021	Cara DC	04.048
Caetano AL	02.013, 02.025, 02.034, 02.042	Cardelli NJA	04.116
Caletti G	03.029	Cardoso MHM	04.001
Calheiros AS	09.086	Cardoso PF	10.010
Caliari MV	05.041	Cardoso PM	09.059
Calil-Elias S	09.072	Cardoso RDR	05.009
Calixto JB	02.006, 02.018, 02.055, 03.011, 04.017, 05.003, 05.056, 05.079, 08.004, 10.005	Carioletti GH	06.069
Calixto MC	04.105, 04.111	Carmo PL	04.012
Callado RB	05.073	Carneiro FS	01.012
Callera GE	06.014	Carneiro LU	09.075
Calou IBF	04.065	Carneiro PC	11.015
Calvo TR	10.010	Carneiro VL	05.068
Camacho F	02.033	Carnio EC	06.004
Camanducaia DSM	09.074	Carolina DM	01.025, 02.049
Câmara NOS	04.079, 09.043	Carraro JLF	09.080
Camarão GC	11.024	Carregaro V	04.075
Camargo E	04.020, 09.096	Carreira EU	05.061
Camargo LL	01.030, 06.063, 06.066, 06.068	Carreiro JN	09.099
Camarini R	04.131	Carrettiero DC	02.021
Campesatto-Mella E	09.107	Caruso-Neves C	04.045, 06.028
Campi P	04.002, 04.026, 04.027	Carvalho AA	09.098
Campi PS	08.008	Carvalho AAF	06.022
Campos D	04.098, 04.104	Carvalho AMR	05.077
Campos DHJ	06.056	Carvalho CE	04.046
Campos DV	01.035	Carvalho FDGF	08.006
Campos EMB	02.041	Carvalho FL	03.003, 03.018
Campos MM	01.019, 01.023, 03.011, 04.016, 04.017, 04.047, 04.067, 04.133, 05.056, 08.004, 10.002, 10.005	Carvalho FLDQ	11.012, 11.014
Campos RDL	03.021	Carvalho JE	09.018
Campos RDL	03.036	Carvalho JGB	02.010, 02.028, 02.029
Campos-Júnior JC	01.002	Carvalho JS	05.055
Canal PF	05.023, 06.078	Carvalho JSM	11.012, 11.014
Candea ALP	01.010, 01.011	Carvalho LCRM	06.013, 09.012, 09.016, 09.104
		Carvalho MHC	01.030, 04.002, 06.063, 10.001
		Carvalho MHC	06.068
		Carvalho MS	03.023
		Carvalho PO	07.009
		Carvalho VF	08.007
		Carvalho WA	11.003
		Carvalho-Sousa CE	01.040, 04.055, 04.093
		Casagrande R	04.049
		Casarini DE	01.038

Casarotto PC	03.001, 03.008, 03.013	Ciambarella BT	01.006
Cassali GD	09.093	Ciccio JF	09.003
Castello Branco MVS	09.035, 09.036	Cicillini SA	06.035
Castor LRG	05.022	Cicogna AC	06.056
Castor MGM	04.010, 04.134	Cintra ACO	09.001, 10.011
Castro MM	06.029, 06.040, 06.085	Cirillo MC	09.078
Castro NG	01.016, 02.009, 02.043, 05.030	Cisalpino D	03.036, 04.044, 04.082, 04.115
Castro TBR	04.132	Cisalpino PS	04.034
Castro-Faria-Neto HC	04.090, 04.106, 04.124, 09.086, 09.103	Claudino MA	06.058, 08.006
Cau SBA	06.060, 06.077	Clemente-Napimoga JT	05.066, 09.014
Caumo W	03.020, 03.028	Clementino-Neto J	09.045
Cavalcante ALC	04.065, 05.064	Clissa PB	04.099
Cavalcante FA	09.034, 09.045	Coelho EB	11.028
Cavalcante-Silva LHA	05.015	Coelho FM	04.019, 04.137
Cavalcanti PP	11.024	Coelho LP	04.050, 08.007
Cavalli RC	06.021, 08.001, 11.031	Coelho MGP	05.011, 09.010, 09.040, 09.071
Cavallini OF	09.075	Coelho MM	04.101
Cavriani G	04.052	Coelho-Sampaio TL	04.071
Cechinel Filho V	05.016, 05.020, 09.003, 09.073, 09.101	Coeli FB	11.010
Celes MRN	06.046	Colares MT	05.064
Celotto AC	06.033	Colotta F	04.132
Cenac N	04.138	Colquhoun A	10.001
Cenedeze	04.079	Cólus IMS	10.010
Centurião FB	03.027, 09.091	Cons BL	09.006, 09.057, 09.072
Ceravolo GS	04.002, 06.063, 06.068	Conserva LM	09.077, 09.081
Cereda CMS	05.026	Contarato KS	09.075
Ceron CS	06.029, 06.031, 06.040, 06.077, 06.085	Contardi EB	02.022
Cerqueira GS	09.047, 09.087	Conte FP	04.035
Cerutti M	05.017, 05.037	Contin DK	01.020
Cerutti ML	05.059	Conto MB	02.029
Chagas DWN	10.013	Contri RV	11.019
Chagas-Silva F	01.004	Cordeiro RSB	01.003, 04.050, 04.056, 04.127, 04.128, 08.007
Chambergo FS	02.052	Cordeiro VSC	09.012, 09.016
Chandler PR	04.119	Cordellini S	06.056
Chavasco LS	04.001	Córdova MM	05.072
Chaves HV	04.112, 05.008, 09.030	Corrêa FMA	02.003, 02.007, 02.008, 02.012, 02.014, 02.019, 02.020, 02.026, 02.030, 02.036, 02.040, 02.051, 03.002, 03.014
Chaves HV	05.042, 05.064, 09.049	Corrêa JD	04.007
Chaves MH	04.113, 05.033, 05.034, 05.035, 09.098	Corrêa JWN	06.014
Chaves MH	05.048	Corrêa MS	09.082
Chen LS	11.013	Corrêa R	04.117
Cheniaux Jr E	03.035	Corrêa RX	11.004
Chichorro JG	05.019, 05.067	Corrêa T	06.046, 06.062
Chignalia AZ	01.030	Correia ACC	09.095
Chudzinski-Tavassi AM	09.038, 09.083	Correia D	03.022
		Côrtes SF	06.003, 06.047, 06.051, 06.065, 09.015

Costa CA	06.013, 09.012, 09.016, 09.104	Cunha FGP	07.007
Costa DL	04.075	Cunha FL	10.003
Costa DL	09.055	Cunha FQ	03.002, 04.035, 04.049, 04.051, 04.054, 04.064, 04.073, 04.075, 04.103, 04.119, 04.120, 04.121, 04.122, 04.123, 04.126, 04.129, 05.009, 05.025, 05.029, 05.038, 05.051, 05.061, 05.068, 06.046, 06.084, 07.006, 09.056
Costa EA	09.011, 09.037		
Costa EB	06.070		
Costa ES	10.008		
Costa GNO	11.026		
Costa JCS	01.003, 04.127		
Costa JL	05.042		
Costa JS	05.013		
Costa JVG	04.095, 07.010		
Costa MFB	06.036		
Costa MFS	04.045		
Costa MFS	04.110		
Costa NF	09.103		
Costa R	05.003, 05.079	Cunha FVM	09.005
Costa RD	03.023	Cunha GH	11.024, 11.025, 11.027
Costa SKP	04.002, 04.004, 04.020, 04.026, 04.027, 04.030, 04.038, 04.086, 04.104, 04.131	Cunha TM	03.002, 04.049, 04.073, 04.129, 05.025, 05.029, 05.038, 05.061
Costa VCO	09.034, 09.045	Cunha TM	04.075, 04.103, 04.122, 05.051
Costa VV	04.011, 04.022, 04.044, 04.082, 04.083, 04.115, 04.137, 05.043	Cunha VMN	01.007, 06.016, 08.002, 08.005
Costa-Lotufo LV	09.050, 10.007, 10.009, 10.018	Curi R	10.008
Costa-Neto CM	01.038, 02.033, 10.012	Cursino NM	06.022
Costentin J	09.008, 09.091	Cury Y	05.006, 05.014, 05.028, 05.055, 05.078, 10.008
Cotias AC	04.127, 04.128		
Coutinho R	01.023, 04.133	Cyrino FZ	09.022
Couto GC	04.127, 04.128	Czaikoski PG	04.051
Couto RO	09.037	D'Andrea ED	05.031, 07.003
Couto-Pereira N	02.046	D'Ávila H	04.106
Crestani A	11.005	Da Costa FB	05.029
Crestani CC	02.008, 03.014	Da Cunha C	02.005
Crestani S	06.038, 06.039, 06.042, 09.007, 09.020, 09.068	da Frota Jr MLC	09.080
Crippa JA	04.041	da Silva DA	06.082
Cruz CCD	04.050, 08.007	da Silva JG	09.021
Cruz L	05.019	da Silva JK	06.025
Cruz MP	09.014	da Silva LM	09.013, 09.019, 09.020, 09.039
Cruz RC	08.008	da Silva O	03.035
Cruz SM	05.016	da Silva RM	06.073, 06.081
Cruz-Höfling MA	01.020	da Silva VC	09.076
Cruz-Machado SS	04.055, 04.093	da Silva-Santos JE	06.038, 06.039, 06.042, 06.055, 06.062, 09.007, 09.068
Cuman RKN	04.068, 09.042, 09.043, 09.051, 09.054, 09.094, 09.097	Dach F	11.011
Cunha A	09.059	Da-Fe AR	04.071, 04.084
Cunha AOS	02.016	Dal Belo CA	09.066, 09.082
Cunha CRM	10.015	DalBó S	04.032, 06.027
Cunha CS	04.079	Dale CS	05.021, 05.062
		Dalla Costa T	11.005, 11.019
		DallAcqua M	05.001
		Dalmau SR	09.040

Dalmolin GD	02.023, 04.118, 05.040, 05.065	Dias L	06.082, 06.083
Dalpra WL	02.046, 03.029	Dias MA	02.055
Dal-Secco D	06.046, 06.075	Dias QM	05.050
Dalsenter PR	09.021	Dias RYS	09.038, 09.083
Damasceno DCF	09.005, 09.053	Dias-Junior CAC	06.040
Damião JM	09.094	Diaz BL	04.014, 04.024, 04.053, 04.110, 04.135, 10.004
Damião MJ	09.043, 09.097	Dillenburg-Pilla P	10.012
Dantas JA	09.051, 09.054	Diniz CRAF	03.013
Dantas RT	06.036	Diniz J	09.050
Darmarco ED	04.062, 09.026	Diniz MFFM	09.024, 09.058
da-Silva-Filho VJ	01.002	Do Nascimento JLM	04.029
Davel APC	01.018	Do Rego JC	09.008, 09.091
De Andrade MCC	01.038	Domiciano TP	04.068, 09.051
de Araújo DR	05.026, 05.039, 05.046	Domingos HV	04.003, 04.040, 04.094
de Assis Ramos MM	04.052	Donadon MF	03.007
de Bortoli VC	03.034	Donato F	05.052
de Campos-Buzzi F	05.020, 05.074	Dong KE	02.013, 02.025
de Lima TCM	09.073	Dórea RSDM	09.014
de Lucca FL	01.033, 01.034	dos Santos FC	09.088
de Oliveira AM	06.052, 06.084	dos Santos MH	06.051
De Oliveira CC	04.102, 07.009	dos Santos RC	09.033
de Paula DCC	06.006	Dotto G	05.019
de Paula E	05.026, 05.039, 05.046	Drewes CC	05.005, 09.038, 09.083
de Paula JR	09.011	Driemeier D	04.047
de Paula Soares V	03.023	Duarte ID	05.027
de Paula TP	04.006	Duarte IDG	05.047, 05.071, 05.076
de Prá MA	06.072	Duarte JC	09.014
de Rezende V	08.001	Dutra AL	06.011, 06.012
de Rico TB	06.028	Dutra RC	02.018, 05.079
de Souza AH	05.075	Eifler-Lima VL	11.005
de Souza DP	09.096	Einicker-Lamas M	04.046, 06.016, 06.019, 08.002, 08.005
de Souza MVN	01.010, 01.011	Ekundi-Valentim E	04.030, 04.038
de Souza P	06.038, 06.055, 09.007	El-Cheikh MC	08.002, 08.005
de Souza RG	02.047, 02.053	Eler GJ	09.021
de Toni LGB	09.001	Elias LLK	02.030, 07.002
Degaspari D	11.033	El-Kik CZ	09.006, 09.084
Del Bel EA	03.025	Elsas MICG	04.074
Delatorre P	09.107	Elsas PPX	04.074
Delbem ACB	06.050	Emanuelli T	02.057, 09.059
Delbin MA	04.107	Emiliano da Silva AF	09.012, 09.104
Delella FK	09.025	Eto C	05.069, 05.070
De-Leon E	04.077	Evangelista JSAM	06.053, 06.059
Della Colleta E	01.035, 01.036	Évora PRB	06.033
Della Justina AM	04.042	Fabri DRS	02.019, 02.020
Della-Casa MS	09.078	Faccim AG	09.067
Delle Monache F	05.013	Faccioli LH	04.008, 10.011
Denadai-Souza A	04.138, 06.063	Fachim H	02.016
Deolindo MV	02.007, 02.014	Fachini FC	04.068, 09.042
Detanico BC	03.020	Fachini RF	04.076
Di Pietro G	11.004, 11.026	Facundo VA	09.013, 09.017
Dias AA	06.066, 06.068	Fagundes CT	04.011, 04.022, 04.044, 04.077,
Dias da Silva VJ	01.002		
Dias DM	09.067		
Dias GEN	09.024, 09.027, 09.058		

	04.082, 04.083, 04.115, 08.008	Ferreira TPT	01.003, 01.006, 04.018, 04.127, 04.128
Faiad OJ	10.008	Ferreira VF	10.007, 10.009, 10.018
Fais RS	05.049, 05.050	Ferreira ZS	01.028, 01.040, 04.055
Falcão HS	09.052, 09.058, 11.017	Ferreira-Junior WA	05.006
Farias-Filho FA	04.056	Ferreira-Sae MC	11.010
Farinha TO	09.054	Ferri MK	02.046
Farsky S	04.037, 04.039, 04.078, 04.087, 04.114, 09.038, 09.061, 09.083	Ferriani R	11.007
Fattori V	04.049	Ferro ES	05.021
Fechine FV	04.109, 11.024	Fidalgo-Neto AA	11.022, 11.030
Fedoce AG	02.012, 02.026	Fierro IM	01.014, 01.015, 04.084
Felisbino S	09.025	Figueira GM	09.018
Fenner R	09.079	Figueira R	09.004
Fernandes ACO	05.006, 05.014, 05.028	Figueiredo CP	02.018, 05.003
Fernandes D	04.042, 06.030	Figueiredo GSM	04.031, 05.036
Fernandes FFA	09.084	Figueiredo IST	04.065
Fernandes HA	03.031	Figueiredo IST	04.080
Fernandes HB	05.034, 05.035	Figueiredo JB	04.013, 04.081
Fernandes JBF	11.007	Figueiredo JG	09.056
Fernandes PACM	01.027, 04.093	Figueiredo LB	02.027
Fernandes PD	04.031, 05.012, 05.013, 05.036	Figueiredo LF	11.034
Fernandes VO	11.025	Figueiredo MJ	04.125, 09.001
Ferraris FK	09.031	Figueiredo MM	04.070
Ferraz KC	06.037	Figueiredo MR	09.031, 09.103
Ferraz-de-Paula V	03.017, 04.021, 04.033, 04.041	Figueiredo Neto JL	03.023
Ferreira AKB	09.055, 09.092	Figueiredo TG	06.087
Ferreira AVM	04.005, 04.097, 04.134	Figueiredo VN	06.048, 06.057
Ferreira BGA	09.046, 09.062, 09.090	Filgueira AA	04.112
Ferreira C	02.004	Finamor IA	06.012
Ferreira EDF	02.039	Fior-Chadi DR	02.021, 02.031
Ferreira HHA	04.098, 04.104	Fischer L	05.001
Ferreira J	02.023, 04.118, 05.005, 05.040, 05.044, 05.058, 05.065, 05.075, 09.017	Florentino FI	09.037
Ferreira Junior NC	02.012, 02.026	Florenzano J	04.004, 04.020, 04.030, 04.131
Ferreira LG	06.033	Flores Toque HA	08.003
Ferreira MRC	09.105	Flower RJ	01.006, 04.018
Ferreira R	03.009	Fogaça MV	10.010
Ferreira RG	04.100, 04.101	Fonsêca DV	03.003, 03.018
Ferreira SH	04.049, 04.122, 04.129, 05.025, 05.029, 05.038, 05.051, 05.061, 05.068	Fonseca EAI	10.001
Ferreira TF	09.099	Fonseca JP	09.043, 09.054, 09.094, 09.097
Ferreira TMI	11.008	Fonseca MJ	04.049
		Fonseca TF	09.084
		Fontana V	11.023
		Fontanini CEM	05.075
		Fonteles MC	06.080
		Fontoura PCS	03.033, 03.035
		Forner S	02.006, 02.037, 02.055
		Fortaleza EAT	02.036
		Fortes ZB	01.030, 06.063, 10.001
		Fraceto LF	05.039, 05.046
		Fraga CAM	01.009, 01.016, 02.009, 02.011,



	03.016, 05.007, 05.010, 05.030, 06.007, 06.020		11.002, 11.015, 11.031
França RT	06.011	Germano G	04.130
Francischi JN	05.041	Gewehr CCV	05.005
Franco J	09.082	Giachini FR	01.012
Franco JJ	09.001	Giannocco G	09.043, 09.097
Franco JL	09.066	Gimenes SNC	09.002
Franco LAM	01.039, 02.049	Gimenes-Junior JA	04.003, 04.094
Franco-Penteado CF	06.058, 08.006	Giorgi R	04.096, 05.045, 05.062
Franz-Montan M	05.039, 05.046	Giusti-Paiva A	06.079, 07.013
Frasson NR	05.052	Godin AM	04.101
Freitag A	09.042, 09.094	Godinho RO	01.022, 02.027
Freitas A	04.064	Golega BA	04.009
Freitas AH	01.026	Gomes AS	07.005, 07.006
Freitas APF	09.047, 09.087	Gomes BS	04.113
Freitas CS	09.041	Gomes FV	02.008, 03.001
Freitas GA	09.075	Gomes FV	02.020, 03.002
Freitas GM	05.011, 09.071	Gomes GM	02.023
Freitas JD	04.096	Gomes IBS	06.005
Freitas LBN	04.080	Gomes MS	06.017
Freitas TC	09.066	Gomes MSR	09.002
Frode TS	04.062	Gomes MVM	03.015
Frota Bezerra FA	11.020, 11.021, 11.025	Gomes VA	11.007
		Gomes VM	06.080
Frussa-Filho R	03.031	Gomez MV	02.023, 02.048, 05.040, 05.075
Fruituoso VS	09.086, 09.103		
Furtado GS	06.089	Gomez R	02.046, 03.029
Gaban GA	09.084	Gomez RS	02.048
Galdino GS	05.027	Gomides LF	04.100
Galdino PM	09.011, 09.037	Gonçalves CJ	05.020
Gambero A	04.102, 07.007, 07.009	Gonçalves DO	04.065, 04.080
		Gonçalves FM	11.011
Gambero S	07.007	Gonçalves RB	03.032
Gambôa NF	01.016	Gonçalves W	04.137
Gandra	05.078	Gondim DV	05.042
Garcia CC	04.061	Gonsalez SR	06.019
Garcia JAD	11.001	Gosmann G	09.079
Garcia LMG	06.022	Gotardo EMF	04.102, 07.009
Garcia-Cairasco N	02.033	Goulart MOF	10.007
Garlet GP	04.054	Grabe-Guimarães A	06.006, 09.044, 06.049
Garlet TP	04.054		
Gasparini G	11.010	Grangeiro NMCG	05.008
Gasparotto FM	09.029	Grespan R	04.066, 04.075, 04.076, 04.119, 09.042, 09.054
Gasparotto Junior A	06.039, 06.055, 09.007, 09.029		
		Grillo LAM	09.055
Gava AL	06.018	Grillo R	05.039, 05.046
Gay BM	03.027	Gris V	09.021
Gayer CRM	05.011, 09.071	Guabiraba R	04.063, 04.115
Gazarini L	03.012	Gualda LBS	02.050
Gazzinelli RT	04.073	Guarido KL	06.038
Gazzoto AF	06.048, 06.057	Guedes GS	06.087
Gehring MP	10.002	Guerra GP	04.118, 05.005
Gelfuso GM	04.008	Guginski G	05.024
Gemignani S	03.032	Guglielmotti A	04.097
Gerardi-Junior CA	03.031	Guilherme VA	05.039, 05.046
Gerlach RF	06.029, 06.031, 06.060, 06.074, 06.077, 06.085,	Guimarães CL	04.062, 09.026

Guimarães DA	06.031, 06.074, 06.077, 06.085	Irulegui RSC	06.089
Guimarães FS	02.008, 02.014, 02.032, 02.038, 02.050, 03.001, 03.002, 03.005, 03.006, 03.008, 03.026	Ishizawa MH	11.003
Guimarães HN	06.006, 09.044	Iyomasa MM	02.041, 02.044, 02.047, 02.053
Guimarães JA	09.022	Izidoro-Toledo TC	06.074, 11.010, 11.011, 11.015, 11.028
Guimaraes MZP	01.009, 02.043, 05.030	Jacob Ferreira ALB	06.004, 11.002, 11.007, 11.010
Gurgueira SA	04.098	Jader ABS	08.004
Gutierrez VP	05.006, 05.028, 05.055, 05.078	Janiszewski M	06.063, 06.066, 06.068
Guzzo LS	05.071, 06.006	Jesse CR	04.036
Gyurko R	04.086	Jesus NZT	09.048
Haas JS	09.008, 09.091	Jesus RPFS	05.063
Haas SE	11.019	Joca SRL	03.002, 03.004, 03.005, 03.006, 03.013, 03.015, 03.026, 03.030
Hallak JEC	04.041	Jorge ARC	06.059
Hamasato EK	04.021	Jorge IP	05.002
Hank A	09.026	Jorge RJB	06.036, 06.053, 06.059
Hara DB	05.057	Juliano L	05.062
HASSE DR	02.011, 03.016, 09.008, 09.079	Juliano MA	05.062
Hayashi MA	09.065	Jurgilas PB	04.050, 04.127, 04.128
He Y	06.014	Jurkiewicz A	01.037
Hebeda CB	04.037, 04.078, 04.087, 04.114, 09.038, 09.061, 09.083	Jurkiewicz NH	01.037
Heimann AS	05.014, 05.021	Justino PFC	04.095, 07.010
Helal Neto E	10.016	Kaiser M	11.019
Henriques AT	09.028, 09.080	Kanashiro A	02.041
Henriques MG	01.010, 01.011, 04.035, 04.045, 04.110, 09.031	Kanazawa LKS	09.088
Henriques-Santos NF	03.025	Kangussu L	06.003
Herrera BS	04.002, 04.026, 04.027, 04.086	Karklin YC	08.008
Hidalgo MP	03.020	Kartnaller MA	07.003
Hipolito UV	06.004, 06.008	Kassuya CAL	05.060, 06.055, 09.007, 09.029, 09.060, 09.068, 09.069
Hiruma-Lima CA	05.022, 09.009, 09.025, 09.033, 09.076	Kato M	01.033
Hiyane M	04.079	Kawamoto EM	01.018, 01.024, 11.033
Hoffmeister C	05.044	Keller AC	04.079
Hollais AW	03.031	Kerbaury LN	02.047, 02.053
Hott SC	02.019, 02.020	Kerber VA	09.028
Humberto MMS	09.055	Kettelhut IC	01.033, 01.034
Hyslop S	06.082, 06.082, 06.083, 06.086, 09.085	Kinoshita PF	01.018
Iacomini M	09.041	Klein A	04.100, 04.101
Ikeda CM	11.008	Klein Jr LC	09.101
Índio-do-Brasil V	11.016, 11.018	Klein LC	09.102
Insuela DBR	08.007	Koepf J	02.006, 02.037, 02.055
Interaminense LFL	06.025	Koifman S	11.016
Irazusta SP	01.020	Konno K	05.006
		Konstantinovas C	11.026
		Krimon S	05.018
		Kroon EG	03.036
		Kubes P	01.013

Kummer R	04.066, 04.068, 09.042	Lemos MTR	02.013
Kummerle AE	06.007, 06.020	Lemos Neto M	09.016
Kunkel SL	04.069, 04.071, 04.084	Lemos VS	06.047, 06.051, 06.065, 09.015
Kushima H	09.076	Lenoir AS	05.020
Lacchini R	11.010	Lepletier A	04.046
Lacerda JSJ	11.006	Lessa LMA	06.080
Lacerda RB	01.009	Liew FY	05.009, 05.051
Lacerda-Queiroz N	03.021, 03.036, 04.085, 04.136	Ligeiro de Oliveira AP	04.003, 04.009, 04.021, 04.023, 04.040
Ladislau L	04.071, 04.084	Lima AAM	07.011
Lage SL	04.106	Lima CB	04.039
Lages PM	04.074	Lima CHS	01.011
Lahlou S	06.025	Lima CJ	09.064
Lameiro TMM	10.003	Lima CKF	01.009, 05.031
Landgraf MA	04.079	Lima EO	09.024, 09.027, 09.052
Landgraf RG	04.079	Lima Filho CF	06.053
Landgraf SS	06.028	Lima FO	05.004, 05.038
Lanna CM	11.015	Lima GRM	09.035, 09.036, 11.017
Lanznaster D	09.017	Lima IO	09.024
Lapa AJ	01.035, 01.036, 06.073, 06.081, 09.065	Lima JT	09.063
Lapa FR	04.009	Lima LM	01.017, 05.015, 05.031, 06.043, 11.019
Lapa MAPC	01.028	Lima LO	09.034, 09.045
Lara Morcillo LS	06.016, 06.019, 08.002, 08.005	Lima ML	05.053, 07.003
Larsen GR	05.073	Lima MMS	02.035
Laurindo FRM	06.068	Lima MRV	03.018
Lavor MSL	02.048, 05.075	Lima PDL	10.017
Lazari MFM	01.021	Lima RL	04.005, 04.006, 04.097
Lazarotto LF	04.016, 04.017, 04.047	Lima SF	09.081
Lazzaretti C	02.015	Lima TS	09.078
Leal CM	05.010, 06.007	Lima VCC	10.013
Leal DM	05.010, 06.007	Lima VV	01.012
Leal LKAM	09.087	Lima-Garcia JF	05.056
Leal NRF	09.010	Lima-Jr DS	04.075
Leal PC	02.055, 04.017, 10.005	Lima-Júnior RCP	04.120, 04.121, 05.073, 07.011, 09.056
Leal-Cardoso JH	06.025	Lima-Landman MTR	01.035, 01.036, 06.073, 06.081
Leão RX	02.002	Limonte FH	02.044, 02.047, 02.053
Leiria LOS	08.006	Linardi A	06.086
Leitão SG	05.013	Linder AE	06.069, 06.070, 06.072
Leite ALAS	04.109, 11.020, 11.021	Linhares JH	04.109
Leite ATJ	09.027	Lino CNR	10.011
Leite CAVG	04.120, 04.121	Lino dos Santos Franco A	04.023, 04.037, 04.040
Leite CE	01.019, 04.047	Lino RC	09.037
Leite CP	05.077	Lintomen L	04.105, 04.111
Leite DFP	02.018, 02.055	Lira	05.078
Leite LL	01.005, 07.011	Lisboa SF	02.032, 02.038, 03.002
Leme TSV	09.029		
Lemes EV	09.106		
Lemes LFN	01.001		
Lemos BC	09.089		
Lemos HP	04.119		
Lemos M	09.102		

Lôbo de Araújo A	01.020	Machado-Silva LDF	05.041
Lobo RR	04.126	Maciel IS	03.011, 04.067
Locati M	04.010, 04.130	Maciel LIS	11.008
Lombardi L	04.114	Mackay CR	04.077
Longhi-Balbinot DT	09.017	Madeira MFM	04.006, 04.007, 04.019, 08.008
Lopes AG	06.058	Magalhães HO	10.013
Lopes AHP	01.002	Magalhães KG	04.053
Lopes ASA	02.034	Magalhães MS	04.109, 11.027
Lopes DCF	01.039, 02.049	Magalhães PJC	04.120, 06.025
Lopes F	04.061, 04.137	Magalhães RC	04.029
Lopes KS	06.036	Magina MDA	09.026, 09.106
Lopes LGF	07.008	Magno LA	11.004, 11.026
Lopes LR	01.030, 06.063, 06.066, 06.068	Maia EP	07.004
Lopes LS	05.033, 05.034, 05.035	Maia I	10.017
Lopes MTP	04.100, 09.093	Maia JGS	06.025
Lopes NP	02.016, 09.061	Maia MBS	09.030
Lopes RM	11.022, 11.030	Maia MBS	09.049
Lopes RS	04.074	Maia RC	05.053
Lopes STA	06.011	Maia-Dantas A	04.002, 04.026, 04.027
Lopes VM	09.094, 09.097	Maique ET	05.021
Lopes-Ferreira M	09.025	Malpezzi-Marinho ELA	03.031
Lopes-Silva S	02.003	Malta MB	02.054
Lopez SMF	05.017	Malvar DC	02.041, 04.070, 04.125
Lorand-Metze I	07.007	Mamede CCN	09.002
Lorenzetti R	06.082	Manjavachi MN	02.018, 05.079
Lorenzi R	09.080	Mantovani A	04.130
Lotufo CMdaC	05.025	Marçal DMO	06.031, 06.077, 06.085
Louback LS	06.076	Marco LAC	11.026
Lourenço EL	06.055, 09.029	Marçola M	01.027
Louzada Jr P	04.129	Marcon R	05.017
Loyola YCS	11.001	Marcondes S	04.107, 04.116
Lucas TFG	01.021	Marcucci MC	04.072
Lucena GMRS	05.037	Marculino DMM	09.052
Lucetti LT	04.103, 07.005, 07.006, 07.008, 07.010	Maria AG	10.012
Lucho APB	09.082	Marinho AD	06.036, 06.053, 06.059
Ludovico ND	06.048, 06.057	Marinho BG	05.012, 05.013, 09.067, 09.075
Luiz AP	05.067	Marinho DG	09.067, 09.075
Luizon MR	08.001, 11.010, 11.028	Marinho EAV	03.031
Luna-Gomes T	04.014, 04.053, 04.135	Marinho-Filho JDB	09.050, 10.007, 10.018
Lunardi CN	06.032	Markus RP	01.026, 01.027, 01.028, 01.040, 04.055, 04.088, 04.093
Luvizuto EL	06.022	Marprates CVB	04.007
Luz PB	09.056	Marques CD	03.010
Luz RA	04.074	Marques de Carvalho RS	09.073
Macedo CL	09.099	Marques EB	06.034, 06.041, 06.076
Macedo DS	09.087	Marques FLN	05.055
Macedo Junior SJ	05.017, 05.037, 05.059	Marques LHS	10.003
Macedo RN	04.109	Marques LM	09.014
Machado BH	02.002, 06.044		
Machado FC	05.014, 05.078		
Machado FS	04.034		
Machado MM	09.006, 09.057, 09.072, 09.089		

Marques MCA	06.038, 06.039, 06.042, 06.055, 09.007, 09.013, 09.019, 09.020, 09.029, 09.039, 09.041, 09.068	Medeiros LF	02.024, 03.020, 03.028, 05.032
Marques PR	09.010	Medeiros R	02.006
Marques RB	05.033, 05.034, 07.001	Medeiros VM	09.034, 09.045
Marques RB	05.035	Meira NA	09.101
Marques SA	06.041	Meireles BA	05.012
Martin L	04.138	Meireles VS	09.014
Martin Z	09.101	Melchiors AC	11.009
Martinez AMB	09.072	Melendes A	04.046
Martinez CAR	10.003	Mello GC	04.057, 04.108
Martini AC	02.006, 02.037	Mello JCP	02.017
Martino T	09.040	Mello LE	02.027
Martins AMC	06.036, 06.053, 06.059	Mello NFS	05.039, 05.046
Martins CL	11.018	Mello SM	06.083
Martins DF	05.017, 09.017, 09.041	Mello WG	04.015
Martins EAC	02.031	Mellor AL	04.119
Martins GG	02.050	Melo CM	07.013
Martins IRR	09.100	Melo DLR	04.120
Martins JM	04.070, 04.125	Melo GAN	09.094
Martins JP	04.133	Melo LFM	04.095, 07.010
Martins JPB	11.033	Melo MCC	04.028
Martins MA	01.003, 01.006, 04.018, 04.050, 04.056, 04.127, 04.128, 08.007	Melo PA	04.081, 09.006, 09.057, 09.072, 09.084, 09.089
Martins MCC	07.004, 09.005, 09.053	Melo PRS	11.004
Martins Porto R	04.002, 04.020, 04.026, 04.027, 04.086	Melo R	11.008
Martins TS	03.016	Melo RCN	04.106
Martins V	04.013	Melo TS	04.065
Martins VV	09.006, 09.057	Melo TV	05.077
Martynhak BJ	03.022	Melo-Filho AF	10.013
Mascarello A	10.005	Mendes DAGB	09.019, 09.046, 09.062, 09.090
Mascarin LZ	05.069, 05.070	Mendes GD	11.013
Maslowski KM	04.077	Mendes JM	09.052
Matheus FC	02.005	Mendes LJ	06.047
Matheus ME	04.031, 05.036	Mendes LVP	06.016
Matheus-Souza D	04.018	Mendes MM	09.002
Mathias PC	06.071	Mendes Ribeiro AC	03.033, 03.035, 06.010
Matias TC	11.006	Mendes TCF	05.007, 05.010
Matsubara CS	02.049	Mendonça MSA	01.011
Matsui TC	04.101	Mendonça PR	04.126
Matsumoto JPP	02.031	Menegatti R	10.015
Matta CBB	05.015	Meneses GC	06.036
Maués LAL	04.029	Menezes CMS	01.017
Maya-Monterio CM	04.090, 04.106	Menezes de Lima Jr O	04.035, 04.042
Mazzardo L	09.041	Menezes GB	01.013, 04.022, 04.043, 04.048
Medeiros J-VR	07.005, 07.006, 07.008	Menezes RRPPB	06.036, 06.053, 06.059
		Menezes Z	04.005, 04.006, 04.097
		Mesquita Jr O	06.061
		Mesquita-Santos FP	04.014, 04.053, 04.135
		Mestriner FL	06.084
		Metzger IF	11.003
		Meyrelles SS	06.005, 06.018
		Micaroni S	06.022

Mielcke TR	10.005	Morais LH	02.035
Milanezi CM	04.075	Morais SRL	04.015
Milani H	02.022	Morandi V	01.029, 10.016
Milani H	02.039	Morcatty TQ	04.011, 04.022,
Milet-Morais MM	06.087		04.044, 04.082,
Miranda ALP	01.009, 05.023,		05.043
	05.031, 05.053,	Moreau RLM	03.017, 04.114
	06.076, 06.078	Moreira ELG	02.005
Miranda AS	03.021, 03.036,	Moreira FA	03.005
	04.085, 04.136,	Moreira JCF	09.080
	05.015	Moreira MM	06.048, 06.057
Miranda CR	09.054	Moreira MMB	09.036
Miranda DM	11.026	Moreno Junior H	06.048, 06.057,
Miranda LSM	05.012, 05.013		06.083
Mirolo M	04.130	Mori MA	02.039
Mitre GC	04.007	Morrone FB	01.023, 03.011,
Miwa MY	04.100		04.016, 04.017,
Miyahara GI	10.006		04.067, 04.133,
Molina L	09.032		10.002, 10.005
Molinaro RC	04.069, 04.124	Morrot A	04.045, 04.046
Monica FZT	08.003, 08.006	Moss MB	06.010
Monte LO	03.019	Mota FD	09.048
Monte-Alto-Costa A	04.013	Mota KSL	09.024
Monteiro APT	04.025, 04.059	Mota VG	03.003, 03.019
Monteiro DLS	04.109	Mothes B	09.080
Monteiro FMF	07.012	Motta EM	05.003, 05.056,
Monteiro FS	09.100		05.078, 05.079
Monteiro HSA	06.036, 06.053,	Motta NAV	05.023, 06.034,
	06.059		06.076, 06.078
Monteiro PF	04.107	Moura AB	09.065
Montenegro CA	09.035, 09.036,	Moura BA	05.077, 09.087
	11.017	Moura MABF	10.007
Montenegro Jr RM	11.021, 11.025	Mourão LTC	04.120
Montenegro MF	06.040	Mourao PAS	09.057
Montenegro RC	09.050, 10.007,	Müller LG	02.057, 09.004
	10.009, 10.017,	Munaro DV	05.030
	10.018	Munhoz CD	01.030, 01.039,
Montenegro VM	02.043		02.054, 04.038,
Montes RC	09.052		11.033
Montezuma K	03.006	Munhoz FC	06.067
Moraes GB	06.053	Muniz GD	03.023
Moraes JA	09.022	Muscará MN	04.002, 04.004,
Moraes JB	06.064		04.020, 04.026,
Moraes MEA	04.109, 11.020,		04.027, 04.030,
	11.021, 11.024,		04.038, 04.086,
	11.025, 11.027		04.087, 04.104,
Moraes MO	04.109, 09.050,		04.131, 04.138,
	10.007, 10.009,		06.063
	10.017, 10.018,	Muxel SM	01.040
	11.020, 11.027	Muzi-Filho H	01.007, 08.002,
Moraes NF	04.096		08.005
Moraes RA	11.020, 11.024,	Nadruz Filho W	11.010
	11.027	Nagem TJ	06.051
Moraes TP	02.041	Naime ACA	11.001
Morais GB	06.059	Napimoga MH	01.002, 05.066,
Morais ICO	06.036, 06.053,		09.014
	06.059	Nardo M	03.008
Morais LCSL	03.003, 03.018,	Nascente LC	01.001
	03.019	Nascimento AR	01.021

Nascimento DCB	04.051, 04.073	Okamoto R	06.022
Nascimento DD	09.103	Okoba W	07.002
Nascimento DF	04.109, 11.020, 11.027	Olchanheski Junior LR	06.030
Nascimento FP	05.017, 05.037, 05.059	Olguins DB	03.029
Nascimento JB	01.001, 01.004	Oliani SM	04.089
Nascimento JHM	06.016	Olinda TM	04.065
Nascimento MVL	04.029	Oliveira AC	09.023
Nascimento MVM	09.011, 09.037	Oliveira AM	06.017, 06.046
Nascimento NRF	06.080	Oliveira AM	06.031, 06.077, 06.085, 11.011
Nascimento-Jr NM	05.007, 05.010	Oliveira AP	09.102
Nascimento-Silva V	01.029, 09.022	Oliveira CC	04.109
Nasciutti LE	01.031	Oliveira CJ	04.075
Natarajan R	01.033	Oliveira CMA	04.076
Nebuloni M	04.130	Oliveira D	05.069
Nejo P	02.032	Oliveira DA	09.055
Neto H	04.064	Oliveira DA	09.092
Neto-Neves EM	06.029, 06.037, 06.040	Oliveira EB	06.015, 06.061, 09.065
Netto CA	02.024, 05.032	Oliveira EM	02.034, 02.052
Neves G	02.011	Oliveira F	09.002
Neves KRT	09.087	Oliveira FA	04.113
Neves TLM	09.088	Oliveira FA	05.034, 07.001
Nicolete R	04.008	Oliveira FGV	07.001, 07.002, 07.012
Nicoletti NF	01.019	Oliveira FL	08.002, 08.005
Nicoli JR	04.077	Oliveira FS	02.044
Niconi-De-Almeida Y	01.015	Oliveira GA	09.095, 09.099
Niero R	05.020, 05.074, 09.102	Oliveira IS	07.001
Nin MS	02.046	Oliveira JAC	02.033
Nishijima CM	09.025	Oliveira JC	06.071, 11.021, 11.024, 11.027
Nobre MJ	03.009	Oliveira JPC	04.113
Nóbrega FFF	03.003	Oliveira L	05.057
Noel F	01.001, 01.004, 01.017, 03.016, 09.004	Oliveira LGT	06.020, 07.003
Nogueira AF	04.095, 07.010	Oliveira LP	11.008
Nogueira AF	10.009	Oliveira MA	01.030
Nogueira CRC	04.061	Oliveira MA	10.001
Nogueira CW	03.027	Oliveira MC	04.005
Nogueira CW	04.036	Oliveira MC	05.018
Nogueira de Melo GA	09.054	Oliveira MR	01.005
Nogueira FM	01.035, 01.036	Oliveira PRB	09.012, 09.016
Nogueira JS	04.098	Oliveira RCS	06.088
Nogueira MCO	05.053	Oliveira RMMW	02.022
Nogueira TO	05.045	Oliveira RMMW	02.050
Nojimoto FD	01.032	Oliveira RMW	02.039
Nomizo A	10.011	Oliveira RSB	04.080
Nonose Y	03.028	Oliveira SHP	04.015, 04.058, 04.060, 10.006
Noronha FJD	07.011	Oliveira SL	09.063
Noviello MLM	04.048	Oliveira SM	04.118
Nucci G	04.026, 06.058, 08.006, 11.013	Oliveira SM	05.058
Nunes LG	07.011	Oliveira-Filho RM	04.003, 04.023, 04.040, 04.052, 04.094
Nunes PHM	07.004	Oliveira-Lima AJ	03.031
Nunes-Filho DM	07.004	Olivon VC	06.046, 06.052, 06.084
Ognibene DT	06.010, 06.013, 09.012	Olsen PC	01.003

Onishi ET	11.032	Pereira DJ	06.048, 06.057
Oriá RB	04.121	Pereira FO	09.024, 09.027
Ornelas FGI	09.032	Pereira HJV	06.015, 06.061
Osorio CBH	04.080	Pereira IT	09.013, 09.088
Otuki MF	04.118, 09.046, 09.062, 09.077, 09.081, 09.090, 09.106	Pereira IT	09.019, 09.039
Pachá BP	04.012	Pereira KMA	09.049
Pacheco-Silva A	04.079	Pereira LMS	05.073
Pacini ESA	08.009	Pereira M	03.022
Padaratz P	05.020	Pereira MF	09.040
Padovan CM	02.001, 02.045, 03.007, 03.024	Pereira MGAG	02.033
Padovan D	02.001, 02.045	Pereira MTR	02.044
Pagano RL	04.096, 05.045	Pereira PAT	04.008
Paiva-Lima P	05.041	Pereira PJS	04.016, 04.017
Palazzin NB	06.008	Pereira SL	06.020
Palei ACT	06.021, 08.001, 11.031	Pereira SS	05.033, 05.034, 05.035
Palermo-Neto J	03.017, 04.021, 04.033, 04.039, 04.041	Pereira TMC	06.018
Palheta Junior RC	07.002, 07.012	Pereira VLP	05.012, 05.013
Pão CRR	04.128	Pereira VS	03.030
Parada CA	05.001, 05.018, 05.028, 05.038	Pereira-Silva PEM	04.048
Parreiras-e-Silva LT	01.038	Pereira-Silva REM	04.063
Pase C	02.057, 02.057	Pereira-Toste F	06.041
Pase CS	09.059	Perez AC	05.027, 05.071
Pasqualini F	04.130	Perez AR	04.046
Passos CS	09.028	Perissé L	01.007
Patricio ES	02.018, 05.003	Pernomian L	06.017, 06.023
Paula AM	04.022, 04.043	Peron JPS	04.004
Paula JR	09.037	Perretti M	01.006, 04.018
Paula TP	08.008	Perri SHV	06.022
Paula-Gomes S	01.033	Pesamosca ME	09.066
Paulino CA	11.032	Pesquero JB	02.018, 05.079, 10.012
Paulino N	04.072	Pessini AC	04.070
Paulo M	06.024	Pessoa AWP	06.053
Pavanato MA	06.012	Pessoa C	09.050, 10.007, 10.018
Pazin A	04.126	Pessoa CO	10.009, 10.017
Pecli CP	04.069	Pessoa DR	09.035, 09.036
Pedroso-Mariani SR	03.032	Pessoa FLC	02.048, 05.075
Peixoto HS	06.073, 06.081	Pessoa ODL	06.080, 09.050, 10.017
Pelayo JS	05.009	Peters-Golden M	04.069, 04.110
Pellegrino R	09.065	Petrilli CL	01.040, 04.093
Pelosi GG	02.051	Piauilino CA	05.048, 07.001, 09.098
Penido C	04.035, 04.110, 04.110, 04.110, 09.031	Picco DCR	06.050
Penteado CF	06.086	Piccolo G	05.006, 05.014, 05.055, 05.078
Pereira AC	02.016, 06.032, 06.067, 06.089, 09.015	Pierosan L	05.072
Pereira B	09.018	Pimenta Costa CS	11.020, 11.021, 11.024, 11.027
Pereira CCS	06.022	Pimenta MT	01.021
Pereira DA	11.008	Pimentel LSB	01.016
Pereira DHS	03.024	Pina dos Santos VP	02.052
		Pinato L	04.055, 04.093
		Pinedo F	04.087
		Pinheiro AAS	04.045, 06.028
		Pinheiro ACN	02.048, 05.075
		Pinheiro ADN	07.001, 07.002



Pinheiro CG	11.012, 11.014	Queiroz Junior CM	04.019, 05.041
Pinheiro CN	04.065	Queiroz MLS	03.017
Pinheiro CS	04.025	Queiroz MR	09.002
Pinheiro CS	04.059	Queiroz RHC	06.004
Pinheiro FV	05.058	Queiroz VA	05.026
Pinheiro LS	03.019	Quesniaux V	04.083
Pinheiro ML	04.021, 04.033, 04.041	Quinaglia TSS	06.048, 06.057
Pinheiro RJ	09.097	Quintão NLM	04.117, 05.002, 05.016, 05.074, 09.003, 09.101
Pinho JF	06.065	Quintas LEM	09.004
Pinho V	04.010, 04.022, 04.061, 04.134, 04.137, 06.065, 08.008	Quinteiro MS	05.066
Pinto AC	04.031, 05.036	Quinteiro-Filho WM	04.033
Pinto Duarte G	06.025, 06.026, 06.087	Rabelo LA	06.087
Pinto FA	05.011, 09.010	RABELO RS	07.004
Pinto LG	04.122, 04.129, 05.029	Rachid M	04.136
Pinto VLM	03.033, 03.035	Radin A	05.055
Piornedo RR	09.060	Rae GA	02.037, 05.024, 05.057, 05.067
Pires ALA	01.006, 04.018, 04.050, 04.127, 04.128	Raimundo JM	06.041, 06.043
Pires MEL	04.107, 04.116	Ramalho L	06.052
Pires NF	06.048, 06.057	Ramirez RRA	11.017
Pires-Oliveira M	01.022	Ramiro JB	09.067
Pitanga QML	11.012, 11.014	Ramos GC	06.027
Pitta LB	11.012, 11.014	Ramos MV	09.047, 09.056
Pittman K	01.013	Ramos-Alves FE	06.025, 06.026
Piva B	04.110, 10.004	Rassam E	03.032
Pizzolatti GM	09.088	Rates SMK	02.011, 02.015, 03.016, 03.027, 09.004, 09.008, 09.079, 09.091
Pizzolatti MG	09.019, 09.020, 09.039, 09.106	Reckziegel P	02.057, 09.059
Pontes AV	11.020, 11.024, 11.025	Rehder VLG	09.018
Pontes LB	06.043	Reis AC	04.010
Portela LOC	06.011, 06.012	Reis DG	02.014, 02.019, 02.020, 02.026, 02.040, 03.014
Portella VG	06.028	Reis GM	05.049, 05.050, 05.054
Porto CS	01.021, 01.025	Reis HJ	03.021, 03.036, 04.136
Poublan LE	04.024	Reis LM	11.001
Prada Morganti R	04.107	Reis MLA	09.105
Prado CM	06.014	Reis PG	06.049
Prado WA	05.049, 05.050, 05.054	Reis RC	04.092, 05.023, 06.078
Pranke M	02.015	Reis RI	01.038, 10.012
Prediger RD	02.005	Renno AL	06.048, 06.057
Prezotto AO	11.032	Rennó AL	06.082, 06.083, 06.086
Prigol M	03.027	Renovato-Martins M	01.008
Priviero FBM	04.107, 08.003	Resende AC	06.010, 06.013, 09.012, 09.016, 09.104
Prosperi T	04.011	Resende LC	05.076
Proudfoot AEI	04.132	Resstel LBM	02.008, 02.012, 02.014, 02.019, 02.020, 02.026, 02.030, 02.032,
Prudente AS	04.118, 09.077, 09.081		
Pupo AS	01.032, 08.009		
Queiroz AC	05.015		
Queiroz ALL	04.061		
Queiroz D B	06.026		

	02.038, 02.040, 03.001, 03.002, 03.014	Rodrigues FSM	01.022
		Rodrigues GCR	05.063
Rezende B	04.010, 04.134	Rodrigues GJ	06.035, 06.044
Rezende RM	05.041	Rodrigues GS	09.022
Rial D	02.005	Rodrigues JA	07.002
Ribeiro A	03.017, 04.021, 04.033, 04.041	Rodrigues L	04.030, 04.038
Ribeiro ACG	04.001	Rodrigues MAP	06.082, 06.083
Ribeiro ALT	04.037, 04.078	Rodrigues MRA	09.088
Ribeiro dos Santos R	05.004	Rodrigues R	09.031
Ribeiro EAN	09.055, 09.092	Rodrigues RV	09.013
Ribeiro JM	04.075	Rodrigues VM	09.002
Ribeiro Junior E	11.033	Rodrigues WF	01.002
Ribeiro KA	04.112	Rodrigues-Junior VS	01.019, 01.023, 08.004
Ribeiro KA	09.030, 09.049	Rodriguez LMP	09.101
Ribeiro LAA	09.063	Rolim TL	09.027
Ribeiro RA	01.005, 04.095, 04.103, 04.112, 04.120, 04.121, 04.123, 05.073, 07.005, 07.006, 07.010, 07.011, 09.047, 09.056, 10.013	Romanini CV	02.039
Ricardo HD	09.006, 09.089	Romano-Silva M	11.026
Ricardo KFS	06.005	Romeiro LAS	01.001, 01.004
Rico TB	04.012	Romero TRL	05.047
Rigo FK	05.040, 05.065	Roncon CM	02.017
Rilson JP	09.043	Roque NR	04.091, 04.106
Rinaldo D	09.009	Rosa EA	04.076
Rios ERV	09.087	Rosa HS	02.015
Rios-Santos F	11.003, 11.004, 11.026	Rosa ML	02.041, 02.044, 02.047, 02.053
Ritter AMV	04.068, 09.051	Rosas EC	01.010
Riul ME	06.014	Rossaneis AC	05.049, 05.054
Rizzi E	06.029, 06.031, 06.077, 06.085	Rossato M	05.005, 05.044
Rizzo LV	04.004	Rossato MF	04.118
Rocco PRM	04.025, 04.051	Rossi MA	06.014, 06.046
Rocha BAM	09.107	Rossoni LV	01.018, 01.030
Rocha DD	10.017	Royer C	01.021
Rocha DR	10.018	Rozisky JR	02.024, 02.056, 03.020, 03.028, 05.032
Rocha JBT	09.059	Rubin MA	02.023, 05.005
Rocha JT	06.009	Ruiz ALTG	09.018
Rocha LR	09.003	Russo RC	04.061, 04.130
Rocha MBS	11.020, 11.025, 11.027	Russowsky D	11.005
Rocha MN	02.034	Ryffel B	04.063, 04.083
Rocha NFM	09.087	Sá LG	05.073
Rocha SS	05.042	Sá Lima L	01.018, 01.024, 01.025, 01.039, 02.049, 11.033
Rocha VHP	06.059	Sabino KCC	09.010, 09.040, 09.071
Rocio AAP	09.021	Sachs D	05.043
Rodrigues C	04.117	Sakamoto S	09.004
Rodrigues CM	09.025, 09.033	Salama Rodrigues C	01.008
Rodrigues DH	03.021, 03.036, 04.085, 04.136	Salas CE	04.100, 09.093
Rodrigues EJM	10.013	Saldanha-Gama RF	10.016
Rodrigues FAR	10.017	Sales AJ	03.004, 03.015
		Sales ALCC	09.005, 09.053
		Sales Filho HLA	05.048, 09.098
		Salgado MCO	01.038, 02.033, 06.002, 06.015, 06.061
		Salgado PRR	03.003, 03.018

Salles LA	02.015	Santos R	03.031
Salles LA	09.004	Santos RC	06.048, 06.057
Salmon DJJ	01.007	Santos RF	09.095, 09.099,
Salomão PAV	03.010		09.100
Salum C	03.025	Santos RGS	07.012
Salzedas LMP	04.058	Santos Sousa O	06.037
Samico RF	04.053, 04.135	Santos TC	09.070
Sampaio AM	06.059	Santos VAC	04.060
Sampaio LRL	09.087, 09.087	Santos VS	02.024, 03.028,
Sampaio SC	04.096, 09.078,		05.032
	10.008	Santos WC	10.018
Sampaio SV	09.001, 10.011	Santos WF	02.016
Sanches AIF	09.074	Sá-Nunes A	04.075
Sanches RS	09.074	Saraiva MIR	07.008
Sandrim VC	06.021, 08.001,	Saridakis HO	05.009
	11.028, 11.031	Sarragioto MH	04.066
Sannomiya M	09.033	Sartim MA	09.001
Santana AEG	09.055, 09.092	Sasaki GL	09.041
Santana APM	07.005, 07.006,	Sato VAH	03.004
	07.008	Saturnino-Oliveira J	09.072
Santana CVN	11.004, 11.026	Saúde-Guimarães DA	06.006
Santiago MB	06.079	Savegnago L	05.052
Santiago RM	02.035	Savino B	04.130
Santin JR	09.102	Savino W	04.045, 04.046
Santoro ML	05.045	Scaramello C	06.034, 06.041,
Santos AA Jr	01.019, 01.023,		06.076
	04.133, 08.004	Scavone C	01.018, 01.024,
Santos AA	04.120, 07.012		01.025, 01.039,
Santos AA	07.001, 07.002		02.049, 02.054,
Santos AAQA	01.005		11.033
Santos AG	04.011, 04.022,	Schenka A	04.057, 04.105,
	04.044, 04.082		08.006
Santos ARS	04.009, 05.017,	Scherrer JV	09.067
	05.037, 09.041,	Scheschowitsch K	04.032
	05.059, 05.072,	Schilter HC	04.077
	09.013, 09.017,	Schneider PH	05.052
	09.068, 09.088	Schowe NM	02.034, 02.052
Santos BLR	05.031	Schreiber R	11.010
Santos CBS	11.012, 11.014	Schroeder SD	05.067
Santos CF	06.080	Scolaro LL	06.071
Santos DA	04.034	Scopa IP	05.043
Santos DB	09.059	Scopinho AA	02.003, 02.036
Santos DF	04.008	Scopinho AA	02.040
Santos DLF	09.107	Scremin Paulino A	04.072
Santos DS	01.019, 01.023,	Serikava SMO	09.076
	04.133, 08.004	Serra CP	09.044
Santos ECS	09.073	Serra MF	01.003, 04.050,
Santos FA	06.030		04.056, 04.127,
Santos GB	04.001		04.128, 08.007
Santos HAS	09.063	Sestito RS	02.047, 02.053
Santos IVF	04.029	Sette-Martins R	04.091
Santos Júnior JC	09.005, 09.053	Setti-Perdigao P	02.043
Santos KT	04.004, 04.020	Shang FLT	04.005
Santos KT	04.131	Shim D	04.077
Santos LFL	06.053	Shimada ALB	04.037, 04.078
Santos MCC	04.097	Shimizu-Bassi G	03.009
Santos MCLFS	06.005	Siba IP	03.022
Santos NSS	03.032	Silva AA	04.104
Santos PC	04.034		

Silva AAR	04.112, 05.008, 09.030, 09.049	Silva PMR	01.003, 01.006, 04.018, 04.050, 04.056, 04.127, 04.128, 08.007
Silva ACL	09.099, 09.100	Silva PS	11.011, 11.023
Silva ADS	09.034, 09.045	Silva RBM	03.011
Silva AFS	09.053	Silva RBM	04.067, 04.133
Silva AKD	09.107	Silva RC	04.079
Silva AMS	04.113	Silva RCMVAF	09.007, 09.068
Silva AR	04.090, 04.124	SILVA RM	01.009
Silva BA	09.095	Silva RS	02.056
Silva BA	09.099, 09.100	Silva RS	06.024, 06.032, 06.035, 06.044, 06.064
Silva Barbosa SD	04.046	Silva S	05.016
Silva BR	06.064	Silva Santos JE	09.029
Silva BV	04.031, 05.036	Silva SM	02.021
Silva CC	04.076	Silva TA	04.007, 04.011, 04.019, 04.054
Silva CD	09.046	Silva TMS	09.095
Silva CFE	09.042	Silva VAO	01.033, 01.034
Silva CLCA	04.074	Silva VP	09.031
Silva CLM	01.001, 01.004, 09.084	Silva-Barcellos NM	06.049
Silva CMG	10.003	Silveira ER	09.050
Silva CR	04.118, 05.058	Silveira GL	07.012
Silva CR	05.040	Silveira JWS	05.050
Silva DB	06.016	Silveira KD	04.011, 04.044, 04.082
Silva DM	04.061	Silvestrin RB	02.015
Silva E L	09.042, 09.051	Simão AAL	04.123
Silva FH	06.058, 08.003	Simão AFL	04.123
Silva Filho JL	04.045, 06.028	Simas AS	05.060
Silva FO	03.032	Simões RL	01.015
Silva GC	05.027	Simões RR	06.011, 06.012
Silva GF	06.088, 09.003	Simons SM	09.038, 09.083
Silva GP	05.011, 09.010	Siqueira AM	09.103
Silva JDP	06.001, 06.002	Siqueira EA	04.024
Silva JF	02.048, 05.075, 06.051	Siqueira RMP	04.065, 04.080, 05.064, 09.087
Silva JM	02.054	Sita LV	02.054
Silva JPV	04.061	Sivieri-Jr DO	06.015
Silva JS	04.075	Smaal A	06.082, 06.083
Silva JS	05.029	Smaniotto S	09.070
Silva Junior ED	01.037	Smiderle FR	09.041
Silva Junior EN	10.007	Soares DdeM	04.028, 04.070, 04.125
Silva Junior IF	09.048	Soares de Moura R	06.010, 06.013, 09.012, 09.016, 09.104
Silva Junior V	09.034	Soares EA	11.001
Silva K	02.001, 02.045	Soares FA	10.013
Silva KM	09.034, 09.045	Soares GFS	09.023
Silva KO	09.014	Soares GM	11.007
Silva LL	04.113, 07.001	Soares LFM	09.005, 09.053
Silva LM	07.010	Soares MA	09.005
Silva LMN	04.095	Soares MBP	05.004
Silva LP	09.009	Soares PMG	04.095, 07.005, 07.006, 07.008, 07.010
Silva M	03.005, 03.026		
Silva MCC	09.040		
Silva MD	05.072		
Silva MDA	09.044		
Silva Medeiros AG	03.023		
Silva MMA	05.005		
Silva MO	09.077		
Silva MS	09.034, 09.045		
Silva OA	06.087		
Silva PCB	09.034, 09.045		

Soledade ES	04.025	Souza MC	04.045, 04.066
Soley BS	09.021, 09.046, 09.062, 09.090	Souza MFV	03.018, 09.024, 11.017
Sônego F	04.073	Souza MHLP	04.095, 04.103, 04.112, 04.121, 07.005, 07.006, 07.008, 07.010, 07.011, 11.021
Sonza DR	04.117, 05.074		
Souza IA	05.063		
Sordi R	04.042		
Sorgi CA	10.011		
Soriani FM	04.061	Souza PS	04.117
Souccar C	01.035, 01.036, 06.073, 06.081	Souza RB	05.008, 09.030
		Souza RS	04.082
Sousa AMA	02.034	Souza SA	03.003
Sousa BF	09.011, 09.037	Souza SMB	11.004
Sousa FCF	05.077	Souza TM	02.015
Sousa JMB	09.026	Souza	09.086
Sousa LFC	03.021, 04.019	Souza-Costa DC	11.015
Sousa LN	07.012	Souza-Filho MVP	04.123
Sousa LP	04.044, 04.061, 04.137	Souza-Martins R	04.110
		Souza-Queiroz J	03.017
Sousa OT	09.023	Souza-Silva E	05.069, 05.070
Sousa PJC	06.025	Spadacci-Morena DD	05.045
Sousa RB	04.103	Speciali JG	11.011
Sousa RB	04.126	Spiller F	04.051, 04.064, 04.126
Sousa TA	01.033, 01.034		
Sousa VR	09.098	Spolidório LC	04.002, 04.026, 04.027, 04.086
Souto AA	01.019, 04.016, 04.067, 08.004	Squebola Cola DM	04.057, 04.108
		Staurengo-Ferrari L	04.049, 05.009
Souto FO	04.049, 04.064, 04.073, 04.123, 04.126, 05.029	Stefanello MEA	05.060, 06.055, 09.007, 09.029, 09.060, 09.069
Souza A	02.024, 03.020, 03.028, 05.032	Steffen VM	09.028
		Stein AC	03.027, 09.004, 09.091
Souza ACG	10.018		
Souza ACM	06.006	Stein G	11.033
Souza AES	09.023	Stern CAJ	03.012
Souza AM	08.002, 08.005	Stoco SM	05.039, 05.046
Souza CL	03.010	Stolz ED	09.008, 09.079
Souza DG	04.005, 04.006, 04.007, 04.011, 04.019, 04.022, 04.034, 04.044, 04.063, 04.082, 04.083, 04.097, 04.115, 05.043, 08.008	Strapasson RLB	09.060
		Strauch MA	09.057, 09.089
		Sudo RT	04.012, 05.007, 05.010, 06.007, 06.020, 06.041, 06.043, 07.003
Souza EP	09.014	Sudo-Hayashi LS	04.052, 04.094
Souza GEP	02.041, 04.028, 04.070, 04.125, 09.001	Sutti R	09.085
		Tadei SR	04.054
Souza GR	05.025, 05.038	Tagliapietra JI	11.021, 11.025
Souza IA	04.057, 04.108	Tagliati CA	09.093
Souza J	06.049	Takeshi FI	06.058
Souza JP	05.074	Takiya CM	06.028, 08.002, 08.005
Souza KPR	03.036		
Souza LA	03.010	Talbot J	04.122, 04.129, 05.025, 11.004
Souza LHJ	02.034, 02.052		
Souza LL	02.033	Tamae AC	10.006
Souza M	04.110	Tamascia ML	09.085
Souza MAV	09.016	Tamashiro WMSC	04.111
		Tambeli CH	05.001
		Tamiozzo LLR	05.065

Tamura EK	01.026, 01.027, 04.055, 04.088, 04.093	Terra-Granado E	04.046
Tanae MM	06.073, 06.081	Thibaut JPB	01.017
Tanus-Santos JE	06.004, 06.029, 06.021, 06.031, 06.037, 06.040, 06.060, 06.060, 06.074, 06.077, 06.085, 08.001, 11.002, 11.003, 11.007, 11.010, 11.011, 11.015, 11.023, 11.028, 11.031	Thomé R	04.111
Tavares BM	07.008	Timóteo RNPD	03.019
Tavares de Lima W	04.003, 04.009, 04.023, 04.037, 04.040, 04.052, 04.078, 04.094	Tirapelli CR	02.001, 06.004, 06.008, 06.031
Tavares JD	06.089	Tirapelli DP	06.004
Tavares JF	03.019, 09.027, 09.034, 09.035, 09.036, 09.045, 09.048, 09.052, 09.058, 09.063, 09.099	Tófoli GR	05.039, 05.046
Tavares LD	04.044, 04.082, 04.083, 05.043	Toma W	09.009, 09.032
Tavares LP	04.061	Tomaz MA	09.006, 09.057, 09.072, 09.089
Tavares RF	02.030, 02.051	Tonso VM	02.044
Teixeira AL	03.021, 04.085	Tonussi CR	05.069, 05.070
Teixeira AL	03.036, 04.136	Torello CO	03.017
Teixeira CCG	05.073	Torres AFC	06.036
Teixeira JMR	09.005, 09.053	Torres B	11.005, 11.019
Teixeira MC	06.049	Torres ILS	02.024, 02.056, 03.020, 03.028, 05.032
Teixeira MM	01.013, 03.021, 04.005, 04.010, 04.011, 04.019, 04.022, 04.028, 04.043, 04.044, 04.061, 04.063, 04.077, 04.082, 04.083, 04.085, 04.097, 04.115, 04.130, 04.132, 04.134, 04.136, 04.137, 05.043, 05.068, 08.008	Torres JNL	04.103, 07.008
Teixeira SA	04.002, 04.020, 04.026, 04.027, 04.030, 04.038, 04.087, 04.104, 04.131	Torres PA	03.018
Teles YCF	09.024	Tostes RCA	01.012, 01.030, 10.001
Telles C	11.016, 11.018	Touyz RM	06.014
Tenório EP	09.055, 09.092	Toyama MH	06.036, 06.053, 06.059
Tenório JAB	09.052, 09.058	Tragante V	01.033, 01.034
Teodoro FC	05.019	Travassos RA	09.099, 09.100
		Trentin PG	01.006, 04.018
		Trevelin SC	04.073
		Trevisan G	05.005
		Trevisan G	05.044
		Trindade LB	02.047, 02.053
		Tronco Junior MF	05.019
		Trovo MC	03.024
		Truzzi RR	04.089
		Turato W	04.073, 04.126, 05.029
		Tytgat	05.006
		Tzanno-Martins CB	11.033
		Uchoa CRA	11.027
		Uchoa FDT	11.005, 11.019
		Val DR	05.008, 09.030
		Valadão DF	04.011, 04.022, 04.044, 04.082
		Valadares MC	10.015
		Vale ML	04.103, 05.042, 05.064, 09.047
		Vale OC	11.021, 11.025
		Valença SS	09.012
		Valenti VE	02.004
		Valenzuela JG	04.075
		Van Dyke TE	04.086
		Varanda EA	10.010
		Vargaftig BB	04.003, 04.052
		Vargas da Silva S	01.008
		Vasconcellos MLAA	05.012, 05.013
		Vasconcelos A	09.093
		Vasconcelos AR	01.024

Vasconcelos LF	05.077	Vilela MC	03.021, 03.036,
Vasconcelos MAM	04.080		04.022, 04.085,
Vasconcelos SMM	09.087		04.136
Vasconcelos TRA	10.009	Villa JKD	09.067
Vasquez EC	06.005, 06.018	Villalba MIC	09.093
Vautier P	04.072	Villarinho JG	05.058, 09.017
Veloso MP	05.023	Villarreal CF	05.004
Veloso RR	05.053	Viola JPB	04.024
Venditti MAC	02.010, 02.028,	Vital MABF	02.035
	02.029	Vitoretto LB	04.003, 04.052,
Vercesi AE	04.098		04.094
Vercesi JA	06.014, 06.024,	Von Poser GL	02.015, 09.004,
	06.044, 06.064		09.008, 09.091
Verdan ML	05.060, 09.069	Wang M	01.033
Verdoorn KS	06.019	Watanabe TTN	04.047
Vergara FMF	01.010	Webb RC	01.012
Vergnolle N	04.138	Werneck SMC	08.008
Verri Jr WA	04.035, 04.049,	Werner MFP	09.013, 09.019,
	04.075, 04.122,		09.020, 09.039,
	05.004, 05.009,		09.041, 09.088
	05.029, 05.038,	Wilhelm EA	04.036
	05.051	Wong DVT	04.120, 04.121,
Viana AF	03.027, 09.008,		05.073, 07.008,
	09.091		07.011
Viana FA	09.050	Wuo-Silva R	03.031
Viana GSB	04.065, 09.087	Xavier FE	06.025, 06.026,
Viana VSL	07.004		06.087
Viana WP	09.024, 09.035,	Ximenes RM	06.059
	09.058	Ximenes VF	05.022
Vianna-Jorge R	11.016, 11.018	Xu D	05.009, 05.051
Victor ML	09.043	Yamamoto M	04.002
Vieira AM	01.014	Yamane T	09.065
Vieira AS	11.009	Yamashiro LH	04.028
Vieira AT	04.077	Yatsuda R	09.014
Vieira BAC	03.010	Yogi A	01.030, 06.014
Vieira CS	11.007	Yonamine CM	09.065
Vieira GC	10.009	Yoneyama B	02.022
Vieira IR	04.080	Yshii LM	01.018, 01.039
Vieira KST	02.009	Yunes RA	10.005
Vieira MAR	06.028	Zager A	04.041
Vieira PMM	04.079	Zaharenko AJ	05.006
Vieira RO	01.004, 01.017,	Zambelli VO	05.006, 05.014,
	03.016		05.028, 05.055
Vieira SAPB	09.002	Zamboni DS	04.082
Vieira SM	04.119, 04.122,	Zamith-Miranda D	04.024
	04.129	Zammataro L	04.130
Vieira-de-Abreu A	04.124	Zampronio AR	04.092, 05.001,
Viel TA	02.013, 02.025,		05.019, 05.060,
	02.034, 02.042,		09.060, 09.069
	02.052	Zamuner SR	09.064
Vieria LQ	04.082	Zanchet EM	06.011, 06.012
Vieyra A	06.016, 06.019,	Zanesco A	04.107
	06.041, 08.002,	Zangrossi Jr H	03.034
	08.005	Zanon NM	01.033, 01.034
Vigliano MV	05.011, 09.010	Zanoni CIS	04.020
Vilegas W	09.009, 09.025,	Zanotto-Filho A	09.080
	09.033, 09.076,	Zapata-Sudo G	04.012, 05.007,
	10.010		05.010, 06.007,
Vilela FC	07.013		

	06.020, 06.041, 06.043, 07.003
Zardo RS	04.031, 05.036
Zaroni ACE	06.089
Zarpelon AC	04.049, 05.029, 05.051
Zoghbi MGB	04.029
Zuardi AW	04.041
Zuffellato-Ribas KC	09.046, 09.062, 09.090
Zychar BC	04.099
Zyngier SZ	10.001